| Symbol | GILD |
|---|---|
| Name | GILEAD SCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 333 LAKESIDE DRIVE, FOSTER CITY, California, 94404, United States |
| Telephone | +1 650 574-3000 |
| Fax | — |
| — | |
| Website | https://www.gilead.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000882095 |
| Description | Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gileads acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gileads exposure to cell therapy and noncell therapy in oncology. Additional info from NASDAQ: |
2026-08-05 01:41
Gilead - CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
Read more
2026-08-05 01:41
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
Read more
2026-07-24 10:26
Gilead - CHMP RecommendsGilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Read more
2026-07-24 10:26
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Read more
2026-07-21 20:05
Gilead - Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Read more
2026-07-21 20:05
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Read more
2026-07-21 14:00
Gilead - Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Read more
2026-07-21 14:00
Gilead - Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00002346 | The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients | Phase1 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002115 | A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosp… | Phase1 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002116 | A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Pho… | Phase1 | Herpes Simplex | Completed | — | — | ClinicalTrials.gov |
| NCT00002128 | Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivalo… | Phase1 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002142 | An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment o… | Na | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT00002161 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effic… | Na | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002180 | A Study of PMPA in HIV-Infected Patients | Phase1 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002181 | Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS | Na | Herpes Simplex | Completed | — | — | ClinicalTrials.gov |
| NCT00002184 | A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Saf… | Phase2 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002206 | A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treate… | Phase1 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002219 | Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Ant… | Phase2 | HIV Infections | Unknown | — | — | ClinicalTrials.gov |
| NCT00002234 | Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dip… | Phase2 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002326 | The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patien… | Phase1 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002327 | The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in… | Phase1 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002379 | The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With… | Phase2 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002384 | A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in P… | Na | Cytomegalovirus Retinitis | Unknown | — | — | ClinicalTrials.gov |
| NCT00002396 | The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients | Phase1 | HIV Infections | Unknown | — | — | ClinicalTrials.gov |
| NCT00002398 | Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs… | Na | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002415 | Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination… | Phase2 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002419 | Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavir… | Phase2 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002426 | A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination Wi… | Na | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00002437 | The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (… | Phase2 | Cytomegalovirus Retinitis | Completed | — | — | ClinicalTrials.gov |
| NCT00002450 | Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus O… | Phase3 | HIV Infections | Completed | — | — | ClinicalTrials.gov |
| NCT00007436 | The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to … | Phase3 | HIV Infections | Unknown | — | — | ClinicalTrials.gov |
| NCT04323761 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment… | — | SARS-CoV2 Infection | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00041691 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Resi… | Phase1 | Colorectal Neoplasms | Terminated | — | — | ClinicalTrials.gov |
| NCT00042393 | An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With L… | — | Chronic Hepatitis B | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04320693 | Expanded Access for IMMU-132 | — | Metastatic Triple-Negative Breast Carcinoma | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00499720 | Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomona… | — | Cystic Fibrosis | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00000799 | HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol | Na | Cytomegalovirus Retinitis | Completed | — | 1996-04-01 | ClinicalTrials.gov |
| NCT06780579 | Expanded Access for Bulevirtide | — | Chronic Hepatitis Delta Virus Infection | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00956176 | Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients … | Na | Cystitis | Withdrawn | — | — | ClinicalTrials.gov |
| NCT02136511 | Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphoc… | — | Chronic Lymphocytic Leukemia (CLL) | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT05627466 | US Expanded Access Program for Magrolimab in Patients With Relapsed or Refracto… | — | Relapsed/Refractory Acute Myeloid Leukemia | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02577094 | Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-i… | Phase1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | Withdrawn | — | 2017-01-01 | ClinicalTrials.gov |
| NCT00199121 | A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infec… | Phase4 | HIV | Unknown | — | — | ClinicalTrials.gov |
| NCT01779518 | Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegyla… | — | Post-transplant Hepatitis C | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00989807 | Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patient… | — | Cystic Fibrosis | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07474558 | SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates | Phase2 | Advanced or Metastatic Solid Tumour | Not_Yet_Recruiting | 2026-09-01 | 2031-09-01 | ClinicalTrials.gov |
| NCT07658976 | Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated… | Phase3 | HIV Infection | Not_Yet_Recruiting | 2026-09-01 | 2029-09-01 | ClinicalTrials.gov |
| NCT07178730 | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemo… | Phase3 | Breast Cancer | Not_Yet_Recruiting | 2026-08-30 | 2033-03-31 | ClinicalTrials.gov |
| NCT05968755 | Leveraging Chatbot to Improve PrEP in the Southern United States | Na | HIV Prevention | Not_Yet_Recruiting | 2026-07-20 | 2027-07-01 | ClinicalTrials.gov |
| NCT07703878 | A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With… | Phase1 | Solid Tumor | Recruiting | 2026-07-17 | 2029-09-01 | ClinicalTrials.gov |
| NCT07652359 | Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable C… | Na | Shared Decision-Making | Recruiting | 2026-07-14 | 2030-01-14 | ClinicalTrials.gov |
| NCT07682961 | Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilp… | Phase3 | HIV Infections | Recruiting | 2026-07-14 | 2033-03-01 | ClinicalTrials.gov |
| NCT07683000 | Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed … | Phase3 | HIV-1-infection | Recruiting | 2026-07-14 | 2033-03-01 | ClinicalTrials.gov |
| NCT07708727 | Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy… | Phase2 | HIV-1-infection | Not_Yet_Recruiting | 2026-07-01 | 2033-04-01 | ClinicalTrials.gov |
| NCT06525389 | Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis … | Phase3 | Talaromycosis | Not_Yet_Recruiting | 2026-07-01 | 2031-07-01 | ClinicalTrials.gov |
| NCT07719491 | Study of GS-0415 and How It Works in People With HIV | Phase1 | HIV -1 Infection | Not_Yet_Recruiting | 2026-07-01 | 2029-08-01 | ClinicalTrials.gov |
| NCT07546812 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in A… | Phase2 | HER2-negative | Recruiting | 2026-07-01 | 2030-01-01 | ClinicalTrials.gov |
| NCT07631442 | Using Digital Health Technology to Monitor Patients With Primary Biliary Cholan… | — | Primary Biliary Cholangitis (PBC) | Enrolling_By_Invitation | 2026-07-01 | 2028-04-01 | ClinicalTrials.gov |
| NCT07476339 | REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine an… | Phase4 | HIV -1 Infection | Recruiting | 2026-06-17 | 2027-06-17 | ClinicalTrials.gov |
| NCT07645287 | A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologic… | Phase2 | HIV-1-infection | Recruiting | 2026-06-15 | 2033-04-01 | ClinicalTrials.gov |
| NCT07601243 | Study of GS-2426 in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Recruiting | 2026-06-02 | 2029-01-01 | ClinicalTrials.gov |
| NCT07635147 | Decision Support Tool for Patients With Advanced Breast Cancer | Na | Breast Cancer Metastatic | Recruiting | 2026-06-01 | 2028-02-01 | ClinicalTrials.gov |
| NCT07031219 | HIV/HBV/HCV Triple Screening in Primary Care | Na | HIV | Not_Yet_Recruiting | 2026-06-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT07527858 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy… | Phase2 | Advanced Microsatellite Stable Colorectal Cancer | Recruiting | 2026-05-19 | 2028-12-01 | ClinicalTrials.gov |
| NCT07339059 | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Ther… | Phase2 | Small Cell Lung Cancer ( SCLC ) | Recruiting | 2026-05-14 | 2029-12-01 | ClinicalTrials.gov |
| NCT07449091 | Adaptability of an Undetectable = Untransmissible Model for HBV | — | Chronic Hepatitis b | Recruiting | 2026-05-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT07462611 | HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the E… | Na | HIV Pre-exposure Prophylaxis | Recruiting | 2026-04-08 | 2028-04-01 | ClinicalTrials.gov |
| NCT07473778 | Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention | — | HIV Infections | Recruiting | 2026-03-17 | 2029-04-01 | ClinicalTrials.gov |
| NCT07385183 | CARE: Comprehensive Assessment of Real-world Effectiveness of F/TAF in Persons … | — | People Who Inject Drugs | Not_Yet_Recruiting | 2026-02-01 | 2027-08-01 | ClinicalTrials.gov |
| NCT07390409 | ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevent… | — | HIV | Not_Yet_Recruiting | 2026-01-29 | 2028-05-01 | ClinicalTrials.gov |
| NCT07379658 | Long-Acting Injectable HIV PrEP PROs | — | HIV Pre-exposure Prophylaxis | Not_Yet_Recruiting | 2026-01-15 | 2028-01-01 | ClinicalTrials.gov |
| NCT07218211 | Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using… | Phase4 | HIV Prevention | Recruiting | 2026-01-13 | 2028-01-05 | ClinicalTrials.gov |
| NCT06817889 | Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in… | Phase2 | Hematopoietic and Lymphatic System Neoplasm | Recruiting | 2025-12-23 | 2027-11-30 | ClinicalTrials.gov |
| NCT03304717 | Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome | Phase1 | Aicardi Goutières Syndrome | Withdrawn | 2025-12-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT06682234 | Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus D… | Phase2 | Filovirus Disease | Withdrawn | 2025-12-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT07014618 | Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in… | — | Breast Cancer | Recruiting | 2025-10-16 | 2030-10-01 | ClinicalTrials.gov |
| NCT06774027 | Prospective Registry of ADC as First- and Second-line Treatment for Breast Canc… | — | HER2-negative Breast Cancer | Recruiting | 2025-10-08 | 2030-12-31 | ClinicalTrials.gov |
| NCT07163481 | A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy… | Phase1 | Stage IV (Metastatic) Breast Cancer | Not_Yet_Recruiting | 2025-10-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06900829 | #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV … | Na | HIV Infection | Recruiting | 2025-10-01 | 2030-02-01 | ClinicalTrials.gov |
| NCT07357038 | A Real-world Prospective Observational Study on the Efficacy and Safety of L-Am… | — | Fungal Disease | Recruiting | 2025-09-30 | 2027-05-31 | ClinicalTrials.gov |
| NCT07053527 | Welcome to PrEP School Utilizing Peer Educators to Improve Uptake of Preexposur… | Na | HIV Prevention Program | Enrolling_By_Invitation | 2025-09-23 | 2026-07-31 | ClinicalTrials.gov |
| NCT07210125 | Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Sett… | Phase4 | HIV | Active_Not_Recruiting | 2025-09-16 | 2027-06-30 | ClinicalTrials.gov |
| NCT07197164 | Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 i… | Phase2 | COVID - 19 | Recruiting | 2025-09-01 | 2027-02-28 | ClinicalTrials.gov |
| NCT07160075 | HIV Prevention With PrEP Among People on Opioid Replacement Therapy | Phase4 | HIV - Human Immunodeficiency Virus | Recruiting | 2025-08-28 | 2027-09-01 | ClinicalTrials.gov |
| NCT07128303 | Study of GS-5319 in Adults With Solid Tumors | Phase1 | Advanced Solid Tumor | Recruiting | 2025-08-28 | 2028-05-01 | ClinicalTrials.gov |
| NCT07055451 | Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to… | Phase1 | HIV-1-infection | Active_Not_Recruiting | 2025-08-12 | 2028-03-01 | ClinicalTrials.gov |
| NCT07115368 | Study of GS-1219 in Participants With HIV-1 | Phase1 | HIV-1-infection | Terminated | 2025-08-11 | 2025-10-02 | ClinicalTrials.gov |
| NCT07238114 | Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Unders… | — | Liver Cirrhosis | Active_Not_Recruiting | 2025-08-01 | 2027-07-31 | ClinicalTrials.gov |
| NCT07096193 | Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatiti… | Phase1 | Chronic Hepatitis Delta | Recruiting | 2025-07-31 | 2030-01-01 | ClinicalTrials.gov |
| NCT07047716 | Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxi… | Phase3 | HIV Pre-exposure Prophylaxis | Active_Not_Recruiting | 2025-07-22 | 2028-09-01 | ClinicalTrials.gov |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With H… | Phase2 | Squamous Cell Carcinoma of Head and Neck | Recruiting | 2025-07-02 | 2028-01-02 | ClinicalTrials.gov |
| NCT07001319 | Study of GS-3242 in Participants With HIV-1; Substudy-05 | Phase1 | HIV-1-infection | Recruiting | 2025-05-29 | 2027-02-01 | ClinicalTrials.gov |
| NCT06902519 | Study of GS-0151 in Participants With Rheumatoid Arthritis | Phase1 | Rheumatoid Arthritis | Recruiting | 2025-05-14 | 2027-03-01 | ClinicalTrials.gov |
| NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in P… | Phase1 | Triple Negative Breast Cancer | Recruiting | 2025-04-30 | 2028-06-01 | ClinicalTrials.gov |
| NCT06401824 | Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | Phase2 | NSCLC Stage IV | Recruiting | 2025-04-24 | 2027-04-01 | ClinicalTrials.gov |
| NCT07456332 | Effect on Body Weight Reduction of a Behavioral Intervention on Lifestyle Using… | Na | Metabolic Dysfunction-Associated Steatotic Liver Disease | Enrolling_By_Invitation | 2025-04-23 | 2028-02-01 | ClinicalTrials.gov |
| NCT06923826 | Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) | Phase2 | Salivary Gland Cancer | Recruiting | 2025-04-15 | 2030-04-01 | ClinicalTrials.gov |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Pre… | Phase3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Recruiting | 2025-04-04 | 2029-10-01 | ClinicalTrials.gov |
| NCT05222945 | A Study to Determine the Cartography of Virologic Reservoir Related to Antiretr… | Na | HIV-1-infection | Not_Yet_Recruiting | 2025-04-01 | 2025-10-31 | ClinicalTrials.gov |
| NCT06665178 | Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd … | Phase2 | Breast Cancer | Recruiting | 2025-03-31 | 2028-12-01 | ClinicalTrials.gov |
| NCT06749054 | Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-e… | Phase2 | HIV-1-infection | Recruiting | 2025-03-26 | 2027-09-01 | ClinicalTrials.gov |
| NCT06996938 | Evaluation of the Acceptability and Impact of a Sexual Health Screening and Pre… | Na | Vulnerable Population | Recruiting | 2025-03-21 | 2028-06-15 | ClinicalTrials.gov |
| NCT07746999 | North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver H… | — | HEPATITIS C (HCV) | Enrolling_By_Invitation | 2025-03-15 | 2027-03-15 | ClinicalTrials.gov |
| NCT06784973 | Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) I… | Phase2 | RSV Infection | Terminated | 2025-03-05 | 2025-04-16 | ClinicalTrials.gov |
| NCT06830668 | Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation | Phase4 | HIV Infection | Not_Yet_Recruiting | 2025-02-28 | 2026-12-31 | ClinicalTrials.gov |
| NCT06683482 | A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in … | — | Breast Cancer | Completed | 2025-02-21 | 2025-07-28 | ClinicalTrials.gov |
| NCT06250036 | Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer | Phase2 | Locally Advanced Gastric Adenocarcinoma | Recruiting | 2025-02-20 | 2031-09-01 | ClinicalTrials.gov |
| NCT06727565 | Study of Novel Treatment Combination Therapies in Participants With Head and Ne… | Phase2 | Head and Neck Squamous Cell Carcinoma | Active_Not_Recruiting | 2025-02-18 | 2026-08-01 | ClinicalTrials.gov |
| NCT06889805 | HDV Screening Study | — | Hepatitis D Virus Infection | Recruiting | 2025-02-15 | 2029-02-17 | ClinicalTrials.gov |
| NCT06612203 | Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNB… | Phase1 | Advanced Breast Cancer | Active_Not_Recruiting | 2025-01-17 | 2027-10-01 | ClinicalTrials.gov |
| NCT05814432 | Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Hist… | Phase3 | Disseminated Histoplasma Capsulatum Infection | Recruiting | 2025-01-16 | 2032-07-01 | ClinicalTrials.gov |
| NCT06759649 | A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignanc… | Phase1 | Neoplasm | Recruiting | 2025-01-07 | 2027-11-22 | ClinicalTrials.gov |
| NCT06539052 | MIGrant Reflex Test HDV (MIGRED) Project | — | Hepatitis D Virus Infection | Not_Yet_Recruiting | 2024-12-20 | 2026-12-20 | ClinicalTrials.gov |
| NCT06238921 | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Tr… | Phase1 | Breast Cancer | Recruiting | 2024-12-19 | 2027-02-01 | ClinicalTrials.gov |
| NCT06528483 | Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invas… | Phase2 | Bladder Cancer | Not_Yet_Recruiting | 2024-12-02 | 2029-12-31 | ClinicalTrials.gov |
| NCT06065371 | Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointes… | Phase1 | Gastrointestinal Cancer | Recruiting | 2024-11-20 | 2027-05-01 | ClinicalTrials.gov |
| NCT06532656 | Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 | Phase2 | HIV-1-infection | Active_Not_Recruiting | 2024-11-20 | 2030-12-01 | ClinicalTrials.gov |
| NCT06682728 | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carc… | Phase2 | Urothelial Carcinoma | Recruiting | 2024-11-15 | 2026-12-01 | ClinicalTrials.gov |
| NCT06613685 | Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With … | Phase2 | HIV-1-infection | Terminated | 2024-10-21 | 2026-03-16 | ClinicalTrials.gov |
| NCT06585150 | Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syn… | Phase2 | RSV Infection | Terminated | 2024-10-14 | 2025-06-09 | ClinicalTrials.gov |
| NCT06717581 | Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Olde… | — | HIV Infections | Recruiting | 2024-10-11 | 2025-10-11 | ClinicalTrials.gov |
| NCT06630286 | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir… | Phase3 | HIV-1-infection | Active_Not_Recruiting | 2024-10-09 | 2030-08-01 | ClinicalTrials.gov |
| NCT06630299 | Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of… | Phase3 | HIV-1-Infection | Active_Not_Recruiting | 2024-10-08 | 2030-08-01 | ClinicalTrials.gov |
| NCT06513312 | Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) | Phase2 | Pre-Exposure Prophylaxis of HIV Infection | Active_Not_Recruiting | 2024-10-07 | 2028-11-01 | ClinicalTrials.gov |
| NCT06465862 | Development of a Silica Microparticle Taggant System to Measure ART Adherence | Na | Hiv | Withdrawn | 2024-09-15 | 2025-04-15 | ClinicalTrials.gov |
| NCT06235216 | Sacituzumab govitEcan in THYroid Cancers | Phase2 | Differentiated Thyroid Cancer | Recruiting | 2024-09-13 | 2027-12-01 | ClinicalTrials.gov |
| NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Partic… | Phase3 | Endometrial Cancer | Active_Not_Recruiting | 2024-08-28 | 2029-06-01 | ClinicalTrials.gov |
| NCT06562907 | Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and N… | Phase1 | Weight Management | Recruiting | 2024-08-28 | 2026-11-01 | ClinicalTrials.gov |
| NCT06337032 | A Study to Provide Continued Access to Study Drug to Children and Adolescents W… | Phase4 | HIV-1-infection | Recruiting | 2024-08-27 | 2034-03-01 | ClinicalTrials.gov |
| NCT06544733 | Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil… | Phase2 | HIV-1-Infection | Active_Not_Recruiting | 2024-08-20 | 2029-06-01 | ClinicalTrials.gov |
| NCT06329869 | Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma | Phase2 | Esophageal Squamous Cell Carcinoma | Recruiting | 2024-08-01 | 2027-11-01 | ClinicalTrials.gov |
| NCT06532565 | Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tu… | Phase1 | Advanced Solid Tumors | Recruiting | 2024-07-26 | 2028-06-01 | ClinicalTrials.gov |
| NCT06477419 | A Study of Sacituzumab Govitecan in People With Mesothelioma | Phase2 | Mesothelioma | Recruiting | 2024-06-21 | 2029-06-21 | ClinicalTrials.gov |
| NCT06263543 | Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC | Phase2 | Breast Cancer | Recruiting | 2024-06-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT05813964 | Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MS… | Phase3 | HIV/AIDS | Recruiting | 2024-06-05 | 2027-05-01 | ClinicalTrials.gov |
| NCT06373198 | Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Foll… | — | Hepatitis C Chronic | Unknown | 2024-05-01 | 2025-01-15 | ClinicalTrials.gov |
| NCT06374758 | Accelerated ART Initiation for PWHIV Who Are Out of Care | Phase4 | HIV Infections | Active_Not_Recruiting | 2024-04-29 | 2027-08-09 | ClinicalTrials.gov |
| NCT06248515 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epit… | Phase2 | Thymoma | Recruiting | 2024-04-25 | 2026-12-01 | ClinicalTrials.gov |
| NCT06353295 | Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: Th… | Na | HIV/AIDS | Active_Not_Recruiting | 2024-04-24 | 2026-06-30 | ClinicalTrials.gov |
| NCT06123468 | Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastati… | Phase1 | Esophagogastric Adenocarcinoma | Completed | 2024-04-17 | 2026-01-07 | ClinicalTrials.gov |
| NCT05833867 | Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscl… | Phase1 | Localized Muscle Invasive Bladder Urothelial Carcinoma | Recruiting | 2024-04-01 | 2027-10-01 | ClinicalTrials.gov |
| NCT06071767 | Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in… | Phase1 | HIV-1-infection | Recruiting | 2024-04-01 | 2029-08-01 | ClinicalTrials.gov |
| NCT05829434 | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS | Phase2 | Acute Myeloid Leukemia | Withdrawn | 2024-03-31 | 2029-08-30 | ClinicalTrials.gov |
| NCT06290934 | Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative … | Phase2 | Ulcerative Colitis | Active_Not_Recruiting | 2024-03-27 | 2028-04-01 | ClinicalTrials.gov |
| NCT06333808 | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With … | Phase3 | HIV-1-infection | Active_Not_Recruiting | 2024-03-25 | 2029-12-01 | ClinicalTrials.gov |
| NCT06349902 | Re-link HCV in Substance-Use Telemedicine Program | — | Hepatitis C | Unknown | 2024-03-12 | 2024-12-31 | ClinicalTrials.gov |
| NCT06019988 | Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Scr… | Na | Breast Cancer | Active_Not_Recruiting | 2024-03-11 | 2026-09-30 | ClinicalTrials.gov |
| NCT06248580 | Find HDV and Determine Its Status in Turkey | — | Chronic Hepatitis D Infection | Recruiting | 2024-03-11 | 2025-03-01 | ClinicalTrials.gov |
| NCT06165614 | Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya | Phase1 | Cervix Cancer | Completed | 2024-03-04 | 2025-04-10 | ClinicalTrials.gov |
| NCT06167317 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid T… | Phase1 | Advanced Solid Tumors | Recruiting | 2024-01-09 | 2028-09-01 | ClinicalTrials.gov |
| NCT06028932 | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cance… | Phase2 | Ovarian Carcinoma | Active_Not_Recruiting | 2024-01-08 | 2027-11-01 | ClinicalTrials.gov |
| NCT05996744 | Study of Obeldesivir in Children and Adolescents With COVID-19 | Phase2 | COVID-19 | Terminated | 2023-12-26 | 2024-02-23 | ClinicalTrials.gov |
| NCT06101342 | Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) fo… | Phase2 | Pre-Exposure Prophylaxis of HIV Infection | Active_Not_Recruiting | 2023-12-13 | 2028-01-01 | ClinicalTrials.gov |
| NCT06104306 | Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 … | Phase4 | HIV-1-infection | Completed | 2023-12-13 | 2025-04-23 | ClinicalTrials.gov |
| NCT06029972 | Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Ac… | Phase2 | Ulcerative Colitis | Recruiting | 2023-12-05 | 2028-02-01 | ClinicalTrials.gov |
| NCT06046482 | Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for … | Phase2 | Head Neck | Terminated | 2023-11-28 | 2024-08-26 | ClinicalTrials.gov |
| NCT06100874 | A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ … | Phase2 | Her 2 Positive Breast Cancer | Active_Not_Recruiting | 2023-11-20 | 2027-11-30 | ClinicalTrials.gov |
| NCT06101329 | Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in… | Phase2 | Pre-Exposure Prophylaxis of HIV Infection | Active_Not_Recruiting | 2023-11-17 | 2028-01-01 | ClinicalTrials.gov |
| NCT05866523 | Teamwork Makes the Dream Work | Na | HIV Infections | Recruiting | 2023-10-16 | 2026-12-01 | ClinicalTrials.gov |
| NCT06082960 | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | Phase1 | Solid Tumors | Active_Not_Recruiting | 2023-10-09 | 2026-12-01 | ClinicalTrials.gov |
| NCT05552001 | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for … | Phase3 | Triple Negative Breast Cancer | Active_Not_Recruiting | 2023-10-05 | 2028-05-06 | ClinicalTrials.gov |
| NCT06631365 | PrEPsmart 2-1-1 Pilot | Phase2 | HIV-1-infection | Recruiting | 2023-10-02 | 2025-04-01 | ClinicalTrials.gov |
| NCT06031415 | Study of GS-0272 in Participants With Rheumatoid Arthritis | Phase1 | Rheumatoid Arthritis | Terminated | 2023-09-28 | 2026-05-11 | ClinicalTrials.gov |
| NCT06051617 | Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated C… | Phase3 | Primary Biliary Cholangitis | Recruiting | 2023-09-07 | 2030-08-01 | ClinicalTrials.gov |
| NCT06060665 | Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Ph… | Phase3 | Primary Biliary Cholangitis | Completed | 2023-09-05 | 2026-05-06 | ClinicalTrials.gov |
| NCT04453436 | HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegr… | — | HIV | Active_Not_Recruiting | 2023-09-01 | 2026-10-31 | ClinicalTrials.gov |
| NCT05884320 | Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretor… | Phase2 | Gland | Recruiting | 2023-07-27 | 2028-07-31 | ClinicalTrials.gov |
| NCT05978232 | NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer … | Na | Breast Cancer | Completed | 2023-07-01 | 2025-11-03 | ClinicalTrials.gov |
| NCT05581589 | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothe… | Phase2 | Muscle Invasive Bladder Carcinoma | Terminated | 2023-06-15 | 2026-03-06 | ClinicalTrials.gov |
| NCT05838521 | A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persi… | Phase2 | Cervical Cancer | Recruiting | 2023-06-02 | 2028-12-01 | ClinicalTrials.gov |
| NCT05650749 | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retino… | Phase1 | Refractory Neuroblastoma | Recruiting | 2023-05-23 | 2030-01-30 | ClinicalTrials.gov |
| NCT05675579 | A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy… | Phase2 | Breast Cancer | Active_Not_Recruiting | 2023-05-23 | 2026-12-31 | ClinicalTrials.gov |
| NCT05729568 | A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Len… | Phase2 | HIV-1 Infection | Active_Not_Recruiting | 2023-05-15 | 2030-12-01 | ClinicalTrials.gov |
| NCT05840224 | Study of GS-4528 in Adults With Solid Tumors | Phase1 | Solid Tumor | Active_Not_Recruiting | 2023-05-11 | 2026-10-01 | ClinicalTrials.gov |
| NCT05840211 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patien… | Phase3 | Locally Advanced or Unresectable Metastatic Breast Cancer | Active_Not_Recruiting | 2023-05-08 | 2028-04-01 | ClinicalTrials.gov |
| NCT05159531 | Virtual PrEP: Rendering PrEP Delivery More Efficient | Phase4 | HIV Infections | Terminated | 2023-05-01 | 2023-06-08 | ClinicalTrials.gov |
| NCT05688592 | Usefulness of PET-CT for Invasive Fungal Infection | — | Invasive Fungal Infections | Recruiting | 2023-04-27 | 2024-12-01 | ClinicalTrials.gov |
| NCT05520905 | TelePrEP for At-risk Youth in Colorado | Na | Hiv | Recruiting | 2023-04-18 | 2025-04-01 | ClinicalTrials.gov |
| NCT05644834 | Pilot Mobile Medical Unit Study for I'm Fully Empowered4Her | Na | HIV Prevention | Completed | 2023-04-18 | 2023-12-11 | ClinicalTrials.gov |
| NCT05087927 | Study for IFE4PrEP Intervention on PrEP Uptake by Southern African American Wom… | — | HIV Prevention | Completed | 2023-04-18 | 2024-03-10 | ClinicalTrials.gov |
| NCT05629208 | Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | Phase2 | Cutaneous Lupus Erythematosus (CLE) | Terminated | 2023-04-17 | 2026-01-14 | ClinicalTrials.gov |
| NCT05140954 | The Women TAF-FTC Benchmark Study | Phase2 | HIV Infections | Completed | 2023-04-10 | 2023-12-19 | ClinicalTrials.gov |
| NCT05770895 | Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants a… | Phase1 | Chronic Hepatitis B | Completed | 2023-04-03 | 2025-01-15 | ClinicalTrials.gov |
| NCT05633667 | Study of Novel Treatment Combinations in Patients With Lung Cancer | Phase2 | Lung Cancer | Active_Not_Recruiting | 2023-03-16 | 2029-09-01 | ClinicalTrials.gov |
| NCT05760300 | A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired R… | Phase1 | Chronic Hepatitis D Infection | Completed | 2023-03-15 | 2024-07-23 | ClinicalTrials.gov |
| NCT05765344 | Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function | Phase1 | Hepatic Impairment | Completed | 2023-03-15 | 2025-01-13 | ClinicalTrials.gov |
| NCT05676931 | Study With Various Immunotherapy Treatments in Participants With Lung Cancer | Phase2 | Advanced Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2023-02-21 | 2027-12-01 | ClinicalTrials.gov |
| NCT05715528 | Study of Obeldesivir in Nonhospitalized Participants With COVID-19 | Phase3 | COVID-19 | Completed | 2023-02-08 | 2024-01-23 | ClinicalTrials.gov |
| NCT05718700 | Study of Bulevirtide in Participants With Chronic Hepatitis D Infection | — | Chronic Hepatitis D Infection | Active_Not_Recruiting | 2023-02-07 | 2028-07-01 | ClinicalTrials.gov |
| NCT05609968 | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Co… | Phase3 | Carcinoma, Non-Small-Cell Lung | Active_Not_Recruiting | 2023-02-06 | 2028-08-23 | ClinicalTrials.gov |
| NCT05520723 | Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- P… | Phase2 | Triple Negative Breast Cancer | Completed | 2023-02-06 | 2025-11-05 | ClinicalTrials.gov |
| NCT05350865 | Thailand HDV Cohort | — | HDV | Recruiting | 2023-01-30 | 2025-05-01 | ClinicalTrials.gov |
| NCT05690815 | Express Testing and Same-day Initiation of PrEP Study | — | HIV Prevention | Unknown | 2023-01-24 | 2024-11-30 | ClinicalTrials.gov |
| NCT05710120 | Hepatitis C Screening Alerts | — | Hepatitis C | Completed | 2023-01-16 | 2023-10-17 | ClinicalTrials.gov |
| NCT05725109 | Hepatitis C Diagnosis to Treatment Management | — | Hepatitis C | Completed | 2023-01-16 | 2023-10-17 | ClinicalTrials.gov |
| NCT04944654 | Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH | Phase4 | Human Immunodeficiency Virus | Terminated | 2023-01-07 | 2023-05-11 | ClinicalTrials.gov |
| NCT05378399 | SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With S… | Phase3 | HIV Infections | Completed | 2022-12-20 | 2026-03-31 | ClinicalTrials.gov |
| NCT06897059 | Effectiveness of Smartphone Application for Adherence Support (Vuka+) | Na | Adherence, Medication | Completed | 2022-12-15 | 2024-11-08 | ClinicalTrials.gov |
| NCT05633654 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physi… | Phase3 | Triple Negative Breast Cancer | Recruiting | 2022-12-12 | 2031-08-01 | ClinicalTrials.gov |
| NCT05503979 | Elimination of Hepatitis C Virus Among Users of Substances | — | Hepatitis C in Substance Users | Unknown | 2022-11-15 | 2024-05-15 | ClinicalTrials.gov |
| NCT05603143 | Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Deve… | Phase3 | COVID-19 | Terminated | 2022-11-05 | 2023-11-07 | ClinicalTrials.gov |
| NCT05394623 | Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperat… | — | Hepatitis D | Unknown | 2022-11-01 | 2023-07-01 | ClinicalTrials.gov |
| NCT05585307 | Study of Novel Antiretrovirals in Participants With HIV-1 | Phase1 | HIV-1-infection | Completed | 2022-10-26 | 2024-03-18 | ClinicalTrials.gov |
| NCT05502237 | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembroliz… | Phase3 | Non-small Cell Lung Cancer | Active_Not_Recruiting | 2022-10-12 | 2029-01-01 | ClinicalTrials.gov |
| NCT05489406 | Relative Bioavailability Study to Investigate a Potential Interaction Between D… | Phase1 | Hiv | Completed | 2022-10-06 | 2023-11-30 | ClinicalTrials.gov |
| NCT06148610 | Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients'… | — | Hematologic Diseases | Unknown | 2022-09-27 | 2024-12-31 | ClinicalTrials.gov |
| NCT04880577 | Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsin… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Withdrawn | 2022-09-15 | 2025-02-14 | ClinicalTrials.gov |
| NCT05526118 | Advanced HIV: Outcomes for Rapid ART | — | HIV-1-infection | Unknown | 2022-08-30 | 2025-01-15 | ClinicalTrials.gov |
| NCT05723068 | Burden of Hepatitis D Virus (HDV) Infection in Italy | — | Chronic Hepatitis D | Completed | 2022-08-24 | 2024-12-31 | ClinicalTrials.gov |
| NCT05458102 | Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very L… | Phase1 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Terminated | 2022-08-19 | 2023-05-01 | ClinicalTrials.gov |
| NCT05502341 | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With … | Phase2 | HIV-1-infection | Active_Not_Recruiting | 2022-08-16 | 2028-07-01 | ClinicalTrials.gov |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physi… | Phase3 | Triple Negative Breast Cancer | Active_Not_Recruiting | 2022-07-25 | 2027-02-01 | ClinicalTrials.gov |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in P… | Phase3 | Triple Negative Breast Cancer | Active_Not_Recruiting | 2022-07-20 | 2028-07-01 | ClinicalTrials.gov |
| NCT05528653 | Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and L… | Phase4 | HIV Prevention | Completed | 2022-07-19 | 2025-03-21 | ClinicalTrials.gov |
| NCT05330429 | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participan… | Phase2 | Metastatic Colorectal Cancer | Terminated | 2022-07-08 | 2024-06-26 | ClinicalTrials.gov |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidi… | Phase3 | Acute Myeloid Leukemia | Terminated | 2022-07-07 | 2024-04-11 | ClinicalTrials.gov |
| NCT05165771 | Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants… | Phase2 | Rheumatoid Arthritis | Withdrawn | 2022-07-01 | 2023-03-01 | ClinicalTrials.gov |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health | Na | Ovarian Cancer | Recruiting | 2022-06-23 | 2027-05-01 | ClinicalTrials.gov |
| NCT05458765 | Project Engage: Oral PrEP Acceptability | Phase2 | Acceptability of Health Care | Completed | 2022-06-21 | 2024-07-25 | ClinicalTrials.gov |
| NCT04937881 | PK of TAF and TDF for PrEP in Pregnant and Postpartum Women | Phase3 | Hiv | Completed | 2022-06-13 | 2023-09-01 | ClinicalTrials.gov |
| NCT05281510 | Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-trea… | Phase2 | HIV-1-infection | Completed | 2022-06-09 | 2025-01-16 | ClinicalTrials.gov |
| NCT05186974 | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Particip… | Phase2 | Non-small Cell Lung Cancer | Active_Not_Recruiting | 2022-05-30 | 2026-09-01 | ClinicalTrials.gov |
| NCT05411146 | A Study Investigating the Safety, Absorption, and Elimination of Radioactively … | Phase1 | Healthy Participants | Completed | 2022-05-25 | 2022-07-07 | ClinicalTrials.gov |
| NCT05097599 | StrataPATH™ (Precision Indications for Approved Therapies) | Phase2 | Cancer | Terminated | 2022-04-29 | 2024-06-12 | ClinicalTrials.gov |
| NCT05169944 | Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain… | Phase1 | Brain Cancer | Completed | 2022-04-22 | 2024-09-30 | ClinicalTrials.gov |
| NCT07618507 | Resistance Profile to Antiretroviral Medications in Individuals Living With HIV… | Na | HIV | Completed | 2022-04-13 | 2024-03-08 | ClinicalTrials.gov |
| NCT05140941 | Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy | Phase4 | Hepatitis C, Chronic | Active_Not_Recruiting | 2022-04-04 | 2027-06-01 | ClinicalTrials.gov |
| NCT05481216 | HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19… | — | HIV-1-infection | Completed | 2022-03-29 | 2023-08-31 | ClinicalTrials.gov |
| NCT05143229 | Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer | Phase1 | Breast Cancer | Active_Not_Recruiting | 2022-03-28 | 2026-12-01 | ClinicalTrials.gov |
| NCT05067374 | Hepatitis C Screening Paired With Mammography | — | Hepatitis C | Completed | 2022-03-23 | 2023-02-14 | ClinicalTrials.gov |
| NCT05319613 | Reducing Disparities in Rural HIV Prevention | Na | HIV Infections | Completed | 2022-03-09 | 2023-07-18 | ClinicalTrials.gov |
| NCT05277012 | A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Fo… | Phase1 | Healthy Participants | Completed | 2022-02-10 | 2022-03-31 | ClinicalTrials.gov |
| NCT05111119 | Making PrEP Smart: An HIV Testing and PrEP Electronic Support Tool ("SmartPrEP"… | Na | HIV/AIDS | Completed | 2022-02-03 | 2024-08-22 | ClinicalTrials.gov |
| NCT04782180 | PrEP at a Syringe Services Program | Phase4 | Hiv | Completed | 2022-02-01 | 2024-11-11 | ClinicalTrials.gov |
| NCT05243602 | BFTAF Elderly Switch Study | Phase4 | HIV-1-infection | Completed | 2022-02-01 | 2024-03-18 | ClinicalTrials.gov |
| NCT05181956 | Testing and Epidemiology of Delta Hepatitis | — | Chronic Hepatitis D Infection With Hepatitis B | Unknown | 2022-01-03 | 2023-03-31 | ClinicalTrials.gov |
| NCT07004933 | Rapid Antiretroviral Treatment Initiation With BIC/FTC/TAF in HIV-infected Peop… | — | HIV Positive People Who Inject Drugs | Completed | 2021-12-22 | 2024-12-09 | ClinicalTrials.gov |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removab… | Phase2 | Triple-Negative Breast Cancer | Terminated | 2021-12-14 | 2024-10-08 | ClinicalTrials.gov |
| NCT04930614 | Prevalence and Risk Factors of HIV Infections in Transgender and Non-binary Peo… | — | HIV Infections | Completed | 2021-12-01 | 2023-07-11 | ClinicalTrials.gov |
| NCT05089734 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advan… | Phase3 | Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2021-11-17 | 2026-01-01 | ClinicalTrials.gov |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple … | Phase2 | Multiple Myeloma | Terminated | 2021-11-09 | 2024-04-25 | ClinicalTrials.gov |
| NCT05101096 | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Soli… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2021-10-20 | 2027-05-01 | ClinicalTrials.gov |
| NCT04962347 | Real World Study of COVID-19 in a Flyover Region | — | Covid19 | Completed | 2021-10-14 | 2022-10-18 | ClinicalTrials.gov |
| NCT05119907 | Study of Sacituzumab Govitecan in Patients With Solid Tumor | Phase2 | Solid Tumor | Active_Not_Recruiting | 2021-10-12 | 2026-10-01 | ClinicalTrials.gov |
| NCT05052996 | Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lena… | Phase2 | HIV-1 Infection | Active_Not_Recruiting | 2021-10-05 | 2028-03-01 | ClinicalTrials.gov |
| NCT04959643 | Systematic Screening for Viral Hepatitis B and C at the PASS Consultation of th… | — | Hepatitis C | Unknown | 2021-10-05 | 2023-10-01 | ClinicalTrials.gov |
| NCT04827576 | Study of Magrolimab in Patients With Solid Tumors | Phase2 | Solid Tumor | Terminated | 2021-10-01 | 2024-10-01 | ClinicalTrials.gov |
| NCT05175339 | Long-term Impact in Intensive Care Survivors of Coronavirus Disease (COVID-19) | — | COVID-19 | Completed | 2021-09-29 | 2023-11-13 | ClinicalTrials.gov |
| NCT04754139 | A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among Hi… | Na | HIV Preexposure Prophylaxis | Completed | 2021-09-24 | 2024-09-30 | ClinicalTrials.gov |
| NCT04950764 | An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primar… | Phase1 | Primary Biliary Cholangitis | Completed | 2021-09-17 | 2025-02-27 | ClinicalTrials.gov |
| NCT05006794 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as … | Phase1 | Solid Malignancies | Terminated | 2021-09-15 | 2025-06-16 | ClinicalTrials.gov |
| NCT04854499 | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous… | Phase2 | Head and Neck Squamous Cell Carcinoma | Terminated | 2021-09-07 | 2024-10-02 | ClinicalTrials.gov |
| NCT04518228 | Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During… | — | HIV Infections | Completed | 2021-09-01 | 2025-07-10 | ClinicalTrials.gov |
| NCT04809623 | Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | Phase1 | Cutaneous Lupus Erythematosus | Terminated | 2021-09-01 | 2022-10-18 | ClinicalTrials.gov |
| NCT05369507 | Eliminating HCV in Rural South Carolina Utilizing NP Led Mobile Clinics and Vir… | Na | Hepatitis C | Completed | 2021-09-01 | 2023-09-16 | ClinicalTrials.gov |
| NCT04994509 | Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafe… | Phase3 | Pre-Exposure Prophylaxis of HIV Infection | Active_Not_Recruiting | 2021-08-30 | 2028-01-01 | ClinicalTrials.gov |
| NCT05007782 | Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Ad… | Phase1 | Advanced Solid Tumor | Recruiting | 2021-08-18 | 2028-12-01 | ClinicalTrials.gov |
| NCT04891770 | Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Co… | Phase2 | Chronic Hepatitis B | Completed | 2021-08-14 | 2024-07-19 | ClinicalTrials.gov |
| NCT04971785 | Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in A… | Phase2 | Nonalcoholic Steatohepatitis | Completed | 2021-08-09 | 2024-12-09 | ClinicalTrials.gov |
| NCT04286347 | HCV, HBV, HIV Testing During Consultation With Anesthesiologist | Na | HCV | Terminated | 2021-08-05 | 2021-10-27 | ClinicalTrials.gov |
| NCT04296695 | Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection | Phase4 | HIV-1-infection | Completed | 2021-07-14 | 2025-06-06 | ClinicalTrials.gov |
| NCT04778397 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice o… | Phase3 | Acute Myeloid Leukemia | Terminated | 2021-07-01 | 2024-03-25 | ClinicalTrials.gov |
| NCT04980664 | Effort to Narrow the Gap Between in Accordance With Guidelines and Consent to T… | Na | Chronic Hepatitis b | Unknown | 2021-07-01 | 2023-07-31 | ClinicalTrials.gov |
| NCT05467930 | CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clini… | — | COVID-19 | Active_Not_Recruiting | 2021-07-01 | 2027-05-01 | ClinicalTrials.gov |
| NCT05147740 | Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV W… | Phase4 | HIV-1-infection | Unknown | 2021-07-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT04827589 | Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Par… | Phase2 | Chronic Spontaneous Urticaria | Withdrawn | 2021-07-01 | 2022-09-01 | ClinicalTrials.gov |
| NCT04778410 | Study of Magrolimab Combinations in Participants With Myeloid Malignancies | Phase2 | Myeloid Malignancies | Terminated | 2021-06-28 | 2024-03-04 | ClinicalTrials.gov |
| NCT04925752 | Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk… | Phase3 | Pre-Exposure Prophylaxis of HIV Infection | Active_Not_Recruiting | 2021-06-28 | 2028-08-01 | ClinicalTrials.gov |
| NCT04075916 | A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney R… | Phase2 | End Stage Renal Disease | Completed | 2021-06-22 | 2026-02-25 | ClinicalTrials.gov |
| NCT04647916 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Can… | Phase2 | Anatomic Stage IV Breast Cancer AJCC v8 | Active_Not_Recruiting | 2021-06-08 | 2028-12-01 | ClinicalTrials.gov |
| NCT04891445 | Hepatitis C in Severe Mental Disorders: Nursing Programme | Na | Hepatitis C | Completed | 2021-06-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | Phase1 | Urothelial Cancer | Recruiting | 2021-05-20 | 2028-05-01 | ClinicalTrials.gov |
| NCT04868864 | The Ontario Multi-Regional Hospital COVID-19 Registry (COREG)- Recovery Traject… | — | COVID-19 Pneumonia | Unknown | 2021-05-15 | 2022-12-31 | ClinicalTrials.gov |
| NCT04660812 | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) … | Phase1 | Metastatic Colorectal Cancer | Completed | 2021-05-10 | 2025-09-05 | ClinicalTrials.gov |
| NCT04551573 | A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegr… | Phase4 | Tuberculosis | Withdrawn | 2021-05-01 | 2021-11-01 | ClinicalTrials.gov |
| NCT04863885 | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Inel… | Phase1 | Metastatic Urothelial Carcinoma | Active_Not_Recruiting | 2021-04-30 | 2027-10-01 | ClinicalTrials.gov |
| NCT04620733 | RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (… | Phase3 | Primary Biliary Cholangitis | Completed | 2021-04-21 | 2023-08-11 | ClinicalTrials.gov |
| NCT06729593 | Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatm… | Phase3 | Covid19 | Completed | 2021-04-20 | 2022-11-20 | ClinicalTrials.gov |
| NCT04843761 | ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 | Phase3 | Covid19 | Completed | 2021-04-20 | 2022-11-20 | ClinicalTrials.gov |
| NCT04756193 | Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 Wi… | — | Covid19 | Completed | 2021-04-15 | 2024-09-24 | ClinicalTrials.gov |
| NCT04811040 | Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Com… | Phase1 | HIV-1 Infection | Completed | 2021-04-08 | 2023-10-26 | ClinicalTrials.gov |
| NCT04617522 | Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Soli… | Phase1 | Advanced or Metastatic Solid Tumor | Recruiting | 2021-04-06 | 2026-12-01 | ClinicalTrials.gov |
| NCT05177926 | Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Ala… | Phase4 | Hepatitis B, Chronic | Unknown | 2021-04-04 | 2023-12-31 | ClinicalTrials.gov |
| NCT05095818 | Impact of Nursing Involvement on Implementation of HIV Prevention Services | Na | Pre-Exposure Prophylaxis (PrEP) | Completed | 2021-04-01 | 2022-03-17 | ClinicalTrials.gov |
| NCT04745351 | Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Se… | Phase3 | COVID-19 | Terminated | 2021-03-31 | 2022-05-24 | ClinicalTrials.gov |
| NCT04582266 | PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregn… | — | COVID-19 | Completed | 2021-03-31 | 2022-04-13 | ClinicalTrials.gov |
| NCT04742491 | Pre-Exposure Prophylaxis for Transgender Women in the US and South America | Phase2 | HIV Prevention | Completed | 2021-03-26 | 2024-08-16 | ClinicalTrials.gov |
| NCT04747470 | Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumo… | Phase1 | Advanced Solid Tumors | Terminated | 2021-03-25 | 2022-11-07 | ClinicalTrials.gov |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanc… | Phase1 | Advanced Solid Tumor | Completed | 2021-03-19 | 2025-08-25 | ClinicalTrials.gov |
| NCT04650269 | Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Li… | Phase4 | Harm Reduction | Completed | 2021-03-04 | 2023-12-31 | ClinicalTrials.gov |
| NCT05090410 | Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoi… | Phase3 | Rheumatoid Arthritis | Unknown | 2021-03-03 | 2023-12-31 | ClinicalTrials.gov |
| NCT04847622 | Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been T… | — | Covid19 | Completed | 2021-02-12 | 2021-04-30 | ClinicalTrials.gov |
| NCT06688149 | NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and… | Na | Non-alcoholic Fatty Liver Disease (NAFLD) | Completed | 2021-01-31 | 2024-01-08 | ClinicalTrials.gov |
| NCT04527991 | Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Partic… | Phase3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | Completed | 2021-01-13 | 2025-07-04 | ClinicalTrials.gov |
| NCT04249037 | Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV | Phase4 | HIV/AIDS | Terminated | 2020-12-15 | 2023-07-01 | ClinicalTrials.gov |
| NCT04066881 | A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Pr… | Phase2 | HIV Infections | Completed | 2020-12-15 | 2024-12-31 | ClinicalTrials.gov |
| NCT04483700 | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Ac… | Phase3 | Ankylosing Spondylitis | Withdrawn | 2020-12-01 | 2024-06-01 | ClinicalTrials.gov |
| NCT04483687 | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Ac… | Phase3 | Ankylosing Spondylitis | Withdrawn | 2020-12-01 | 2024-09-01 | ClinicalTrials.gov |
| NCT03897725 | Evaluating The Acceptability and Uptake of Pre-Exposure Prophylaxis (PrEP) for … | Na | Adolescent Behavior | Withdrawn | 2020-12-01 | 2022-09-30 | ClinicalTrials.gov |
| NCT04639986 | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast … | Phase3 | Metastatic Breast Cancer | Active_Not_Recruiting | 2020-11-23 | 2026-12-01 | ClinicalTrials.gov |
| NCT04610762 | HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug U… | — | Hepatitis C, Chronic | Completed | 2020-11-17 | 2022-11-17 | ClinicalTrials.gov |
| NCT04502706 | Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Ritu… | Phase1 | Non-hodgkin Lymphoma | Terminated | 2020-11-17 | 2022-03-31 | ClinicalTrials.gov |
| NCT04560556 | Linking Persons With HIV, Discharged From Jail, With Community Care | — | Human Immunodeficiency Virus | Completed | 2020-11-10 | 2021-11-24 | ClinicalTrials.gov |
| NCT04530630 | Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Ren… | Phase4 | HIV Infections | Completed | 2020-11-09 | 2024-08-28 | ClinicalTrials.gov |
| NCT04608344 | Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Med… | Phase1 | Rheumatoid Arthritis | Completed | 2020-11-04 | 2021-01-13 | ClinicalTrials.gov |
| NCT04595565 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | Phase3 | HER2-negative Breast Cancer | Active_Not_Recruiting | 2020-10-28 | 2029-03-30 | ClinicalTrials.gov |
| NCT06177574 | Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïv… | Phase4 | HIV Infections | Completed | 2020-10-27 | 2023-10-30 | ClinicalTrials.gov |
| NCT04454437 | Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negat… | Phase2 | Metastatic Triple-negative Breast Cancer | Active_Not_Recruiting | 2020-10-23 | 2027-12-01 | ClinicalTrials.gov |
| NCT04495348 | Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on En… | — | HIV-1-infection | Completed | 2020-10-22 | 2023-06-05 | ClinicalTrials.gov |
| NCT04382404 | Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir | Phase1 | Hepatitis C, Chronic | Completed | 2020-10-22 | 2023-10-16 | ClinicalTrials.gov |
| NCT04029454 | Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vacc… | Na | Hepatitis B | Completed | 2020-10-19 | 2023-12-15 | ClinicalTrials.gov |
| NCT04416906 | A Test and Treat Strategy in New HIV Diagnosis. | Phase3 | HIV-1-infection | Completed | 2020-10-05 | 2023-05-11 | ClinicalTrials.gov |
| NCT03639324 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL | Phase1 | Chronic Lymphocytic Leukemia | Withdrawn | 2020-10-02 | 2021-10-18 | ClinicalTrials.gov |
| NCT04653194 | Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infec… | Phase3 | Human Immunodeficiency Virus | Completed | 2020-09-30 | 2023-07-31 | ClinicalTrials.gov |
| NCT04448886 | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | Phase2 | Invasive Breast Cancer | Active_Not_Recruiting | 2020-09-23 | 2027-06-01 | ClinicalTrials.gov |
| NCT04501952 | Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of… | Phase3 | COVID-19 | Terminated | 2020-09-18 | 2021-05-06 | ClinicalTrials.gov |
| NCT04193787 | EPIC-P Intervention | Na | HIV | Completed | 2020-09-15 | 2024-09-01 | ClinicalTrials.gov |
| NCT04539262 | Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to E… | Phase1 | COVID-19 | Completed | 2020-09-14 | 2021-03-22 | ClinicalTrials.gov |
| NCT04313881 | Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants… | Phase3 | Myelodysplastic Syndromes | Terminated | 2020-09-09 | 2023-09-13 | ClinicalTrials.gov |
| NCT04226131 | MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics | Na | Rheumatoid Arthritis | Completed | 2020-09-09 | 2023-07-07 | ClinicalTrials.gov |
| NCT04519970 | Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Conne… | Na | Hiv | Completed | 2020-09-03 | 2024-04-06 | ClinicalTrials.gov |
| NCT05370053 | The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of … | Na | Fatty Liver | Unknown | 2020-09-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT04319198 | Rollover Study in Participants With Metastatic Solid Tumors Benefiting From The… | Phase4 | Metastatic Solid Tumors | Completed | 2020-08-04 | 2024-10-18 | ClinicalTrials.gov |
| NCT05064020 | Bictegravir in the Elderly Living With HIV (BICEP) | — | HIV-1-infection | Active_Not_Recruiting | 2020-08-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT04431453 | Study of Remdesivir in Participants Below 18 Years Old With COVID-19 | Phase2 | COVID-19 | Completed | 2020-07-21 | 2023-02-10 | ClinicalTrials.gov |
| NCT04468061 | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Phase2 | Breast Cancer | Recruiting | 2020-07-20 | 2029-04-01 | ClinicalTrials.gov |
| NCT07580482 | The Referral to Hepatology Can be Improved Through an Electronic Medical Record… | Na | Liver Diseases | Completed | 2020-07-15 | 2022-07-15 | ClinicalTrials.gov |
| NCT04230109 | Sacituzumab Govitecan In TNBC | Phase2 | Invasive Breast Cancer | Recruiting | 2020-07-14 | 2029-10-01 | ClinicalTrials.gov |
| NCT04467684 | Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406 | Phase1 | Healthy Volunteers | Completed | 2020-07-07 | 2021-06-06 | ClinicalTrials.gov |
| NCT04381832 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resis… | Phase1 | Prostatic Neoplasms, Castration-Resistant | Completed | 2020-07-07 | 2024-08-30 | ClinicalTrials.gov |
| NCT03987503 | The No One Waits Study: Acceptability and Feasibility of Community-based Point-… | Phase4 | Hepatitis C, Chronic | Completed | 2020-07-01 | 2022-12-29 | ClinicalTrials.gov |
| NCT04409262 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Comp… | Phase3 | COVID-19 Pneumonia | Completed | 2020-06-16 | 2021-03-08 | ClinicalTrials.gov |
| NCT04240691 | Instacare - Rapid ART Initiation Among Persons With HIV and Out of Care | — | Hiv | Completed | 2020-05-20 | 2024-04-05 | ClinicalTrials.gov |
| NCT04354818 | Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Aus… | — | HIV-1-infection | Unknown | 2020-05-11 | 2022-04-27 | ClinicalTrials.gov |
| NCT04251416 | A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma | Phase2 | Endometrial Carcinoma | Active_Not_Recruiting | 2020-03-17 | 2027-02-01 | ClinicalTrials.gov |
| NCT04956445 | Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasu… | — | Covid19 | Recruiting | 2020-03-17 | 2027-12-01 | ClinicalTrials.gov |
| NCT04292730 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in… | Phase3 | COVID-19 | Completed | 2020-03-15 | 2020-06-26 | ClinicalTrials.gov |
| NCT04292899 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in… | Phase3 | COVID-19 | Completed | 2020-03-06 | 2020-06-30 | ClinicalTrials.gov |
| NCT05401136 | Evaluating the Chain of Addiction Care (CAC) | — | Hepatitis C, Chronic | Unknown | 2020-03-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT04364035 | Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatol… | Phase2 | HIV/AIDS | Completed | 2020-02-20 | 2022-12-16 | ClinicalTrials.gov |
| NCT04211909 | Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL… | Phase3 | Hepatitis C Virus Infection | Completed | 2020-01-03 | 2020-11-12 | ClinicalTrials.gov |
| NCT04130919 | Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderat… | Phase2 | Ulcerative Colitis | Terminated | 2019-12-20 | 2021-12-14 | ClinicalTrials.gov |
| NCT04328298 | French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (D… | — | Hematopathology Eligible or CAR-t Cell Treatment | Recruiting | 2019-12-19 | 2038-12-19 | ClinicalTrials.gov |
| NCT04538040 | Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine | Phase4 | HIV-1-infection | Completed | 2019-12-19 | 2021-11-11 | ClinicalTrials.gov |
| NCT04115748 | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Ac… | Phase3 | Psoriatic Arthritis | Terminated | 2019-12-03 | 2021-05-11 | ClinicalTrials.gov |
| NCT04143594 | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combinati… | Phase2 | HIV-1-infection | Completed | 2019-11-22 | 2023-09-19 | ClinicalTrials.gov |
| NCT04150068 | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combinati… | Phase2 | HIV-1-infection | Active_Not_Recruiting | 2019-11-21 | 2027-01-01 | ClinicalTrials.gov |
| NCT04115839 | Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Ac… | Phase3 | Psoriatic Arthritis | Terminated | 2019-11-13 | 2021-03-18 | ClinicalTrials.gov |
| NCT04024813 | A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in… | Phase2 | Primary Sclerosing Cholangitis | Terminated | 2019-11-12 | 2020-01-09 | ClinicalTrials.gov |
| NCT03696290 | Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis | Phase4 | Bronchiectasis Adult | Terminated | 2019-10-19 | 2025-03-04 | ClinicalTrials.gov |
| NCT04060147 | Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Ch… | Phase1 | Primary Sclerosing Cholangitis | Terminated | 2019-10-17 | 2021-09-02 | ClinicalTrials.gov |
| NCT04112303 | Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Do… | Phase3 | Hepatitis C Virus Infection | Completed | 2019-10-16 | 2021-06-25 | ClinicalTrials.gov |
| NCT03964727 | Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors | Phase2 | Metastatic Solid Tumor | Active_Not_Recruiting | 2019-10-15 | 2026-12-01 | ClinicalTrials.gov |
| NCT03998176 | Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Pat… | Phase4 | HIV-1-infection | Completed | 2019-10-09 | 2022-04-01 | ClinicalTrials.gov |
| NCT04087018 | Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected P… | Phase1 | Advanced Solid Tumors | Completed | 2019-09-24 | 2024-06-17 | ClinicalTrials.gov |
| NCT03949764 | The Kentucky Viral Hepatitis Treatment Study | Phase4 | Hepatitis C | Completed | 2019-09-23 | 2025-06-30 | ClinicalTrials.gov |
| NCT04049617 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixa… | Phase1 | Advanced Solid Tumors | Terminated | 2019-08-26 | 2021-03-30 | ClinicalTrials.gov |
| NCT03313414 | HCV Post-Exposure Prophylaxis for Health Care Workers | Phase4 | Hepatitis C | Withdrawn | 2019-08-13 | 2020-01-16 | ClinicalTrials.gov |
| NCT03987074 | Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in P… | Phase2 | Nonalcoholic Steatohepatitis | Completed | 2019-07-29 | 2020-07-13 | ClinicalTrials.gov |
| NCT04026165 | Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With M… | Phase2 | Diabetic Kidney Disease | Completed | 2019-07-24 | 2021-09-03 | ClinicalTrials.gov |
| NCT03995706 | Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | Early_Phase1 | Glioblastoma | Completed | 2019-07-17 | 2024-03-20 | ClinicalTrials.gov |
| NCT04009057 | Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 I… | — | HIV-1-infection | Completed | 2019-07-09 | 2022-03-21 | ClinicalTrials.gov |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in T… | Phase2 | Stage III Breast Cancer | Active_Not_Recruiting | 2019-07-08 | 2027-01-31 | ClinicalTrials.gov |
| NCT03960645 | Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in… | Phase1 | HIV-1-infection | Completed | 2019-06-28 | 2022-08-18 | ClinicalTrials.gov |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Pa… | Phase1 | Ovarian Cancer | Terminated | 2019-06-28 | 2022-04-22 | ClinicalTrials.gov |
| NCT03945448 | Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia | Phase2 | Cryptococcal Meningitis | Recruiting | 2019-06-20 | 2027-08-01 | ClinicalTrials.gov |
| NCT03512418 | Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Use… | Phase3 | HIV Infections | Completed | 2019-06-20 | 2024-04-10 | ClinicalTrials.gov |
| NCT03954704 | Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Soli… | Phase1 | Advanced Solid Tumors | Terminated | 2019-06-03 | 2021-04-15 | ClinicalTrials.gov |
| NCT03349346 | Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Childre… | Phase1 | Diffuse Large B-Cell Lymphoma | Withdrawn | 2019-06-01 | 2026-02-01 | ClinicalTrials.gov |
| NCT03852433 | Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylate… | Phase2 | Chronic Hepatitis Delta | Completed | 2019-05-31 | 2022-09-28 | ClinicalTrials.gov |
| NCT03818308 | Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpat… | Phase2 | Hepatitis C | Completed | 2019-05-28 | 2021-06-08 | ClinicalTrials.gov |
| NCT03926195 | Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males W… | Phase2 | Rheumatoid Arthritis | Completed | 2019-05-28 | 2023-05-10 | ClinicalTrials.gov |
| NCT03876470 | Conquering Hepatitis C Via Micro-Elimination in Southwest Virginia | — | Hepatitis C | Unknown | 2019-05-15 | 2020-11-30 | ClinicalTrials.gov |
| NCT04418037 | DHFS for Medication Adherence Support During Hospital Admissions for Person Liv… | Phase4 | HIV/AIDS | Completed | 2019-05-15 | 2021-12-31 | ClinicalTrials.gov |
| NCT03901339 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in P… | Phase3 | Metastatic Breast Cancer | Completed | 2019-05-08 | 2023-10-20 | ClinicalTrials.gov |
| NCT04873609 | Electronic Record Assimilation and Subsequent Eradication of Hepatitis C | Na | Hepatitis C | Completed | 2019-05-01 | 2020-04-30 | ClinicalTrials.gov |
| NCT03912831 | Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults Wi… | Phase1 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | Terminated | 2019-04-30 | 2022-02-18 | ClinicalTrials.gov |
| NCT03797014 | B/F/TAF Switch Study for HIV-HBV Coinfection | Phase4 | HIV-1-infection | Completed | 2019-04-30 | 2023-05-05 | ClinicalTrials.gov |
| NCT03852719 | Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic… | Phase3 | Chronic Hepatitis Delta | Completed | 2019-04-17 | 2024-08-08 | ClinicalTrials.gov |
| NCT03717129 | Analysis of Crushed and Whole Tablet Genvoya | Phase4 | Healthy Volunteers | Completed | 2019-04-15 | 2021-11-01 | ClinicalTrials.gov |
| NCT03251144 | Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Di… | Phase1 | HIV/AIDS | Completed | 2019-04-01 | 2021-07-01 | ClinicalTrials.gov |
| NCT03846310 | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | Phase1 | Non Small Cell Lung Cancer Metastatic | Completed | 2019-04-01 | 2024-11-18 | ClinicalTrials.gov |
| NCT03890120 | Study of Cilofexor in Adults With Primary Sclerosing Cholangitis | Phase3 | Primary Sclerosing Cholangitis | Terminated | 2019-03-27 | 2022-12-23 | ClinicalTrials.gov |
| NCT03877536 | Antiretroviral Therapy for Acute HIV Infection | Na | HIV Infections | Withdrawn | 2019-03-17 | 2025-09-14 | ClinicalTrials.gov |
| NCT04952207 | Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of… | — | Hepatitis C, Chronic | Unknown | 2019-03-06 | 2021-08-31 | ClinicalTrials.gov |
| NCT03696160 | The Late Presenter Treatment Optimisation Study | Phase3 | HIV/AIDS | Completed | 2019-03-05 | 2024-06-17 | ClinicalTrials.gov |
| NCT03794791 | A Comprehensive HBsAg-positive Patients Centered Screening Strategy | — | Hepatitis B and Hepatitis C (Disorder) | Completed | 2019-02-20 | 2020-12-31 | ClinicalTrials.gov |
| NCT03820258 | Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpat… | Phase2 | Hepatitis C Virus Infection | Terminated | 2019-01-28 | 2020-02-19 | ClinicalTrials.gov |
| NCT03752658 | TAF Real World Study for Universal Effectiveness | — | Chronic Hepatitis b | Unknown | 2019-01-25 | 2023-09-01 | ClinicalTrials.gov |
| NCT03772002 | Hepatitis C Surveillance With Linkage to Care of Patients From Non-ID Departmen… | Na | Hepatitis C, Chronic | Unknown | 2019-01-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT03278990 | Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future… | Na | HIV Prevention | Terminated | 2018-12-19 | 2020-12-16 | ClinicalTrials.gov |
| NCT03739866 | Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapav… | Phase1 | HIV-1 Infection | Completed | 2018-11-26 | 2020-06-15 | ClinicalTrials.gov |
| NCT03580668 | Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 I… | — | HIV-1-infection | Completed | 2018-11-13 | 2024-06-03 | ClinicalTrials.gov |
| NCT03532425 | B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults | Phase4 | HIV-1-infection | Terminated | 2018-10-29 | 2020-09-03 | ClinicalTrials.gov |
| NCT03725761 | Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate… | Phase2 | Prostate Cancer | Active_Not_Recruiting | 2018-10-24 | 2027-09-01 | ClinicalTrials.gov |
| NCT03701438 | Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated… | — | B-cell Malignancies | Terminated | 2018-10-23 | 2019-10-09 | ClinicalTrials.gov |
| NCT03842436 | Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM… | Phase4 | HIV/AIDS | Completed | 2018-10-01 | 2020-04-22 | ClinicalTrials.gov |
| NCT03602560 | ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an I… | Phase3 | Primary Biliary Cholangitis | Completed | 2018-10-01 | 2020-02-16 | ClinicalTrials.gov |
| NCT03627546 | HCV Seek, Test and Rapid Treatment for Young PWID | Na | Hepatitis C | Completed | 2018-09-18 | 2021-06-30 | ClinicalTrials.gov |
| NCT04208035 | Hepatitis C Elimination in the Netherlands | — | Chronic Hepatitis c | Unknown | 2018-09-17 | 2021-01-01 | ClinicalTrials.gov |
| NCT03582098 | Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leu… | — | Chronic Lymphocytic Leukaemia | Completed | 2018-09-12 | 2019-03-26 | ClinicalTrials.gov |
| NCT03628677 | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With A… | Phase1 | Solid Tumor, Unspecified, Adult | Completed | 2018-09-12 | 2025-01-23 | ClinicalTrials.gov |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Phase1 | Multiple Myeloma | Terminated | 2018-09-05 | 2020-10-09 | ClinicalTrials.gov |
| NCT03631732 | Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcr… | Phase3 | HIV-1 Infection | Completed | 2018-08-28 | 2020-08-19 | ClinicalTrials.gov |
| NCT03615066 | Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantol… | Phase2 | Chronic Hepatitis B | Completed | 2018-08-28 | 2021-04-12 | ClinicalTrials.gov |
| NCT03581383 | Community Access, Retention in Care, and Engagement for Hepatitis C Treatment | Na | Hepatitis C | Completed | 2018-08-21 | 2022-12-31 | ClinicalTrials.gov |
| NCT03547973 | Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cann… | Phase2 | Metastatic Urothelial Cancer | Recruiting | 2018-08-13 | 2030-04-01 | ClinicalTrials.gov |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell … | Phase1 | B Cells-Tumors | Terminated | 2018-07-31 | 2022-07-20 | ClinicalTrials.gov |
| NCT03442192 | A Comparative Effectiveness Demonstration Project for Linkage and Retention in … | Na | Adherence, Patient | Terminated | 2018-07-30 | 2021-12-31 | ClinicalTrials.gov |
| NCT03595527 | Universal HIV Screening and Targeted HCV Screening in Emergency Department | Na | Hepatitis C | Completed | 2018-07-10 | 2020-10-10 | ClinicalTrials.gov |
| NCT03386578 | Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral… | Phase2 | HIV Infections | Completed | 2018-07-03 | 2024-02-24 | ClinicalTrials.gov |
| NCT03607396 | Study for Evaluating the Real Use of Inhaled Aztreonam Lysine in Patients With … | — | Cystic Fibrosis | Unknown | 2018-07-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT03472950 | Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Scle… | Phase2 | ALS | Completed | 2018-06-11 | 2022-12-09 | ClinicalTrials.gov |
| NCT03570112 | Transmission of Chronic Hepatitis C in Pregnancy | — | Hepatitis C | Completed | 2018-06-08 | 2023-02-27 | ClinicalTrials.gov |
| NCT03348163 | (mo)BETTA Trial in Transwomen for Optimization of ART | Phase4 | HIV Infections | Terminated | 2018-06-06 | 2020-12-15 | ClinicalTrials.gov |
| NCT03547908 | Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus D… | Phase3 | HIV-1/HBV Co-Infection | Completed | 2018-05-30 | 2024-03-07 | ClinicalTrials.gov |
| NCT03568929 | Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma | — | Follicular Non-Hodgkin's Lymphoma Refractory | Completed | 2018-05-25 | 2021-10-29 | ClinicalTrials.gov |
| NCT03558139 | Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Part… | Phase1 | Ovarian Cancer | Completed | 2018-05-23 | 2020-12-03 | ClinicalTrials.gov |
| NCT05685810 | Genetic Determinants of Kidney Disease in People of African Ancestry With HIV | — | HIV Nephropathy | Active_Not_Recruiting | 2018-05-01 | 2030-01-31 | ClinicalTrials.gov |
| NCT03471624 | Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With T… | Phase4 | Hepatitis B, Chronic | Completed | 2018-05-01 | 2022-04-19 | ClinicalTrials.gov |
| NCT03405194 | Same-Day Treatment With Genvoya vs. EFV/TDF/3TC | Na | HIV/AIDS | Withdrawn | 2018-05-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT03551522 | A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (N… | Phase2 | NASH - Nonalcoholic Steatohepatitis | Terminated | 2018-04-30 | 2020-08-10 | ClinicalTrials.gov |
| NCT03491553 | Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppres… | Phase2 | Chronic Hepatitis B | Completed | 2018-04-06 | 2020-08-10 | ClinicalTrials.gov |
| NCT03417778 | Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impai… | Phase1 | Rheumatoid Arthritis | Completed | 2018-04-03 | 2018-08-09 | ClinicalTrials.gov |
| NCT03472326 | Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immun… | Phase2 | HIV-1-infection | Terminated | 2018-04-03 | 2019-12-09 | ClinicalTrials.gov |
| NCT03424005 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations i… | Phase1 | Metastatic Breast Cancer | Recruiting | 2018-03-30 | 2030-09-30 | ClinicalTrials.gov |
| NCT03449446 | Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexo… | Phase2 | Nonalcoholic Steatohepatitis | Completed | 2018-03-21 | 2019-11-19 | ClinicalTrials.gov |
| NCT03498625 | Crohn's Disease Endoscopic REmission Definition in an Objective Way | Na | CD | Completed | 2018-03-13 | 2021-12-31 | ClinicalTrials.gov |
| NCT03487900 | Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD P… | Na | CD | Unknown | 2018-03-13 | 2023-12-31 | ClinicalTrials.gov |
| NCT03502005 | Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Viro… | Phase4 | Human Immunodeficiency Virus | Completed | 2018-03-01 | 2019-12-30 | ClinicalTrials.gov |
| NCT03405935 | Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regi… | Phase3 | HIV-1 Infection | Completed | 2018-03-01 | 2020-05-29 | ClinicalTrials.gov |
| NCT03434353 | Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (For… | Phase2 | Chronic Hepatitis B | Terminated | 2018-02-28 | 2021-01-26 | ClinicalTrials.gov |
| NCT03343223 | Rural PrEP Delivery | Na | HIV/AIDS | Completed | 2018-02-01 | 2019-02-28 | ClinicalTrials.gov |
| NCT03986099 | Community Based Antiretroviral Therapy (CBART) Among Children on Chronic ART | Na | ART | Completed | 2018-02-01 | 2020-11-15 | ClinicalTrials.gov |
| NCT03549312 | Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplificati… | Phase4 | HIV-1-infection | Unknown | 2018-02-01 | 2021-06-22 | ClinicalTrials.gov |
| NCT03312023 | Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection | Phase2 | Hepatitis B | Completed | 2018-02-01 | 2021-06-30 | ClinicalTrials.gov |
| NCT04965662 | The Role of Home Packs of HIV PEPSE in High Risk Individuals | Phase4 | HIV-1-infection | Completed | 2018-01-01 | 2021-03-16 | ClinicalTrials.gov |
| NCT03387397 | Assessing Differential Adherence to Medications and Quality of Life Among Peopl… | — | HIV Infection Primary | Completed | 2017-12-12 | 2023-09-27 | ClinicalTrials.gov |
| NCT03301506 | Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC) | Phase3 | Primary Biliary Cirrhosis | Active_Not_Recruiting | 2017-12-12 | 2028-11-01 | ClinicalTrials.gov |
| NCT03282474 | HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E … | Phase2 | Hepatitis E | Completed | 2017-12-07 | 2019-02-18 | ClinicalTrials.gov |
| NCT03219164 | Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infe… | Phase3 | Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization | Terminated | 2017-11-28 | 2021-09-23 | ClinicalTrials.gov |
| NCT03369002 | Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar … | Phase1 | Hepatic Impairment | Completed | 2017-11-27 | 2018-05-15 | ClinicalTrials.gov |
| NCT03489239 | Entecavir to TAF Switch | Phase3 | Hepatitis B | Active_Not_Recruiting | 2017-11-16 | 2020-09-16 | ClinicalTrials.gov |
| NCT03350672 | Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Teno… | Phase4 | Hiv | Completed | 2017-11-16 | 2018-05-01 | ClinicalTrials.gov |
| NCT02574455 | Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metasta… | Phase3 | Breast Cancer | Completed | 2017-11-07 | 2020-12-08 | ClinicalTrials.gov |
| NCT03074786 | Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH) | Phase2 | HIV-1-infection | Withdrawn | 2017-11-01 | 2020-12-30 | ClinicalTrials.gov |
| NCT03133221 | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous … | Phase2 | Non Hodgkin Lymphoma | Completed | 2017-10-23 | 2024-09-29 | ClinicalTrials.gov |
| NCT03309592 | Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With P… | Phase4 | Portopulmonary Hypertension | Withdrawn | 2017-10-12 | 2018-11-01 | ClinicalTrials.gov |
| NCT03235154 | A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Cl… | Phase4 | Hepatitis C, Chronic | Completed | 2017-10-11 | 2019-09-26 | ClinicalTrials.gov |
| NCT03285711 | Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adul… | Phase2 | Lupus Membranous Nephropathy | Completed | 2017-10-06 | 2020-02-03 | ClinicalTrials.gov |
| NCT03257722 | Pembrolizumab + Idelalisib for Lung Cancer Study | Phase1 | Non Small Cell Lung Cancer | Terminated | 2017-09-26 | 2021-08-25 | ClinicalTrials.gov |
| NCT03112044 | Lung Transplant HCV, Pilot Study | Early_Phase1 | Lung Transplant Infection | Active_Not_Recruiting | 2017-09-19 | 2026-05-31 | ClinicalTrials.gov |
| NCT02815566 | Bone Health in Aging HIV Infected Women | Phase4 | Osteoporosis | Completed | 2017-09-12 | 2021-02-25 | ClinicalTrials.gov |
| NCT03248479 | Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Partici… | Phase1 | Hematological Malignancies | Terminated | 2017-09-08 | 2023-09-05 | ClinicalTrials.gov |
| NCT03118674 | Harvoni Treatment Porphyria Cutanea Tarda | Phase2 | Porphyria Cutanea Tarda | Completed | 2017-09-06 | 2022-03-04 | ClinicalTrials.gov |
| NCT03134105 | A Wearable EducAtional Intervention to REduce Angina | Na | Angina | Withdrawn | 2017-09-01 | 2018-07-01 | ClinicalTrials.gov |
| NCT03207815 | Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active N… | Phase2 | Noninfectious Uveitis | Terminated | 2017-07-26 | 2021-04-22 | ClinicalTrials.gov |
| NCT03010358 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymph… | Phase1 | Anemia | Completed | 2017-07-17 | 2021-04-29 | ClinicalTrials.gov |
| NCT03201445 | Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moder… | Phase2 | Inflammatory Bowel Disease | Terminated | 2017-07-11 | 2023-10-24 | ClinicalTrials.gov |
| NCT03158116 | The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomon… | Phase4 | Tracheostomy Infection | Terminated | 2017-07-01 | 2020-02-20 | ClinicalTrials.gov |
| NCT03231930 | Rapid Point-of-care Testing for Hepatitis C in Community Clinics (RAPID-EC) Pil… | Na | Hepatitis C | Completed | 2017-06-29 | 2018-05-17 | ClinicalTrials.gov |
| NCT03180619 | Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide… | Phase2 | Chronic Hepatitis B | Completed | 2017-06-29 | 2020-09-04 | ClinicalTrials.gov |
| NCT03036839 | Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection … | Phase2 | Hepatitis C Virus Infection | Completed | 2017-06-27 | 2019-02-14 | ClinicalTrials.gov |
| NCT03110380 | Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Al… | Phase3 | HIV-1-infection | Completed | 2017-06-12 | 2021-02-10 | ClinicalTrials.gov |
| NCT03195205 | Identification to Elimination in HCV-Infected Individuals | Early_Phase1 | Hepatitis C | Completed | 2017-06-01 | 2020-04-20 | ClinicalTrials.gov |
| NCT03134222 | Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females … | Phase2 | Cutaneous Lupus Erythematosus | Completed | 2017-05-24 | 2019-12-18 | ClinicalTrials.gov |
| NCT03135028 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Jap… | Phase1 | Hematologic Malignancy | Terminated | 2017-05-19 | 2019-02-26 | ClinicalTrials.gov |
| NCT03038763 | Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers | — | Hepatitis C | Completed | 2017-05-11 | 2019-06-30 | ClinicalTrials.gov |
| NCT03060447 | Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Trea… | Phase1 | HIV-1 Infection | Completed | 2017-05-09 | 2020-02-13 | ClinicalTrials.gov |
| NCT03100942 | Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib… | Phase2 | Sjogren's Syndrome | Completed | 2017-05-01 | 2019-10-02 | ClinicalTrials.gov |
| NCT03032666 | Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion… | Phase4 | Thalassemia | Completed | 2017-05-01 | 2018-08-06 | ClinicalTrials.gov |
| NCT03118843 | Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combinati… | Phase3 | Hepatitis C Virus Infection | Completed | 2017-04-25 | 2018-03-19 | ClinicalTrials.gov |
| NCT03121235 | PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outc… | — | Aspergillosis, Invasive Pulmonary | Completed | 2017-04-20 | 2022-03-20 | ClinicalTrials.gov |
| NCT03155802 | Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breas… | — | Cardiotoxicity | Unknown | 2017-04-18 | 2020-12-01 | ClinicalTrials.gov |
| NCT03046056 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Sma… | Phase2 | Small Bowel Crohn's Disease | Completed | 2017-04-11 | 2020-07-20 | ClinicalTrials.gov |
| NCT03077412 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Per… | Phase2 | Fistulizing Crohn's Disease | Completed | 2017-04-06 | 2021-02-17 | ClinicalTrials.gov |
| NCT02983617 | Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With a… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2017-04-06 | 2020-10-01 | ClinicalTrials.gov |
| NCT03078153 | Effect of Social Media Support and Financial Incentives on PrEP Adherence | Na | Pre-Exposure Prophylaxis | Completed | 2017-04-01 | 2020-12-15 | ClinicalTrials.gov |
| NCT03074331 | Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chron… | Phase3 | Hepatitis C Virus Infection | Completed | 2017-03-23 | 2018-02-07 | ClinicalTrials.gov |
| NCT03036852 | Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who A… | Phase2 | Chronic Hepatitis C | Completed | 2017-03-22 | 2018-11-07 | ClinicalTrials.gov |
| NCT02914600 | Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease | Phase3 | Crohn's Disease | Terminated | 2017-03-17 | 2023-08-01 | ClinicalTrials.gov |
| NCT03049176 | The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discor… | — | HIV Infections | Completed | 2017-03-13 | 2019-07-31 | ClinicalTrials.gov |
| NCT02998320 | Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophyl… | Phase3 | HIV Risk | Completed | 2017-03-10 | 2018-09-30 | ClinicalTrials.gov |
| NCT03018353 | Curing HCV in Incarcerated Patients | Phase4 | Hepatitis C, Chronic | Unknown | 2017-03-05 | 2018-06-04 | ClinicalTrials.gov |
| NCT03025308 | Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Ad… | Phase3 | Rheumatoid Arthritis | Completed | 2017-02-28 | 2025-05-16 | ClinicalTrials.gov |
| NCT02914535 | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | Phase3 | Ulcerative Colitis | Active_Not_Recruiting | 2017-02-23 | 2026-09-01 | ClinicalTrials.gov |
| NCT03053050 | Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis … | Phase3 | Nonalcoholic Steatohepatitis | Terminated | 2017-02-13 | 2019-06-19 | ClinicalTrials.gov |
| NCT03493568 | Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase In… | Phase3 | HIV-1-infection | Terminated | 2017-02-06 | 2020-07-31 | ClinicalTrials.gov |
| NCT03053063 | Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to … | Phase3 | Nonalcoholic Steatohepatitis | Terminated | 2017-01-30 | 2019-05-06 | ClinicalTrials.gov |
| NCT03022981 | Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adole… | Phase2 | Hepatitis C Virus Infection | Completed | 2017-01-26 | 2020-02-26 | ClinicalTrials.gov |
| NCT03043326 | Demonstration Project on the Feasibility to Implement PrEP in MSM and TG Women | — | HIV Prevention | Unknown | 2017-01-23 | 2022-01-31 | ClinicalTrials.gov |
| NCT02994056 | Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combinati… | Phase2 | Hepatitis C Virus Infection | Completed | 2017-01-23 | 2018-12-12 | ClinicalTrials.gov |
| NCT02983604 | GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Es… | Phase1 | Advanced Estrogen Receptor Positive HER2- Breast Cancer | Terminated | 2017-01-10 | 2018-07-19 | ClinicalTrials.gov |
| NCT03044964 | Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based … | Phase4 | Angina | Unknown | 2017-01-10 | 2017-10-01 | ClinicalTrials.gov |
| NCT02755402 | Accelerated Pre-treatment Evaluation for HCV Infected Persons Who Inject Drugs | Na | Hepatitis C | Completed | 2017-01-01 | 2021-05-01 | ClinicalTrials.gov |
| NCT04090151 | The RESPOND Outcomes Study | — | HIV | Recruiting | 2017-01-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT02979613 | Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults Wi… | Phase3 | Chronic Hepatitis B | Completed | 2016-12-29 | 2020-01-30 | ClinicalTrials.gov |
| NCT02996682 | Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adult… | Phase3 | Hepatitis C Virus Infection | Completed | 2016-12-26 | 2018-05-08 | ClinicalTrials.gov |
| NCT02720094 | Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and … | Phase2 | HIV Infections | Completed | 2016-12-19 | 2025-03-31 | ClinicalTrials.gov |
| NCT02862574 | Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methot… | Phase2 | Rheumatoid Arthritis | Terminated | 2016-12-15 | 2017-08-07 | ClinicalTrials.gov |
| NCT02968563 | Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib an… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2016-12-13 | 2021-01-14 | ClinicalTrials.gov |
| NCT02951364 | Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea | — | Hepatitis C Virus | Completed | 2016-12-05 | 2021-06-11 | ClinicalTrials.gov |
| NCT03693040 | Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used … | Na | HIV Prevention | Unknown | 2016-12-01 | 2022-12-31 | ClinicalTrials.gov |
| NCT02858180 | Hepatitis C Virus(HCV) Heart and Lung Study | Phase4 | Hepatitis C, Chronic | Completed | 2016-12-01 | 2019-07-04 | ClinicalTrials.gov |
| NCT04061551 | Eliminate Hepatitis C/EC Partnership Evaluation Protocol | Na | Hepatitis C | Unknown | 2016-12-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT02986984 | Transformative Research in Diabetic Nephropathy | — | Diabetic Nephropathies | Recruiting | 2016-12-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT02943447 | Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults… | Phase2 | Primary Biliary Cholangitis | Terminated | 2016-12-01 | 2019-09-04 | ClinicalTrials.gov |
| NCT02943460 | Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults… | Phase2 | Primary Sclerosing Cholangitis | Completed | 2016-11-29 | 2020-05-18 | ClinicalTrials.gov |
| NCT02955602 | Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) | Phase2 | Primary Biliary Cirrhosis | Completed | 2016-11-28 | 2019-07-08 | ClinicalTrials.gov |
| NCT02959138 | Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function | Phase1 | Inflammatory Disease | Completed | 2016-11-21 | 2018-10-05 | ClinicalTrials.gov |
| NCT02953509 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Che… | Phase1 | Non Hodgkin Lymphoma | Terminated | 2016-11-21 | 2024-03-25 | ClinicalTrials.gov |
| NCT02914522 | Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Ma… | Phase3 | Ulcerative Colitis | Completed | 2016-11-14 | 2020-03-31 | ClinicalTrials.gov |
| NCT02759562 | Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis | Phase2 | Cystic Fibrosis | Terminated | 2016-11-04 | 2017-07-21 | ClinicalTrials.gov |
| NCT02953782 | Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants Wi… | Phase1 | Solid Tumor | Completed | 2016-11-02 | 2020-02-10 | ClinicalTrials.gov |
| NCT02932150 | Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chr… | Phase2 | Chronic Hepatitis B | Active_Not_Recruiting | 2016-11-01 | 2029-10-01 | ClinicalTrials.gov |
| NCT03116932 | Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in … | — | HIV/AIDS | Unknown | 2016-11-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT03120494 | Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in … | Phase4 | HIV/AIDS | Unknown | 2016-11-01 | 2019-11-01 | ClinicalTrials.gov |
| NCT02914561 | Filgotinib in the Induction and Maintenance of Remission in Adults With Moderat… | Phase3 | Crohn's Disease | Completed | 2016-10-31 | 2022-11-11 | ClinicalTrials.gov |
| NCT02783976 | Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Inf… | — | HCV Infection | Completed | 2016-10-28 | 2018-06-20 | ClinicalTrials.gov |
| NCT02854605 | Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants Wi… | Phase2 | Nonalcoholic Steatohepatitis (NASH) | Completed | 2016-10-26 | 2018-01-09 | ClinicalTrials.gov |
| NCT02732730 | Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Yo… | Phase4 | HIV | Completed | 2016-10-12 | 2018-10-25 | ClinicalTrials.gov |
| NCT02957864 | Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenami… | Phase4 | Renal Insufficiency,Chronic | Unknown | 2016-10-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT03000023 | Anticipated and Perceived Benefits Following Hepatitis C Treatment | — | Hepatitis C | Completed | 2016-10-01 | 2018-07-01 | ClinicalTrials.gov |
| NCT02891408 | Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults … | Phase1 | Nonalcoholic Steatohepatitis (NASH) | Completed | 2016-09-23 | 2019-05-13 | ClinicalTrials.gov |
| NCT02885181 | Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheum… | Phase2 | Rheumatoid Arthritis | Completed | 2016-09-21 | 2017-09-20 | ClinicalTrials.gov |
| NCT02881320 | Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination… | Phase2 | HIV-1 Infection | Active_Not_Recruiting | 2016-09-21 | 2026-11-01 | ClinicalTrials.gov |
| NCT02862535 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy a… | Phase1 | Gastric Adenocarcinoma | Terminated | 2016-09-20 | 2019-10-25 | ClinicalTrials.gov |
| NCT02862548 | Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil … | Phase2 | Chronic Hepatitis B | Completed | 2016-09-16 | 2021-05-05 | ClinicalTrials.gov |
| NCT02907996 | Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic H… | — | Hepatitis C Virus | Completed | 2016-09-09 | 2021-12-09 | ClinicalTrials.gov |
| NCT02842086 | Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafen… | Phase3 | Pre-Exposure Prophylaxis of HIV-1 Infection | Active_Not_Recruiting | 2016-09-02 | 2027-09-01 | ClinicalTrials.gov |
| NCT02854631 | Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Parti… | Phase2 | Alcoholic Hepatitis (AH) | Completed | 2016-09-01 | 2018-05-31 | ClinicalTrials.gov |
| NCT02683005 | Study of Hepatitis C Treatment During Pregnancy | Phase1 | Hepatitis C | Completed | 2016-09-01 | 2020-02-03 | ClinicalTrials.gov |
| NCT02864381 | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolu… | Phase2 | Gastric Adenocarcinoma | Completed | 2016-09-01 | 2019-08-23 | ClinicalTrials.gov |
| NCT02889796 | Filgotinib in Combination With Methotrexate in Adults With Moderately to Severe… | Phase3 | Rheumatoid Arthritis | Completed | 2016-08-30 | 2019-06-20 | ClinicalTrials.gov |
| NCT02868242 | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Trea… | Phase2 | Hepatitis C Virus Infection | Completed | 2016-08-28 | 2019-02-03 | ClinicalTrials.gov |
| NCT02856555 | Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With … | Phase2 | Nonalcoholic Steatohepatitis (NASH) | Completed | 2016-08-08 | 2017-07-18 | ClinicalTrials.gov |
| NCT02886728 | Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Mode… | Phase3 | Rheumatoid Arthritis | Completed | 2016-08-08 | 2019-05-08 | ClinicalTrials.gov |
| NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients… | Phase2 | Triple-negative Breast Cancer | Withdrawn | 2016-08-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02781558 | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and … | Phase2 | Hepatitis C Virus Infection | Completed | 2016-07-29 | 2017-10-27 | ClinicalTrials.gov |
| NCT02781571 | Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepa… | Phase2 | Hepatitis C Virus Infection | Completed | 2016-07-27 | 2017-07-28 | ClinicalTrials.gov |
| NCT02873936 | Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who H… | Phase3 | Rheumatoid Arthritis | Completed | 2016-07-27 | 2018-06-26 | ClinicalTrials.gov |
| NCT02822794 | Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks … | Phase3 | Hepatitis C Virus Infection | Completed | 2016-07-25 | 2017-08-25 | ClinicalTrials.gov |
| NCT02808312 | Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Im… | Phase1 | Nonalcoholic Steatohepatitis (NASH) | Completed | 2016-07-13 | 2018-10-16 | ClinicalTrials.gov |
| NCT02818582 | GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus,… | Phase2 | Ebola | Completed | 2016-07-01 | 2020-08-31 | ClinicalTrials.gov |
| NCT02829034 | Targeting Right Ventricle in Pulmonary Hypertension Gilead | Phase4 | Pulmonary Hypertension | Completed | 2016-07-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT02781584 | Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor i… | Phase2 | Nonalcoholic Steatohepatitis (NASH) | Completed | 2016-06-13 | 2020-12-17 | ClinicalTrials.gov |
| NCT02728206 | Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Un… | Phase2 | Hepatitis C Virus Infection | Completed | 2016-06-12 | 2018-01-16 | ClinicalTrials.gov |
| NCT02800655 | Digital Health Feedback System for Longitudinal Measurement of Medication Adher… | Phase4 | HIV | Unknown | 2016-06-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT02701634 | Efficacy and Tolerability of Entospletinib in Combination With Systemic Cortico… | Phase2 | Chronic Graft Versus Host Disease | Terminated | 2016-05-27 | 2018-03-06 | ClinicalTrials.gov |
| NCT02739360 | Roll Over Study to Provide Idelalisib to Participants Previously Treated With t… | Phase4 | Lymphoid Malignancies | Terminated | 2016-05-04 | 2017-12-28 | ClinicalTrials.gov |
| NCT02852226 | CRUSH-PrEP for Women Project | Na | Sexually Transmitted Diseases | Completed | 2016-05-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02619604 | A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia | Na | Chronic Lymphocytic Leukemia | Completed | 2016-05-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02745535 | Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir … | Phase2 | Chronic Hepatitis C | Completed | 2016-05-01 | 2018-10-24 | ClinicalTrials.gov |
| NCT02671500 | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Wee… | Phase3 | Hepatitis C Virus Infection | Completed | 2016-04-19 | 2018-03-27 | ClinicalTrials.gov |
| NCT02738333 | Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With … | Phase3 | Hepatitis C Virus Infection | Completed | 2016-04-12 | 2017-05-11 | ClinicalTrials.gov |
| NCT02722837 | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Partici… | Phase3 | Hepatitis C Virus Infection | Completed | 2016-04-04 | 2017-09-13 | ClinicalTrials.gov |
| NCT02707601 | Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment… | Phase3 | HIV-1 Infection | Completed | 2016-04-01 | 2017-09-29 | ClinicalTrials.gov |
| NCT02660905 | HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection | Phase3 | Human Immunodeficiency Virus | Completed | 2016-04-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT02652624 | Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF,… | Phase3 | HIV-1 Infection | Completed | 2016-02-19 | 2018-11-26 | ClinicalTrials.gov |
| NCT02568683 | Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine… | Phase1 | Non-Hodgkin Lymphoma | Terminated | 2016-02-11 | 2017-06-22 | ClinicalTrials.gov |
| NCT02689141 | Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutini… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2016-02-04 | 2020-02-06 | ClinicalTrials.gov |
| NCT02691728 | Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dos… | Phase4 | Chronic Hepatitis C | Unknown | 2016-02-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT02687061 | Chronic Hepatitis B and C Recall Northern Holland | — | Hepatitis B | Unknown | 2016-02-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02740556 | Evaluation of HepCure Toolkit to Improve Harvoni Adherence | Na | Hepatitis C | Completed | 2016-02-01 | 2019-03-31 | ClinicalTrials.gov |
| NCT02928510 | Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic … | — | Absence of Signs or Symptoms | Terminated | 2016-02-01 | 2018-06-05 | ClinicalTrials.gov |
| NCT02825212 | Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infec… | Phase2 | Hepatitis C | Completed | 2016-02-01 | 2019-07-19 | ClinicalTrials.gov |
| NCT02626026 | Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Heal… | Phase1 | Rheumatoid Arthritis | Completed | 2016-01-26 | 2016-09-01 | ClinicalTrials.gov |
| NCT02600117 | Use of TDF in Patients With Inactive Chronic Hepatitis B Infection | Phase3 | Hepatitis B, Chronic | Completed | 2016-01-26 | 2023-02-28 | ClinicalTrials.gov |
| NCT02654002 | Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinet… | Phase1 | Nonalcoholic Steatohepatitis (NASH) | Completed | 2016-01-20 | 2016-07-14 | ClinicalTrials.gov |
| NCT02536300 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | Phase3 | Follicular Lymphoma | Terminated | 2016-01-14 | 2022-09-27 | ClinicalTrials.gov |
| NCT02251236 | Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected I… | Na | HIV | Completed | 2016-01-01 | 2017-01-18 | ClinicalTrials.gov |
| NCT02590588 | Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis | Phase2 | Amyloidosis | Terminated | 2016-01-01 | 2017-03-27 | ClinicalTrials.gov |
| NCT02597166 | Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C … | Phase3 | Hepatitis C, Chronic | Completed | 2016-01-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT02534350 | Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus … | Phase2 | Respiratory Syncytial Virus (RSV) | Completed | 2015-12-31 | 2017-09-27 | ClinicalTrials.gov |
| NCT02538614 | Study of Idelalisib in Combination With BI 836826 in Participants With Chronic … | Phase1 | Chronic Lymphocytic Leukemia (CLL) | Terminated | 2015-12-29 | 2017-07-05 | ClinicalTrials.gov |
| NCT02639247 | Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in… | Phase3 | Hepatitis C Virus Infection | Completed | 2015-12-23 | 2017-01-18 | ClinicalTrials.gov |
| NCT02639338 | Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in … | Phase3 | Hepatitis C Virus Infection | Completed | 2015-12-23 | 2017-01-02 | ClinicalTrials.gov |
| NCT02613871 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults W… | Phase3 | Hepatitis C Virus Infection | Completed | 2015-12-22 | 2018-11-07 | ClinicalTrials.gov |
| NCT02616783 | Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvi… | Phase3 | HIV-1 Infection | Completed | 2015-12-22 | 2018-03-21 | ClinicalTrials.gov |
| NCT02616029 | Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir … | Phase3 | HIV-1 Infection | Completed | 2015-12-17 | 2019-07-11 | ClinicalTrials.gov |
| NCT02600819 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E… | Phase3 | HIV-1 Infection | Completed | 2015-12-14 | 2019-10-15 | ClinicalTrials.gov |
| NCT02607228 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobre… | Phase1 | Metastatic Castrate-Resistant Prostate Cancer | Terminated | 2015-12-08 | 2019-09-03 | ClinicalTrials.gov |
| NCT01528865 | Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA … | Phase1 | Lymphoma | Withdrawn | 2015-12-01 | — | ClinicalTrials.gov |
| NCT02656511 | Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection | Phase4 | HIV | Active_Not_Recruiting | 2015-12-01 | 2028-05-01 | ClinicalTrials.gov |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (No… | — | Metastatic Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2015-12-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT02591277 | Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Ge… | — | Hepatitis C | Completed | 2015-11-30 | 2017-11-01 | ClinicalTrials.gov |
| NCT02592057 | Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the T… | — | Hepatitis C Virus | Completed | 2015-11-30 | 2018-04-23 | ClinicalTrials.gov |
| NCT02603107 | Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting… | Phase3 | HIV-1 Infection | Completed | 2015-11-20 | 2019-12-23 | ClinicalTrials.gov |
| NCT02605954 | Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/… | Phase3 | HIV-1 Infection | Completed | 2015-11-18 | 2018-01-24 | ClinicalTrials.gov |
| NCT02521376 | Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Func… | Phase1 | Oncology | Completed | 2015-11-16 | 2017-10-25 | ClinicalTrials.gov |
| NCT02607800 | Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpa… | Phase3 | Hepatitis C | Completed | 2015-11-16 | 2017-01-11 | ClinicalTrials.gov |
| NCT02607930 | Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovi… | Phase3 | HIV-1 Infection | Completed | 2015-11-13 | 2021-07-02 | ClinicalTrials.gov |
| NCT02562742 | Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients W… | — | Hepatitis C | Completed | 2015-11-12 | 2017-06-12 | ClinicalTrials.gov |
| NCT02607735 | Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chron… | Phase3 | Hepatitis C | Completed | 2015-11-11 | 2017-06-21 | ClinicalTrials.gov |
| NCT02607956 | Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovi… | Phase3 | HIV-1 Infection | Completed | 2015-11-11 | 2021-07-05 | ClinicalTrials.gov |
| NCT02603120 | Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC t… | Phase3 | HIV-1 Infection | Completed | 2015-11-11 | 2019-10-23 | ClinicalTrials.gov |
| NCT02600351 | Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV… | Phase3 | Hepatitis C Virus Infection | Terminated | 2015-11-11 | 2017-05-29 | ClinicalTrials.gov |
| NCT02579382 | Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Comb… | Phase2 | Chronic Hepatitis B | Completed | 2015-11-10 | 2019-05-03 | ClinicalTrials.gov |
| NCT02609048 | Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects… | Phase2 | Primary Biliary Cirrhosis (PBC) | Terminated | 2015-11-04 | 2016-07-01 | ClinicalTrials.gov |
| NCT02573376 | Antiviral Pharmacology and Adherence in Drug Users | Na | HEPATITIS C | Completed | 2015-11-01 | 2021-06-01 | ClinicalTrials.gov |
| NCT02585947 | To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the … | Phase4 | Non-Hodgkin's Lymphoma, Burkitt's | Unknown | 2015-11-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT02529059 | SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System … | Phase4 | HIV | Completed | 2015-11-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT02678338 | CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies | Phase1 | Acute Myeloid Leukemia | Completed | 2015-11-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT02533427 | Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combinati… | Phase1 | HCV Infection | Completed | 2015-10-29 | 2016-03-18 | ClinicalTrials.gov |
| NCT02510300 | A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepa… | — | Hepatitis C Virus Infection | Terminated | 2015-10-21 | 2023-01-06 | ClinicalTrials.gov |
| NCT02545504 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gas… | Phase3 | Gastric Adenocarcinoma | Completed | 2015-10-13 | 2019-05-15 | ClinicalTrials.gov |
| NCT02533544 | Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve C… | — | Chronic Hepatitis B | Completed | 2015-10-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02439138 | Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in… | Phase2 | Waldenstrom's Macroglobulinemia | Terminated | 2015-10-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02537379 | Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients W… | — | Hepatitis C Virus Infection | Completed | 2015-09-15 | 2017-06-05 | ClinicalTrials.gov |
| NCT02258529 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Ly… | Phase2 | Follicular Lymphoma | Terminated | 2015-09-14 | 2016-05-03 | ClinicalTrials.gov |
| NCT02457559 | Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults Wit… | Phase1 | Relapsed/Refractory B-cell Malignancies | Completed | 2015-09-10 | 2020-12-30 | ClinicalTrials.gov |
| NCT02487030 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Wi… | Phase3 | Hepatitis C Virus Infection | Completed | 2015-09-07 | 2017-02-04 | ClinicalTrials.gov |
| NCT02638233 | Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Re… | Phase4 | Chronic Hepatitis C | Unknown | 2015-09-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02712346 | The Role of Endothelin-1 in Sickle Cell Disease | Phase1 | Sickle Cell Anemia | Completed | 2015-09-01 | 2019-11-30 | ClinicalTrials.gov |
| NCT02520284 | Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Sev… | Phase2 | Ulcerative Colitis | Terminated | 2015-09-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02253394 | The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertens… | Phase4 | Pulmonary Arterial Hypertension | Terminated | 2015-09-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT02547844 | Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to E… | Phase4 | HIV-1 | Completed | 2015-09-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02509624 | Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Norm… | Phase1 | Diabetic Kidney Disease | Completed | 2015-08-18 | 2015-12-15 | ClinicalTrials.gov |
| NCT02147834 | Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage Bu… | Phase2 | Angina | Terminated | 2015-08-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02876796 | Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 … | Phase1 | PD Effects of GS-0976 (NDI-010976) on Fractional DNL | Completed | 2015-08-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02468557 | Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Che… | Phase1 | Previously Untreated Pancreatic Ductal Adenocarcinoma | Terminated | 2015-07-30 | 2016-04-27 | ClinicalTrials.gov |
| NCT02536313 | Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combinati… | Phase2 | Hepatitis C Virus Infection | Completed | 2015-07-29 | 2016-06-28 | ClinicalTrials.gov |
| NCT02365506 | Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in P… | Phase1 | LQT2 Syndrome | Completed | 2015-07-20 | 2016-06-13 | ClinicalTrials.gov |
| NCT02479880 | Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis … | Phase4 | Hepatitis B | Terminated | 2015-07-03 | 2018-04-11 | ClinicalTrials.gov |
| NCT02042001 | Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognit… | Phase4 | Impaired Cognition | Completed | 2015-07-01 | 2018-01-15 | ClinicalTrials.gov |
| NCT02480712 | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Wee… | Phase3 | Hepatitis C Virus Infection | Completed | 2015-07-01 | 2016-06-22 | ClinicalTrials.gov |
| NCT02343939 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With A… | Phase1 | Acute Myeloid Leukemia | Terminated | 2015-07-01 | 2019-02-21 | ClinicalTrials.gov |
| NCT02469246 | Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically S… | Phase3 | HIV-1 Infection | Completed | 2015-06-29 | 2019-03-13 | ClinicalTrials.gov |
| NCT02836236 | Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hep… | Phase3 | HBV | Completed | 2015-06-19 | 2023-09-18 | ClinicalTrials.gov |
| NCT02836249 | Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hep… | Phase3 | HBV | Completed | 2015-06-19 | 2023-08-31 | ClinicalTrials.gov |
| NCT02472886 | Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infecti… | Phase3 | Hepatitis C Virus Infection | Completed | 2015-06-17 | 2016-06-30 | ClinicalTrials.gov |
| NCT02457598 | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Ot… | Phase1 | B-cell Malignancies | Terminated | 2015-06-16 | 2024-09-25 | ClinicalTrials.gov |
| NCT02466516 | Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simt… | Phase2 | Non-Alcoholic Steatohepatitis (NASH) | Completed | 2015-06-08 | 2016-10-11 | ClinicalTrials.gov |
| NCT02436135 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in A… | Phase1 | Myelofibrosis | Terminated | 2015-06-05 | 2017-11-20 | ClinicalTrials.gov |
| NCT02427204 | Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2… | — | Hepatitis C Infection | Completed | 2015-06-01 | 2018-01-18 | ClinicalTrials.gov |
| NCT02423265 | Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Ar… | Phase4 | Myocardial Ischemia | Withdrawn | 2015-06-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02457611 | Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (… | Phase2 | Hepatitis C Infection With HIV Co-Infection | Completed | 2015-06-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02480166 | Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 1… | Phase4 | PT-NANBH | Completed | 2015-06-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02445131 | Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Indu… | Phase2 | Chronic Lymphocytic Leucemia | Completed | 2015-05-28 | 2022-03-09 | ClinicalTrials.gov |
| NCT02350569 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administere… | Phase2 | Hepatitis C Virus Infection | Completed | 2015-05-22 | 2016-04-22 | ClinicalTrials.gov |
| NCT02404220 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adul… | Phase1 | Acute Lymphoblastic Leukemia | Terminated | 2015-05-06 | 2018-12-17 | ClinicalTrials.gov |
| NCT02402452 | Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Sever… | Phase1 | HCV Infection | Completed | 2015-05-05 | 2015-09-28 | ClinicalTrials.gov |
| NCT02441829 | Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function | Phase1 | Long QT Syndrome | Completed | 2015-05-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02377336 | GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease | Phase2 | Ischemic Heart Disease | Withdrawn | 2015-05-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02405442 | Safety and Efficacy of Andecaliximab in Participants With Moderately to Severel… | Phase2 | Crohn's Disease | Terminated | 2015-04-30 | 2016-12-22 | ClinicalTrials.gov |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to … | Phase3 | Chronic Lymphocytic Leukemia | Terminated | 2015-04-21 | 2016-05-13 | ClinicalTrials.gov |
| NCT02400307 | Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Functi… | Phase1 | HIV | Completed | 2015-04-17 | 2015-07-13 | ClinicalTrials.gov |
| NCT02404792 | Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function an… | Na | HIV | Completed | 2015-04-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02413593 | Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination T… | Phase2 | Hepatitis C Virus Infection | Completed | 2015-04-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02472535 | Study to Evaluate the Effects of MBX-8025 in Patients With HoFH | Phase2 | Homozygous Familial Hypercholesterolemia | Completed | 2015-04-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02167386 | PrEPared and Strong: Clinic-Based PrEP for Black MSM | Phase4 | HIV/AIDS | Completed | 2015-03-30 | 2018-02-28 | ClinicalTrials.gov |
| NCT02344290 | Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease… | Phase3 | HIV | Completed | 2015-03-26 | 2023-08-21 | ClinicalTrials.gov |
| NCT02397707 | Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Mod… | Phase1 | HCV Infection | Completed | 2015-03-24 | 2016-03-04 | ClinicalTrials.gov |
| NCT02397694 | Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus… | Phase2 | HIV-1 Infection | Completed | 2015-03-23 | 2019-02-27 | ClinicalTrials.gov |
| NCT02412098 | Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Funct… | Phase1 | Long QT Syndrome | Completed | 2015-03-19 | 2016-04-22 | ClinicalTrials.gov |
| NCT02392611 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics … | Phase1 | Solid Tumors and Lymphomas | Completed | 2015-03-16 | 2017-10-11 | ClinicalTrials.gov |
| NCT02301936 | Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 o… | Phase2 | Hepatitis C Virus Infection | Completed | 2015-03-02 | 2016-04-18 | ClinicalTrials.gov |
| NCT02179710 | Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study | — | Cystic Fibrosis | Completed | 2015-03-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02357602 | Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women | Phase1 | Healthy | Completed | 2015-03-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02346721 | Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infect… | Phase3 | Hepatitis C Virus Infection | Completed | 2015-02-23 | 2016-06-15 | ClinicalTrials.gov |
| NCT02378935 | Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Comb… | Phase2 | Hepatitis C Virus Infection | Completed | 2015-02-17 | 2016-04-12 | ClinicalTrials.gov |
| NCT02378961 | Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Comb… | Phase2 | Hepatitis C Virus Infection | Completed | 2015-02-16 | 2016-01-26 | ClinicalTrials.gov |
| NCT02291237 | Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomati… | Phase2 | Hypertrophic Cardiomyopathy | Terminated | 2015-02-05 | 2017-02-17 | ClinicalTrials.gov |
| NCT02308332 | Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functio… | Phase4 | Neurocognitive Decline | Completed | 2015-02-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02342821 | Empowering Immigrants in the Greater Boston Area to Connect to HBV Care | — | Hepatitis | Unknown | 2015-02-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02365532 | Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Toler… | Phase1 | Long QT Syndrome | Completed | 2015-02-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02477527 | Atripla to Stribild Switch Study to Evaluate Sleep Disturbances | Phase4 | HIV | Completed | 2015-02-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02254421 | Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncyti… | Phase2 | Respiratory Syncytial Virus Infection | Completed | 2015-01-31 | 2017-04-17 | ClinicalTrials.gov |
| NCT02858401 | Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically … | Phase1 | HIV-1 Infection | Completed | 2015-01-29 | 2019-02-14 | ClinicalTrials.gov |
| NCT02345252 | Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/T… | Phase3 | HIV-1 Infection | Completed | 2015-01-26 | 2019-01-09 | ClinicalTrials.gov |
| NCT02345226 | Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabin… | Phase3 | HIV-1 Infection | Completed | 2015-01-26 | 2019-01-02 | ClinicalTrials.gov |
| NCT02254408 | Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncyti… | Phase2 | Respiratory Syncytial Virus | Completed | 2015-01-23 | 2017-07-14 | ClinicalTrials.gov |
| NCT02285114 | Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunode… | Phase2 | HIV-1 | Completed | 2015-01-20 | 2024-12-11 | ClinicalTrials.gov |
| NCT02258555 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults W… | Phase1 | Follicular Lymphoma | Terminated | 2015-01-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02292706 | A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Re… | — | Hepatitis C Virus Infection | Terminated | 2014-12-29 | 2021-12-31 | ClinicalTrials.gov |
| NCT02296853 | Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults… | Phase1 | Hepatitis B Virus | Completed | 2014-12-22 | 2015-04-17 | ClinicalTrials.gov |
| NCT02300558 | Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability… | Phase3 | Long QT Syndrome Type 3 | Terminated | 2014-12-17 | 2017-02-15 | ClinicalTrials.gov |
| NCT02367599 | Effect of Vitamin D Supplementation on Bone Turnover Markers During PrEP in MSM | Phase4 | Patient Adherence | Completed | 2014-12-15 | 2018-07-11 | ClinicalTrials.gov |
| NCT02246998 | Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to … | Phase4 | HIV-1 Infection | Completed | 2014-12-15 | 2016-02-17 | ClinicalTrials.gov |
| NCT02258581 | Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial… | — | Chronic Hepatitis B | Terminated | 2014-12-09 | 2017-08-14 | ClinicalTrials.gov |
| NCT02276612 | Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenam… | Phase2 | HIV | Completed | 2014-12-03 | 2017-10-23 | ClinicalTrials.gov |
| NCT02360397 | Ranolazine Mediated PVC Reduction in Ischemic Heart Disease | Phase2 | Ventricular Premature Complexes | Completed | 2014-12-01 | 2018-02-23 | ClinicalTrials.gov |
| NCT02300103 | Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribav… | Phase2 | Hepatitis C Virus Infection | Completed | 2014-12-01 | 2016-09-15 | ClinicalTrials.gov |
| NCT02249182 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavir… | Phase2 | Hepatitis C Virus Infection | Completed | 2014-11-05 | 2018-08-24 | ClinicalTrials.gov |
| NCT02306577 | STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY) | — | HIV | Unknown | 2014-11-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02295384 | Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community … | — | HIV | Completed | 2014-11-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02309918 | HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infecti… | Phase2 | Acute Hepatitis C | Completed | 2014-11-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02272062 | Patient-Reported Preferences Affecting Revascularization Decisions | Na | Coronary Artery Disease | Completed | 2014-11-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02234141 | Selonsertib in Adults With Pulmonary Arterial Hypertension | Phase2 | Pulmonary Arterial Hypertension | Completed | 2014-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02275065 | Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegrav… | Phase1 | HIV-1 Infection | Completed | 2014-10-24 | 2015-01-29 | ClinicalTrials.gov |
| NCT02251717 | Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (… | Phase2 | Hepatitis C Virus Infection | Completed | 2014-10-14 | 2016-06-16 | ClinicalTrials.gov |
| NCT02237027 | Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Am… | Phase4 | Adherence to Medication Regime | Completed | 2014-10-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02247934 | Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patient… | — | Primary Sclerosing Cholangitis | Completed | 2014-10-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02242045 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in J… | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2014-10-01 | 2017-10-17 | ClinicalTrials.gov |
| NCT02199613 | Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Sim… | Phase4 | HIV Infection | Completed | 2014-10-01 | 2017-02-14 | ClinicalTrials.gov |
| NCT02149888 | PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY,… | Phase4 | HIV | Completed | 2014-10-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02074891 | Sustainable Healthcenter Implementation PrEP Pilot Study | — | HIV Chemoprophylaxis | Completed | 2014-10-01 | 2018-11-01 | ClinicalTrials.gov |
| NCT02265796 | Ranolazine Among Unrevascularized Chronic Stable Angina Patients | Phase2 | Angina | Completed | 2014-09-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02283060 | Sleep and Cognition After Atripla to Stribild Switch | Phase4 | HIV | Unknown | 2014-09-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02220998 | Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With S… | Phase3 | Hepatitis C Virus Infection | Completed | 2014-09-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02104583 | Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Def… | Phase2 | Ventricular Arrhythmia | Completed | 2014-09-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02147067 | Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARI… | Phase2 | Microvascular Angina | Completed | 2014-09-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT02180438 | An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected A… | Phase4 | HIV-2 Infection | Completed | 2014-09-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02958358 | FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisent… | Na | Pulmonary Arterial Hypertension | Withdrawn | 2014-09-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02044822 | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients Wit… | Phase2 | B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion | Terminated | 2014-08-06 | 2016-05-17 | ClinicalTrials.gov |
| NCT02202980 | Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection | Phase2 | Chronic Hepatitis C | Completed | 2014-08-04 | 2016-05-09 | ClinicalTrials.gov |
| NCT02219685 | Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neuroco… | Phase2 | Hepatitis C Virus Infection | Completed | 2014-08-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02251457 | Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic … | Phase1 | Myotonia Congenita | Completed | 2014-08-01 | 2017-12-18 | ClinicalTrials.gov |
| NCT02176876 | Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumato… | Phase1 | Rheumatoid Arthritis | Completed | 2014-08-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02216409 | Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody | Phase1 | Solid Tumor | Completed | 2014-08-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02209987 | Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in H… | Phase1 | Ulcerative Colitis | Completed | 2014-08-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02252835 | Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat … | Phase2 | Gout | Completed | 2014-08-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02174276 | Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarat… | Phase2 | Chronic Hepatitis B | Completed | 2014-07-24 | 2018-05-30 | ClinicalTrials.gov |
| NCT02175758 | Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With … | Phase2 | Hepatitis C Virus Infection | Completed | 2014-07-07 | 2018-09-13 | ClinicalTrials.gov |
| NCT02233192 | PrEPception: Expanding Assisted Reproductive Options for Serodiscordant Couples | — | PrEP for Conception Purposes | Completed | 2014-07-01 | 2017-06-15 | ClinicalTrials.gov |
| NCT01987453 | Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With C… | Phase2 | HCV Infection | Completed | 2014-07-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02203461 | Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication | Phase1 | Insulin Resistance | Completed | 2014-07-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02201953 | Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With S… | Phase3 | Hepatitis C Virus Infection | Completed | 2014-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02201940 | Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chron… | Phase3 | Hepatitis C Virus Infection | Completed | 2014-07-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02201901 | Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infect… | Phase3 | Hepatitis C Virus Infection | Completed | 2014-07-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02226549 | Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ri… | Phase2 | Hepatitis C Virus Infection | Completed | 2014-07-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02166047 | Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chron… | Phase2 | Chronic Hepatitis B | Completed | 2014-06-30 | 2016-10-20 | ClinicalTrials.gov |
| NCT02185794 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activit… | Phase1 | Hepatitis C Virus Infection | Completed | 2014-06-13 | 2015-09-28 | ClinicalTrials.gov |
| NCT02135614 | Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults Wit… | Phase2 | Respiratory Syncytial Virus Infection | Completed | 2014-06-09 | 2017-04-12 | ClinicalTrials.gov |
| NCT02177786 | Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants Wit… | Phase2 | Diabetic Kidney Disease | Completed | 2014-06-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02167100 | Patient Retention in HIV Medical Care in a Primary Care Practice in Australia | — | HIV | Completed | 2014-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02135133 | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2014-06-01 | 2020-10-06 | ClinicalTrials.gov |
| NCT02128542 | Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Vet… | Phase4 | Hepatitis C Virus Infection | Completed | 2014-06-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02121795 | Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologic… | Phase3 | HIV-1 Infection | Completed | 2014-05-06 | 2019-03-01 | ClinicalTrials.gov |
| NCT02156336 | Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP) | Phase4 | Diabetic Peripheral Neuropathic Pain | Terminated | 2014-05-01 | 2017-02-08 | ClinicalTrials.gov |
| NCT02196064 | Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Withou… | — | Human Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Coinfected Subjects | Completed | 2014-05-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02110914 | A Coaching Intervention to Young Adults With Cystic Fibrosis | Na | Cystic Fibrosis | Completed | 2014-05-01 | 2016-12-21 | ClinicalTrials.gov |
| NCT02052011 | Ranolazine and Microvascular Angina by PET in the Emergency Department | Phase4 | Microvascular Angina | Completed | 2014-04-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02104700 | Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Te… | Phase2 | HIV | Completed | 2014-04-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02120300 | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbu… | Phase2 | Chronic HCV Infection | Completed | 2014-04-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02081469 | Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy | Phase4 | Hepatitis B, Chronic | Completed | 2014-03-17 | 2019-08-05 | ClinicalTrials.gov |
| NCT02077465 | Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chro… | Phase1 | Chronic Obstructive Pulmonary Disease | Completed | 2014-03-11 | 2014-10-27 | ClinicalTrials.gov |
| NCT02074514 | Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With… | Phase3 | Chronic HCV Infection | Completed | 2014-03-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02081079 | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatmen… | Phase2 | Chronic Genotype 4 HCV | Completed | 2014-03-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02063997 | Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Redu… | Phase2 | Gout | Completed | 2014-03-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02071082 | Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Ad… | Phase3 | HIV | Completed | 2014-02-25 | 2016-10-26 | ClinicalTrials.gov |
| NCT02065700 | Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participan… | Phase2 | Rheumatoid Arthritis | Completed | 2014-02-25 | 2023-01-19 | ClinicalTrials.gov |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituxima… | Phase3 | Chronic Lymphocytic Leukemia | Terminated | 2014-02-05 | 2016-06-16 | ClinicalTrials.gov |
| NCT02073656 | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Week… | Phase3 | Hepatitis C Virus | Completed | 2014-02-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02037594 | Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting | Na | Human Immunodeficiency Virus (HIV) | Completed | 2014-01-30 | 2018-06-01 | ClinicalTrials.gov |
| NCT02016924 | Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (… | Phase2 | Acquired Immune Deficiency Syndrome (AIDS) | Active_Not_Recruiting | 2014-01-16 | 2027-03-01 | ClinicalTrials.gov |
| NCT02010255 | Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants Wit… | Phase2 | Chronic HCV Infection | Completed | 2014-01-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01929759 | Advanced Neuroimaging Evaluation of the Central Nervous System Biological Chang… | Na | HIV Disease | Completed | 2014-01-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02002767 | Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Norm… | Phase1 | Hepatitis C Virus | Completed | 2013-12-16 | 2014-06-09 | ClinicalTrials.gov |
| NCT02021643 | Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Inf… | Phase3 | Chronic HCV Infection | Completed | 2013-12-10 | 2016-11-03 | ClinicalTrials.gov |
| NCT02021656 | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Particip… | Phase3 | Chronic HCV Infection | Completed | 2013-12-10 | 2017-09-29 | ClinicalTrials.gov |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | Phase1 | GVHD (Acute or Chronic) | Terminated | 2013-12-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01956812 | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcita… | Phase3 | Metastatic Pancreatic Cancer | Terminated | 2013-12-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01948310 | Effects of Ranolazine and Exercise on Daily Physical Activity Trial | Phase4 | Chronic Stable Angina | Completed | 2013-12-01 | 2016-10-10 | ClinicalTrials.gov |
| NCT01967940 | Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Fol… | Phase3 | HIV | Completed | 2013-10-25 | 2017-07-31 | ClinicalTrials.gov |
| NCT01958281 | Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infectio… | Phase2 | HCV Infection | Completed | 2013-10-07 | 2017-10-19 | ClinicalTrials.gov |
| NCT01906255 | Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in… | — | HIV | Completed | 2013-10-07 | 2021-04-27 | ClinicalTrials.gov |
| NCT01965535 | Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin… | Phase2 | HCV Infection | Completed | 2013-10-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01975675 | Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participan… | Phase3 | Chronic HCV Infection | Completed | 2013-10-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01984294 | Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subje… | Phase2 | Chronic HCV Infection | Completed | 2013-10-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01962441 | SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adul… | Phase3 | Hepatitis C | Completed | 2013-09-24 | 2016-07-07 | ClinicalTrials.gov |
| NCT01943799 | Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B | Phase2 | Chronic HBV Infection | Completed | 2013-09-13 | 2015-03-03 | ClinicalTrials.gov |
| NCT01940341 | Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumara… | Phase3 | HBeAg-negative Chronic Hepatitis B | Completed | 2013-09-12 | 2022-08-31 | ClinicalTrials.gov |
| NCT01940471 | Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumara… | Phase3 | HBeAg-positive Chronic Hepatitis B | Completed | 2013-09-11 | 2022-10-13 | ClinicalTrials.gov |
| NCT01968551 | Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretrov… | Phase3 | HIV-1 | Completed | 2013-09-03 | 2016-07-09 | ClinicalTrials.gov |
| NCT01902472 | A Prospective, Observational Study of Individuals Who Seroconvert While Taking … | — | HIV | Completed | 2013-09-02 | 2017-10-30 | ClinicalTrials.gov |
| NCT01938430 | Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chron… | Phase2 | Chronic HCV Infection | Completed | 2013-09-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01816646 | Intravesical Cidofovir for Hemorrhagic Cystitis | Phase1 | Blood And Marrow Transplantation | Completed | 2013-09-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01915472 | A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer | Phase2 | Metastatic Colorectal Cancer | Withdrawn | 2013-09-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01923311 | Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of … | Phase2 | Acquired Immune Deficiency Syndrome (AIDS) | Terminated | 2013-08-26 | 2017-11-03 | ClinicalTrials.gov |
| NCT01644799 | Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymp… | Phase1 | Recurrent Follicular Lymphoma | Completed | 2013-08-02 | 2017-05-01 | ClinicalTrials.gov |
| NCT01961232 | Trans-pulmonary Biomarkers in Pulmonary Hypertension | — | Pulmonary Hypertension | Active_Not_Recruiting | 2013-08-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT01705054 | Angina Prevalence and Provider Evaluation of Angina Relief | — | Stable Coronary Artery Disease CAD | Completed | 2013-07-01 | 2015-07-22 | ClinicalTrials.gov |
| NCT01924949 | Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype… | Phase2 | Hepatitis C | Completed | 2013-07-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refract… | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2013-06-20 | 2016-12-22 | ClinicalTrials.gov |
| NCT01832571 | SCOPE: Strategies to Combine PrEP With Prevention Efforts | Na | HIV | Withdrawn | 2013-06-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01909804 | Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in… | Phase2 | Hepatitis C | Completed | 2013-06-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01896193 | Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adult… | Phase3 | Hepatitis C | Completed | 2013-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01887353 | The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure | Phase2 | Atrial Fibrillation | Terminated | 2013-06-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01854775 | Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the E… | Phase2 | Acquired Immune Deficiency Syndrome (AIDS) | Completed | 2013-05-06 | 2025-06-18 | ClinicalTrials.gov |
| NCT01841489 | A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of … | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2013-05-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01847391 | A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6… | Phase1 | Ischemic Heart Disease | Completed | 2013-05-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01797419 | Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV) | Phase1 | Respiratory Syncytial Virus Infections | Withdrawn | 2013-05-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01855867 | HIV Non-Occupational Post-Exposure Prophylaxis | Phase4 | Human Immunodeficiency Virus | Completed | 2013-05-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01849003 | Study of the Effect of GS-6615 in Subjects With LQT-3 | Phase1 | Long QT Syndrome | Completed | 2013-05-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01840735 | Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With … | Phase1 | Cystic Fibrosis | Completed | 2013-05-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01851330 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin… | Phase3 | Chronic Hepatitis C Virus | Completed | 2013-05-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01865799 | A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada… | — | Pre-exposure Prophylaxis for Prevention of HIV Infection | Completed | 2013-04-22 | 2018-01-22 | ClinicalTrials.gov |
| NCT01826981 | Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chro… | Phase2 | Chronic Hepatitis C | Completed | 2013-04-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01711567 | Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients Wit… | Phase4 | Chronic Hepatitis B | Completed | 2013-04-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01737047 | The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in Peop… | — | HIV Positive | Completed | 2013-04-01 | 2023-03-13 | ClinicalTrials.gov |
| NCT01881529 | A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2)… | — | Limited Scleroderma | Completed | 2013-04-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01864603 | Sustainable East Africa Research in Community Health | Na | HIV | Completed | 2013-04-01 | 2021-04-01 | ClinicalTrials.gov |
| NCT01858766 | Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Tr… | Phase2 | Hepatitis C | Completed | 2013-04-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01843127 | A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjec… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2013-04-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT02603536 | WelTelOAKTREE: Text Messaging to Support Patients With HIV/AIDS in British Colu… | Na | HIV | Completed | 2013-04-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01803282 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy a… | Phase1 | Pancreatic Cancer | Completed | 2013-03-29 | 2019-04-23 | ClinicalTrials.gov |
| NCT01831427 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS… | Phase1 | Ulcerative Colitis | Completed | 2013-03-28 | 2015-02-06 | ClinicalTrials.gov |
| NCT01815736 | Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-… | Phase3 | HIV | Completed | 2013-03-27 | 2020-04-01 | ClinicalTrials.gov |
| NCT01818596 | Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With… | Phase3 | HIV | Completed | 2013-03-27 | 2018-07-18 | ClinicalTrials.gov |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entos… | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2013-03-14 | 2020-01-30 | ClinicalTrials.gov |
| NCT01797445 | Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-… | Phase3 | HIV | Completed | 2013-03-12 | 2018-10-03 | ClinicalTrials.gov |
| NCT01672853 | Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adul… | Phase2 | Primary Sclerosing Cholangitis (PSC) | Completed | 2013-03-04 | 2016-08-24 | ClinicalTrials.gov |
| NCT01817985 | A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With No… | Phase1 | Chronic Hepatitis C | Completed | 2013-03-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | Phase1 | Non-hodgkin's Lymphoma | Terminated | 2013-03-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01236261 | Prospective Population Study on Candidemia in Spain | — | Fungemia | Completed | 2013-03-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01838590 | Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-N… | Phase3 | Hepatitis C Virus | Completed | 2013-03-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01807208 | PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial I… | Na | Acute Myocardial Infarction | Completed | 2013-03-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01801293 | A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of … | Phase1 | RSV Infection | Completed | 2013-03-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01469364 | Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Earl… | Phase4 | Complication of Transplanted Lung | Completed | 2013-03-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01769456 | An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure P… | Phase2 | HIV Infection | Completed | 2013-03-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01641367 | A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combinatio… | Phase4 | HIV-1 Infection | Completed | 2013-02-22 | 2018-12-31 | ClinicalTrials.gov |
| NCT01605318 | Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer | Phase1 | Metastatic Colorectal Cancer | Terminated | 2013-02-12 | 2017-01-03 | ClinicalTrials.gov |
| NCT01850212 | A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subje… | — | HIV Infections | Completed | 2013-02-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01910636 | Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chroni… | Phase3 | Hepatitis C | Completed | 2013-02-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01790633 | Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests | Na | HIV | Completed | 2013-02-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01808248 | Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Trea… | Phase2 | Hepatitis C | Completed | 2013-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01769196 | Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With … | Phase2 | Idiopathic Pulmonary Fibrosis | Terminated | 2013-01-31 | 2016-02-23 | ClinicalTrials.gov |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for P… | Phase3 | Indolent Non-Hodgkin's Lymphomas | Terminated | 2013-01-16 | 2016-05-18 | ClinicalTrials.gov |
| NCT01732926 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine an… | Phase3 | Indolent Non-Hodgkin's Lymphomas | Terminated | 2013-01-02 | 2016-05-17 | ClinicalTrials.gov |
| NCT01730638 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma. | Phase1 | Medullary Thyroid Carcinoma | Completed | 2013-01-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01745822 | Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B… | Phase3 | Hepatitis B Chronic Infection | Completed | 2013-01-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT01783678 | A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvi… | Phase3 | Chronic Hepatitis C | Completed | 2013-01-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01865786 | A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to… | — | HIV Infection | Completed | 2013-01-01 | 2018-03-13 | ClinicalTrials.gov |
| NCT01768286 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin… | Phase3 | Chronic Hepatitis C Virus | Completed | 2013-01-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01779505 | A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4… | Phase1 | Healthy Volunteers | Completed | 2013-01-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01780506 | Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/… | Phase3 | HIV | Completed | 2012-12-26 | 2017-09-06 | ClinicalTrials.gov |
| NCT01761643 | CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk… | Phase4 | Patient Adherence | Completed | 2012-12-19 | 2018-07-11 | ClinicalTrials.gov |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | Phase1 | Gastric Adenocarcinoma | Completed | 2012-12-17 | 2020-08-13 | ClinicalTrials.gov |
| NCT01721109 | Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine… | Phase2 | Acquired Immunodeficiency Syndrome | Completed | 2012-12-06 | 2018-01-29 | ClinicalTrials.gov |
| NCT01651403 | Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir … | Phase3 | Chronic Hepatitis B | Active_Not_Recruiting | 2012-12-06 | 2027-07-01 | ClinicalTrials.gov |
| NCT01672866 | Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver … | Phase2 | Liver Fibrosis Due to NASH | Terminated | 2012-12-05 | 2016-12-29 | ClinicalTrials.gov |
| NCT01659021 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously… | Phase3 | Chronic Lymphocytic Leukemia | Terminated | 2012-12-04 | 2018-08-15 | ClinicalTrials.gov |
| NCT01766726 | Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-… | — | HIV | Completed | 2012-12-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01641822 | Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alter… | Phase3 | Cystic Fibrosis | Completed | 2012-12-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01730612 | ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Bre… | Phase1 | HER2 Negative Breast Carcinoma Expressing CEA | Completed | 2012-12-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT01740791 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Act… | Phase1 | Chronic Hepatitis C Virus | Completed | 2012-11-06 | 2014-01-24 | ClinicalTrials.gov |
| NCT01767987 | Ranolazine Cardioprotection in PCI | Phase2 | Acute Coronary Syndrome | Terminated | 2012-11-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01756482 | Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respir… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2012-11-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01754428 | Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects <… | — | Respiratory Syncytial Virus Infections | Completed | 2012-11-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01721967 | Ranolazine for the Treatment of Chest Pain in HCM Patients | Phase4 | Hypertrophic Cardiomyopathy | Completed | 2012-11-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01705847 | A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies | Phase1 | Lymphoid Malignancies | Completed | 2012-11-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01687270 | Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chroni… | Phase2 | Recurrent Chronic Hepatitis C Virus | Completed | 2012-11-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01672879 | Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH | Phase2 | Liver Fibrosis Due to NASH | Terminated | 2012-10-29 | 2017-01-03 | ClinicalTrials.gov |
| NCT01705574 | Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 I… | Phase3 | Acquired Immunodeficiency Syndrome | Completed | 2012-10-24 | 2018-09-06 | ClinicalTrials.gov |
| NCT01759511 | Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis … | Phase2 | Idiopathic Pulmonary Fibrosis | Terminated | 2012-10-18 | 2016-02-19 | ClinicalTrials.gov |
| NCT01707472 | Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibro… | Phase2 | Liver Fibrosis | Completed | 2012-10-04 | 2014-10-17 | ClinicalTrials.gov |
| NCT01539291 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia… | Phase3 | Chronic Lymphocytic Leukemia | Terminated | 2012-10-03 | 2018-06-29 | ClinicalTrials.gov |
| NCT01793649 | A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliar… | Phase1 | Cystic Fibrosis | Terminated | 2012-10-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01713283 | Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian… | Phase2 | Hepatitis C Virus | Completed | 2012-10-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01726517 | Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV … | Phase2 | Chronic Hepatitis C Virus | Completed | 2012-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01701895 | Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Wo… | — | HIV-1 Infection | Completed | 2012-10-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01691768 | Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Fami… | Phase2 | HIV | Completed | 2012-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01648205 | Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients | Phase2 | Long QT Syndrome | Completed | 2012-09-01 | 2018-07-20 | ClinicalTrials.gov |
| NCT01705509 | The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patient… | Na | Cardiomyopathy | Terminated | 2012-09-01 | 2017-03-31 | ClinicalTrials.gov |
| NCT01701401 | Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With … | Phase3 | Chronic Hepatitis C Virus | Completed | 2012-09-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01682720 | Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects … | Phase3 | Hepatitis C | Completed | 2012-09-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01872988 | Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV R… | Phase3 | Chronic Hepatitis B | Terminated | 2012-09-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT01659255 | Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Giv… | Phase1 | Non Hodgkins Lymphoma | Completed | 2012-08-17 | 2016-01-11 | ClinicalTrials.gov |
| NCT01953458 | Therapeutic Option for Hepatitis B and C: a French Cohort | — | Viral Hepatitis B | Unknown | 2012-08-06 | 2024-12-31 | ClinicalTrials.gov |
| NCT01659047 | A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of S… | Phase2 | Chronic Lymphocytic Leukemia | Withdrawn | 2012-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01695512 | Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Sampl… | — | Invasive Aspergillosis | Unknown | 2012-08-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT01585688 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | Phase1 | Non-Hodgkin's Lymphoma | Terminated | 2012-08-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT01687257 | Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal… | Phase2 | Hepatitis C | Completed | 2012-07-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01667731 | Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3… | Phase3 | Hepatitis C | Completed | 2012-07-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01646541 | Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery | — | Pulmonary Hypertension | Completed | 2012-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01605890 | Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabi… | Phase2 | HIV-2 Infection | Completed | 2012-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01675973 | A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmaco… | Phase1 | Severe Renal Impairment | Terminated | 2012-07-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01569295 | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bend… | Phase3 | Chronic Lymphocytic Leukemia | Completed | 2012-06-15 | 2019-06-10 | ClinicalTrials.gov |
| NCT01804543 | Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovas… | — | Angina | Unknown | 2012-06-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01641640 | Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-N… | Phase3 | Chronic Hepatitis C | Completed | 2012-06-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01555164 | A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequa… | Phase3 | Type 2 Diabetes Mellitus | Completed | 2012-06-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01625338 | Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a … | Phase3 | Chronic Hepatitis C | Completed | 2012-06-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01617369 | Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliar… | Na | Healthy Subjects | Completed | 2012-06-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01614405 | Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis | Na | Primary Biliary Cirrhosis | Terminated | 2012-06-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01604850 | Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects Wit… | Phase3 | Chronic Hepatitis C | Completed | 2012-06-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01815957 | Impact of Ranolazine on Coronary Microcirculatory Resistance | Na | Coronary Microcirculation | Completed | 2012-05-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01772121 | Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepati… | — | Hepatitis B | Completed | 2012-05-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01590615 | Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy | — | Hepatitis B | Completed | 2012-04-26 | 2017-04-04 | ClinicalTrials.gov |
| NCT01457755 | Gilead Sustained Virologic Response (SVR) Registry | — | Hepatitis C, Chronic | Completed | 2012-04-13 | 2018-01-08 | ClinicalTrials.gov |
| NCT01565850 | D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretrovira… | Phase2 | Acquired Immunodeficiency Syndrome | Completed | 2012-04-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01590654 | A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic He… | Phase1 | Hepatitis B | Completed | 2012-04-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01590641 | A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B | Phase1 | Hepatitis B | Completed | 2012-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01667068 | Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 7.5 Years Fol… | — | Coronary Heart Disease | Completed | 2012-04-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01590979 | Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atr… | Na | Atrial Fibrillation New Onset | Terminated | 2012-04-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01539512 | A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combinati… | Phase3 | Chronic Lymphocytic Leukemia | Completed | 2012-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01488526 | Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Vir… | Phase4 | Hepatitis B Infection | Completed | 2012-03-01 | 2018-06-28 | ClinicalTrials.gov |
| NCT01671787 | A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepat… | Phase1 | Chronic Hepatitis B | Completed | 2012-03-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01591668 | A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C | Phase1 | Hepatitis C | Completed | 2012-03-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01565889 | Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) C… | Phase1 | Hepatitis C | Completed | 2012-03-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01559844 | Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing… | Phase2 | Hepatitis C | Completed | 2012-03-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01542788 | Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 He… | Phase3 | Chronic Hepatitis C | Completed | 2012-03-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patient… | Phase1 | Metastatic Pancreatic Adenocarcinoma | Withdrawn | 2012-03-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01349491 | Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardiover… | Phase3 | Atrial Fibrillation | Terminated | 2012-03-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01602822 | Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following … | Phase4 | HIV | Terminated | 2012-02-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01546597 | Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and … | Phase1 | Type 2 Diabetes Mellitus | Completed | 2012-02-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01546558 | Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2012-02-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01448616 | Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding | Phase4 | Herpes Simplex Type II | Completed | 2012-02-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01767597 | Application of HBV Rapid Tests as a Tool for Wide-Use Screening | Na | Hepatitis B | Completed | 2012-02-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01522651 | Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and… | Phase2 | Atrial Fibrillation | Completed | 2012-01-24 | 2014-03-10 | ClinicalTrials.gov |
| NCT01494987 | Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus | Phase3 | Type 2 Diabetes Mellitus | Completed | 2012-01-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01522625 | Tenofovir in Chronic Hepatitis B With Mild ALT Elevation | Phase4 | Chronic Hepatitis B | Completed | 2012-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT01533259 | Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Ralte… | Phase3 | Acquired Immunodeficiency Syndrome | Completed | 2012-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01558830 | Safety of Amiodarone and Ranolazine Together in Patients With Angina | Phase4 | Chronic Stable Angina | Unknown | 2012-01-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01466790 | A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C … | Phase2 | Hepatitis C | Completed | 2012-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01497899 | Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV… | Phase2 | Acquired Immunodeficiency Syndrome | Completed | 2011-12-28 | 2016-08-22 | ClinicalTrials.gov |
| NCT01457768 | A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic … | — | Hepatitis C, Chronic | Completed | 2011-12-19 | 2018-04-09 | ClinicalTrials.gov |
| NCT01495702 | Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse… | Phase3 | Acquired Immunodeficiency Syndrome | Completed | 2011-12-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01497366 | Phase 3 Study of Sofosbuvir and Ribavirin | Phase3 | Hepatitis C | Completed | 2011-12-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01479465 | Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment i… | Phase2 | Colorectal Cancer | Terminated | 2011-12-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01404234 | Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Ae… | Phase3 | Cystic Fibrosis | Completed | 2011-12-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01475838 | Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Pro… | Phase3 | Acquired Immunodeficiency Syndrome | Completed | 2011-11-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01472198 | A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcita… | Phase2 | Pancreatic Cancer | Completed | 2011-11-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01452308 | Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis | Phase2 | Liver Fibrosis | Completed | 2011-11-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01472185 | Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus | Phase3 | Type 2 Diabetes Mellitus | Completed | 2011-11-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01435174 | Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients | Phase4 | End-stage Renal Disease | Completed | 2011-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01442038 | Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary I… | Phase3 | Coronary Artery Disease | Completed | 2011-10-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01440569 | Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults | Phase3 | Acquired Immunodeficiency Syndrome | Completed | 2011-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01435226 | GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects Wit… | Phase2 | Hepatitis C, Chronic | Completed | 2011-09-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01435044 | Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With… | Phase2 | Hepatitis C, Chronic | Completed | 2011-09-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01434498 | GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Int… | Phase2 | Chronic Genotype 1a or 1b HCV Infection | Completed | 2011-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01431898 | Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Sub… | Phase1 | Hepatitis C | Completed | 2011-09-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01425359 | Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina | Phase4 | Angina Pectoris | Completed | 2011-09-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01393106 | Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | Phase2 | Hodgkin Lymphoma | Completed | 2011-09-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01375049 | Aztreonam Lysine for Pseudomonas Infection Eradication Study | Phase2 | Cystic Fibrosis | Completed | 2011-08-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT02318524 | Clinical Impact of Fungal Domestic Environmental Exposure on COPD Patients | — | COPD | Completed | 2011-08-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT01416402 | Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat… | Phase2 | Hyperuricemia | Completed | 2011-08-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01384383 | GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Na… | Phase2 | Chronic Hepatitis C | Terminated | 2011-08-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01375036 | Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa I… | — | Cystic Fibrosis | Completed | 2011-08-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01497327 | Open-Label Hepatic Impairment Study | Phase1 | Hepatitis C | Completed | 2011-07-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01356160 | GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Rib… | Phase2 | Hepatitis C, Chronic | Completed | 2011-07-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01371578 | Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a… | Phase2 | Hepatitis C, Chronic | Completed | 2011-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT02133352 | Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With … | Phase4 | Pulmonary Hypertension | Completed | 2011-07-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01369498 | Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Ver… | Phase2 | Myelofibrosis | Completed | 2011-06-30 | 2014-09-24 | ClinicalTrials.gov |
| NCT01399008 | Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in… | Phase2 | Gout | Completed | 2011-06-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01353248 | GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) … | Phase2 | Hepatitis C, Chronic | Completed | 2011-05-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01334203 | A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chro… | Phase4 | Angina Pectoris | Withdrawn | 2011-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01336686 | Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients … | Phase2 | Hyperuricemia | Completed | 2011-05-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01363011 | Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected P… | Phase3 | Acquired Immunodeficiency Syndrome | Completed | 2011-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01214759 | Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP) | Phase4 | HIV | Completed | 2011-05-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01270698 | Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer | Phase1 | Metastatic Colorectal Cancer | Completed | 2011-05-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01320943 | Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative … | Phase4 | Chronic Hepatitis B | Completed | 2011-04-26 | 2016-08-23 | ClinicalTrials.gov |
| NCT01277601 | Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2… | Phase4 | Chronic Hepatitis B | Completed | 2011-04-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01313624 | Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cys… | Phase3 | Bronchiectasis | Completed | 2011-04-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01259713 | Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemother… | Phase3 | Invasive Fungal Disease | Completed | 2011-04-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01345188 | Ranolazine in Ischemic Cardiomyopathy | Phase4 | Cardiomyopathy | Completed | 2011-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01314716 | Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cys… | Phase3 | Bronchiectasis | Completed | 2011-04-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01066858 | Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and B… | — | HIV Infections | Completed | 2011-03-22 | 2015-11-30 | ClinicalTrials.gov |
| NCT01282424 | Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell No… | Phase2 | Follicular Lymphoma | Completed | 2011-03-18 | 2018-05-16 | ClinicalTrials.gov |
| NCT01329978 | Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Geno… | Phase2 | Hepatitis C, Chronic | Completed | 2011-03-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01319253 | A Comparator Study Evaluating Microbiological Resistance and Effects of Alterna… | — | Cystic Fibrosis | Completed | 2011-03-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01505179 | The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure W… | Na | Heart Failure With Preserved Ejection Fraction | Completed | 2011-02-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01751555 | Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection | Phase4 | Hiv | Completed | 2011-02-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01480336 | The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot | Na | Arrhythmia | Completed | 2011-02-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01309243 | Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtrici… | Phase3 | HIV-1 Infection | Completed | 2011-02-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01306643 | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Pre… | Phase1 | Indolent Non-Hodgkin's Lymphoma | Completed | 2011-02-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT01273402 | Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastati… | Phase1 | Metastatic Colorectal Cancer | Withdrawn | 2011-02-01 | 2018-08-01 | ClinicalTrials.gov |
| NCT01304095 | Ranolazine, Ethnicity and the Metabolic Syndrome | Phase4 | Coronary Artery Disease | Unknown | 2011-01-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01286740 | Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricit… | Phase2 | HIV-1 Infection | Completed | 2011-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01316237 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Act… | Phase1 | Hepatitis C, Chronic | Completed | 2011-01-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01362231 | A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Pat… | Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2010-12-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01260350 | Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Na… | Phase2 | Chronic Hepatitis C Infection | Completed | 2010-12-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01252940 | Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Pro… | Phase3 | HIV-1 Infection | Completed | 2010-11-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01178073 | A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects… | Phase3 | Hypertension, Pulmonary | Completed | 2010-10-01 | 2014-07-31 | ClinicalTrials.gov |
| NCT01225380 | A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-925… | Phase2 | Chronic Hepatitis C Infection | Completed | 2010-10-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01147393 | Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in … | Phase1 | Follicular Lymphoma | Terminated | 2010-10-01 | 2015-07-31 | ClinicalTrials.gov |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or S… | Phase2 | Chronic Lymphocytic Leukemia (CLL) | Terminated | 2010-10-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01271790 | A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasy… | Phase2 | Hepatitis C, Chronic | Completed | 2010-10-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01352416 | Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery | Phase3 | Heart; Dysfunction Postoperative, Cardiac Surgery | Terminated | 2010-09-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01221272 | Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Ex… | Phase4 | Myocardial Perfusion Imaging | Completed | 2010-09-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01193478 | A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects Wit… | Phase1 | HCV Infection | Completed | 2010-08-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01334567 | Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for S… | Phase2 | Hepatitis B | Completed | 2010-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01188772 | Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatm… | Phase2 | Hepatitis C Virus | Completed | 2010-08-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patien… | Phase1 | Multiple Myeloma | Terminated | 2010-07-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01322932 | Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' … | — | HIV Infection | Completed | 2010-07-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01174173 | Ranolazine and Pulmonary Hypertension | Phase3 | Angina | Completed | 2010-06-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01323933 | First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults Wi… | Phase1 | Neoplasms | Completed | 2010-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01163721 | Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects Wit… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2010-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01101581 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | Phase1 | Non Hodgkin's Lymphoma | Withdrawn | 2010-05-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01108510 | Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazana… | Phase3 | HIV | Completed | 2010-04-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01163734 | Ranolazine in Diastolic Heart Failure | Phase2 | Diastolic Heart Failure | Completed | 2010-04-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01033760 | Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) | Phase3 | HIV-1 Infections | Completed | 2010-04-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01106586 | Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted … | Phase3 | HIV | Completed | 2010-04-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01088048 | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Im… | Phase1 | Indolent Non-Hodgkin's Lymphoma | Completed | 2010-03-25 | 2015-04-28 | ClinicalTrials.gov |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-11… | Phase1 | Chronic Lymphocytic Leukemia | Terminated | 2010-03-22 | 2018-06-18 | ClinicalTrials.gov |
| NCT01095796 | Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human I… | Phase3 | HIV | Completed | 2010-03-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01224210 | Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open La… | Phase3 | Portopulmonary Hypertension | Completed | 2010-03-01 | 2020-03-01 | ClinicalTrials.gov |
| NCT01067443 | Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG)… | Phase2 | Primary Visceral Leishmaniasis | Completed | 2010-03-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT06607601 | CARE Initiative: Real-world Emulation of the PALOMA-2 Trial | — | Metastatic Breast Cancer | Completed | 2010-02-01 | 2023-07-20 | ClinicalTrials.gov |
| NCT01093885 | Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Sys… | Na | Systemic Sclerosis | Completed | 2010-02-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01072695 | Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With … | Phase2 | HCV Infection | Completed | 2010-02-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01072669 | Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow… | Na | Ischemia | Completed | 2010-02-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01059565 | Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patien… | Phase3 | Cystic Fibrosis | Completed | 2010-02-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT06607393 | CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] | — | Metastatic Nonsmall Cell Lung Cancer | Completed | 2010-02-01 | 2023-06-28 | ClinicalTrials.gov |
| NCT06585189 | CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | — | Metastatic Non Small Cell Lung Cancer | Completed | 2010-02-01 | 2023-04-13 | ClinicalTrials.gov |
| NCT01054729 | Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and R… | Phase2 | Hepatitis C | Completed | 2010-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01066611 | Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Expo… | Phase1 | Allergic Rhinitis | Completed | 2010-01-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00936195 | Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in … | Phase3 | HIV Infection | Withdrawn | 2010-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01279707 | Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leu… | Phase1 | Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | Unknown | 2010-01-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01025713 | A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS … | Phase1 | Cystic Fibrosis | Withdrawn | 2009-12-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01025427 | HIV Persistence and Viral Reservoirs | Phase4 | HIV | Completed | 2009-12-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01035879 | Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M… | Phase2 | Diabetes | Completed | 2009-12-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00946595 | Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintena… | Phase2 | HIV Infections | Completed | 2009-11-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00650949 | Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma | Phase1 | Glioblastoma Multiforme | Terminated | 2009-11-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00928187 | Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Afric… | Phase3 | HIV | Completed | 2009-11-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT00999531 | A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 i… | Phase1 | Cystic Fibrosis | Completed | 2009-10-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00989586 | Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-C… | Phase1 | Lymphoma | Completed | 2009-09-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT00951522 | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in … | Phase1 | Cystic Fibrosis | Completed | 2009-09-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00936715 | Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumara… | Phase2 | Chronic Hepatitis B | Completed | 2009-08-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT00879229 | ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Assoc… | Phase3 | Idiopathic Pulmonary Fibrosis | Terminated | 2009-07-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00822315 | Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Rec… | Phase2 | HIV Infections | Completed | 2009-07-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00932971 | HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis | Phase2 | Hepatitis D | Completed | 2009-06-01 | 2017-08-02 | ClinicalTrials.gov |
| NCT00738049 | Darusentan Effect on PET Uptake Heterogeneity | Phase2 | Coronary Artery Disease | Completed | 2009-06-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00892437 | Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boos… | Phase2 | HIV-1 Infection | Completed | 2009-05-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT00811954 | Comparative Study of Three NNRTI-Sparing HAART Regimens | Phase3 | HIV Infection | Completed | 2009-05-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00874796 | Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Ch… | Phase2 | HCV Infection | Terminated | 2009-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00867048 | Strategic Timing of Antiretroviral Treatment | Phase4 | HIV Infection | Completed | 2009-04-15 | 2022-07-27 | ClinicalTrials.gov |
| NCT00868478 | The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocyti… | Phase1 | Chronic Lymphocytic Leukemia | Unknown | 2009-04-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00907764 | Stress Echocardiography Study With Regadenoson | Phase2 | Heart Disease | Terminated | 2009-04-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00869557 | Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodefi… | Phase2 | HIV | Completed | 2009-04-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01051960 | Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment Wit… | Phase4 | Systemic Sclerosis | Completed | 2009-03-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00825929 | Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. | — | HIV Infections | Recruiting | 2009-02-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT00836914 | Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Expo… | Phase1 | Allergic Rhinitis | Completed | 2009-02-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00832572 | Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneurop… | Phase4 | Coronary Artery Disease | Terminated | 2009-01-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00905151 | HIV and Kidney Function Study | — | HIV Infections | Completed | 2009-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00832507 | Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) | Phase2 | Pulmonary Arterial Hypertension | Terminated | 2009-01-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00840463 | Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan | Phase4 | Pulmonary Hypertension | Terminated | 2009-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT00823342 | ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monoth… | Phase3 | HBe Negative Chronic Hepatitis B | Terminated | 2008-12-14 | 2008-12-14 | ClinicalTrials.gov |
| NCT01772940 | Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a… | Phase4 | HIV-1 Infection | Completed | 2008-12-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00734162 | Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatit… | Phase3 | Hepatitis B Virus (HBV) | Completed | 2008-12-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT00814372 | Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With P… | Phase2 | Type 2 Diabetes Mellitus | Terminated | 2008-12-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00805025 | Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patie… | Phase2 | Bronchiectasis | Completed | 2008-12-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00768300 | (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effec… | Phase3 | Idiopathic Pulmonary Fibrosis | Terminated | 2008-12-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00777920 | Study of Ambrisentan in Participants With Pulmonary Hypertension | Phase3 | Pulmonary Hypertension | Completed | 2008-11-17 | 2019-09-11 | ClinicalTrials.gov |
| NCT00851929 | Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension | Phase2 | Sarcoidosis | Completed | 2008-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00800579 | Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Hea… | Phase1 | Cystic Fibrosis | Completed | 2008-11-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00794586 | Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patien… | Phase2 | Cystic Fibrosis | Completed | 2008-11-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00775606 | Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in … | Phase4 | Acquired Immune Deficiency Syndrome | Terminated | 2008-10-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00772902 | ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + … | Phase4 | HIV-1 | Completed | 2008-10-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00743795 | Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Co… | Phase2 | HCV Infection | Completed | 2008-10-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01326221 | Single Dose Truvada in HIV-negative Men and Women | — | Pharmacokinetic Study in Healthy Volunteers | Completed | 2008-10-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT01338636 | An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in P… | Phase4 | Exercise-induced Pulmonary Arterial Hypertension | Completed | 2008-09-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT00737568 | Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF … | Phase3 | Hepatitis B | Completed | 2008-09-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT00757237 | Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients… | Phase3 | Cystic Fibrosis | Completed | 2008-08-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00740610 | Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With N… | Phase2 | Nonalcoholic Steatohepatitis | Completed | 2008-08-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00736190 | A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults… | Phase4 | Chronic Hepatitis B | Completed | 2008-08-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00603668 | Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in… | Phase1 | Chronic Lymphocytic Lymphoma | Completed | 2008-08-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00724711 | Safety and Efficacy Study of Switching From Epzicom to Truvada | Phase4 | HIV Infection | Completed | 2008-07-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00573001 | Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infecte… | Phase3 | HIV Infections | Completed | 2008-07-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00708162 | Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safet… | Phase3 | HIV Infection | Completed | 2008-07-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT00710528 | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic M… | Phase1 | Chronic Lymphocytic Leukemia (CLL) | Completed | 2008-06-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00712166 | Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patien… | Phase3 | Cystic Fibrosis | Completed | 2008-05-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00725803 | Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-94… | Phase2 | HCV Infection | Completed | 2008-04-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00615745 | ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV … | Phase4 | HIV Infections | Completed | 2008-04-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00617305 | Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhi… | Phase4 | Pulmonary Arterial Hypertension | Completed | 2008-04-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00660361 | A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance … | — | HIV Infections | Unknown | 2008-04-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01728935 | Tenofovir in Asian Chronic Hepatitis B Patients | Na | Chronic Hepatitis B | Completed | 2008-04-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00495651 | Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuber… | Phase3 | HIV Infections | Completed | 2008-03-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT00615810 | ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Eva… | Phase4 | HIV Infections | Completed | 2008-03-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00697944 | Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patie… | Phase4 | Sepsis | Unknown | 2008-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00713401 | Safety Study of Tecadenoson to Treat Atrial Fibrillation | Phase2 | Atrial Fibrillation | Completed | 2008-02-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00645736 | CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study | — | Chronic Hepatitis B | Completed | 2008-02-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00664378 | Efficacy Study of CYT997 in Multiple Myeloma | Phase2 | Relapsed and Refractory Multiple Myeloma | Terminated | 2008-01-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00546793 | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | Phase1 | NHL | Completed | 2008-01-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT00528060 | Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infe… | Phase2 | HIV Infections | Completed | 2008-01-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00603863 | Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcita… | Phase1 | Pancreatic Cancer | Completed | 2008-01-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00644332 | An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Res… | Phase4 | Chronic Angina | Completed | 2007-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00547066 | Study of Veltuzumab (hA20) at Different Doses in Patients With ITP | Phase1 | Purpura, Thrombocytopenic, Idiopathic | Terminated | 2007-11-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00419770 | The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study | Phase2 | Mucormycosis | Completed | 2007-10-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00499187 | Fanconi Syndrome Due to ARVs in HIV-Infected Persons | — | HIV Infections | Completed | 2007-09-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00507507 | A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Te… | Phase2 | Chronic Hepatitis B | Completed | 2007-09-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00507689 | Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of … | Phase2 | Chronic Hepatitis B | Completed | 2007-09-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00499967 | Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) fo… | Phase1 | Genital Warts | Completed | 2007-08-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00701883 | Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Modera… | Phase2 | Hyperlipidemia | Completed | 2007-08-01 | 2008-08-01 | ClinicalTrials.gov |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphom… | Phase1 | Non-Hodgkin's Lymphoma | Terminated | 2007-07-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00504972 | Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2007-06-01 | 2015-10-07 | ClinicalTrials.gov |
| NCT00389675 | DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Stu… | Phase3 | Hypertension | Terminated | 2007-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00451711 | Intermittent Liposomal Amphotericin B Primary Prophylaxis | Phase2 | Acute Myeloid Leukemia | Unknown | 2007-05-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT00670657 | CRITIC - Treatment of Candidemia and Invasive Candidiasis | Phase4 | Candidemia | Completed | 2007-05-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00444379 | Anti-Retrovirals for Kaposi's Sarcoma | Phase4 | Kaposi's Sarcoma | Completed | 2007-04-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00548041 | Rapid HIV Testing Program in the Emergency Department | Na | HIV Infections | Completed | 2007-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00561496 | Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel | Phase1 | HIV Infections | Completed | 2007-03-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00448669 | Botswana TDF/FTC Oral HIV Prophylaxis Trial | Phase2 | HIV Infections | Completed | 2007-03-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00421187 | Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to A… | Phase4 | Febrile Neutropenia | Terminated | 2007-03-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00445146 | Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatme… | Phase2 | HIV Infections | Completed | 2007-02-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT03577197 | Southeast Netherlands Advanced Metastatic Breast Cancer Registry | — | Advanced Breast Cancer | Recruiting | 2007-01-01 | 2027-12-31 | ClinicalTrials.gov |
| NCT01845740 | Phase Ib Study of SC Milatuzumab in SLE | Phase1 | Lupus Erythematosus, Cutaneous | Completed | 2007-01-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00391638 | Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtric… | Phase2 | Hepatitis B | Completed | 2007-01-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00421525 | Phase I/II Study of hLL1 in Multiple Myeloma | Phase1 | Multiple Myeloma | Completed | 2007-01-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00528957 | Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF i… | Phase3 | HIV Infections | Completed | 2006-12-28 | 2017-08-16 | ClinicalTrials.gov |
| NCT00362687 | GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Inter… | Phase4 | HIV Infections | Completed | 2006-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00386997 | ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifung… | Phase4 | Fungal Infection | Terminated | 2006-11-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00422487 | Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes | Phase2 | Type 2 Diabetes Mellitus | Completed | 2006-10-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00334256 | Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA) | Phase2 | HIV Infection | Completed | 2006-10-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00353574 | DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protoc… | Phase3 | Hypertension | Terminated | 2006-09-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00389779 | DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in R… | Phase3 | Hypertension | Completed | 2006-09-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00960622 | Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects | Phase4 | HIV | Completed | 2006-08-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00380068 | Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension | Phase3 | Pulmonary Hypertension | Completed | 2006-08-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00389402 | BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes | Phase4 | HIV Infections | Completed | 2006-07-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00648817 | Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infec… | Phase4 | HIV Infections | Completed | 2006-07-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00330369 | DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hyperten… | Phase3 | Hypertension | Completed | 2006-06-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00352053 | Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their… | Phase3 | HIV Infections | Completed | 2006-06-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00326157 | PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk P… | Phase2 | Fungus Diseases | Completed | 2006-06-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00353587 | Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Subopt… | Phase2 | Type 2 Diabetes | Completed | 2006-05-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00324649 | Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to T… | Phase4 | HIV-1 | Completed | 2006-05-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00302822 | Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130) | Phase3 | HIV Infections | Completed | 2006-04-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00298363 | Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, a… | Phase2 | Chronic Hepatitis B | Completed | 2006-04-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00389194 | PREventing Progression of Adipose Tissue Redistribution | Phase4 | HIV Infections | Completed | 2006-04-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT01146808 | Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Recei… | Phase1 | Hepatitis B | Completed | 2006-03-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00307489 | Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subject… | Phase2 | Chronic Hepatitis B | Completed | 2006-03-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00298350 | Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combin… | Phase2 | HIV | Completed | 2006-02-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00263614 | Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or … | — | Chronic Hepatitis B | Completed | 2005-12-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00743340 | Rollover Study Protocol for Pediatric Patients in South Africa for Continued Ac… | Phase2 | HIV-1 Infection | Completed | 2005-11-22 | 2017-02-13 | ClinicalTrials.gov |
| NCT00126308 | Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic… | Phase4 | HIV-Associated Lipodystrophy | Terminated | 2005-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00885664 | Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral… | Phase4 | HIV Infections | Completed | 2005-10-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00111150 | Botswana Tenofovir Oral HIV Prophylaxis Trial | Phase2 | HIV Infection | Terminated | 2005-09-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00323492 | TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to… | Phase4 | HIV Infections | Completed | 2005-09-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00224445 | Boosted Atazanavir and Truvada Given Once-Daily - BATON Study | Phase4 | HIV Infections | Completed | 2005-09-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00128492 | Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic… | Phase3 | Cystic Fibrosis | Completed | 2005-08-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00185081 | Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imagi… | Phase1 | Colonic Neoplasms | Completed | 2005-07-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00116805 | A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for … | Phase3 | Chronic Hepatitis B | Completed | 2005-06-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT00112359 | International Safety and Efficacy Study of Aztreonam for Inhalation Solution (A… | Phase3 | Cystic Fibrosis | Completed | 2005-05-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00423592 | Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arteri… | Phase2 | Pulmonary Hypertension | Completed | 2005-05-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00120367 | Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-… | Phase2 | Leukoencephalopathy, Progressive Multifocal | Completed | 2005-04-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00476463 | Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-i… | Phase2 | Hepatitis B Virus | Completed | 2005-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00377949 | Multi-center, Web Based Observational Study of Pulmonary Hypertension in Sclero… | — | Systemic Sclerosis | Completed | 2005-02-01 | — | ClinicalTrials.gov |
| NCT00104520 | Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic… | Phase3 | Cystic Fibrosis | Completed | 2005-02-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00117676 | A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for … | Phase3 | Chronic Hepatitis B | Completed | 2005-02-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT00924898 | Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805) | Phase4 | Acute HIV Infection | Completed | 2005-01-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00323544 | SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV … | Phase3 | HIV Infections | Completed | 2004-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00099788 | Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acut… | Phase3 | Myocardial Ischemia | Completed | 2004-10-01 | 2007-02-01 | ClinicalTrials.gov |
| NCT00106379 | Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 P… | Phase4 | HIV Infections | Completed | 2004-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00285428 | Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lympho… | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2004-09-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00224458 | Combination of Efavirenz and Truvada - COMET Study | Phase4 | HIV Infections | Completed | 2004-09-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00323687 | SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada | Phase4 | HIV-1 Infection | Completed | 2004-09-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00597129 | Safety and Efficacy Study of 90Y-hPAM4 at Different Doses | Phase1 | Pancreatic Cancer | Completed | 2004-08-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00113802 | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | Phase2 | Waldenstrom Macroglobulinemia | Terminated | 2004-08-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00091429 | Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Ma… | Phase3 | Angina | Completed | 2004-08-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT00095121 | Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chro… | Phase3 | Chronic Hepatitis B | Completed | 2004-06-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00364026 | A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy i… | Phase2 | Hypertension | Completed | 2004-06-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00158457 | Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavire… | Phase3 | HIV Infection | Completed | 2004-06-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00148148 | A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for… | Phase2 | Hematopoietic Stem Cell Transplantation | Completed | 2004-05-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00208312 | ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing My… | Phase3 | Coronary Artery Disease | Completed | 2004-04-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00127959 | Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and… | Phase4 | HIV Infections | Completed | 2004-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00334412 | COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Inva… | Phase4 | Invasive Aspergillosis | Completed | 2004-03-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00596804 | Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lym… | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2004-03-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00578786 | A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Ha… | Phase3 | Pulmonary Arterial Hypertension | Completed | 2004-02-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00644761 | PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipi… | Phase2 | Hepatitis B | Completed | 2004-02-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00091598 | ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hype… | Phase3 | Pulmonary Hypertension | Completed | 2004-01-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00192595 | Tenofovir in HIV/HBV Coinfection | Phase4 | HIV Infection | Completed | 2004-01-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00423202 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety … | Phase3 | Pulmonary Arterial Hypertension | Completed | 2003-12-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00423748 | Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary A… | Phase3 | Pulmonary Arterial Hypertension | Completed | 2003-12-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00362544 | PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBi… | Phase4 | Leukemia | Completed | 2003-10-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00208299 | ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing My… | Phase3 | Coronary Artery Disease | Completed | 2003-10-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00112047 | Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz… | Phase3 | HIV Infections | Completed | 2003-07-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00077948 | Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced … | Phase3 | Heart Failure, Congestive | Terminated | 2003-07-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT01055847 | Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa … | Phase2 | Cystic Fibrosis | Completed | 2003-06-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00071201 | Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Pat… | Phase3 | Chronic Hepatitis B | Completed | 2003-06-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00424021 | Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension | Phase2 | Pulmonary Hypertension | Completed | 2003-04-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00230477 | Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in … | Phase4 | Hepatitis B | Completed | 2003-04-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00158717 | Observational Study of the Durability of Seroconversion Chronic HBV Patients Wh… | — | Hepatitis B | Completed | 2003-04-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00158730 | Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome… | Phase3 | Invasive Aspergillosis | Completed | 2003-04-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00324688 | Safety Study of Once a Day ART and Opiate Substitute. | Phase4 | HIV Infections | Completed | 2003-03-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00643968 | Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine… | Phase4 | HIV Infections | Completed | 2003-03-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00054834 | Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma | Phase1 | Non-Hodgkins Lymphoma | Terminated | 2003-03-01 | — | ClinicalTrials.gov |
| NCT00645294 | Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil i… | Phase1 | Hepatitis B | Completed | 2003-02-01 | 2003-08-01 | ClinicalTrials.gov |
| NCT00647946 | Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue | Phase2 | Lipodystrophy | Completed | 2003-02-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00642291 | An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral A… | Phase2 | HIV Infections | Completed | 2002-11-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00046319 | Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Art… | Phase2 | Pulmonary Hypertension | Completed | 2002-09-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00421395 | Safety Study of NHL With 90Y-hLL2 IgG | Phase1 | NHL | Completed | 2002-08-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00122577 | Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritona… | Phase2 | HIV Infections | Terminated | 2002-03-01 | 2004-07-01 | ClinicalTrials.gov |
| NCT00036634 | A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients | Phase1 | HIV Infections | Completed | 2002-03-01 | 2003-02-01 | ClinicalTrials.gov |
| NCT00051285 | ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure" | Phase3 | Heart Failure, Congestive | Terminated | 2002-02-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT00158704 | Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV I… | Na | Hepatitis B | Terminated | 2002-01-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00016588 | Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti… | Na | HIV Infections | Completed | 2001-05-01 | — | ClinicalTrials.gov |
| NCT00196612 | Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART | Phase3 | HIV Infections | Completed | 2001-04-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00011089 | Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success… | Na | HIV Infections | Unknown | 2001-02-01 | — | ClinicalTrials.gov |
| NCT00061425 | Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2000-08-01 | — | ClinicalTrials.gov |
| NCT00158821 | Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing T… | Phase3 | HIV Infections | Completed | 2000-03-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | Phase1 | Colorectal Cancer | Completed | 2000-02-01 | 2003-06-01 | ClinicalTrials.gov |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | Phase1 | Colorectal Cancer | Completed | 2000-01-01 | 2004-01-01 | ClinicalTrials.gov |
| NCT00263315 | Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis | Phase2 | Aspergillosis | Completed | 2000-01-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00041639 | Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer | Phase1 | Pancreatic Neoplasms | Completed | 2000-01-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00002453 | A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV… | Na | HIV Infections | Completed | 1999-12-01 | — | ClinicalTrials.gov |
| NCT00196599 | Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Nai… | Phase2 | HIV Infections | Completed | 1999-02-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00003337 | Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With … | Phase3 | Lymphoma | Unknown | 1997-03-01 | — | ClinicalTrials.gov |
| NCT00003338 | Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been T… | Phase2 | Lymphoma | Unknown | 1997-03-01 | — | ClinicalTrials.gov |
| NCT00404989 | Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any M… | — | HIV Infections | Recruiting | 1989-01-01 | 2099-01-01 | ClinicalTrials.gov |
Total clinical trials: 1181
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Stable Baseline Regimen | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT05502341 |
| BIC/LEN FDC | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT05502341 |
| Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT05502341 |
| Bictegravir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT05502341 |
| GS-1206 | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT07703878 |
| PTM F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| PTM F/TAF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| PTM Oral LEN | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| Placebo SC LEN | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| F/TAF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| Subcutaneous (SC) Lenacapavir (LEN) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| Oral Lenacapavir (LEN) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| Nasal Swab | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Biospecimen Collection | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Survey Administration | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Remdesivir | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| B/F/TAF | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT07645287 |
| Lenacapavir Injection | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT07645287 |
| Lenacapavir Tablet | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT07645287 |
| GS-3242 Injection | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT07645287 |
| GS-3242 Tablet | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT07645287 |
| bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg | Other | Phase PHASE4 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT06374758 |
| The Accelerate model of care | Other | Phase PHASE4 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT06374758 |
| SoC Chemotherapy | Drug | Phase PHASE3 | Breast Cancer | NOT_YET_RECRUITING | NCT07178730 |
| Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA] | Other | Phase PHASE3 | Breast Cancer | NOT_YET_RECRUITING | NCT07178730 |
| Sacituzumab govitecan | Other | Phase PHASE3 | Breast Cancer | NOT_YET_RECRUITING | NCT07178730 |
| GS-2426 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07601243 |
| SBR | Other | Phase PHASE3 | HIV-1-infection | RECRUITING | NCT07683000 |
| Zinlirvimab | Other | Phase PHASE3 | HIV-1-infection | RECRUITING | NCT07683000 |
| Teropavimab | Other | Phase PHASE3 | HIV-1-infection | RECRUITING | NCT07683000 |
| Lenacapavir Tablet | Other | Phase PHASE3 | HIV-1-infection | RECRUITING | NCT07683000 |
| Lenacapavir | Other | Phase PHASE3 | HIV-1-infection | RECRUITING | NCT07683000 |
| GS-4321 Placebo | Other | Phase PHASE1 | Chronic Hepatitis Delta | RECRUITING | NCT07096193 |
| GS-4321 | Other | Phase PHASE1 | Chronic Hepatitis Delta | RECRUITING | NCT07096193 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT06486441 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT06486441 |
| Sacituzumab govitecan-hziy | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT06486441 |
| Durvalumab | Other | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | RECRUITING | NCT07339059 |
| Atezolizumab | Other | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | RECRUITING | NCT07339059 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | RECRUITING | NCT07339059 |
| Trifluridine-Tipiracil | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Bevacizumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Nivolumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Denikitug | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Zimberelimab | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05840224 |
| GS-4528 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05840224 |
| Placebo to match filgotinib | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT03025308 |
| Filgotinib | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT03025308 |
| L-AmB standard dose | Other | Phase PHASE3 | Disseminated Histoplasma Capsulatum Infection | RECRUITING | NCT05814432 |
| Single high dose of liposomal amphotericin B | Other | Phase PHASE3 | Disseminated Histoplasma Capsulatum Infection | RECRUITING | NCT05814432 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT05838521 |
| Lenacapavir Tablet | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Cabotegravir (CAB) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Emtricitabine/tenofovir alafenamide (F/TAF) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Lenacapavir Injection | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Rilpivirine | Other | Phase PHASE3 | HIV Infections | RECRUITING | NCT07682961 |
| Cabotegravir | Other | Phase PHASE3 | HIV Infections | RECRUITING | NCT07682961 |
| Zinlirvimab | Other | Phase PHASE3 | HIV Infections | RECRUITING | NCT07682961 |
| Teropavimab | Other | Phase PHASE3 | HIV Infections | RECRUITING | NCT07682961 |
| Lenacapavir Tablet | Other | Phase PHASE3 | HIV Infections | RECRUITING | NCT07682961 |
| Lenacapavir | Other | Phase PHASE3 | HIV Infections | RECRUITING | NCT07682961 |
| GS-0415 Placebo | Other | Phase PHASE1 | HIV -1 Infection | NOT_YET_RECRUITING | NCT07719491 |
| GS-0415 | Other | Phase PHASE1 | HIV -1 Infection | NOT_YET_RECRUITING | NCT07719491 |
| Beiwe | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT05378399 |
| ID-Cap System | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT05378399 |
| Descovy or Truvada | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT05378399 |
| Sacituzumab govitecan | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05552001 |
| Adaptive Radiotherapy | Drug | Phase PHASE1 | Localized Muscle Invasive Bladder Urothelial Carcinoma | RECRUITING | NCT05833867 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Localized Muscle Invasive Bladder Urothelial Carcinoma | RECRUITING | NCT05833867 |
| Pembrolizumab | Other | Phase PHASE2 | Invasive Breast Cancer | RECRUITING | NCT04230109 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Invasive Breast Cancer | RECRUITING | NCT04230109 |
| Emtricitabine/Tenofovir | Other | Phase PHASE4 | HIV | ACTIVE_NOT_RECRUITING | NCT02656511 |
| Dolutegravir | Other | Phase PHASE4 | HIV | ACTIVE_NOT_RECRUITING | NCT02656511 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Decision Support Tool | Other | Approved | Breast Cancer Metastatic | RECRUITING | NCT07635147 |
| sacituzumab govitecan-hziy | Other | Phase PHASE1 | Solid Malignancies | TERMINATED | NCT05006794 |
| Docetaxel | Other | Phase PHASE1 | Solid Malignancies | TERMINATED | NCT05006794 |
| zamzetoclax | Other | Phase PHASE1 | Solid Malignancies | TERMINATED | NCT05006794 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| B/F/TAF | Other | Phase PHASE2 | HIV-1-infection | NOT_YET_RECRUITING | NCT07708727 |
| Lenacapavir Injection | Other | Phase PHASE2 | HIV-1-infection | NOT_YET_RECRUITING | NCT07708727 |
| Lenacapavir Tablet | Other | Phase PHASE2 | HIV-1-infection | NOT_YET_RECRUITING | NCT07708727 |
| GS-3242 Injection | Other | Phase PHASE2 | HIV-1-infection | NOT_YET_RECRUITING | NCT07708727 |
| GS-3242 Tablet | Other | Phase PHASE2 | HIV-1-infection | NOT_YET_RECRUITING | NCT07708727 |
| Research Assistant Support | Other | Approved | Shared Decision-Making | RECRUITING | NCT07652359 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Gland | RECRUITING | NCT05884320 |
| Capecitabine | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| Pembrolizumab | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| Sacituzumab govitecan-hziy (SG) | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| GS-1206 | Other | Phase PHASE1 | Solid Tumor | NOT_YET_RECRUITING | NCT07703878 |
| Giredestrant | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Atirmociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Metformin | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Palbociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Empagliflozin | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Inavolisib (Dose #2) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Letrozole | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ribociclib (Dose #2) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Trastuzumab Deruxtecan | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Inavolisib (Dose #1) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ribociclib (Dose #1) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Fulvestrant | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Abemaciclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Sacituzumab Govitecan | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Nab-Paclitaxel | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Tocilizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Selicrelumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Chemotherapy (Gemcitabine + Carboplatin or Eribulin) | Drug | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Bevacizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| SGN-LIV1A | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ipatasertib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Atezolizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Capecitabine | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05101096 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Bictegravir, emtricitabine, and tenofovir alafenamide | Other | Phase PHASE4 | HIV -1 Infection | RECRUITING | NCT07476339 |
| B/F/TAF | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT07645287 |
| Lenacapavir Injection | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT07645287 |
| Lenacapavir Tablet | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT07645287 |
| GS-3242 Injection | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT07645287 |
| GS-3242 Tablet | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT07645287 |
| Rilpivirine | Other | Phase PHASE3 | HIV Infections | NOT_YET_RECRUITING | NCT07682961 |
| Cabotegravir | Other | Phase PHASE3 | HIV Infections | NOT_YET_RECRUITING | NCT07682961 |
| Zinlirvimab | Other | Phase PHASE3 | HIV Infections | NOT_YET_RECRUITING | NCT07682961 |
| Teropavimab | Other | Phase PHASE3 | HIV Infections | NOT_YET_RECRUITING | NCT07682961 |
| Lenacapavir Tablet | Other | Phase PHASE3 | HIV Infections | NOT_YET_RECRUITING | NCT07682961 |
| Lenacapavir | Other | Phase PHASE3 | HIV Infections | NOT_YET_RECRUITING | NCT07682961 |
| SBR | Other | Phase PHASE3 | HIV-1-infection | NOT_YET_RECRUITING | NCT07683000 |
| Zinlirvimab | Other | Phase PHASE3 | HIV-1-infection | NOT_YET_RECRUITING | NCT07683000 |
| Teropavimab | Other | Phase PHASE3 | HIV-1-infection | NOT_YET_RECRUITING | NCT07683000 |
| Lenacapavir Tablet | Other | Phase PHASE3 | HIV-1-infection | NOT_YET_RECRUITING | NCT07683000 |
| Lenacapavir | Other | Phase PHASE3 | HIV-1-infection | NOT_YET_RECRUITING | NCT07683000 |
| General educational messages | Other | Approved | HIV Prevention | NOT_YET_RECRUITING | NCT05968755 |
| A chatbot designed to promote PrEP awareness and uptake for Black MSM | Other | Approved | HIV Prevention | NOT_YET_RECRUITING | NCT05968755 |
| Trifluridine-Tipiracil | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Bevacizumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Nivolumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Denikitug | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Obeldesivir Placebo | Other | Phase PHASE2 | RSV Infection | TERMINATED | NCT06585150 |
| Obeldesivir | Other | Phase PHASE2 | RSV Infection | TERMINATED | NCT06585150 |
| Lenacapavir Tablet | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Cabotegravir (CAB) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Emtricitabine/tenofovir alafenamide (F/TAF) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Lenacapavir Injection | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| GS-2426 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07601243 |
| Thymoglobulines | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| Fludarabine | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| allogeneic stem cell transplantation. | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| Busulfan | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Decision Support Tool | Other | Approved | Breast Cancer Metastatic | RECRUITING | NCT07635147 |
| Lenacapavir Tablet | Other | Phase PHASE3 | HIV Pre-exposure Prophylaxis | ACTIVE_NOT_RECRUITING | NCT07047716 |
| Lenacapavir Injection | Other | Phase PHASE3 | HIV Pre-exposure Prophylaxis | ACTIVE_NOT_RECRUITING | NCT07047716 |
| Standard-of-care HIV PrEP counseling from qualified study staff | Other | Phase PHASE3 | HIV Infection | NOT_YET_RECRUITING | NCT07658976 |
| Handout about HIV PrEP options available at the site | Other | Phase PHASE3 | HIV Infection | NOT_YET_RECRUITING | NCT07658976 |
| 3P mHealth package | Other | Phase PHASE3 | HIV Infection | NOT_YET_RECRUITING | NCT07658976 |
| STI PEP - Doxycycline as Doxy-PEP | Other | Phase PHASE3 | HIV Infection | NOT_YET_RECRUITING | NCT07658976 |
| HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA | Other | Phase PHASE3 | HIV Infection | NOT_YET_RECRUITING | NCT07658976 |
| Omeprazole | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| GS-4571 | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| co-formulated 25mg TAF/ 200mg FTC | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT05140954 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT02932150 |
| TAF | Other | Phase PHASE2 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT02932150 |
| B/F/TAF | Other | Phase PHASE1 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT07055451 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Giredestrant | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Atirmociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Metformin | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Palbociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Empagliflozin | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Inavolisib (Dose #2) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Letrozole | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ribociclib (Dose #2) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Trastuzumab Deruxtecan | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Inavolisib (Dose #1) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ribociclib (Dose #1) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Fulvestrant | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Abemaciclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Sacituzumab Govitecan | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Nab-Paclitaxel | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Tocilizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Selicrelumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Chemotherapy (Gemcitabine + Carboplatin or Eribulin) | Drug | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Bevacizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| SGN-LIV1A | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ipatasertib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Atezolizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Capecitabine | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Research Assistant Support | Other | Approved | Shared Decision-Making | NOT_YET_RECRUITING | NCT07652359 |
| lenalidomide | Other | Phase PHASE1 | Recurrent Follicular Lymphoma | COMPLETED | NCT01644799 |
| idelalisib | Other | Phase PHASE1 | Recurrent Follicular Lymphoma | COMPLETED | NCT01644799 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| efavirenz (drug) | Drug | Phase PHASE2 | HIV Infections | COMPLETED | NCT00196599 |
| didanosine, ddI (drug) | Drug | Phase PHASE2 | HIV Infections | COMPLETED | NCT00196599 |
| emtricitabine, FTC (drug) | Drug | Phase PHASE2 | HIV Infections | COMPLETED | NCT00196599 |
| efavirenz (drug) | Drug | Phase PHASE3 | HIV Infections | COMPLETED | NCT00196612 |
| didanosine, ddI (drug) | Drug | Phase PHASE3 | HIV Infections | COMPLETED | NCT00196612 |
| emtricitabine, FTC (drug) | Drug | Phase PHASE3 | HIV Infections | COMPLETED | NCT00196612 |
| Placebo to match BIC/LEN | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| Placebo to match B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| Lenacapavir | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| Bictegravir | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| B/F/TAF | Other | Phase PHASE2 | HIV-1-infection | NOT_YET_RECRUITING | NCT07645287 |
| Lenacapavir Injection | Other | Phase PHASE2 | HIV-1-infection | NOT_YET_RECRUITING | NCT07645287 |
| Lenacapavir Tablet | Other | Phase PHASE2 | HIV-1-infection | NOT_YET_RECRUITING | NCT07645287 |
| GS-3242 Injection | Other | Phase PHASE2 | HIV-1-infection | NOT_YET_RECRUITING | NCT07645287 |
| GS-3242 Tablet | Other | Phase PHASE2 | HIV-1-infection | NOT_YET_RECRUITING | NCT07645287 |
| Trifluridine-Tipiracil | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Bevacizumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Nivolumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Denikitug | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | RECRUITING | NCT07527858 |
| Bulevirtide | Other | Preclinical | Chronic Hepatitis Delta Virus Infection | APPROVED_FOR_MARKETING | NCT06780579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Endometrial Carcinoma | ACTIVE_NOT_RECRUITING | NCT04251416 |
| Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening | Other | Approved | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06019988 |
| GS-4321 Placebo | Other | Phase PHASE1 | Chronic Hepatitis Delta | RECRUITING | NCT07096193 |
| GS-4321 | Other | Phase PHASE1 | Chronic Hepatitis Delta | RECRUITING | NCT07096193 |
| Placebo | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| GS-2872 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| GS-5423 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| Vesatolimod (VES) | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| MVA.tHIVconsv4 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| MVA.tHIVconsv3 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| ChAdOx1.HIVconsv62 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| ChAdOx1.tHIVconsv1 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| Capecitabine | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| Pembrolizumab | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| Sacituzumab govitecan-hziy (SG) | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| TL+D antiretroviral | Other | Approved | HIV | COMPLETED | NCT07618507 |
| Lopinavir Boosted with ritonavir (LPV/r) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| DRV | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| ATV | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Nucleos(t)ide reverse transcriptase inhibitors (NRTI) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| 3rd ARV Agent | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (Lowest Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (Low Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (High Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (Low Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (High Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Cobicistat (TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Cobicistat (Low Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Cobicistat (High Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| E/C/F/TAF (Low Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| E/C/F/TAF | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Lowest Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Low Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (High Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Lowest Dose Tablet) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Low Dose Tablet) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (High Dose Tablet) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Decision Support Tool | Other | Approved | Breast Cancer Metastatic | NOT_YET_RECRUITING | NCT07635147 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06902519 |
| GS-0151 | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06902519 |
| Obeldesivir Placebo | Other | Phase PHASE2 | RSV Infection | TERMINATED | NCT06784973 |
| Obeldesivir | Other | Phase PHASE2 | RSV Infection | TERMINATED | NCT06784973 |
| SoC Chemotherapy | Drug | Phase PHASE3 | Breast Cancer | NOT_YET_RECRUITING | NCT07178730 |
| Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA] | Other | Phase PHASE3 | Breast Cancer | NOT_YET_RECRUITING | NCT07178730 |
| Sacituzumab govitecan | Other | Phase PHASE3 | Breast Cancer | NOT_YET_RECRUITING | NCT07178730 |
| TDF/3TC/EFV | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT04296695 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT04296695 |
| BIC/LEN FDC | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06532656 |
| Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06532656 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT03725761 |
| Sample Collection | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Medical History Review | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Survey | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | COMPLETED | NCT06060665 |
| Seladelpar 10 mg | Other | Phase PHASE3 | Primary Biliary Cholangitis | COMPLETED | NCT06060665 |
| Nasal Swab | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Biospecimen Collection | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Survey Administration | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Remdesivir | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Pre-Exposure Prophylaxis (PrEP) Persistence | Other | Approved | HIV Pre-exposure Prophylaxis | RECRUITING | NCT07462611 |
| PrEP Uptake with Rapid Start | Other | Approved | HIV Pre-exposure Prophylaxis | RECRUITING | NCT07462611 |
| Pembrolizumab | Other | Phase PHASE2 | Invasive Breast Cancer | RECRUITING | NCT04230109 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Invasive Breast Cancer | RECRUITING | NCT04230109 |
| Vinflunine | Other | Phase PHASE3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | COMPLETED | NCT04527991 |
| Docetaxel | Other | Phase PHASE3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | COMPLETED | NCT04527991 |
| Paclitaxel | Other | Phase PHASE3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | COMPLETED | NCT04527991 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | COMPLETED | NCT04527991 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumor | RECRUITING | NCT04617522 |
| TL+D antiretroviral | Other | Approved | HIV | COMPLETED | NCT07618507 |
| Nivolumab | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Docetaxel | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Nab-paclitaxel | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Paclitaxel | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Pemetrexed | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Cisplatin | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Carboplatin | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Etrumadenant (ETRUMA) | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Sacituzumab govitecan-hziy (SG) | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Domvanalimab (DOM) | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Zimberelimab (ZIM) | Other | Phase PHASE2 | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05633667 |
| Tenofovir Disoproxil | Other | Preclinical | HIV | ACTIVE_NOT_RECRUITING | NCT04453436 |
| Platinum-Based Doublet | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Docetaxel | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Zimberelimab | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Quemliclustat | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Domvanalimab | Other | Phase PHASE2 | Advanced Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05676931 |
| Antiretroviral Combinations | Other | Phase PHASE3 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06630299 |
| ISL/LEN | Other | Phase PHASE3 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06630299 |
| Lenacapavir Tablet | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Cabotegravir (CAB) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Emtricitabine/tenofovir alafenamide (F/TAF) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Lenacapavir Injection | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Sacituzumab govitecan-hziy | Other | Phase PHASE2 | Mesothelioma | RECRUITING | NCT06477419 |
| Sacituzumab Govitecan | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06167317 |
| GS-0201 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06167317 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| GS-0272 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| Omeprazole | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| GS-4571 | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| GS-0272 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| Omeprazole | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| GS-4571 | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| GS-0272 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| Omeprazole | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| GS-4571 | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| GS-0272 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Omeprazole | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| GS-4571 | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| GS-0272 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Omeprazole | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| GS-4571 | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| GS-0272 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Omeprazole | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| GS-4571 | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| GS-0272 | Other | Phase PHASE1 | Rheumatoid Arthritis | TERMINATED | NCT06031415 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Omeprazole | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| GS-4571 | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| GS-2426 | Other | Phase PHASE1 | Advanced Solid Tumors | NOT_YET_RECRUITING | NCT07601243 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| Filgotinib | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| GS-2426 | Other | Phase PHASE1 | Advanced Solid Tumors | NOT_YET_RECRUITING | NCT07601243 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| Filgotinib | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| GS-2426 | Other | Phase PHASE1 | Advanced Solid Tumors | NOT_YET_RECRUITING | NCT07601243 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| Filgotinib | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| GS-2426 | Other | Phase PHASE1 | Advanced Solid Tumors | NOT_YET_RECRUITING | NCT07601243 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| Filgotinib | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| GS-2426 | Other | Phase PHASE1 | Advanced Solid Tumors | NOT_YET_RECRUITING | NCT07601243 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| Filgotinib | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Lurbinectedin (regions/countries where approved and available) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | RECRUITING | NCT07546812 |
| Adefovir dipivoxil | Other | Approved | HIV Infections | COMPLETED | NCT00002398 |
| Levocarnitine | Other | Approved | HIV Infections | COMPLETED | NCT00002398 |
| Adefovir dipivoxil | Other | Approved | HIV Infections | COMPLETED | NCT00002398 |
| Levocarnitine | Other | Approved | HIV Infections | COMPLETED | NCT00002398 |
| Adefovir dipivoxil | Other | Approved | HIV Infections | COMPLETED | NCT00002398 |
| Levocarnitine | Other | Approved | HIV Infections | COMPLETED | NCT00002398 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE1 | HIV Infections | UNKNOWN | NCT00002396 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE1 | HIV Infections | UNKNOWN | NCT00002396 |
| Adefovir dipivoxil | Other | Approved | HIV Infections | COMPLETED | NCT00002161 |
| Adefovir dipivoxil | Other | Approved | HIV Infections | COMPLETED | NCT00002161 |
| Hepsera | Other | Approved | Hepatitis B | TERMINATED | NCT00158704 |
| Hepsera | Other | Approved | Hepatitis B | TERMINATED | NCT00158704 |
| Tenofovir disoproxil fumarate | Other | Approved | HIV Infections | COMPLETED | NCT00016588 |
| Tenofovir disoproxil fumarate | Other | Approved | HIV Infections | COMPLETED | NCT00016588 |
| Tenofovir disoproxil fumarate | Other | Approved | HIV Infections | UNKNOWN | NCT00011089 |
| Tenofovir disoproxil fumarate | Other | Approved | HIV Infections | UNKNOWN | NCT00011089 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE3 | HIV Infections | UNKNOWN | NCT00007436 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE3 | HIV Infections | UNKNOWN | NCT00007436 |
| Tenofovir disoproxil fumarate | Other | Approved | HIV Infections | COMPLETED | NCT00002453 |
| Tenofovir disoproxil fumarate | Other | Approved | HIV Infections | COMPLETED | NCT00002453 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00002450 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00002450 |
| Probenecid | Other | Phase PHASE2 | Cytomegalovirus Retinitis | COMPLETED | NCT00002437 |
| Cidofovir | Other | Phase PHASE2 | Cytomegalovirus Retinitis | COMPLETED | NCT00002437 |
| Adefovir dipivoxil | Other | Approved | HIV Infections | COMPLETED | NCT00002426 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002415 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002415 |
| Cidofovir | Other | Approved | Cytomegalovirus Retinitis | UNKNOWN | NCT00002384 |
| Zidovudine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Stavudine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Lamivudine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Adefovir dipivoxil | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Levocarnitine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Indinavir sulfate | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Zidovudine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Stavudine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Lamivudine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Adefovir dipivoxil | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Levocarnitine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Indinavir sulfate | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002379 |
| Adefovir dipivoxil | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002346 |
| Adefovir dipivoxil | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002346 |
| Cidofovir | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002327 |
| Cidofovir | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002327 |
| Zidovudine | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002326 |
| Adefovir | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002326 |
| Zidovudine | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002326 |
| Adefovir | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002326 |
| Adefovir dipivoxil | Other | Phase PHASE2 | HIV Infections | UNKNOWN | NCT00002219 |
| Levocarnitine | Other | Phase PHASE2 | HIV Infections | UNKNOWN | NCT00002219 |
| Nelfinavir mesylate | Other | Phase PHASE2 | HIV Infections | UNKNOWN | NCT00002219 |
| Adefovir dipivoxil | Other | Phase PHASE2 | HIV Infections | UNKNOWN | NCT00002219 |
| Levocarnitine | Other | Phase PHASE2 | HIV Infections | UNKNOWN | NCT00002219 |
| Nelfinavir mesylate | Other | Phase PHASE2 | HIV Infections | UNKNOWN | NCT00002219 |
| Adefovir dipivoxil | Other | Phase PHASE2 | HIV Infections | UNKNOWN | NCT00002219 |
| Levocarnitine | Other | Phase PHASE2 | HIV Infections | UNKNOWN | NCT00002219 |
| Nelfinavir mesylate | Other | Phase PHASE2 | HIV Infections | UNKNOWN | NCT00002219 |
| Adefovir dipivoxil | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002206 |
| Adefovir dipivoxil | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002206 |
| Zidovudine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002184 |
| Stavudine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002184 |
| Lamivudine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002184 |
| Saquinavir | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002184 |
| Adefovir dipivoxil | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002184 |
| Levocarnitine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002184 |
| Nelfinavir mesylate | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00002184 |
| Cidofovir | Other | Approved | Herpes Simplex | COMPLETED | NCT00002181 |
| Cidofovir | Other | Approved | Herpes Simplex | COMPLETED | NCT00002181 |
| Tenofovir | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002180 |
| Tenofovir | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002180 |
| Tenofovir | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002180 |
| Probenecid | Other | Approved | Cytomegalovirus Retinitis | COMPLETED | NCT00002142 |
| Cidofovir | Other | Approved | Cytomegalovirus Retinitis | COMPLETED | NCT00002142 |
| Probenecid | Other | Approved | Cytomegalovirus Retinitis | COMPLETED | NCT00002142 |
| Cidofovir | Other | Approved | Cytomegalovirus Retinitis | COMPLETED | NCT00002142 |
| Adefovir dipivoxil | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002128 |
| Adefovir dipivoxil | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002128 |
| Cidofovir | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT00002116 |
| Cidofovir | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT00002116 |
| Cidofovir | Other | Phase PHASE1 | Herpes Simplex | COMPLETED | NCT00002116 |
| Adefovir | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002115 |
| Adefovir | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00002115 |
| AmBisome | Other | Phase PHASE3 | Invasive Aspergillosis | COMPLETED | NCT00158730 |
| AmBisome | Other | Phase PHASE3 | Invasive Aspergillosis | COMPLETED | NCT00158730 |
| Zidovudine (drug) | Drug | Phase PHASE4 | HIV | UNKNOWN | NCT00199121 |
| Zidovudine (drug) | Drug | Phase PHASE4 | HIV | UNKNOWN | NCT00199121 |
| nebulised liposomal amphotericin B | Other | Phase PHASE2 | Aspergillosis | COMPLETED | NCT00263315 |
| nebulised liposomal amphotericin B | Other | Phase PHASE2 | Aspergillosis | COMPLETED | NCT00263315 |
| darusentan | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00364026 |
| darusentan | Other | Phase PHASE2 | Hypertension | COMPLETED | NCT00364026 |
| Tenofovir Disoproxil Fumarate 300 mg daily | Other | Phase PHASE2 | HIV Infection | TERMINATED | NCT00111150 |
| Tenofovir Disoproxil Fumarate 300 mg daily | Other | Phase PHASE2 | HIV Infection | TERMINATED | NCT00111150 |
| efavirenz | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00127959 |
| zidovudine | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00127959 |
| emtricitabine | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00127959 |
| tenofovir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00127959 |
| efavirenz | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00127959 |
| zidovudine | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00127959 |
| emtricitabine | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00127959 |
| tenofovir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00127959 |
| Efavirenz (EFV) | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00158457 |
| Emtricitabine (FTC) | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00158457 |
| Tenofovir (TDF) | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00158457 |
| Efavirenz (EFV) | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00158457 |
| Emtricitabine (FTC) | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00158457 |
| Tenofovir (TDF) | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00158457 |
| liposomal amphotericin B (AmBisome®) | Other | Phase PHASE4 | Fungal Infection | TERMINATED | NCT00386997 |
| liposomal amphotericin B (AmBisome®) | Other | Phase PHASE4 | Fungal Infection | TERMINATED | NCT00386997 |
| Hepsera and lamivudine | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00230477 |
| Hepsera | Other | Phase PHASE4 | Hepatitis B | COMPLETED | NCT00230477 |
| Sample Collection | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Medical History Review | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Survey | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Sample Collection | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Medical History Review | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Survey | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Sample Collection | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Medical History Review | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Survey | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Sample Collection | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Medical History Review | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Survey | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Viread (tenofovir DF) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00106379 |
| Emtriva (emtricitabine) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00106379 |
| Truvada (tenofovir DF + emtricitabine) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00106379 |
| Viread (tenofovir DF) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00106379 |
| Emtriva (emtricitabine) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00106379 |
| Truvada (tenofovir DF + emtricitabine) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00106379 |
| Lamivudine/zidovudine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00112047 |
| FTC/TDF/EFV | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00112047 |
| FTC/TDF | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00112047 |
| Efavirenz (EFV) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00112047 |
| Tenofovir Disoproxil Fumarate (TDF) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00112047 |
| Emtricitabine (FTC) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00112047 |
| Placebo three times daily (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00712166 |
| AZLI 75 mg three times daily (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00712166 |
| Placebo three times daily (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00712166 |
| AZLI 75 mg three times daily (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00712166 |
| Placebo three times daily (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00712166 |
| AZLI 75 mg three times daily (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00712166 |
| Liposomal amphotericin B (AmBisome®) | Other | Phase PHASE4 | Febrile Neutropenia | TERMINATED | NCT00421187 |
| Placebo two times a day (BID)/three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00104520 |
| AZLI 75 mg two times a day (BID)/three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00104520 |
| Placebo two times a day (BID)/three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00104520 |
| AZLI 75 mg two times a day (BID)/three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00104520 |
| Placebo two times a day (BID)/three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00104520 |
| AZLI 75 mg two times a day (BID)/three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00104520 |
| Placebo | Other | Phase PHASE1 | Allergic Rhinitis | COMPLETED | NCT01066611 |
| CAL-263 | Other | Phase PHASE1 | Allergic Rhinitis | COMPLETED | NCT01066611 |
| Sample Collection | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Medical History Review | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Survey | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Sample Collection | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Medical History Review | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Survey | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Sample Collection | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Medical History Review | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Survey | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Sample Collection | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Medical History Review | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Survey | Other | Preclinical | COVID-19 | ACTIVE_NOT_RECRUITING | NCT05467930 |
| Adefovir Dipivoxil | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT00645294 |
| Adefovir dipivoxil | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT00645294 |
| Adefovir Dipivoxil | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT00645294 |
| Adefovir dipivoxil | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT00645294 |
| Tenofovir DF placebo | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00648817 |
| Tenofovir Disoproxil Fumarate | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00648817 |
| Adefovir Dipivoxil | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00644761 |
| Emtricitabine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00642291 |
| efavirenz | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224458 |
| Truvada | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224458 |
| Tenofovir gel | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00561496 |
| Tenofovir gel | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00561496 |
| Truvada | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT00323687 |
| Truvada | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT00323687 |
| Amphotericine in liposome (Ambisome®) | Other | Phase PHASE4 | Sepsis | UNKNOWN | NCT00697944 |
| Amphotericine in liposome (Ambisome®) | Other | Phase PHASE4 | Sepsis | UNKNOWN | NCT00697944 |
| abacavir 300mg twice daily | Other | Phase PHASE2 | Lipodystrophy | COMPLETED | NCT00647946 |
| tenofovir DF | Other | Phase PHASE2 | Lipodystrophy | COMPLETED | NCT00647946 |
| abacavir 300mg twice daily | Other | Phase PHASE2 | Lipodystrophy | COMPLETED | NCT00647946 |
| tenofovir DF | Other | Phase PHASE2 | Lipodystrophy | COMPLETED | NCT00647946 |
| EFV+3TC+TDF | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00643968 |
| EFV+TDF | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00643968 |
| EFV+3TC+TDF | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00643968 |
| EFV+TDF | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00643968 |
| emtricitabine and tenofovir DF | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00323544 |
| zidovudine and lamivudine (Combivir®) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00323544 |
| emtricitabine and tenofovir DF | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00323544 |
| zidovudine and lamivudine (Combivir®) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00323544 |
| GS-9137 - A Novel HIV-1 Integrase Inhibitor | Other | Phase PHASE2 | HIV | COMPLETED | NCT00298350 |
| GS-9137 - A Novel HIV-1 Integrase Inhibitor | Other | Phase PHASE2 | HIV | COMPLETED | NCT00298350 |
| AmBisome | Other | Phase PHASE4 | Candidemia | COMPLETED | NCT00670657 |
| AmBisome | Other | Phase PHASE4 | Candidemia | COMPLETED | NCT00670657 |
| No HAART | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00362687 |
| FTC alone | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00362687 |
| Truvada (TDF+FTC) alone | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00362687 |
| No HAART | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00362687 |
| FTC alone | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00362687 |
| Truvada (TDF+FTC) alone | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00362687 |
| No HAART | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00362687 |
| FTC alone | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00362687 |
| Truvada (TDF+FTC) alone | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00362687 |
| Placebo | Other | Phase PHASE1 | Genital Warts | COMPLETED | NCT00499967 |
| GS-9191 | Other | Phase PHASE1 | Genital Warts | COMPLETED | NCT00499967 |
| GS-9191 ointment | Other | Phase PHASE1 | Genital Warts | COMPLETED | NCT00499967 |
| Placebo | Other | Phase PHASE1 | Genital Warts | COMPLETED | NCT00499967 |
| GS-9191 | Other | Phase PHASE1 | Genital Warts | COMPLETED | NCT00499967 |
| GS-9191 ointment | Other | Phase PHASE1 | Genital Warts | COMPLETED | NCT00499967 |
| ambrisentan | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | COMPLETED | NCT00423748 |
| ambrisentan | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | COMPLETED | NCT00423202 |
| ambrisentan | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | COMPLETED | NCT00423202 |
| BSF 208075 | Other | Phase PHASE2 | Pulmonary Hypertension | COMPLETED | NCT00046319 |
| BSF 208075 | Other | Phase PHASE2 | Pulmonary Hypertension | COMPLETED | NCT00046319 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00951522 |
| GS-9411 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00951522 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00951522 |
| GS-9411 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00951522 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00800579 |
| GS-9411 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00800579 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00800579 |
| GS-9411 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00800579 |
| Placebo | Other | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00099788 |
| Ranolazine | Other | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00099788 |
| Placebo | Other | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00099788 |
| Ranolazine | Other | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00099788 |
| Placebo | Other | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00099788 |
| Ranolazine | Other | Phase PHASE3 | Myocardial Ischemia | COMPLETED | NCT00099788 |
| Ranolazine | Other | Phase PHASE3 | Angina | COMPLETED | NCT00091429 |
| Current HAART regimen | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00323492 |
| Truvada | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00323492 |
| Current HAART regimen | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00323492 |
| Truvada | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00323492 |
| Placebo | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT01055847 |
| Aztreonam for Inhalation (AI) | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT01055847 |
| Placebo | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT01055847 |
| Aztreonam for Inhalation (AI) | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT01055847 |
| Placebo | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT01055847 |
| Aztreonam for Inhalation (AI) | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT01055847 |
| AmBisome | Other | Phase PHASE2 | Fungus Diseases | COMPLETED | NCT00326157 |
| AmBisome | Other | Phase PHASE2 | Fungus Diseases | COMPLETED | NCT00326157 |
| Ambrisentan | Other | Phase PHASE3 | Pulmonary Hypertension | COMPLETED | NCT00091598 |
| Ambrisentan | Other | Phase PHASE3 | Pulmonary Hypertension | COMPLETED | NCT00091598 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00999531 |
| GS-9411 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00999531 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00999531 |
| GS-9411 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT00999531 |
| Milatuzumab | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | UNKNOWN | NCT00868478 |
| Milatuzumab | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | UNKNOWN | NCT00868478 |
| atazanavir/ritonavir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00389402 |
| saquinavir/ritonavir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00389402 |
| atazanavir/ritonavir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00389402 |
| saquinavir/ritonavir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00389402 |
| continuing AZT+3TC or switching AZT+3TC to TDF+ FTC | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00389194 |
| continuing AZT+3TC or switching AZT+3TC to TDF+ FTC | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00389194 |
| Kivexa plus Sustiva | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00615810 |
| Atripla | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00615810 |
| Kivexa plus Sustiva | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00615810 |
| Atripla | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00615810 |
| Placebo three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00112359 |
| AZLI 75 mg three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00112359 |
| Placebo three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00112359 |
| AZLI 75 mg three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00112359 |
| AZLI 75 mg two times a day (BID)/ three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00128492 |
| AZLI 75 mg two times a day (BID)/ three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00128492 |
| AZLI 75 mg two times a day (BID)/ three times a day (TID) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00128492 |
| Tobramycin Inhalation Solution (TIS) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00757237 |
| Aztreonam for Inhalation Solution (AZLI) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00757237 |
| Tobramycin Inhalation Solution (TIS) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00757237 |
| Aztreonam for Inhalation Solution (AZLI) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00757237 |
| Tobramycin Inhalation Solution (TIS) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00757237 |
| Aztreonam for Inhalation Solution (AZLI) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00757237 |
| Tobramycin Inhalation Solution (TIS) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00757237 |
| Aztreonam for Inhalation Solution (AZLI) | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT00757237 |
| Aztreonam Lysine for Inhalation | Other | Preclinical | Cystic Fibrosis | APPROVED_FOR_MARKETING | NCT00499720 |
| Aztreonam Lysine for Inhalation | Other | Preclinical | Cystic Fibrosis | APPROVED_FOR_MARKETING | NCT00499720 |
| Aztreonam Lysine for Inhalation | Other | Preclinical | Cystic Fibrosis | APPROVED_FOR_MARKETING | NCT00499720 |
| emtricitabine /tenofovir DF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00307489 |
| tenofovir DF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00307489 |
| emtricitabine /tenofovir DF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00307489 |
| tenofovir DF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00307489 |
| emtricitabine /tenofovir DF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00307489 |
| tenofovir DF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00307489 |
| Kivexa + Kaletra | Other | Phase PHASE4 | HIV-1 | COMPLETED | NCT00772902 |
| Truvada + Kaletra | Other | Phase PHASE4 | HIV-1 | COMPLETED | NCT00772902 |
| Kivexa + Kaletra | Other | Phase PHASE4 | HIV-1 | COMPLETED | NCT00772902 |
| Truvada + Kaletra | Other | Phase PHASE4 | HIV-1 | COMPLETED | NCT00772902 |
| Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00615745 |
| No intervention | Other | Preclinical | Chronic Hepatitis B | COMPLETED | NCT00645736 |
| No intervention | Other | Preclinical | Chronic Hepatitis B | COMPLETED | NCT00645736 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT00736190 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT00736190 |
| Emtricitabine (FTC) | Other | Phase PHASE2 | HIV Infection | COMPLETED | NCT00334256 |
| Tenofovir (TDF) | Other | Phase PHASE2 | HIV Infection | COMPLETED | NCT00334256 |
| Emtricitabine (FTC) | Other | Phase PHASE2 | HIV Infection | COMPLETED | NCT00334256 |
| Tenofovir (TDF) | Other | Phase PHASE2 | HIV Infection | COMPLETED | NCT00334256 |
| ambrisentan | Other | Phase PHASE2 | Pulmonary Hypertension | COMPLETED | NCT00424021 |
| Ranolazine | Other | Phase PHASE4 | Chronic Angina | COMPLETED | NCT00644332 |
| tenofovir + emtricitabine | Other | Preclinical | Pharmacokinetic Study in Healthy Volunteers | COMPLETED | NCT01326221 |
| Probenecid | Other | Approved | Cytomegalovirus Retinitis | COMPLETED | NCT00000799 |
| Cidofovir | Other | Approved | Cytomegalovirus Retinitis | COMPLETED | NCT00000799 |
| Probenecid | Other | Approved | Cytomegalovirus Retinitis | COMPLETED | NCT00000799 |
| Cidofovir | Other | Approved | Cytomegalovirus Retinitis | COMPLETED | NCT00000799 |
| Probenecid | Other | Approved | Cytomegalovirus Retinitis | COMPLETED | NCT00000799 |
| Cidofovir | Other | Approved | Cytomegalovirus Retinitis | COMPLETED | NCT00000799 |
| Zidovudine-Lamivudine-Lopinavir/Ritonavir | Other | Phase PHASE3 | HIV Infection | WITHDRAWN | NCT00936195 |
| Efavirenz-Tenofovir-Emtricitabine | Other | Phase PHASE3 | HIV Infection | WITHDRAWN | NCT00936195 |
| Zidovudine-Lamivudine-Lopinavir/Ritonavir | Other | Phase PHASE3 | HIV Infection | WITHDRAWN | NCT00936195 |
| Efavirenz-Tenofovir-Emtricitabine | Other | Phase PHASE3 | HIV Infection | WITHDRAWN | NCT00936195 |
| placebo | Other | Phase PHASE4 | Chronic Stable Angina | UNKNOWN | NCT01558830 |
| ranolazine | Other | Phase PHASE4 | Chronic Stable Angina | UNKNOWN | NCT01558830 |
| placebo | Other | Phase PHASE4 | Chronic Stable Angina | UNKNOWN | NCT01558830 |
| ranolazine | Other | Phase PHASE4 | Chronic Stable Angina | UNKNOWN | NCT01558830 |
| GS-6620 tablet | Other | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT01316237 |
| GS-6620 tablet, 450 mg BID | Other | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT01316237 |
| GS-6620 | Other | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT01316237 |
| Ambrisentan | Other | Phase PHASE3 | Pulmonary Hypertension | COMPLETED | NCT00380068 |
| Ambrisentan | Other | Phase PHASE3 | Pulmonary Hypertension | COMPLETED | NCT00380068 |
| Ambrisentan | Other | Phase PHASE3 | Pulmonary Hypertension | COMPLETED | NCT00380068 |
| AB0024 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT01323933 |
| AB0024 | Other | Phase PHASE1 | Neoplasms | COMPLETED | NCT01323933 |
| Tenofovir/Emtricitabine (Truvada) and Zidovudine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir/Emtricitabine/Efavirenz (Atripla) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir/Emtricitabine (Truvada) and Nevirapine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir/Emtricitabine (Truvada) and Zidovudine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir/Emtricitabine/Efavirenz (Atripla) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir/Emtricitabine (Truvada) and Nevirapine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir/Emtricitabine (Truvada) and Zidovudine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir/Emtricitabine/Efavirenz (Atripla) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Tenofovir/Emtricitabine (Truvada) and Nevirapine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00573001 |
| Lamivudine | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00095121 |
| Adefovir Dipivoxil (ADV) | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00095121 |
| Placebo (PLB) | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00095121 |
| Lamivudine | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00095121 |
| Adefovir Dipivoxil (ADV) | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00095121 |
| Placebo (PLB) | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00095121 |
| abacavir (ABC)/lamivudine (3TC) | Other | Phase PHASE4 | HIV Infection | COMPLETED | NCT00724711 |
| emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) | Other | Phase PHASE4 | HIV Infection | COMPLETED | NCT00724711 |
| Peginterferon alfa-2a | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01072695 |
| Ribavirin | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01072695 |
| GS-9190 | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01072695 |
| GS-9256 | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01072695 |
| PSI-7977 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01497327 |
| PSI-352938 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01497327 |
| PSI-7977 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01497327 |
| PSI-352938 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01497327 |
| PSI-7977 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01497327 |
| PSI-352938 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01497327 |
| Ranolazine | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01546597 |
| Metformin | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01546597 |
| Ranolazine | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01546597 |
| Metformin | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01546597 |
| Ranolazine | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01546597 |
| Metformin | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01546597 |
| Ranolazine | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01546558 |
| Metformin | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01546558 |
| Ranolazine | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01546558 |
| Metformin | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01546558 |
| Saline 0.9% and placebo tablet | Other | Phase PHASE2 | Diastolic Heart Failure | COMPLETED | NCT01163734 |
| Ranolazine | Other | Phase PHASE2 | Diastolic Heart Failure | COMPLETED | NCT01163734 |
| Placebo to Match GS-9669 tablet | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01431898 |
| GS-9669 tablets | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01431898 |
| Placebo to Match GS-9669 tablet | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01431898 |
| GS-9669 tablets | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01431898 |
| Tadalafil | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | COMPLETED | NCT00617305 |
| Sildenafil | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | COMPLETED | NCT00617305 |
| Placebo | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | COMPLETED | NCT00617305 |
| Ambrisentan | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | COMPLETED | NCT00617305 |
| Tadalafil | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | COMPLETED | NCT00617305 |
| Sildenafil | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | COMPLETED | NCT00617305 |
| Placebo | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | COMPLETED | NCT00617305 |
| Ambrisentan | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | COMPLETED | NCT00617305 |
| Ranolazine | Other | Phase PHASE4 | Angina Pectoris | WITHDRAWN | NCT01334203 |
| Ranolazine | Other | Phase PHASE4 | Angina Pectoris | WITHDRAWN | NCT01334203 |
| CAL-101 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT00710528 |
| CAL-101 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT00710528 |
| GS-1101 | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | WITHDRAWN | NCT01659047 |
| GS-1101 | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | WITHDRAWN | NCT01659047 |
| Ranolazine | Other | Preclinical | Angina | UNKNOWN | NCT01804543 |
| Ranolazine | Other | Preclinical | Angina | UNKNOWN | NCT01804543 |
| FTC/RPV/TDF | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT01286740 |
| FTC/RPV/TDF | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT01286740 |
| FTC/RPV/TDF | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT01286740 |
| GS-4774 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01779505 |
| GS-4774 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01779505 |
| GS-9451 placebo | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Tegobuvir placebo | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Copegus® | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Pegasys® | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Tegobuvir (GS-9190) | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| GS-9451 placebo | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Tegobuvir placebo | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Copegus® | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Pegasys® | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Tegobuvir (GS-9190) | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| PEG | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01641640 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01641640 |
| Sofosbuvir | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01641640 |
| AZLI | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01404234 |
| GS-5745 IV | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT02209987 |
| GS-5745 SC | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT02209987 |
| GS-5745 IV | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT02209987 |
| GS-5745 SC | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT02209987 |
| RANEXA | Other | Phase PHASE1 | Severe Renal Impairment | TERMINATED | NCT01675973 |
| RANEXA | Other | Phase PHASE1 | Severe Renal Impairment | TERMINATED | NCT01675973 |
| Aztreonam lysine | Other | Preclinical | Cystic Fibrosis | APPROVED_FOR_MARKETING | NCT00989807 |
| Aztreonam lysine | Other | Preclinical | Cystic Fibrosis | APPROVED_FOR_MARKETING | NCT00989807 |
| Ritonavir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224445 |
| Atazanavir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224445 |
| Truvada | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224445 |
| Ritonavir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224445 |
| Atazanavir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224445 |
| Truvada | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224445 |
| Ritonavir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224445 |
| Atazanavir | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224445 |
| Truvada | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00224445 |
| ambrisentan | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | COMPLETED | NCT00578786 |
| ambrisentan | Other | Phase PHASE3 | Pulmonary Arterial Hypertension | COMPLETED | NCT00578786 |
| Placebo | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT01193478 |
| GS-5885 | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT01193478 |
| Placebo | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT01193478 |
| GS-5885 | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT01193478 |
| Trizivir | Other | Phase PHASE4 | HIV | COMPLETED | NCT00960622 |
| Combivir | Other | Phase PHASE4 | HIV | COMPLETED | NCT00960622 |
| Truvada | Other | Phase PHASE4 | HIV | COMPLETED | NCT00960622 |
| Trizivir | Other | Phase PHASE4 | HIV | COMPLETED | NCT00960622 |
| Combivir | Other | Phase PHASE4 | HIV | COMPLETED | NCT00960622 |
| Truvada | Other | Phase PHASE4 | HIV | COMPLETED | NCT00960622 |
| Amiodarone with Placebo | Other | Approved | Arrhythmia | COMPLETED | NCT01480336 |
| Amiodarone Plus Ranolazine | Other | Approved | Arrhythmia | COMPLETED | NCT01480336 |
| Amiodarone with Placebo | Other | Approved | Arrhythmia | COMPLETED | NCT01480336 |
| Amiodarone Plus Ranolazine | Other | Approved | Arrhythmia | COMPLETED | NCT01480336 |
| Amiodarone with Placebo | Other | Approved | Arrhythmia | COMPLETED | NCT01480336 |
| Amiodarone Plus Ranolazine | Other | Approved | Arrhythmia | COMPLETED | NCT01480336 |
| ETV placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| FTC/TDF placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| TDF placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| Entecavir (ETV) | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| Tenofovir disoproxil fumarate (tenofovir DF; TDF) | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| ETV placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| FTC/TDF placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| TDF placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| Entecavir (ETV) | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| Tenofovir disoproxil fumarate (tenofovir DF; TDF) | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00298363 |
| ambrisentan | Other | Approved | Ischemia | COMPLETED | NCT01072669 |
| ambrisentan | Other | Approved | Ischemia | COMPLETED | NCT01072669 |
| Carboplatin | Other | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT00650949 |
| CYT997 | Other | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT00650949 |
| GS-5806 | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT01801293 |
| ambrisentan | Other | Phase PHASE2 | Pulmonary Hypertension | COMPLETED | NCT00423592 |
| ambrisentan | Other | Phase PHASE2 | Pulmonary Hypertension | COMPLETED | NCT00423592 |
| Zerit (Stavudine) Placebo | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Epivir (Lamivudine) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Sustiva (Efavirenz) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Viread (tenofovir disoproxil fumarate) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Zerit (Stavudine) Placebo | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Epivir (Lamivudine) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Sustiva (Efavirenz) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Viread (tenofovir disoproxil fumarate) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Zerit (Stavudine) Placebo | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Epivir (Lamivudine) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Sustiva (Efavirenz) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Viread (tenofovir disoproxil fumarate) | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00158821 |
| Regimen:TDF+3TC+EFV | Other | Phase PHASE4 | Hiv | COMPLETED | NCT01751555 |
| Regimen:TDF+3TC+EFV | Other | Phase PHASE4 | Hiv | COMPLETED | NCT01751555 |
| Ranolazine | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT01304095 |
| Ranolazine | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT01304095 |
| Once daily Truvada® | Other | Approved | HIV | WITHDRAWN | NCT01832571 |
| Once daily Truvada® | Other | Approved | HIV | WITHDRAWN | NCT01832571 |
| Once daily Truvada® | Other | Approved | HIV | WITHDRAWN | NCT01832571 |
| raltegravir | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00822315 |
| efavirenz | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00822315 |
| raltegravir | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00822315 |
| efavirenz | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00822315 |
| raltegravir | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00822315 |
| efavirenz | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00822315 |
| Multiple Ascending Dose Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01591668 |
| Single Ascending Dose Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01591668 |
| Zidovudine/lamivudine | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT01772940 |
| Tenofovir/emtricitabine | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT01772940 |
| ritonavir-boosted Lopinavir | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT01772940 |
| nevirapine | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT01772940 |
| Zidovudine/lamivudine | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT01772940 |
| Tenofovir/emtricitabine | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT01772940 |
| ritonavir-boosted Lopinavir | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT01772940 |
| nevirapine | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT01772940 |
| GS-5816 | Other | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT01817985 |
| GS-5816 | Other | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT01817985 |
| GS-5816 | Other | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT01817985 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01163721 |
| Ranolazine | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01163721 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01163721 |
| Ranolazine | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT01163721 |
| Adefovir Dipivoxil for oral suspension, 2 mg/mL | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00071201 |
| Adefovir Dipivoxil for oral suspension, 2 mg/mL | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00071201 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | WITHDRAWN | NCT01797419 |
| GS-5806 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | WITHDRAWN | NCT01797419 |
| Placebo | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | WITHDRAWN | NCT01797419 |
| GS-5806 | Other | Phase PHASE1 | Respiratory Syncytial Virus Infections | WITHDRAWN | NCT01797419 |
| Ribavirin | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00743795 |
| Peginterferon Alfa 2a | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00743795 |
| GS-9190 | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00743795 |
| placebo | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00743795 |
| Ribavirin | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00743795 |
| Peginterferon Alfa 2a | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00743795 |
| GS-9190 | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00743795 |
| placebo | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00743795 |
| Placebo | Other | Phase PHASE1 | Ischemic Heart Disease | COMPLETED | NCT01847391 |
| GS-6615 | Other | Phase PHASE1 | Ischemic Heart Disease | COMPLETED | NCT01847391 |
| Placebo | Other | Phase PHASE1 | Ischemic Heart Disease | COMPLETED | NCT01847391 |
| GS-6615 | Other | Phase PHASE1 | Ischemic Heart Disease | COMPLETED | NCT01847391 |
| Multiple Ascending Dose (MAD) Cohorts | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590641 |
| Single Ascending Dose (SAD) Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590641 |
| Multiple Ascending Dose (MAD) Cohorts | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590641 |
| Single Ascending Dose (SAD) Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590641 |
| Multiple Ascending Dose (MAD) Cohorts | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590641 |
| Single Ascending Dose (SAD) Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590641 |
| Liposomal amphotericin B | Other | Phase PHASE2 | Acute Myeloid Leukemia | UNKNOWN | NCT00451711 |
| Liposomal amphotericin B | Other | Phase PHASE2 | Acute Myeloid Leukemia | UNKNOWN | NCT00451711 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| placebo to match RBV | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| placebo to match tegobuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| tegobuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| GS-5885 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| placebo to match RBV | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| placebo to match tegobuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| tegobuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| GS-5885 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| placebo to match RBV | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| placebo to match tegobuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| tegobuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| GS-5885 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| placebo to match RBV | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| placebo to match tegobuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| tegobuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| GS-5885 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435226 |
| Multiple Ascending Dose (MAD) Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590654 |
| Single Ascending Dose (SAD) Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590654 |
| Multiple Ascending Dose (MAD) Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590654 |
| Single Ascending Dose (SAD) Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590654 |
| Multiple Ascending Dose (MAD) Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590654 |
| Single Ascending Dose (SAD) Cohorts GS-9620 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01590654 |
| placebo matching tegobuvir capsule | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| placebo matching ribavirin tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| ribavirin tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| tegobuvir capsule | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| GS-9451 tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| GS-5885 tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| placebo matching tegobuvir capsule | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| placebo matching ribavirin tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| ribavirin tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| tegobuvir capsule | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| GS-9451 tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| GS-5885 tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| placebo matching tegobuvir capsule | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| placebo matching ribavirin tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| ribavirin tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| tegobuvir capsule | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| GS-9451 tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| GS-5885 tablet | Other | Phase PHASE2 | Chronic Genotype 1a or 1b HCV Infection | COMPLETED | NCT01434498 |
| ribavirin tablet | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01353248 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01353248 |
| Tegobuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01353248 |
| GS-5885 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01353248 |
| ribavirin tablet | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01353248 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01353248 |
| Tegobuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01353248 |
| GS-5885 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01353248 |
| Placebo, AZLI | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT00794586 |
| FTI, AZLI | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT00794586 |
| Placebo, AZLI | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT00794586 |
| FTI, AZLI | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT00794586 |
| Placebo, AZLI | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT00794586 |
| FTI, AZLI | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT00794586 |
| Guanfacine | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT00389675 |
| Darusentan | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT00389675 |
| Hepsera | Other | Preclinical | Hepatitis B | COMPLETED | NCT00158717 |
| Hepsera | Other | Preclinical | Hepatitis B | COMPLETED | NCT00158717 |
| Adefovir Dipivoxil | Other | Preclinical | Chronic Hepatitis B | APPROVED_FOR_MARKETING | NCT00042393 |
| Adefovir Dipivoxil | Other | Preclinical | Chronic Hepatitis B | APPROVED_FOR_MARKETING | NCT00042393 |
| Placebo to match metoprolol succinate | Other | Phase PHASE3 | Heart Failure, Congestive | TERMINATED | NCT00077948 |
| Placebo to match enoximone | Other | Phase PHASE3 | Heart Failure, Congestive | TERMINATED | NCT00077948 |
| Metoprolol succinate | Other | Phase PHASE3 | Heart Failure, Congestive | TERMINATED | NCT00077948 |
| Enoximone | Other | Phase PHASE3 | Heart Failure, Congestive | TERMINATED | NCT00077948 |
| Enoximone placebo | Other | Phase PHASE3 | Heart Failure, Congestive | TERMINATED | NCT00051285 |
| Enoximone | Other | Phase PHASE3 | Heart Failure, Congestive | TERMINATED | NCT00051285 |
| Enoximone placebo | Other | Phase PHASE3 | Heart Failure, Congestive | TERMINATED | NCT00051285 |
| Enoximone | Other | Phase PHASE3 | Heart Failure, Congestive | TERMINATED | NCT00051285 |
| Tenofovir alafenamide | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00036634 |
| Tenofovir DF | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00036634 |
| Tenofovir alafenamide | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00036634 |
| Tenofovir DF | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00036634 |
| Tenofovir alafenamide | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00036634 |
| Tenofovir DF | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00036634 |
| Pegylated Interferon | Other | Preclinical | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | NCT01779518 |
| Ribavirin | Other | Preclinical | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | NCT01779518 |
| Sofosbuvir | Other | Preclinical | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | NCT01779518 |
| Pegylated Interferon | Other | Preclinical | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | NCT01779518 |
| Ribavirin | Other | Preclinical | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | NCT01779518 |
| Sofosbuvir | Other | Preclinical | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | NCT01779518 |
| Pegylated Interferon | Other | Preclinical | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | NCT01779518 |
| Ribavirin | Other | Preclinical | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | NCT01779518 |
| Sofosbuvir | Other | Preclinical | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | NCT01779518 |
| regadenoson | Other | Phase PHASE2 | Heart Disease | TERMINATED | NCT00907764 |
| regadenoson | Other | Phase PHASE2 | Heart Disease | TERMINATED | NCT00907764 |
| regadenoson | Other | Phase PHASE2 | Heart Disease | TERMINATED | NCT00907764 |
| GS-9256 placebo | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9190 placebo | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| Copegus® | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| Pegasys® | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9256 | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9190 | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9256 placebo | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9190 placebo | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| Copegus® | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| Pegasys® | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9256 | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9190 | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9256 placebo | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9190 placebo | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| Copegus® | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| Pegasys® | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9256 | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| GS-9190 | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01225380 |
| Simtuzumab | Other | Phase PHASE2 | Liver Fibrosis | COMPLETED | NCT01452308 |
| Simtuzumab | Other | Phase PHASE2 | Liver Fibrosis | COMPLETED | NCT01452308 |
| PEG | Other | Phase PHASE2 | Chronic Hepatitis C | TERMINATED | NCT01384383 |
| RBV | Other | Phase PHASE2 | Chronic Hepatitis C | TERMINATED | NCT01384383 |
| GS-9451 | Other | Phase PHASE2 | Chronic Hepatitis C | TERMINATED | NCT01384383 |
| GS-5885 | Other | Phase PHASE2 | Chronic Hepatitis C | TERMINATED | NCT01384383 |
| PEG | Other | Phase PHASE2 | Chronic Hepatitis C | TERMINATED | NCT01384383 |
| RBV | Other | Phase PHASE2 | Chronic Hepatitis C | TERMINATED | NCT01384383 |
| GS-9451 | Other | Phase PHASE2 | Chronic Hepatitis C | TERMINATED | NCT01384383 |
| GS-5885 | Other | Phase PHASE2 | Chronic Hepatitis C | TERMINATED | NCT01384383 |
| GS-9451 Placebo | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01356160 |
| ribavirin tablet | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01356160 |
| peginterferon alfa-2a | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01356160 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01356160 |
| GS-5885 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01356160 |
| GS-9451 Placebo | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01356160 |
| ribavirin tablet | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01356160 |
| peginterferon alfa-2a | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01356160 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01356160 |
| GS-5885 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01356160 |
| Placebo | Other | Phase PHASE2 | HCV Infection | TERMINATED | NCT00874796 |
| GS-9450 | Other | Phase PHASE2 | HCV Infection | TERMINATED | NCT00874796 |
| Placebo | Other | Phase PHASE2 | HCV Infection | TERMINATED | NCT00874796 |
| GS-9450 | Other | Phase PHASE2 | HCV Infection | TERMINATED | NCT00874796 |
| Placebo | Other | Phase PHASE2 | HCV Infection | TERMINATED | NCT00874796 |
| GS-9450 | Other | Phase PHASE2 | HCV Infection | TERMINATED | NCT00874796 |
| Cicletanine Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | TERMINATED | NCT00832507 |
| Cicletanine | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | TERMINATED | NCT00832507 |
| Cicletanine Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | TERMINATED | NCT00832507 |
| Cicletanine | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | TERMINATED | NCT00832507 |
| GS-9450 Placebo | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT00740610 |
| GS-9450 | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT00740610 |
| GS-9450 Placebo | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT00740610 |
| GS-9450 | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT00740610 |
| GS-9219 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00499239 |
| GS-9219 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00499239 |
| darunavir; ritonavir; emtricitabine/tenofovir | Other | Phase PHASE3 | HIV-1 Infections | COMPLETED | NCT01033760 |
| raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine | Other | Phase PHASE3 | HIV-1 Infections | COMPLETED | NCT01033760 |
| darunavir; ritonavir; emtricitabine/tenofovir | Other | Phase PHASE3 | HIV-1 Infections | COMPLETED | NCT01033760 |
| raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine | Other | Phase PHASE3 | HIV-1 Infections | COMPLETED | NCT01033760 |
| Placebo to match GS-0938 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435044 |
| Placebo to match sofosbuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435044 |
| RBV | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435044 |
| GS-0938 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435044 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435044 |
| Placebo to match GS-0938 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435044 |
| Placebo to match sofosbuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435044 |
| RBV | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435044 |
| GS-0938 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435044 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01435044 |
| GS-9451 placebo | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Tegobuvir placebo | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Copegus® | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Pegasys® | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| GS-9451 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Tegobuvir (GS-9190) | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01271790 |
| Treatment J | Drug | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01841489 |
| Treatment I | Drug | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01841489 |
| Treatment H | Drug | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01841489 |
| Treatment G | Drug | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01841489 |
| Treatment F | Drug | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01841489 |
| Treatment E | Drug | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01841489 |
| Treatment D | Drug | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01841489 |
| Treatment C | Drug | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01841489 |
| Treatment B | Drug | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01841489 |
| Treatment A | Drug | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01841489 |
| ribavirin tablet | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01371578 |
| peginterferon alfa-2a | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01371578 |
| GS-9451 tablet | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01371578 |
| GS-5885 tablet | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01371578 |
| ribavirin tablet | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01371578 |
| peginterferon alfa-2a | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01371578 |
| GS-9451 tablet | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01371578 |
| GS-5885 tablet | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01371578 |
| Tenofovir DF | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01334567 |
| Tenofovir DF | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT01334567 |
| Placebo | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01059565 |
| AZLI | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01059565 |
| Esmolol | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT00713401 |
| Tecadenoson | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT00713401 |
| Esmolol | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT00713401 |
| Tecadenoson | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT00713401 |
| Viread | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00324688 |
| Viread | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00324688 |
| Hepatitis B Immunoglobulin (HBIg) | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507689 |
| FTC/TDF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507689 |
| Hepatitis B Immunoglobulin (HBIg) | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507689 |
| FTC/TDF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507689 |
| Hepatitis B Immunoglobulin (HBIg) | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507689 |
| FTC/TDF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507689 |
| Blood Draws | Other | Preclinical | HIV Infections | COMPLETED | NCT00499187 |
| Blood Draws | Other | Preclinical | HIV Infections | COMPLETED | NCT00499187 |
| Darusentan Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00389779 |
| Guanfacine | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00389779 |
| Darusentan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00389779 |
| Darusentan Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00389779 |
| Guanfacine | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00389779 |
| Darusentan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00389779 |
| Darusentan Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00389779 |
| Guanfacine | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00389779 |
| Darusentan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00389779 |
| Darusentan | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT00353574 |
| Darusentan | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT00353574 |
| Darusentan | Other | Phase PHASE3 | Hypertension | TERMINATED | NCT00353574 |
| Darusentan Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00330369 |
| Darusentan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00330369 |
| Darusentan Placebo | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00330369 |
| Darusentan | Other | Phase PHASE3 | Hypertension | COMPLETED | NCT00330369 |
| GS-5737 | Other | Phase PHASE1 | Cystic Fibrosis | TERMINATED | NCT01793649 |
| AZLI | Other | Phase PHASE2 | Bronchiectasis | COMPLETED | NCT00805025 |
| AZLI | Other | Phase PHASE2 | Bronchiectasis | COMPLETED | NCT00805025 |
| Exenatide | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01843127 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01843127 |
| Ranolazine | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01843127 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01497366 |
| PEG | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01497366 |
| Sofosbuvir | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01497366 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01497366 |
| PEG | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01497366 |
| Sofosbuvir | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01497366 |
| Placebo | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT00768300 |
| Ambrisentan | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT00768300 |
| Placebo | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT00768300 |
| Ambrisentan | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT00768300 |
| Placebo | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT00768300 |
| Ambrisentan | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT00768300 |
| Placebo | Other | Phase PHASE3 | Bronchiectasis | COMPLETED | NCT01314716 |
| AZLI | Other | Phase PHASE3 | Bronchiectasis | COMPLETED | NCT01314716 |
| Placebo | Other | Phase PHASE3 | Bronchiectasis | COMPLETED | NCT01314716 |
| AZLI | Other | Phase PHASE3 | Bronchiectasis | COMPLETED | NCT01314716 |
| Placebo | Other | Phase PHASE3 | Bronchiectasis | COMPLETED | NCT01313624 |
| AZLI | Other | Phase PHASE3 | Bronchiectasis | COMPLETED | NCT01313624 |
| Placebo | Other | Phase PHASE3 | Bronchiectasis | COMPLETED | NCT01313624 |
| AZLI | Other | Phase PHASE3 | Bronchiectasis | COMPLETED | NCT01313624 |
| RBV | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01054729 |
| PEG | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01054729 |
| Placebo | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01054729 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01054729 |
| RBV | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01054729 |
| PEG | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01054729 |
| Placebo | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01054729 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01054729 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01188772 |
| PEG | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01188772 |
| Placebo to match sofosbuvir | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01188772 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01188772 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01188772 |
| PEG | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01188772 |
| Placebo to match sofosbuvir | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01188772 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01188772 |
| Placebo | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT00879229 |
| Ambrisentan | Other | Phase PHASE3 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT00879229 |
| Placebo to match RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| Placebo to match SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| Placebo to match RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| Placebo to match SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| Placebo to match RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| Placebo to match SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01542788 |
| PEG | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01329978 |
| RBV | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01329978 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01329978 |
| PEG | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01329978 |
| RBV | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01329978 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01329978 |
| Placebo to match RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01604850 |
| Placebo to match SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01604850 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01604850 |
| SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01604850 |
| Atripla | Other | Phase PHASE2 | HIV | COMPLETED | NCT00869557 |
| Stribild | Other | Phase PHASE2 | HIV | COMPLETED | NCT00869557 |
| Atripla | Other | Phase PHASE2 | HIV | COMPLETED | NCT00869557 |
| Stribild | Other | Phase PHASE2 | HIV | COMPLETED | NCT00869557 |
| GS-9450 Placebo | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00725803 |
| GS-9450 | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00725803 |
| GS-9450 Placebo | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00725803 |
| GS-9450 | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT00725803 |
| Placebo | Other | Phase PHASE4 | Coronary Artery Disease | TERMINATED | NCT00832572 |
| Ranolazine | Other | Phase PHASE4 | Coronary Artery Disease | TERMINATED | NCT00832572 |
| Placebo | Other | Phase PHASE4 | Coronary Artery Disease | TERMINATED | NCT00832572 |
| Ranolazine | Other | Phase PHASE4 | Coronary Artery Disease | TERMINATED | NCT00832572 |
| humanised monoclonal antibodies veltuzumab and epratuzumab | Other | Phase PHASE1 | Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | UNKNOWN | NCT01279707 |
| humanised monoclonal antibody epratuzumab | Other | Phase PHASE1 | Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | UNKNOWN | NCT01279707 |
| humanised monoclonal antibody, veltuzumab | Other | Phase PHASE1 | Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | UNKNOWN | NCT01279707 |
| humanised monoclonal antibodies veltuzumab and epratuzumab | Other | Phase PHASE1 | Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | UNKNOWN | NCT01279707 |
| humanised monoclonal antibody epratuzumab | Other | Phase PHASE1 | Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | UNKNOWN | NCT01279707 |
| humanised monoclonal antibody, veltuzumab | Other | Phase PHASE1 | Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | UNKNOWN | NCT01279707 |
| Aztreonam for Inhalation Solution (AZLI) | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT01375049 |
| Aztreonam for Inhalation Solution (AZLI) | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT01375049 |
| Aztreonam for Inhalation Solution (AZLI) | Other | Phase PHASE2 | Cystic Fibrosis | COMPLETED | NCT01375049 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT01840735 |
| GS-5737 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT01840735 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT01840735 |
| GS-5737 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT01840735 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT01840735 |
| GS-5737 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT01840735 |
| darusentan 100 mg | Other | Phase PHASE2 | Coronary Artery Disease | COMPLETED | NCT00738049 |
| darusentan 100 mg | Other | Phase PHASE2 | Coronary Artery Disease | COMPLETED | NCT00738049 |
| Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir | Other | Phase PHASE4 | Kaposi's Sarcoma | COMPLETED | NCT00444379 |
| Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir | Other | Phase PHASE4 | Kaposi's Sarcoma | COMPLETED | NCT00444379 |
| Exercise | Other | Phase PHASE4 | Myocardial Perfusion Imaging | COMPLETED | NCT01221272 |
| SPECT MPI | Other | Phase PHASE4 | Myocardial Perfusion Imaging | COMPLETED | NCT01221272 |
| Placebo to match ranolazine | Other | Phase PHASE4 | Myocardial Perfusion Imaging | COMPLETED | NCT01221272 |
| Ranolazine | Other | Phase PHASE4 | Myocardial Perfusion Imaging | COMPLETED | NCT01221272 |
| Placebo | Other | Phase PHASE3 | Chronic Hepatitis B | TERMINATED | NCT01872988 |
| Tenofovir | Other | Phase PHASE3 | Chronic Hepatitis B | TERMINATED | NCT01872988 |
| RBV | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01808248 |
| PEG | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01808248 |
| SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01808248 |
| RBV | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01808248 |
| PEG | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01808248 |
| SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01808248 |
| RBV | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01808248 |
| PEG | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01808248 |
| SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01808248 |
| Exercise | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Diet | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Placebo to match metformin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Metformin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Placebo to match ranolazine | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Ranolazine | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Exercise | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Diet | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Placebo to match metformin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Metformin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Placebo to match ranolazine | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Ranolazine | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Exercise | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Diet | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Placebo to match metformin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Metformin | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Placebo to match ranolazine | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| Ranolazine | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555164 |
| RBV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| PEG | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| RAL | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| DRV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| FTC/TDF | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| Ritonavir | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| ATV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| ZDV/3TC | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| EFV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| EFV/FTC/TDF | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| SOF | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| RBV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| PEG | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| RAL | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| DRV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| FTC/TDF | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| Ritonavir | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| ATV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| ZDV/3TC | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| EFV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| EFV/FTC/TDF | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| SOF | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| RBV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| PEG | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| RAL | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| DRV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| FTC/TDF | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| Ritonavir | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| ATV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| ZDV/3TC | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| EFV | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| EFV/FTC/TDF | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| SOF | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01565889 |
| Placebo to match RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| Placebo to match SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| Placebo to match RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| Placebo to match SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| Placebo to match RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| Placebo to match SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01682720 |
| Exercise | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01472185 |
| Diet | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01472185 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01472185 |
| Ranolazine | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01472185 |
| Exercise | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01472185 |
| Diet | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01472185 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01472185 |
| Ranolazine | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01472185 |
| Rituximab | Other | Preclinical | Chronic Lymphocytic Leukemia (CLL) | APPROVED_FOR_MARKETING | NCT02136511 |
| Idelalisib | Other | Preclinical | Chronic Lymphocytic Leukemia (CLL) | APPROVED_FOR_MARKETING | NCT02136511 |
| Rituximab | Other | Preclinical | Chronic Lymphocytic Leukemia (CLL) | APPROVED_FOR_MARKETING | NCT02136511 |
| Idelalisib | Other | Preclinical | Chronic Lymphocytic Leukemia (CLL) | APPROVED_FOR_MARKETING | NCT02136511 |
| GS-6615 | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT01849003 |
| GS-6615 | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT01849003 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01667731 |
| SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01667731 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01667731 |
| SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01667731 |
| EFV/FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT01309243 |
| FTC/RPV/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT01309243 |
| EFV/FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT01309243 |
| FTC/RPV/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT01309243 |
| EFV/FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT01309243 |
| FTC/RPV/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT01309243 |
| GS-9901 | Other | Phase PHASE1 | Follicular Lymphoma | TERMINATED | NCT02258555 |
| NRTIs | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT01252940 |
| RTV | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT01252940 |
| FTC/RPV/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT01252940 |
| FTC/TDF Placebo | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00737568 |
| TDF Placebo | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00737568 |
| FTC/TDF | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00737568 |
| TDF | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00737568 |
| Fructose solution | Other | Phase PHASE1 | PD Effects of GS-0976 (NDI-010976) on Fractional DNL | COMPLETED | NCT02876796 |
| 1-13C acetate | Other | Phase PHASE1 | PD Effects of GS-0976 (NDI-010976) on Fractional DNL | COMPLETED | NCT02876796 |
| Placebo | Other | Phase PHASE1 | PD Effects of GS-0976 (NDI-010976) on Fractional DNL | COMPLETED | NCT02876796 |
| GS-0976 | Other | Phase PHASE1 | PD Effects of GS-0976 (NDI-010976) on Fractional DNL | COMPLETED | NCT02876796 |
| GS-7340 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02357602 |
| GS-7340 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02357602 |
| Placebo | Other | Phase PHASE3 | Heart; Dysfunction Postoperative, Cardiac Surgery | TERMINATED | NCT01352416 |
| Ranolazine | Other | Phase PHASE3 | Heart; Dysfunction Postoperative, Cardiac Surgery | TERMINATED | NCT01352416 |
| Placebo | Other | Phase PHASE3 | Heart; Dysfunction Postoperative, Cardiac Surgery | TERMINATED | NCT01352416 |
| Ranolazine | Other | Phase PHASE3 | Heart; Dysfunction Postoperative, Cardiac Surgery | TERMINATED | NCT01352416 |
| GS-1101 | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | TERMINATED | NCT02439138 |
| GS-1101 | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | TERMINATED | NCT02439138 |
| GS-1101 | Other | Phase PHASE2 | Waldenstrom's Macroglobulinemia | TERMINATED | NCT02439138 |
| Coaching | Other | Approved | Cystic Fibrosis | COMPLETED | NCT02110914 |
| Coaching | Other | Approved | Cystic Fibrosis | COMPLETED | NCT02110914 |
| Coaching | Other | Approved | Cystic Fibrosis | COMPLETED | NCT02110914 |
| Educational Tool | Other | Approved | Acute Myocardial Infarction | COMPLETED | NCT01807208 |
| Educational Tool | Other | Approved | Acute Myocardial Infarction | COMPLETED | NCT01807208 |
| Educational Tool | Other | Approved | Acute Myocardial Infarction | COMPLETED | NCT01807208 |
| Placebo | Other | Phase PHASE4 | Chronic Stable Angina | COMPLETED | NCT01948310 |
| Aerobic Exercise | Other | Phase PHASE4 | Chronic Stable Angina | COMPLETED | NCT01948310 |
| Ranolazine | Other | Phase PHASE4 | Chronic Stable Angina | COMPLETED | NCT01948310 |
| Placebo | Other | Phase PHASE4 | Chronic Stable Angina | COMPLETED | NCT01948310 |
| Aerobic Exercise | Other | Phase PHASE4 | Chronic Stable Angina | COMPLETED | NCT01948310 |
| Ranolazine | Other | Phase PHASE4 | Chronic Stable Angina | COMPLETED | NCT01948310 |
| Eleclazine placebo | Other | Phase PHASE3 | Long QT Syndrome Type 3 | TERMINATED | NCT02300558 |
| Eleclazine | Other | Phase PHASE3 | Long QT Syndrome Type 3 | TERMINATED | NCT02300558 |
| PrEP knowledge and acceptability questionnaire | Other | Preclinical | HIV/AIDS | UNKNOWN | NCT03116932 |
| PrEP knowledge and acceptability questionnaire | Other | Preclinical | HIV/AIDS | UNKNOWN | NCT03116932 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT02254408 |
| Presatovir | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT02254408 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT02254408 |
| Presatovir | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT02254408 |
| LDV/SOF | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01958281 |
| RBV | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01958281 |
| SOF | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01958281 |
| Standard of Care Adherence Support (Active Control) | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| PrEP Information (Active Control) | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| Enhanced Adherence Intervention | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| Sexual Health Counseling | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| Standard of Care Adherence Support (Active Control) | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| PrEP Information (Active Control) | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| Enhanced Adherence Intervention | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| Sexual Health Counseling | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02738333 |
| SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02738333 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02738333 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02738333 |
| SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02738333 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02738333 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02671500 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02671500 |
| Hu5F9-G4 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02678338 |
| Hu5F9-G4 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02678338 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT02520284 |
| Andecaliximab | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT02520284 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT02520284 |
| Andecaliximab | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT02520284 |
| Sugar pill | Other | Phase PHASE2 | Angina | TERMINATED | NCT02147834 |
| Ranolazine | Other | Phase PHASE2 | Angina | TERMINATED | NCT02147834 |
| Sugar pill | Other | Phase PHASE2 | Angina | TERMINATED | NCT02147834 |
| Ranolazine | Other | Phase PHASE2 | Angina | TERMINATED | NCT02147834 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01539291 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01539291 |
| Idelalisib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01090414 |
| Idelalisib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01090414 |
| FTC/RPV/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345252 |
| FTC/RPV/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345252 |
| FTC/RPV/TDF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345252 |
| FTC/RPV/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345252 |
| FTC/RPV/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345252 |
| FTC/RPV/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345252 |
| FTC/RPV/TDF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345252 |
| FTC/RPV/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345252 |
| FTC/RPV/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345226 |
| EFV/FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345226 |
| EFV/FTC/TDF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345226 |
| FTC/RPV/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02345226 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01818596 |
| E/C/F/TAF Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01797445 |
| E/C/F/TDF Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01797445 |
| E/C/F/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01797445 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01797445 |
| Voxilaprevir | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT02397707 |
| Voxilaprevir | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT02397707 |
| Voxilaprevir | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT02397707 |
| Social Media Group | Other | Approved | Pre-Exposure Prophylaxis | COMPLETED | NCT03078153 |
| Financial Incentive | Other | Approved | Pre-Exposure Prophylaxis | COMPLETED | NCT03078153 |
| Social Media Group | Other | Approved | Pre-Exposure Prophylaxis | COMPLETED | NCT03078153 |
| Financial Incentive | Other | Approved | Pre-Exposure Prophylaxis | COMPLETED | NCT03078153 |
| Rilpivirine/Emtricitabine/Tenofovir | Other | Phase PHASE2 | HIV | COMPLETED | NCT02104700 |
| Rilpivirine/Emtricitabine/Tenofovir | Other | Phase PHASE2 | HIV | COMPLETED | NCT02104700 |
| Ranolazine placebo | Other | Phase PHASE4 | Angina Pectoris | COMPLETED | NCT01425359 |
| Ranolazine | Other | Phase PHASE4 | Angina Pectoris | COMPLETED | NCT01425359 |
| Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir | Other | Phase PHASE1 | Insulin Resistance | COMPLETED | NCT02203461 |
| Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir | Other | Phase PHASE1 | Insulin Resistance | COMPLETED | NCT02203461 |
| Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat | Other | Phase PHASE1 | Insulin Resistance | COMPLETED | NCT02203461 |
| Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir | Other | Phase PHASE1 | Insulin Resistance | COMPLETED | NCT02203461 |
| Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir | Other | Phase PHASE1 | Insulin Resistance | COMPLETED | NCT02203461 |
| Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat | Other | Phase PHASE1 | Insulin Resistance | COMPLETED | NCT02203461 |
| LDV/SOF | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| GS-9669 | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| LDV | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| PEG | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| RBV | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| SOF | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| LDV/SOF | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| GS-9669 | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| LDV | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| PEG | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| RBV | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| SOF | Other | Phase PHASE2 | Chronic Hepatitis C Infection | COMPLETED | NCT01260350 |
| Exercise | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01494987 |
| Diet | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01494987 |
| Glimepiride | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01494987 |
| Placebo | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01494987 |
| Ranolazine | Other | Phase PHASE3 | Type 2 Diabetes Mellitus | COMPLETED | NCT01494987 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01713283 |
| SOF | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01713283 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01713283 |
| SOF | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01713283 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01713283 |
| SOF | Other | Phase PHASE2 | Hepatitis C Virus | COMPLETED | NCT01713283 |
| RBV | Other | Phase PHASE2 | Recurrent Chronic Hepatitis C Virus | COMPLETED | NCT01687270 |
| Sofosbuvir | Other | Phase PHASE2 | Recurrent Chronic Hepatitis C Virus | COMPLETED | NCT01687270 |
| Tenofovir disoproxil | Other | Approved | Chronic Hepatitis B | COMPLETED | NCT01728935 |
| Tenofovir disoproxil | Other | Approved | Chronic Hepatitis B | COMPLETED | NCT01728935 |
| PEGASYS 180μg (Interféron pégylé alpha -2a) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00391638 |
| TRUVADA (EMTRICITABINE + TENOFOVIR DF) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00391638 |
| PEGASYS 180μg (Interféron pégylé alpha -2a) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00391638 |
| TRUVADA (EMTRICITABINE + TENOFOVIR DF) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00391638 |
| PEGASYS 180μg (Interféron pégylé alpha -2a) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00391638 |
| TRUVADA (EMTRICITABINE + TENOFOVIR DF) | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT00391638 |
| Stribild | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01533259 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01466790 |
| PSI-7977 (GS7977) | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01466790 |
| TMC435 | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01466790 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01466790 |
| PSI-7977 (GS7977) | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01466790 |
| TMC435 | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01466790 |
| Placebo to match simtuzumab | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT01472198 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT01472198 |
| Simtuzumab | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT01472198 |
| Placebo to match simtuzumab | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT01472198 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT01472198 |
| Simtuzumab | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT01472198 |
| Placebo to match simtuzumab | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT01472198 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT01472198 |
| Simtuzumab | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT01472198 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01910636 |
| Sofosbuvir | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01910636 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01910636 |
| Sofosbuvir | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01910636 |
| Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV) | Other | Phase PHASE4 | HIV Infection | COMPLETED | NCT00192595 |
| Tenofovir | Other | Phase PHASE4 | HIV Infection | COMPLETED | NCT00192595 |
| Colchicine | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01416402 |
| Febuxostat | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01416402 |
| Arhalofenate | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01416402 |
| Colchicine | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01416402 |
| Febuxostat | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01416402 |
| Arhalofenate | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01416402 |
| Colchicine | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01416402 |
| Febuxostat | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01416402 |
| Arhalofenate | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01416402 |
| Colchicine | Other | Phase PHASE2 | Gout | COMPLETED | NCT02252835 |
| Febuxostat | Other | Phase PHASE2 | Gout | COMPLETED | NCT02252835 |
| Arhalofenate | Other | Phase PHASE2 | Gout | COMPLETED | NCT02252835 |
| Colchicine | Other | Phase PHASE2 | Gout | COMPLETED | NCT02252835 |
| Febuxostat | Other | Phase PHASE2 | Gout | COMPLETED | NCT02252835 |
| Arhalofenate | Other | Phase PHASE2 | Gout | COMPLETED | NCT02252835 |
| Colchicine | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01336686 |
| Placebo comparator | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01336686 |
| Arhalofenate | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01336686 |
| Colchicine | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01336686 |
| Placebo comparator | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01336686 |
| Arhalofenate | Other | Phase PHASE2 | Hyperuricemia | COMPLETED | NCT01336686 |
| placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01035879 |
| Sitagliptin | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01035879 |
| MBX-2982 | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01035879 |
| placebo | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01035879 |
| Sitagliptin | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01035879 |
| MBX-2982 | Other | Phase PHASE2 | Diabetes | COMPLETED | NCT01035879 |
| Metformin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT00814372 |
| Actos | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT00814372 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT00814372 |
| MBX-102 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT00814372 |
| Metformin | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT00814372 |
| Actos | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT00814372 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT00814372 |
| MBX-102 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | TERMINATED | NCT00814372 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01783678 |
| Sofosbuvir | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01783678 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01783678 |
| Sofosbuvir | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01783678 |
| Placebo for MBX-2044 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT00422487 |
| MBX-2044 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT00422487 |
| Placebo for MBX-2044 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT00422487 |
| MBX-2044 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT00422487 |
| Actos | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00353587 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00353587 |
| MBX-102 | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00353587 |
| Actos | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00353587 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00353587 |
| MBX-102 | Other | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00353587 |
| Placebo | Other | Phase PHASE3 | Invasive Fungal Disease | COMPLETED | NCT01259713 |
| Liposomal amphotericin B | Other | Phase PHASE3 | Invasive Fungal Disease | COMPLETED | NCT01259713 |
| Placebo | Other | Phase PHASE3 | Invasive Fungal Disease | COMPLETED | NCT01259713 |
| Liposomal amphotericin B | Other | Phase PHASE3 | Invasive Fungal Disease | COMPLETED | NCT01259713 |
| Dofetilide | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT02365532 |
| Placebo to match dofetilide | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT02365532 |
| Placebo to match GS-6615 | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT02365532 |
| GS-6615 | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT02365532 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT01838590 |
| SOF | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT01838590 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT01838590 |
| SOF | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT01838590 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT01838590 |
| SOF | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT01838590 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01896193 |
| SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01896193 |
| STRIBILD | Other | Preclinical | HIV | UNKNOWN | NCT02306577 |
| STRIBILD | Other | Preclinical | HIV | UNKNOWN | NCT02306577 |
| Antiretroviral medications+Isoniazid prophylaxis | Drug | Phase PHASE3 | HIV Infections | COMPLETED | NCT00495651 |
| Antiretroviral medications | Drug | Phase PHASE3 | HIV Infections | COMPLETED | NCT00495651 |
| Placebo | Other | Phase PHASE2 | Ischemic Heart Disease | WITHDRAWN | NCT02377336 |
| GS-6615 | Other | Phase PHASE2 | Ischemic Heart Disease | WITHDRAWN | NCT02377336 |
| Placebo | Other | Phase PHASE2 | Ischemic Heart Disease | WITHDRAWN | NCT02377336 |
| GS-6615 | Other | Phase PHASE2 | Ischemic Heart Disease | WITHDRAWN | NCT02377336 |
| Placebo | Other | Phase PHASE2 | Ischemic Heart Disease | WITHDRAWN | NCT02377336 |
| GS-6615 | Other | Phase PHASE2 | Ischemic Heart Disease | WITHDRAWN | NCT02377336 |
| Atorvastatin | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT00701883 |
| MBX-8025 | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT00701883 |
| Placebo | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT00701883 |
| Atorvastatin | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT00701883 |
| MBX-8025 | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT00701883 |
| Placebo | Other | Phase PHASE2 | Hyperlipidemia | COMPLETED | NCT00701883 |
| Placebo to match GS-5745 | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT02176876 |
| GS-5745 | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT02176876 |
| Placebo to match GS-5745 | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT02176876 |
| GS-5745 | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT02176876 |
| GS-6624 | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT01362231 |
| GS-6624 | Other | Phase PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT01362231 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | WITHDRAWN | NCT01025713 |
| GS-9411 | Other | Phase PHASE1 | Cystic Fibrosis | WITHDRAWN | NCT01025713 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | WITHDRAWN | NCT01025713 |
| GS-9411 | Other | Phase PHASE1 | Cystic Fibrosis | WITHDRAWN | NCT01025713 |
| Ambisome | Other | Phase PHASE4 | Leukemia | COMPLETED | NCT00362544 |
| Ambisome | Other | Phase PHASE4 | Leukemia | COMPLETED | NCT00362544 |
| caspofungin | Other | Phase PHASE4 | Invasive Aspergillosis | COMPLETED | NCT00334412 |
| Ambisome | Other | Phase PHASE4 | Invasive Aspergillosis | COMPLETED | NCT00334412 |
| caspofungin | Other | Phase PHASE4 | Invasive Aspergillosis | COMPLETED | NCT00334412 |
| Ambisome | Other | Phase PHASE4 | Invasive Aspergillosis | COMPLETED | NCT00334412 |
| Placebo | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00352053 |
| Tenofovir DF | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00352053 |
| Placebo | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00352053 |
| Tenofovir DF | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00352053 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507507 |
| FTC | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507507 |
| Tenofovir DF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507507 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507507 |
| FTC | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507507 |
| Tenofovir DF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00507507 |
| Placebo | Other | Phase PHASE2 | Atrial Fibrillation | TERMINATED | NCT01887353 |
| Ranolazine | Other | Phase PHASE2 | Atrial Fibrillation | TERMINATED | NCT01887353 |
| Placebo | Other | Phase PHASE2 | Atrial Fibrillation | TERMINATED | NCT01887353 |
| Ranolazine | Other | Phase PHASE2 | Atrial Fibrillation | TERMINATED | NCT01887353 |
| Zidovudine/lamivudine | Other | Phase PHASE4 | HIV-1 | COMPLETED | NCT00324649 |
| Truvada | Other | Phase PHASE4 | HIV-1 | COMPLETED | NCT00324649 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT01756482 |
| GS-5806 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT01756482 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT01756482 |
| GS-5806 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT01756482 |
| Placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT01399008 |
| Colchicine | Other | Phase PHASE2 | Gout | COMPLETED | NCT01399008 |
| Allopurinol | Other | Phase PHASE2 | Gout | COMPLETED | NCT01399008 |
| Arhalofenate | Other | Phase PHASE2 | Gout | COMPLETED | NCT01399008 |
| Placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT01399008 |
| Colchicine | Other | Phase PHASE2 | Gout | COMPLETED | NCT01399008 |
| Allopurinol | Other | Phase PHASE2 | Gout | COMPLETED | NCT01399008 |
| Arhalofenate | Other | Phase PHASE2 | Gout | COMPLETED | NCT01399008 |
| HIV test by oral swab | Other | Approved | HIV Infections | COMPLETED | NCT00548041 |
| HIV test by oral swab | Other | Approved | HIV Infections | COMPLETED | NCT00548041 |
| Peg-IFN | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01625338 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01625338 |
| SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01625338 |
| Peg-IFN | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01625338 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01625338 |
| SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01625338 |
| Peg-IFN | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01625338 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01625338 |
| SOF | Other | Phase PHASE3 | Chronic Hepatitis C | COMPLETED | NCT01625338 |
| FTC/TDF Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| RTV Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| ATV Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| Stribild Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| FTC/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| Ritonavir | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| ATV | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| Stribild | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| FTC/TDF Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| RTV Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| ATV Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| Stribild Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| FTC/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| Ritonavir | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| ATV | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| Stribild | Other | Phase PHASE3 | HIV | COMPLETED | NCT01106586 |
| Atripla Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01095796 |
| Stribild Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01095796 |
| Atripla | Other | Phase PHASE3 | HIV | COMPLETED | NCT01095796 |
| Stribild | Other | Phase PHASE3 | HIV | COMPLETED | NCT01095796 |
| Atripla Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01095796 |
| Stribild Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01095796 |
| Atripla | Other | Phase PHASE3 | HIV | COMPLETED | NCT01095796 |
| Stribild | Other | Phase PHASE3 | HIV | COMPLETED | NCT01095796 |
| Eleclazine | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT02441829 |
| Eleclazine | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT02441829 |
| Eleclazine | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT02441829 |
| Sofosbuvir 400mg / Ledipasvir 90 mg (FDC) | Other | Phase PHASE4 | Chronic Hepatitis C | UNKNOWN | NCT02638233 |
| Sofosbuvir 400mg / Ledipasvir 90 mg (FDC) | Other | Phase PHASE4 | Chronic Hepatitis C | UNKNOWN | NCT02638233 |
| Stribild | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01495702 |
| FTC/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01495702 |
| NNRTI | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01495702 |
| Stribild | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01495702 |
| FTC/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01495702 |
| NNRTI | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01495702 |
| Stribild | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01495702 |
| FTC/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01495702 |
| NNRTI | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01495702 |
| Status Post Lung Transplant | Other | Phase PHASE4 | Complication of Transplanted Lung | COMPLETED | NCT01469364 |
| Aztreonam Lysine for Inhalation (AZLI) | Other | Phase PHASE4 | Complication of Transplanted Lung | COMPLETED | NCT01469364 |
| Status Post Lung Transplant | Other | Phase PHASE4 | Complication of Transplanted Lung | COMPLETED | NCT01469364 |
| Aztreonam Lysine for Inhalation (AZLI) | Other | Phase PHASE4 | Complication of Transplanted Lung | COMPLETED | NCT01469364 |
| RTV placebo | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| COBI placebo | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| FTC/TDF | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| ATV | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| RTV | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| COBI | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| RTV placebo | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| COBI placebo | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| FTC/TDF | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| ATV | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| RTV | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| COBI | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00892437 |
| Emtricitabine | Other | Phase PHASE2 | Hepatitis B Virus | COMPLETED | NCT00476463 |
| LDV/SOF FDC | Other | Phase PHASE4 | Chronic Hepatitis C | UNKNOWN | NCT02691728 |
| MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| MBX-8025 50 mg (Dose Escalation Period 1) | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| Run-In Period: Placebo | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| MBX-8025 50 mg (Dose Escalation Period 1) | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| Run-In Period: Placebo | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| MBX-8025 50 mg (Dose Escalation Period 1) | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| Run-In Period: Placebo | Other | Phase PHASE2 | Homozygous Familial Hypercholesterolemia | COMPLETED | NCT02472535 |
| FTC/TDF Placebo | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00737568 |
| TDF Placebo | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00737568 |
| FTC/TDF | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00737568 |
| TDF | Other | Phase PHASE3 | Hepatitis B | COMPLETED | NCT00737568 |
| Atripla | Other | Phase PHASE4 | HIV | UNKNOWN | NCT02283060 |
| Stribild | Other | Phase PHASE4 | HIV | UNKNOWN | NCT02283060 |
| Atripla | Other | Phase PHASE4 | HIV | UNKNOWN | NCT02283060 |
| Stribild | Other | Phase PHASE4 | HIV | UNKNOWN | NCT02283060 |
| Indium labeled IMP-205xm734 | Other | Phase PHASE1 | Colonic Neoplasms | COMPLETED | NCT00185081 |
| Indium labeled IMP-205xm734 | Other | Phase PHASE1 | Colonic Neoplasms | COMPLETED | NCT00185081 |
| FTC/TDF Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| COBI Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| DRV Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| D/C/F/TAF Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| FTC/TDF | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| COBI | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| DRV | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| D/C/F/TAF | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| FTC/TDF Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| COBI Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| DRV Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| D/C/F/TAF Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| FTC/TDF | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| COBI | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| DRV | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| D/C/F/TAF | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01565850 |
| ARV regimen | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00445146 |
| RTV | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00445146 |
| EVG | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00445146 |
| ARV regimen | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00445146 |
| RTV | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00445146 |
| EVG | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00445146 |
| NRTI | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01363011 |
| DRV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01363011 |
| ATV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01363011 |
| COBI | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01363011 |
| E/C/F/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01363011 |
| NRTI | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01363011 |
| DRV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01363011 |
| ATV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01363011 |
| COBI | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01363011 |
| E/C/F/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01363011 |
| Tobramycin inhalation solution | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01641822 |
| Placebo to match AZLI | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01641822 |
| AZLI | Other | Phase PHASE3 | Cystic Fibrosis | COMPLETED | NCT01641822 |
| GS-9820 | Other | Phase PHASE1 | Lymphoid Malignancies | COMPLETED | NCT01705847 |
| GS-9820 | Other | Phase PHASE1 | Lymphoid Malignancies | COMPLETED | NCT01705847 |
| RTV placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01108510 |
| COBI placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01108510 |
| FTC/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01108510 |
| ATV | Other | Phase PHASE3 | HIV | COMPLETED | NCT01108510 |
| RTV | Other | Phase PHASE3 | HIV | COMPLETED | NCT01108510 |
| COBI | Other | Phase PHASE3 | HIV | COMPLETED | NCT01108510 |
| Background regimen | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00708162 |
| RAL placebo | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00708162 |
| EVG placebo | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00708162 |
| Raltegravir | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00708162 |
| Elvitegravir | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00708162 |
| Background regimen | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00708162 |
| RAL placebo | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00708162 |
| EVG placebo | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00708162 |
| Raltegravir | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00708162 |
| Elvitegravir | Other | Phase PHASE3 | HIV Infection | COMPLETED | NCT00708162 |
| Stribild | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01475838 |
| FTC/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01475838 |
| RTV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01475838 |
| Stribild | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01475838 |
| FTC/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01475838 |
| RTV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01475838 |
| Stribild | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01475838 |
| FTC/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01475838 |
| RTV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01475838 |
| Placebo | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01442038 |
| Ranolazine | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01442038 |
| Placebo | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01442038 |
| Ranolazine | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01442038 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01559844 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01559844 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01559844 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01559844 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01559844 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01559844 |
| Decision-making tool for coronary artery disease treatment | Drug | Approved | Coronary Artery Disease | COMPLETED | NCT02272062 |
| RBV | Other | Phase PHASE4 | Hepatitis C Virus Infection | COMPLETED | NCT02128542 |
| Sofosbuvir | Other | Phase PHASE4 | Hepatitis C Virus Infection | COMPLETED | NCT02128542 |
| RBV | Other | Phase PHASE4 | Hepatitis C Virus Infection | COMPLETED | NCT02128542 |
| Sofosbuvir | Other | Phase PHASE4 | Hepatitis C Virus Infection | COMPLETED | NCT02128542 |
| Peg-IFN | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01277601 |
| TDF | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01277601 |
| Peg-IFN | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01277601 |
| TDF | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01277601 |
| Peg-IFN | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01277601 |
| TDF | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01277601 |
| Placebo | Other | Phase PHASE3 | Hepatitis B Virus (HBV) | COMPLETED | NCT00734162 |
| Tenofovir disoproxil fumarate (TDF) | Other | Phase PHASE3 | Hepatitis B Virus (HBV) | COMPLETED | NCT00734162 |
| Placebo | Other | Phase PHASE3 | Hepatitis B Virus (HBV) | COMPLETED | NCT00734162 |
| Tenofovir disoproxil fumarate (TDF) | Other | Phase PHASE3 | Hepatitis B Virus (HBV) | COMPLETED | NCT00734162 |
| Adherence dashboard motivational interviewing | Other | Preclinical | Cystic Fibrosis | COMPLETED | NCT02179710 |
| Adherence dashboard motivational interviewing | Other | Preclinical | Cystic Fibrosis | COMPLETED | NCT02179710 |
| Adherence dashboard motivational interviewing | Other | Preclinical | Cystic Fibrosis | COMPLETED | NCT02179710 |
| Retrospective Audit | Other | Preclinical | HIV | COMPLETED | NCT02295384 |
| Retrospective Audit | Other | Preclinical | HIV | COMPLETED | NCT02295384 |
| RBV | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01687257 |
| SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01687257 |
| Tenofovir/emtricitabine | Other | Phase PHASE4 | HIV | COMPLETED | NCT02149888 |
| RBV | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02074514 |
| Sofosbuvir | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02074514 |
| RBV | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02074514 |
| Sofosbuvir | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02074514 |
| entecavir | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01711567 |
| tenofovir | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01711567 |
| entecavir | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01711567 |
| tenofovir | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01711567 |
| CT imaging, functional PET imaging | Other | Approved | Pulmonary Arterial Hypertension | WITHDRAWN | NCT02958358 |
| CT imaging, functional PET imaging | Other | Approved | Pulmonary Arterial Hypertension | WITHDRAWN | NCT02958358 |
| RBV | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02120300 |
| SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02120300 |
| LDV/SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02120300 |
| RBV | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02120300 |
| SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02120300 |
| LDV/SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02120300 |
| RBV | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02120300 |
| SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02120300 |
| LDV/SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02120300 |
| Probenecid | Other | Phase PHASE1 | Blood And Marrow Transplantation | COMPLETED | NCT01816646 |
| Cidofovir | Other | Phase PHASE1 | Blood And Marrow Transplantation | COMPLETED | NCT01816646 |
| Probenecid | Other | Phase PHASE1 | Blood And Marrow Transplantation | COMPLETED | NCT01816646 |
| Cidofovir | Other | Phase PHASE1 | Blood And Marrow Transplantation | COMPLETED | NCT01816646 |
| Probenecid | Other | Phase PHASE1 | Blood And Marrow Transplantation | COMPLETED | NCT01816646 |
| Cidofovir | Other | Phase PHASE1 | Blood And Marrow Transplantation | COMPLETED | NCT01816646 |
| Rapid Test | Other | Approved | HIV | COMPLETED | NCT01790633 |
| ELISA | Other | Approved | HIV | COMPLETED | NCT01790633 |
| Rapid Test | Other | Approved | HIV | COMPLETED | NCT01790633 |
| ELISA | Other | Approved | HIV | COMPLETED | NCT01790633 |
| Rapid Test | Other | Approved | HIV | COMPLETED | NCT01790633 |
| ELISA | Other | Approved | HIV | COMPLETED | NCT01790633 |
| Rapid testing | Other | Approved | Hepatitis B | COMPLETED | NCT01767597 |
| ELISA testing | Other | Approved | Hepatitis B | COMPLETED | NCT01767597 |
| Rapid testing | Other | Approved | Hepatitis B | COMPLETED | NCT01767597 |
| ELISA testing | Other | Approved | Hepatitis B | COMPLETED | NCT01767597 |
| NRTIs | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01440569 |
| DRV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01440569 |
| COBI | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01440569 |
| NRTIs | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01440569 |
| DRV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01440569 |
| COBI | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01440569 |
| NRTIs | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01440569 |
| DRV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01440569 |
| COBI | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01440569 |
| Tenofovir | Other | Phase PHASE4 | Non-Hodgkin's Lymphoma, Burkitt's | UNKNOWN | NCT02585947 |
| Tenofovir | Other | Phase PHASE4 | Non-Hodgkin's Lymphoma, Burkitt's | UNKNOWN | NCT02585947 |
| Thymoglobulines | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| Fludarabine | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| allogeneic stem cell transplantation. | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| Busulfan | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| Thymoglobulines | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| Fludarabine | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| allogeneic stem cell transplantation. | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| Busulfan | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG | Other | Phase PHASE1 | Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia | WITHDRAWN | NCT02577094 |
| WelTel | Other | Approved | HIV | COMPLETED | NCT02603536 |
| WelTel | Other | Approved | HIV | COMPLETED | NCT02603536 |
| WelTel | Other | Approved | HIV | COMPLETED | NCT02603536 |
| veltuzumab and milatuzumab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00989586 |
| Human Anti-Human Antibodies | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00989586 |
| Pharmacokinetics | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00989586 |
| Quantitative T-, B-, and NK cell subsets | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00989586 |
| Correlative/Special Studies | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00989586 |
| veltuzumab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00989586 |
| milatuzumab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00989586 |
| Placebo | Other | Phase PHASE4 | Angina | UNKNOWN | NCT03044964 |
| Ranolazine | Other | Phase PHASE4 | Angina | UNKNOWN | NCT03044964 |
| Placebo | Other | Phase PHASE4 | Angina | UNKNOWN | NCT03044964 |
| Ranolazine | Other | Phase PHASE4 | Angina | UNKNOWN | NCT03044964 |
| Placebo | Other | Phase PHASE4 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT02156336 |
| Ranolazine | Other | Phase PHASE4 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT02156336 |
| Placebo | Other | Phase PHASE4 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT02156336 |
| Ranolazine | Other | Phase PHASE4 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT02156336 |
| Education Intervention | Other | Approved | Chronic Lymphocytic Leukemia | COMPLETED | NCT02619604 |
| emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation) | Other | Phase PHASE3 | HIV | COMPLETED | NCT00928187 |
| abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line) | Other | Phase PHASE3 | HIV | COMPLETED | NCT00928187 |
| emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line) | Other | Phase PHASE3 | HIV | COMPLETED | NCT00928187 |
| emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation) | Other | Phase PHASE3 | HIV | COMPLETED | NCT00928187 |
| abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line) | Other | Phase PHASE3 | HIV | COMPLETED | NCT00928187 |
| emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line) | Other | Phase PHASE3 | HIV | COMPLETED | NCT00928187 |
| Ranolazine | Other | Phase PHASE4 | Hypertrophic Cardiomyopathy | COMPLETED | NCT01721967 |
| FTC/TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| ADV placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| TDF placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| ADV | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| FTC/TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| ADV placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| TDF placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| ADV | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| FTC/TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| ADV placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| TDF placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| ADV | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00117676 |
| FTC/TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| ADV placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| TDF placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| ADV | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| FTC/TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| ADV placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| TDF placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| ADV | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| FTC/TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| ADV placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| TDF placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| ADV | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT00116805 |
| Placebo | Other | Approved | Atrial Fibrillation New Onset | TERMINATED | NCT01590979 |
| Ranolazine | Other | Approved | Atrial Fibrillation New Onset | TERMINATED | NCT01590979 |
| Placebo | Other | Approved | Atrial Fibrillation New Onset | TERMINATED | NCT01590979 |
| Ranolazine | Other | Approved | Atrial Fibrillation New Onset | TERMINATED | NCT01590979 |
| Simtuzumab | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT01759511 |
| Simtuzumab | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT01759511 |
| Anti-HBV nucleoside/nucleotide therapy | Drug | Preclinical | Hepatitis B | COMPLETED | NCT01590615 |
| Anti-HBV nucleoside/nucleotide therapy | Drug | Preclinical | Hepatitis B | COMPLETED | NCT01590615 |
| Miltefosine | Other | Phase PHASE2 | Primary Visceral Leishmaniasis | COMPLETED | NCT01067443 |
| Liposomal amphotericin B + miltefosine | Other | Phase PHASE2 | Primary Visceral Leishmaniasis | COMPLETED | NCT01067443 |
| Liposomal amphotericin B (AmBisome®) and sodium stibogluconate | Other | Phase PHASE2 | Primary Visceral Leishmaniasis | COMPLETED | NCT01067443 |
| Miltefosine | Other | Phase PHASE2 | Primary Visceral Leishmaniasis | COMPLETED | NCT01067443 |
| Liposomal amphotericin B + miltefosine | Other | Phase PHASE2 | Primary Visceral Leishmaniasis | COMPLETED | NCT01067443 |
| Liposomal amphotericin B (AmBisome®) and sodium stibogluconate | Other | Phase PHASE2 | Primary Visceral Leishmaniasis | COMPLETED | NCT01067443 |
| Matching placebo | Other | Phase PHASE3 | Atrial Fibrillation | TERMINATED | NCT01349491 |
| Ranolazine | Other | Phase PHASE3 | Atrial Fibrillation | TERMINATED | NCT01349491 |
| Matching placebo | Other | Phase PHASE3 | Atrial Fibrillation | TERMINATED | NCT01349491 |
| Ranolazine | Other | Phase PHASE3 | Atrial Fibrillation | TERMINATED | NCT01349491 |
| Hypertonic Saline | Other | Approved | Healthy Subjects | COMPLETED | NCT01617369 |
| Hypertonic Saline | Other | Approved | Healthy Subjects | COMPLETED | NCT01617369 |
| Placebo | Other | Phase PHASE4 | Microvascular Angina | COMPLETED | NCT02052011 |
| Ranolazine | Other | Phase PHASE4 | Microvascular Angina | COMPLETED | NCT02052011 |
| Simtuzumab placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT01769196 |
| Simtuzumab | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT01769196 |
| Simtuzumab placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT01769196 |
| Simtuzumab | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT01769196 |
| Patients receiving Sof/Vel (Epclusa) and Navigation services | Other | Phase PHASE4 | Hepatitis C, Chronic | UNKNOWN | NCT03018353 |
| Patients receiving Sof/Vel (Epclusa) and Navigation services | Other | Phase PHASE4 | Hepatitis C, Chronic | UNKNOWN | NCT03018353 |
| FTC/TDF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT00936715 |
| rilpivirina + emtricitabina + tenofovir | Other | Phase PHASE4 | HIV-1 | COMPLETED | NCT02547844 |
| efavirenz + emtricitabina + tenofovir | Other | Phase PHASE4 | HIV-1 | COMPLETED | NCT02547844 |
| rilpivirina + emtricitabina + tenofovir | Other | Phase PHASE4 | HIV-1 | COMPLETED | NCT02547844 |
| efavirenz + emtricitabina + tenofovir | Other | Phase PHASE4 | HIV-1 | COMPLETED | NCT02547844 |
| Peg-IFN | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01962441 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01962441 |
| SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01962441 |
| Peg-IFN | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01962441 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01962441 |
| SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01962441 |
| Peg-IFN | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01962441 |
| RBV | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01962441 |
| SOF | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT01962441 |
| COPE | Other | Preclinical | Hepatitis C Virus Infection | COMPLETED | NCT02537379 |
| SOF | Other | Preclinical | Hepatitis C Virus Infection | COMPLETED | NCT02537379 |
| COPE | Other | Preclinical | Hepatitis C Virus Infection | COMPLETED | NCT02537379 |
| SOF | Other | Preclinical | Hepatitis C Virus Infection | COMPLETED | NCT02537379 |
| PrEP using Truvada | Other | Phase PHASE4 | Adherence to Medication Regime | COMPLETED | NCT02237027 |
| TasP using ART regimen as per Benin guidelines | Other | Phase PHASE4 | Adherence to Medication Regime | COMPLETED | NCT02237027 |
| Stribild | Other | Phase PHASE4 | HIV | COMPLETED | NCT02477527 |
| Stribild | Other | Phase PHASE4 | HIV | COMPLETED | NCT02477527 |
| Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir) | Other | Approved | HIV Disease | COMPLETED | NCT01929759 |
| Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir) | Other | Approved | HIV Disease | COMPLETED | NCT01929759 |
| Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir) | Other | Approved | HIV Disease | COMPLETED | NCT01929759 |
| REB | Other | Preclinical | Hepatitis C | COMPLETED | NCT02562742 |
| SOF | Other | Preclinical | Hepatitis C | COMPLETED | NCT02562742 |
| REB | Other | Preclinical | Hepatitis C | COMPLETED | NCT02562742 |
| SOF | Other | Preclinical | Hepatitis C | COMPLETED | NCT02562742 |
| End-of-Study Feedback | Other | Approved | Angina | WITHDRAWN | NCT03134105 |
| Monthly Feedback on activity and patient-reported angina | Other | Approved | Angina | WITHDRAWN | NCT03134105 |
| End-of-Study Feedback | Other | Approved | Angina | WITHDRAWN | NCT03134105 |
| Monthly Feedback on activity and patient-reported angina | Other | Approved | Angina | WITHDRAWN | NCT03134105 |
| End-of-Study Feedback | Other | Approved | Angina | WITHDRAWN | NCT03134105 |
| Monthly Feedback on activity and patient-reported angina | Other | Approved | Angina | WITHDRAWN | NCT03134105 |
| LDV/SOF FDC | Other | Phase PHASE2 | Acute Hepatitis C | COMPLETED | NCT02309918 |
| LDV/SOF FDC | Other | Phase PHASE2 | Acute Hepatitis C | COMPLETED | NCT02309918 |
| Stop TDF | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01320943 |
| TDF | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01320943 |
| Stop TDF | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01320943 |
| TDF | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01320943 |
| Truvada | Other | Phase PHASE2 | HIV-1-infection | WITHDRAWN | NCT03074786 |
| Dapivirine | Other | Phase PHASE2 | HIV-1-infection | WITHDRAWN | NCT03074786 |
| Truvada | Other | Phase PHASE2 | HIV-1-infection | WITHDRAWN | NCT03074786 |
| Dapivirine | Other | Phase PHASE2 | HIV-1-infection | WITHDRAWN | NCT03074786 |
| Placebo | Other | Phase PHASE2 | Acute Coronary Syndrome | TERMINATED | NCT01767987 |
| Ranolazine | Other | Phase PHASE2 | Acute Coronary Syndrome | TERMINATED | NCT01767987 |
| Eviplera | Other | Phase PHASE4 | HIV | COMPLETED | NCT02529059 |
| Eviplera | Other | Phase PHASE4 | HIV | COMPLETED | NCT02529059 |
| 12 weeks SOF/LED | Other | Phase PHASE4 | PT-NANBH | COMPLETED | NCT02480166 |
| 8 weeks SOF/LED | Other | Phase PHASE4 | PT-NANBH | COMPLETED | NCT02480166 |
| 12 weeks SOF/LED | Other | Phase PHASE4 | PT-NANBH | COMPLETED | NCT02480166 |
| 8 weeks SOF/LED | Other | Phase PHASE4 | PT-NANBH | COMPLETED | NCT02480166 |
| Idelalisib | Other | Phase PHASE2 | Amyloidosis | TERMINATED | NCT02590588 |
| Idelalisib | Other | Phase PHASE2 | Amyloidosis | TERMINATED | NCT02590588 |
| Idelalisib | Other | Phase PHASE2 | Amyloidosis | TERMINATED | NCT02590588 |
| Tenofovir disoproxil fumarate (TDF) | Other | Preclinical | Chronic Hepatitis B | TERMINATED | NCT02258581 |
| GS-9620 | Other | Preclinical | Chronic Hepatitis B | TERMINATED | NCT02258581 |
| GS-4774 | Other | Preclinical | Chronic Hepatitis B | TERMINATED | NCT02258581 |
| QT Interval | Other | Phase PHASE4 | End-stage Renal Disease | COMPLETED | NCT01435174 |
| Pharmacokinetic Blood and Dialysate Sampling | Other | Phase PHASE4 | End-stage Renal Disease | COMPLETED | NCT01435174 |
| Ranolazine | Other | Phase PHASE4 | End-stage Renal Disease | COMPLETED | NCT01435174 |
| QT Interval | Other | Phase PHASE4 | End-stage Renal Disease | COMPLETED | NCT01435174 |
| Pharmacokinetic Blood and Dialysate Sampling | Other | Phase PHASE4 | End-stage Renal Disease | COMPLETED | NCT01435174 |
| Ranolazine | Other | Phase PHASE4 | End-stage Renal Disease | COMPLETED | NCT01435174 |
| QT Interval | Other | Phase PHASE4 | End-stage Renal Disease | COMPLETED | NCT01435174 |
| Pharmacokinetic Blood and Dialysate Sampling | Other | Phase PHASE4 | End-stage Renal Disease | COMPLETED | NCT01435174 |
| Ranolazine | Other | Phase PHASE4 | End-stage Renal Disease | COMPLETED | NCT01435174 |
| Eviplera | Other | Phase PHASE4 | Neurocognitive Decline | COMPLETED | NCT02308332 |
| Eviplera | Other | Phase PHASE4 | Neurocognitive Decline | COMPLETED | NCT02308332 |
| Treatment simplification | Drug | Phase PHASE4 | HIV Infection | COMPLETED | NCT02199613 |
| Treatment simplification | Drug | Phase PHASE4 | HIV Infection | COMPLETED | NCT02199613 |
| Treatment simplification | Drug | Phase PHASE4 | HIV Infection | COMPLETED | NCT02199613 |
| Iohexol | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| ABC/3TC | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| ATV | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| RTV | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| ATR | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| TVD | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| STB | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| Iohexol | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| ABC/3TC | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| ATV | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| RTV | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| ATR | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| TVD | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| STB | Other | Phase PHASE4 | HIV-1 Infection | COMPLETED | NCT02246998 |
| Eleclazine placebo | Other | Phase PHASE3 | Long QT Syndrome Type 3 | TERMINATED | NCT02300558 |
| Eleclazine | Other | Phase PHASE3 | Long QT Syndrome Type 3 | TERMINATED | NCT02300558 |
| Emtricitabine/tenofovir (FTC/TDF (Truvada®)) | Other | Phase PHASE2 | HIV Infection | COMPLETED | NCT01769456 |
| PCC | Other | Phase PHASE2 | HIV Infection | COMPLETED | NCT01769456 |
| Emtricitabine/tenofovir (FTC/TDF (Truvada®)) | Other | Phase PHASE2 | HIV Infection | COMPLETED | NCT01769456 |
| PCC | Other | Phase PHASE2 | HIV Infection | COMPLETED | NCT01769456 |
| Arhalofenate 800 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Colchicine 0.6 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Allopurinol 300 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Arhalofenate 600 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Arhalofenate 800 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Colchicine 0.6 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Allopurinol 300 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Arhalofenate 600 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Arhalofenate 800 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Placebo | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Colchicine 0.6 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Allopurinol 300 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| Arhalofenate 600 mg | Other | Phase PHASE2 | Gout | COMPLETED | NCT02063997 |
| PEG-IFN alfa-2a, placebo | Other | Phase PHASE2 | Hepatitis D | COMPLETED | NCT00932971 |
| PEG-IFN alfa-2a, Tenofovir | Other | Phase PHASE2 | Hepatitis D | COMPLETED | NCT00932971 |
| lenalidomide | Other | Phase PHASE1 | Recurrent Follicular Lymphoma | COMPLETED | NCT01644799 |
| idelalisib | Other | Phase PHASE1 | Recurrent Follicular Lymphoma | COMPLETED | NCT01644799 |
| lenalidomide | Other | Phase PHASE1 | Recurrent Follicular Lymphoma | COMPLETED | NCT01644799 |
| idelalisib | Other | Phase PHASE1 | Recurrent Follicular Lymphoma | COMPLETED | NCT01644799 |
| PEG | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02021643 |
| RBV | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02021643 |
| Sofosbuvir | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02021643 |
| PEG | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02021643 |
| RBV | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02021643 |
| Sofosbuvir | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02021643 |
| veltuzumab | Other | Phase PHASE1 | Follicular Lymphoma | TERMINATED | NCT01147393 |
| 90Y-epratuzumab tetraxetan | Other | Phase PHASE1 | Follicular Lymphoma | TERMINATED | NCT01147393 |
| veltuzumab | Other | Phase PHASE1 | Follicular Lymphoma | TERMINATED | NCT01147393 |
| 90Y-epratuzumab tetraxetan | Other | Phase PHASE1 | Follicular Lymphoma | TERMINATED | NCT01147393 |
| veltuzumab | Other | Phase PHASE1 | Follicular Lymphoma | TERMINATED | NCT01147393 |
| 90Y-epratuzumab tetraxetan | Other | Phase PHASE1 | Follicular Lymphoma | TERMINATED | NCT01147393 |
| Stavudine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00528957 |
| Zidovudine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00528957 |
| Tenofovir DF | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00528957 |
| Stavudine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00528957 |
| Zidovudine | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00528957 |
| Tenofovir DF | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00528957 |
| Emtricitabine and Tenofovir | Other | Phase PHASE4 | HIV/AIDS | UNKNOWN | NCT03120494 |
| Emtricitabine | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00743340 |
| Emtricitabine | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT00743340 |
| SOF | Other | Preclinical | Hepatitis C Virus | COMPLETED | NCT02592057 |
| SOF | Other | Preclinical | Hepatitis C Virus | COMPLETED | NCT02592057 |
| Standard PrEP Adherence | Other | Phase PHASE4 | HIV/AIDS | COMPLETED | NCT02167386 |
| Enhanced PrEP Adherence | Other | Phase PHASE4 | HIV/AIDS | COMPLETED | NCT02167386 |
| Standard PrEP Adherence | Other | Phase PHASE4 | HIV/AIDS | COMPLETED | NCT02167386 |
| Enhanced PrEP Adherence | Other | Phase PHASE4 | HIV/AIDS | COMPLETED | NCT02167386 |
| seladelpar | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03369002 |
| seladelpar | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03369002 |
| hLL1 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00504972 |
| hLL1 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00504972 |
| CYT997 | Other | Phase PHASE2 | Relapsed and Refractory Multiple Myeloma | TERMINATED | NCT00664378 |
| CYT997 | Other | Phase PHASE2 | Relapsed and Refractory Multiple Myeloma | TERMINATED | NCT00664378 |
| TNF Inhibitor | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| Andecaliximab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| TNF Inhibitor | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| Andecaliximab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| TNF Inhibitor | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| Andecaliximab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT02862574 |
| Switch to TDF/FTC/RPV after 24 weeks | Other | Phase PHASE4 | Impaired Cognition | COMPLETED | NCT02042001 |
| Immediate switch to TDF/FTC/RPV | Other | Phase PHASE4 | Impaired Cognition | COMPLETED | NCT02042001 |
| Switch to TDF/FTC/RPV after 24 weeks | Other | Phase PHASE4 | Impaired Cognition | COMPLETED | NCT02042001 |
| Immediate switch to TDF/FTC/RPV | Other | Phase PHASE4 | Impaired Cognition | COMPLETED | NCT02042001 |
| Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks | Other | Phase PHASE4 | HIV-2 Infection | COMPLETED | NCT02180438 |
| Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks | Other | Phase PHASE4 | HIV-2 Infection | COMPLETED | NCT02180438 |
| TF2 - 68 Ga-IMP-288: | Other | Phase PHASE1 | HER2 Negative Breast Carcinoma Expressing CEA | COMPLETED | NCT01730612 |
| TF2 - 68 Ga-IMP-288: | Other | Phase PHASE1 | HER2 Negative Breast Carcinoma Expressing CEA | COMPLETED | NCT01730612 |
| TF2 - 68 Ga-IMP-288: | Other | Phase PHASE1 | HER2 Negative Breast Carcinoma Expressing CEA | COMPLETED | NCT01730612 |
| Ambrisentan | Other | Phase PHASE2 | Sarcoidosis | COMPLETED | NCT00851929 |
| Ambrisentan | Other | Phase PHASE2 | Sarcoidosis | COMPLETED | NCT00851929 |
| Background regimen | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | TERMINATED | NCT01923311 |
| EVG | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | TERMINATED | NCT01923311 |
| Placebo | Other | Phase PHASE2 | Cystic Fibrosis | TERMINATED | NCT02759562 |
| Andecaliximab | Other | Phase PHASE2 | Cystic Fibrosis | TERMINATED | NCT02759562 |
| EVG/COBI/FTC/TDF | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01721109 |
| EVG/COBI/FTC/TDF | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01721109 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02885181 |
| Filgotinib placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02885181 |
| GS-9876 placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02885181 |
| Filgotinib | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02885181 |
| GS-9876 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02885181 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02885181 |
| Filgotinib placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02885181 |
| GS-9876 placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02885181 |
| Filgotinib | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02885181 |
| GS-9876 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT02885181 |
| Placebo | Other | Phase PHASE2 | Hypertrophic Cardiomyopathy | TERMINATED | NCT02291237 |
| Eleclazine | Other | Phase PHASE2 | Hypertrophic Cardiomyopathy | TERMINATED | NCT02291237 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus Infection | COMPLETED | NCT02254421 |
| Presatovir | Other | Phase PHASE2 | Respiratory Syncytial Virus Infection | COMPLETED | NCT02254421 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus Infection | COMPLETED | NCT02254421 |
| Presatovir | Other | Phase PHASE2 | Respiratory Syncytial Virus Infection | COMPLETED | NCT02254421 |
| Presatovir placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus Infection | COMPLETED | NCT02135614 |
| Presatovir | Other | Phase PHASE2 | Respiratory Syncytial Virus Infection | COMPLETED | NCT02135614 |
| Sovaldi | Other | Preclinical | HCV Infection | COMPLETED | NCT02783976 |
| Sovaldi | Other | Preclinical | HCV Infection | COMPLETED | NCT02783976 |
| Sovaldi | Other | Preclinical | HCV Infection | COMPLETED | NCT02783976 |
| sofosbuvir/velpatasvir | Other | Phase PHASE4 | Thalassemia | COMPLETED | NCT03032666 |
| sofosbuvir/velpatasvir | Other | Phase PHASE4 | Thalassemia | COMPLETED | NCT03032666 |
| Standard of Care Adherence Support (Active Control) | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| PrEP Information (Active Control) | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| Enhanced Adherence Intervention | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| Sexual Health Counseling | Other | Approved | Human Immunodeficiency Virus (HIV) | COMPLETED | NCT02037594 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT01671787 |
| GS-7340 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT01671787 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT01671787 |
| GS-7340 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT01671787 |
| Placebo | Other | Phase PHASE1 | Allergic Rhinitis | COMPLETED | NCT00836914 |
| CAL-101 | Other | Phase PHASE1 | Allergic Rhinitis | COMPLETED | NCT00836914 |
| Placebo | Other | Phase PHASE1 | Allergic Rhinitis | COMPLETED | NCT00836914 |
| CAL-101 | Other | Phase PHASE1 | Allergic Rhinitis | COMPLETED | NCT00836914 |
| Ledipasvir/Sofosbuvir | Other | Phase PHASE3 | Hepatitis C, Chronic | COMPLETED | NCT02597166 |
| Ledipasvir/Sofosbuvir | Other | Phase PHASE3 | Hepatitis C, Chronic | COMPLETED | NCT02597166 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02822794 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02822794 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02781571 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02781571 |
| LDV/SOF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02707601 |
| F/R/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02707601 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02707601 |
| Third Antiretroviral Agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02605954 |
| ABC/3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02605954 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02605954 |
| Third Antiretroviral Agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02605954 |
| ABC/3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02605954 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02605954 |
| Third Antiretroviral Agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02605954 |
| ABC/3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02605954 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02605954 |
| RBV | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01858766 |
| VEL | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01858766 |
| SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01858766 |
| RBV | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01858766 |
| VEL | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01858766 |
| SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01858766 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02220998 |
| SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02220998 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02220998 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02220998 |
| SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02220998 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02220998 |
| Placebo | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201940 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201940 |
| Placebo | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201940 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201940 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201901 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201901 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201901 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201901 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201901 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201901 |
| RBV | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01909804 |
| VEL | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01909804 |
| SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01909804 |
| RBV | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01909804 |
| VEL | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01909804 |
| SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01909804 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02722837 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | TERMINATED | NCT02600351 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | TERMINATED | NCT02600351 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | TERMINATED | NCT02600351 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | TERMINATED | NCT02600351 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | TERMINATED | NCT02600351 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | TERMINATED | NCT02600351 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02487030 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02487030 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02480712 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02480712 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02472886 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02472886 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Infection With HIV Co-Infection | COMPLETED | NCT02457611 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02413593 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02413593 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02413593 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02413593 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02413593 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02413593 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02346721 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02346721 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02300103 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02300103 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02300103 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02300103 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02300103 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02300103 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02226549 |
| VDV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02226549 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02226549 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02226549 |
| VDV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02226549 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02226549 |
| Placebo | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02219685 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02219685 |
| Placebo | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02219685 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02219685 |
| VOX | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02202980 |
| SOF/VEL | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02202980 |
| RBV | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02202980 |
| LDV/SOF | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02202980 |
| VOX | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02202980 |
| SOF/VEL | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02202980 |
| RBV | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02202980 |
| LDV/SOF | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02202980 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201953 |
| SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201953 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02201953 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT02073656 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT02073656 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT02073656 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT02073656 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT02073656 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus | COMPLETED | NCT02073656 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT02071082 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT02071082 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT02071082 |
| RBV | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT01975675 |
| LDV/SOF | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT01975675 |
| RBV | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT01975675 |
| LDV/SOF | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT01975675 |
| RBV | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT01975675 |
| LDV/SOF | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT01975675 |
| Baseline DRV- containing ARV regimen | Other | Phase PHASE3 | HIV-1 | COMPLETED | NCT01968551 |
| DRV | Other | Phase PHASE3 | HIV-1 | COMPLETED | NCT01968551 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 | COMPLETED | NCT01968551 |
| Baseline DRV- containing ARV regimen | Other | Phase PHASE3 | HIV-1 | COMPLETED | NCT01968551 |
| DRV | Other | Phase PHASE3 | HIV-1 | COMPLETED | NCT01968551 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 | COMPLETED | NCT01968551 |
| ATV | Other | Phase PHASE3 | HIV | COMPLETED | NCT01967940 |
| Current failing ARV regimen | Other | Phase PHASE3 | HIV | COMPLETED | NCT01967940 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01967940 |
| Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01967940 |
| TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01967940 |
| ATV | Other | Phase PHASE3 | HIV | COMPLETED | NCT01967940 |
| Current failing ARV regimen | Other | Phase PHASE3 | HIV | COMPLETED | NCT01967940 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01967940 |
| Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01967940 |
| TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01967940 |
| Placebo to match RBV | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01965535 |
| Placebo to match LDV/SOF | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01965535 |
| RBV | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01965535 |
| LDV/SOF | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01965535 |
| RBV | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT01938430 |
| LDV/SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT01938430 |
| RBV | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT01938430 |
| LDV/SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT01938430 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01851330 |
| LDV/SOF | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01851330 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01851330 |
| LDV/SOF | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01851330 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01851330 |
| LDV/SOF | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01851330 |
| VEL | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| GS-9669 | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| Peg-IFN | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| RBV | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| SOF | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| LDV/SOF | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| VEL | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| GS-9669 | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| Peg-IFN | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| RBV | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| SOF | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| LDV/SOF | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT01826981 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01768286 |
| LDV/SOF | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01768286 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01768286 |
| LDV/SOF | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01768286 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01768286 |
| LDV/SOF | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01768286 |
| Placebo | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732926 |
| Bendamustine | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732926 |
| Rituximab | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732926 |
| Idelalisib | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732926 |
| Placebo | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732926 |
| Bendamustine | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732926 |
| Rituximab | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732926 |
| Idelalisib | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732926 |
| Idelalisib | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732913 |
| Rituximab | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732913 |
| Placebo | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732913 |
| Idelalisib | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732913 |
| Rituximab | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732913 |
| Placebo | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732913 |
| Idelalisib | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732913 |
| Rituximab | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732913 |
| Placebo | Other | Phase PHASE3 | Indolent Non-Hodgkin's Lymphomas | TERMINATED | NCT01732913 |
| RBV | Other | Phase PHASE2 | Chronic Hepatitis C Virus | COMPLETED | NCT01726517 |
| LDV/SOF | Other | Phase PHASE2 | Chronic Hepatitis C Virus | COMPLETED | NCT01726517 |
| RBV | Other | Phase PHASE2 | Chronic Hepatitis C Virus | COMPLETED | NCT01726517 |
| LDV/SOF | Other | Phase PHASE2 | Chronic Hepatitis C Virus | COMPLETED | NCT01726517 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01701401 |
| LDV/SOF | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01701401 |
| RBV | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01701401 |
| LDV/SOF | Other | Phase PHASE3 | Chronic Hepatitis C Virus | COMPLETED | NCT01701401 |
| Rituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | TERMINATED | NCT01203930 |
| Idelalisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | TERMINATED | NCT01203930 |
| Rituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | TERMINATED | NCT01203930 |
| Idelalisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | TERMINATED | NCT01203930 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02350569 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02350569 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02301936 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02301936 |
| E/C/F/TAF | Other | Phase PHASE2 | HIV | COMPLETED | NCT02276612 |
| E/C/F/TAF | Other | Phase PHASE2 | HIV | COMPLETED | NCT02276612 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02251717 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02251717 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02251717 |
| LDV/SOF | Other | Phase PHASE2 | Chronic Genotype 4 HCV | COMPLETED | NCT02081079 |
| Rituximab | Other | Phase PHASE2 | B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion | TERMINATED | NCT02044822 |
| Idelalisib | Other | Phase PHASE2 | B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion | TERMINATED | NCT02044822 |
| Rituximab | Other | Phase PHASE2 | B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion | TERMINATED | NCT02044822 |
| Idelalisib | Other | Phase PHASE2 | B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion | TERMINATED | NCT02044822 |
| RBV | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02010255 |
| LDV/SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02010255 |
| RBV | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02010255 |
| LDV/SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT02010255 |
| RBV | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01987453 |
| LDV/SOF | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01987453 |
| RBV | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01987453 |
| LDV/SOF | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01987453 |
| RBV | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01987453 |
| LDV/SOF | Other | Phase PHASE2 | HCV Infection | COMPLETED | NCT01987453 |
| GS-9669 | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT01984294 |
| RBV | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT01984294 |
| LDV/SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT01984294 |
| GS-9669 | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT01984294 |
| RBV | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT01984294 |
| LDV/SOF | Other | Phase PHASE2 | Chronic HCV Infection | COMPLETED | NCT01984294 |
| Placebo | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Bendamustine | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Placebo | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Bendamustine | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Placebo | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Bendamustine | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980888 |
| Obinutuzumab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980875 |
| Chlorambucil | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980875 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980875 |
| Obinutuzumab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980875 |
| Chlorambucil | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980875 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01980875 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01924949 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01924949 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01924949 |
| E/C/F/TAF Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01780506 |
| E/C/F/TDF Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01780506 |
| E/C/F/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01780506 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01780506 |
| E/C/F/TAF Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01780506 |
| E/C/F/TDF Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01780506 |
| E/C/F/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01780506 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01780506 |
| E/C/F/TDF Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01497899 |
| E/C/F/TAF | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01497899 |
| E/C/F/TAF Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01497899 |
| E/C/F/TDF | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01497899 |
| E/C/F/TDF Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01497899 |
| E/C/F/TAF | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01497899 |
| E/C/F/TAF Placebo | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01497899 |
| E/C/F/TDF | Other | Phase PHASE2 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01497899 |
| Idelalisib | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT01393106 |
| Idelalisib | Other | Phase PHASE2 | Hodgkin Lymphoma | COMPLETED | NCT01393106 |
| Idelalisib | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01306643 |
| Idelalisib | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01306643 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02781558 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02781558 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02781558 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02781558 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02534350 |
| Presatovir | Other | Phase PHASE2 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02534350 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02534350 |
| Presatovir | Other | Phase PHASE2 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT02534350 |
| Ambrisentan | Other | Approved | Systemic Sclerosis | COMPLETED | NCT01093885 |
| Ambrisentan | Other | Approved | Systemic Sclerosis | COMPLETED | NCT01093885 |
| Tadalafil Pill | Other | Phase PHASE4 | Portopulmonary Hypertension | WITHDRAWN | NCT03309592 |
| Ambrisentan Pill | Other | Phase PHASE4 | Portopulmonary Hypertension | WITHDRAWN | NCT03309592 |
| Tadalafil Pill | Other | Phase PHASE4 | Portopulmonary Hypertension | WITHDRAWN | NCT03309592 |
| Ambrisentan Pill | Other | Phase PHASE4 | Portopulmonary Hypertension | WITHDRAWN | NCT03309592 |
| Etoposide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT03349346 |
| Carboplatin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT03349346 |
| Ifosfamide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT03349346 |
| Rituximab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT03349346 |
| Idelalisib | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT03349346 |
| Etoposide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT03349346 |
| Carboplatin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT03349346 |
| Ifosfamide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT03349346 |
| Rituximab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT03349346 |
| Idelalisib | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT03349346 |
| HCV screening | Other | Approved | Hepatitis C, Chronic | UNKNOWN | NCT03772002 |
| HCV screening | Other | Approved | Hepatitis C, Chronic | UNKNOWN | NCT03772002 |
| HCV screening | Other | Approved | Hepatitis C, Chronic | UNKNOWN | NCT03772002 |
| Placebo | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | TERMINATED | NCT02701634 |
| ENTO | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | TERMINATED | NCT02701634 |
| Placebo | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | TERMINATED | NCT02701634 |
| ENTO | Other | Phase PHASE2 | Chronic Graft Versus Host Disease | TERMINATED | NCT02701634 |
| Moderate-intensity cardiovascular and resistance exercise | Other | Approved | HIV | COMPLETED | NCT02404792 |
| High-intensity cardiovascular and resistance exercise | Other | Approved | HIV | COMPLETED | NCT02404792 |
| Placebo to match GS-9674 | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02854605 |
| GS-9674 | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02854605 |
| tenofovir disoproxil fumarate | Other | Preclinical | Chronic Hepatitis B | COMPLETED | NCT02533544 |
| Hu5F9-G4 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT02216409 |
| Hu5F9-G4 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT02216409 |
| Placebo | Other | Phase PHASE2 | Alcoholic Hepatitis (AH) | COMPLETED | NCT02854631 |
| Prednisolone | Other | Phase PHASE2 | Alcoholic Hepatitis (AH) | COMPLETED | NCT02854631 |
| Selonsertib | Other | Phase PHASE2 | Alcoholic Hepatitis (AH) | COMPLETED | NCT02854631 |
| Placebo | Other | Phase PHASE2 | Alcoholic Hepatitis (AH) | COMPLETED | NCT02854631 |
| Prednisolone | Other | Phase PHASE2 | Alcoholic Hepatitis (AH) | COMPLETED | NCT02854631 |
| Selonsertib | Other | Phase PHASE2 | Alcoholic Hepatitis (AH) | COMPLETED | NCT02854631 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02728206 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02728206 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02728206 |
| Harvoni | Other | Preclinical | Hepatitis C | COMPLETED | NCT02591277 |
| Harvoni | Other | Preclinical | Hepatitis C | COMPLETED | NCT02591277 |
| Placebo | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01522625 |
| tenofovir disoproxil fumarate 300mg per day | Other | Phase PHASE4 | Chronic Hepatitis B | COMPLETED | NCT01522625 |
| Genvoya | Other | Phase PHASE3 | HIV Risk | COMPLETED | NCT02998320 |
| Genvoya | Other | Phase PHASE3 | HIV Risk | COMPLETED | NCT02998320 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02536313 |
| SOF/VEL/VOX | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02536313 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02996682 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02996682 |
| RBV | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02996682 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02996682 |
| Placebo | Other | Phase PHASE4 | Pulmonary Hypertension | COMPLETED | NCT02829034 |
| Ranolazine | Other | Phase PHASE4 | Pulmonary Hypertension | COMPLETED | NCT02829034 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02639338 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02639338 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02639338 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02639338 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02639247 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02639247 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02639247 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02639247 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02639247 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02639247 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT02607800 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT02607800 |
| Placebo | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT02607735 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT02607735 |
| Placebo | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT02607735 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C | COMPLETED | NCT02607735 |
| Ranolazine | Other | Phase PHASE1 | Myotonia Congenita | COMPLETED | NCT02251457 |
| Ranolazine | Other | Phase PHASE1 | Myotonia Congenita | COMPLETED | NCT02251457 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis E | COMPLETED | NCT03282474 |
| Sofosbuvir | Other | Phase PHASE2 | Hepatitis E | COMPLETED | NCT03282474 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT03074331 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT03074331 |
| SIM | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672879 |
| Placebo | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672879 |
| SIM | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672879 |
| Placebo | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672879 |
| SIM | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672879 |
| Placebo | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672879 |
| SIM | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672866 |
| Placebo | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672866 |
| SIM | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672866 |
| Placebo | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672866 |
| SIM | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672866 |
| Placebo | Other | Phase PHASE2 | Liver Fibrosis Due to NASH | TERMINATED | NCT01672866 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT03118843 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT03118843 |
| Placebo to match eleclazine | Other | Phase PHASE2 | Ventricular Arrhythmia | COMPLETED | NCT02104583 |
| Eleclazine | Other | Phase PHASE2 | Ventricular Arrhythmia | COMPLETED | NCT02104583 |
| Placebo to match eleclazine | Other | Phase PHASE2 | Ventricular Arrhythmia | COMPLETED | NCT02104583 |
| Eleclazine | Other | Phase PHASE2 | Ventricular Arrhythmia | COMPLETED | NCT02104583 |
| Selonsertib | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT02234141 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT02234141 |
| Selonsertib | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT02234141 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT02234141 |
| Selonsertib | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT02234141 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT02234141 |
| Rituximab | Other | Preclinical | Chronic Lymphocytic Leukaemia | COMPLETED | NCT03582098 |
| Idelalisib | Other | Preclinical | Chronic Lymphocytic Leukaemia | COMPLETED | NCT03582098 |
| Rituximab | Other | Preclinical | Chronic Lymphocytic Leukaemia | COMPLETED | NCT03582098 |
| Idelalisib | Other | Preclinical | Chronic Lymphocytic Leukaemia | COMPLETED | NCT03582098 |
| Hepatitis C treatment as chosen by provider | Drug | Preclinical | Hepatitis C | UNKNOWN | NCT03876470 |
| Hepatitis C treatment as chosen by provider | Drug | Preclinical | Hepatitis C | UNKNOWN | NCT03876470 |
| Hepatitis C treatment as chosen by provider | Drug | Preclinical | Hepatitis C | UNKNOWN | NCT03876470 |
| Vincristine | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | TERMINATED | NCT02568683 |
| Entospletinib | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | TERMINATED | NCT02568683 |
| Vincristine | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | TERMINATED | NCT02568683 |
| Entospletinib | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | TERMINATED | NCT02568683 |
| Fluorouracil | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT01479465 |
| Irinotecan | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT01479465 |
| Leucovorin | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT01479465 |
| Placebo to match SIM | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT01479465 |
| Simtuzumab | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT01479465 |
| Fluorouracil | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT01479465 |
| Irinotecan | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT01479465 |
| Leucovorin | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT01479465 |
| Placebo to match SIM | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT01479465 |
| Simtuzumab | Other | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT01479465 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT02405442 |
| Andecaliximab | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT02405442 |
| Placebo | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT02405442 |
| Andecaliximab | Other | Phase PHASE2 | Crohn's Disease | TERMINATED | NCT02405442 |
| Genvoya 150Mg-150Mg-200Mg-10Mg Tablet | Other | Approved | HIV Infections | WITHDRAWN | NCT03877536 |
| Genvoya 150Mg-150Mg-200Mg-10Mg Tablet | Other | Approved | HIV Infections | WITHDRAWN | NCT03877536 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02175758 |
| SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02175758 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02175758 |
| SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02175758 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT02258529 |
| Idelalisib | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT02258529 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT02258529 |
| Idelalisib | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT02258529 |
| Placebo to match idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01539512 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01539512 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01539512 |
| Placebo to match idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01539512 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01539512 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01539512 |
| Cidofovir | Other | Approved | Cystitis | WITHDRAWN | NCT00956176 |
| Cidofovir | Other | Approved | Cystitis | WITHDRAWN | NCT00956176 |
| DEXA Scan | Other | Phase PHASE4 | Hepatitis B | TERMINATED | NCT02479880 |
| Tenofovir DF | Other | Phase PHASE4 | Hepatitis B | TERMINATED | NCT02479880 |
| DEXA Scan | Other | Phase PHASE4 | Hepatitis B | TERMINATED | NCT02479880 |
| Tenofovir DF | Other | Phase PHASE4 | Hepatitis B | TERMINATED | NCT02479880 |
| DEXA Scan | Other | Phase PHASE4 | Hepatitis B | TERMINATED | NCT02479880 |
| Tenofovir DF | Other | Phase PHASE4 | Hepatitis B | TERMINATED | NCT02479880 |
| Placebo | Other | Phase PHASE2 | Microvascular Angina | COMPLETED | NCT02147067 |
| Ranolazine | Other | Phase PHASE2 | Microvascular Angina | COMPLETED | NCT02147067 |
| Placebo | Other | Phase PHASE2 | Microvascular Angina | COMPLETED | NCT02147067 |
| Ranolazine | Other | Phase PHASE2 | Microvascular Angina | COMPLETED | NCT02147067 |
| Placebo | Other | Phase PHASE2 | Microvascular Angina | COMPLETED | NCT02147067 |
| Ranolazine | Other | Phase PHASE2 | Microvascular Angina | COMPLETED | NCT02147067 |
| GS-4774 | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02174276 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02174276 |
| GS-4774 | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02174276 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02174276 |
| SIM | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT02466516 |
| SEL | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT02466516 |
| SIM | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT02466516 |
| SEL | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT02466516 |
| SIM | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT02466516 |
| SEL | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT02466516 |
| Tenofovir Disoproxil Fumarate and Emtricitabine | Other | Preclinical | HIV Prevention | UNKNOWN | NCT03043326 |
| Tenofovir Disoproxil Fumarate and Emtricitabine | Other | Preclinical | HIV Prevention | UNKNOWN | NCT03043326 |
| Idelalisib | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT01282424 |
| Idelalisib | Other | Phase PHASE2 | Follicular Lymphoma | COMPLETED | NCT01282424 |
| Xpert HCV viral load test | Other | Approved | Hepatitis C | COMPLETED | NCT03231930 |
| OraQuick HCV Ab test | Other | Approved | Hepatitis C | COMPLETED | NCT03231930 |
| Xpert HCV viral load test | Other | Approved | Hepatitis C | COMPLETED | NCT03231930 |
| OraQuick HCV Ab test | Other | Approved | Hepatitis C | COMPLETED | NCT03231930 |
| Xpert HCV viral load test | Other | Approved | Hepatitis C | COMPLETED | NCT03231930 |
| OraQuick HCV Ab test | Other | Approved | Hepatitis C | COMPLETED | NCT03231930 |
| Xpert HCV viral load test | Other | Approved | Hepatitis C | COMPLETED | NCT03231930 |
| OraQuick HCV Ab test | Other | Approved | Hepatitis C | COMPLETED | NCT03231930 |
| HCV test | Other | Preclinical | Hepatitis C | COMPLETED | NCT03038763 |
| Eligibility Screening | Other | Preclinical | Hepatitis C | COMPLETED | NCT03038763 |
| HCV test | Other | Preclinical | Hepatitis C | COMPLETED | NCT03038763 |
| Eligibility Screening | Other | Preclinical | Hepatitis C | COMPLETED | NCT03038763 |
| HCV test | Other | Preclinical | Hepatitis C | COMPLETED | NCT03038763 |
| Eligibility Screening | Other | Preclinical | Hepatitis C | COMPLETED | NCT03038763 |
| Entospletinib | Other | Phase PHASE1 | Oncology | COMPLETED | NCT02521376 |
| Entospletinib | Other | Phase PHASE1 | Oncology | COMPLETED | NCT02521376 |
| Entospletinib | Other | Phase PHASE1 | Oncology | COMPLETED | NCT02521376 |
| Eleclazine | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT02412098 |
| Eleclazine | Other | Phase PHASE1 | Long QT Syndrome | COMPLETED | NCT02412098 |
| Fulvestrant | Other | Phase PHASE1 | Advanced Estrogen Receptor Positive HER2- Breast Cancer | TERMINATED | NCT02983604 |
| Exemestane | Other | Phase PHASE1 | Advanced Estrogen Receptor Positive HER2- Breast Cancer | TERMINATED | NCT02983604 |
| GS-5829 | Other | Phase PHASE1 | Advanced Estrogen Receptor Positive HER2- Breast Cancer | TERMINATED | NCT02983604 |
| Fulvestrant | Other | Phase PHASE1 | Advanced Estrogen Receptor Positive HER2- Breast Cancer | TERMINATED | NCT02983604 |
| Exemestane | Other | Phase PHASE1 | Advanced Estrogen Receptor Positive HER2- Breast Cancer | TERMINATED | NCT02983604 |
| GS-5829 | Other | Phase PHASE1 | Advanced Estrogen Receptor Positive HER2- Breast Cancer | TERMINATED | NCT02983604 |
| Fulvestrant | Other | Phase PHASE1 | Advanced Estrogen Receptor Positive HER2- Breast Cancer | TERMINATED | NCT02983604 |
| Exemestane | Other | Phase PHASE1 | Advanced Estrogen Receptor Positive HER2- Breast Cancer | TERMINATED | NCT02983604 |
| GS-5829 | Other | Phase PHASE1 | Advanced Estrogen Receptor Positive HER2- Breast Cancer | TERMINATED | NCT02983604 |
| Ofatumumab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01659021 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01659021 |
| Ofatumumab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01659021 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01659021 |
| Sugar pill | Other | Phase PHASE2 | Angina | COMPLETED | NCT02265796 |
| Ranolazine | Other | Phase PHASE2 | Angina | COMPLETED | NCT02265796 |
| referral sources of women who enroll | Other | Approved | Sexually Transmitted Diseases | COMPLETED | NCT02852226 |
| Characteristics of women who enroll | Other | Approved | Sexually Transmitted Diseases | COMPLETED | NCT02852226 |
| Pre Exposure Prophylaxis | Other | Approved | Sexually Transmitted Diseases | COMPLETED | NCT02852226 |
| referral sources of women who enroll | Other | Approved | Sexually Transmitted Diseases | COMPLETED | NCT02852226 |
| Characteristics of women who enroll | Other | Approved | Sexually Transmitted Diseases | COMPLETED | NCT02852226 |
| Pre Exposure Prophylaxis | Other | Approved | Sexually Transmitted Diseases | COMPLETED | NCT02852226 |
| E/C/F/TAF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| FTC/TDF Placebo | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| RTV Placebo | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| ATV Placebo | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| E/C/F/TDF Placebo | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| FTC/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| RTV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| ATV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| E/C/F/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| E/C/F/TAF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| FTC/TDF Placebo | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| RTV Placebo | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| ATV Placebo | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| E/C/F/TDF Placebo | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| FTC/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| RTV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| ATV | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| E/C/F/TDF | Other | Phase PHASE3 | Acquired Immunodeficiency Syndrome | COMPLETED | NCT01705574 |
| Artificial vaginal insemination | Other | Preclinical | HIV Infections | COMPLETED | NCT03049176 |
| Semen washing | Other | Preclinical | HIV Infections | COMPLETED | NCT03049176 |
| Antiretrovirals | Other | Preclinical | HIV Infections | COMPLETED | NCT03049176 |
| PrEP (Truvada) | Other | Preclinical | HIV Infections | COMPLETED | NCT03049176 |
| Artificial vaginal insemination | Other | Preclinical | HIV Infections | COMPLETED | NCT03049176 |
| Semen washing | Other | Preclinical | HIV Infections | COMPLETED | NCT03049176 |
| Antiretrovirals | Other | Preclinical | HIV Infections | COMPLETED | NCT03049176 |
| PrEP (Truvada) | Other | Preclinical | HIV Infections | COMPLETED | NCT03049176 |
| Bictegravir | Other | Phase PHASE1 | HIV | COMPLETED | NCT02400307 |
| Bictegravir | Other | Phase PHASE1 | HIV | COMPLETED | NCT02400307 |
| Placebo | Other | Phase PHASE2 | Primary Sclerosing Cholangitis (PSC) | COMPLETED | NCT01672853 |
| Simtuzumab | Other | Phase PHASE2 | Primary Sclerosing Cholangitis (PSC) | COMPLETED | NCT01672853 |
| Placebo | Other | Phase PHASE2 | Primary Sclerosing Cholangitis (PSC) | COMPLETED | NCT01672853 |
| Simtuzumab | Other | Phase PHASE2 | Primary Sclerosing Cholangitis (PSC) | COMPLETED | NCT01672853 |
| Lanraplenib. | Other | Phase PHASE1 | Inflammatory Disease | COMPLETED | NCT02959138 |
| 3rd ARV agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02469246 |
| F/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02469246 |
| ABC/3TC Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02469246 |
| ABC/3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02469246 |
| F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02469246 |
| 3rd ARV agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02469246 |
| F/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02469246 |
| ABC/3TC Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02469246 |
| ABC/3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02469246 |
| F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02469246 |
| Genvoya | Other | Approved | HIV | COMPLETED | NCT02251236 |
| Stribild | Other | Approved | HIV | COMPLETED | NCT02251236 |
| Genvoya | Other | Approved | HIV | COMPLETED | NCT02251236 |
| Stribild | Other | Approved | HIV | COMPLETED | NCT02251236 |
| OAV Regimen | Other | Phase PHASE2 | Chronic HBV Infection | COMPLETED | NCT01943799 |
| GS-4774 | Other | Phase PHASE2 | Chronic HBV Infection | COMPLETED | NCT01943799 |
| OAV Regimen | Other | Phase PHASE2 | Chronic HBV Infection | COMPLETED | NCT01943799 |
| GS-4774 | Other | Phase PHASE2 | Chronic HBV Infection | COMPLETED | NCT01943799 |
| Placebo to match selonsertib | Other | Phase PHASE2 | Diabetic Kidney Disease | COMPLETED | NCT02177786 |
| Selonsertib | Other | Phase PHASE2 | Diabetic Kidney Disease | COMPLETED | NCT02177786 |
| Placebo to match selonsertib | Other | Phase PHASE2 | Diabetic Kidney Disease | COMPLETED | NCT02177786 |
| Selonsertib | Other | Phase PHASE2 | Diabetic Kidney Disease | COMPLETED | NCT02177786 |
| Simtuzumab | Other | Phase PHASE2 | Liver Fibrosis | COMPLETED | NCT01707472 |
| Simtuzumab | Other | Phase PHASE2 | Liver Fibrosis | COMPLETED | NCT01707472 |
| Simtuzumab | Other | Phase PHASE2 | Liver Fibrosis | COMPLETED | NCT01707472 |
| Azacitidine | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT02343939 |
| Decitabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT02343939 |
| Cytarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT02343939 |
| Daunorubicin | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT02343939 |
| Entospletinib | Other | Phase PHASE1 | Acute Myeloid Leukemia | TERMINATED | NCT02343939 |
| Ambrisentan plus Placebo | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | TERMINATED | NCT02253394 |
| Ambrisentan plus Spironolactone | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | TERMINATED | NCT02253394 |
| Ambrisentan plus Placebo | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | TERMINATED | NCT02253394 |
| Ambrisentan plus Spironolactone | Other | Phase PHASE4 | Pulmonary Arterial Hypertension | TERMINATED | NCT02253394 |
| Tenofovir Alafenamide | Other | Preclinical | Chronic Hepatitis b | UNKNOWN | NCT03752658 |
| Tenofovir Alafenamide | Other | Preclinical | Chronic Hepatitis b | UNKNOWN | NCT03752658 |
| 1% tenofovir gel | Other | Phase PHASE2 | HIV | COMPLETED | NCT01691768 |
| 1% tenofovir gel | Other | Phase PHASE2 | HIV | COMPLETED | NCT01691768 |
| TDF treatment | Drug | Phase PHASE4 | Hepatitis B Infection | COMPLETED | NCT01488526 |
| TDF treatment | Drug | Phase PHASE4 | Hepatitis B Infection | COMPLETED | NCT01488526 |
| Biktarvy | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT03549312 |
| Epclusa | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT03549312 |
| Genvoya | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT03549312 |
| Biktarvy | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT03549312 |
| Epclusa | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT03549312 |
| Genvoya | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT03549312 |
| Biktarvy | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT03549312 |
| Epclusa | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT03549312 |
| Genvoya | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT03549312 |
| CNS Prophylaxis | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02404220 |
| Dexamethasone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02404220 |
| Vincristine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02404220 |
| Entospletinib | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02404220 |
| CNS Prophylaxis | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02404220 |
| Dexamethasone | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02404220 |
| Vincristine | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02404220 |
| Entospletinib | Other | Phase PHASE1 | Acute Lymphoblastic Leukemia | TERMINATED | NCT02404220 |
| Placebo | Other | Approved | Heart Failure With Preserved Ejection Fraction | COMPLETED | NCT01505179 |
| Ranolazine | Other | Approved | Heart Failure With Preserved Ejection Fraction | COMPLETED | NCT01505179 |
| Sofosbuvir/Velpatasvir Treatment for 14 days | Drug | Phase PHASE4 | Hepatitis C | WITHDRAWN | NCT03313414 |
| abacavir | Other | Phase PHASE4 | Renal Insufficiency,Chronic | UNKNOWN | NCT02957864 |
| tenofovir alafenamide | Other | Phase PHASE4 | Renal Insufficiency,Chronic | UNKNOWN | NCT02957864 |
| abacavir | Other | Phase PHASE4 | Renal Insufficiency,Chronic | UNKNOWN | NCT02957864 |
| tenofovir alafenamide | Other | Phase PHASE4 | Renal Insufficiency,Chronic | UNKNOWN | NCT02957864 |
| TDF | Other | Phase PHASE4 | Hepatitis B, Chronic | COMPLETED | NCT02081469 |
| TDF | Other | Phase PHASE4 | Hepatitis B, Chronic | COMPLETED | NCT02081469 |
| Placebo Oral Tablet | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00448669 |
| Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00448669 |
| Placebo Oral Tablet | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00448669 |
| Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00448669 |
| Ranolazine | Other | Approved | Cardiomyopathy | TERMINATED | NCT01705509 |
| Ranolazine | Other | Approved | Cardiomyopathy | TERMINATED | NCT01705509 |
| Influenza Vaccine | Other | Preclinical | B-cell Malignancies | TERMINATED | NCT03701438 |
| Influenza Vaccine | Other | Preclinical | B-cell Malignancies | TERMINATED | NCT03701438 |
| Influenza Vaccine | Other | Preclinical | B-cell Malignancies | TERMINATED | NCT03701438 |
| ARV regimen | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT02858401 |
| Placebo | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT02858401 |
| Vesatolimod | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT02858401 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT03036839 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT03036839 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02994056 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02994056 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02994056 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02994056 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02868242 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02868242 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02868242 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02249182 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02249182 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02249182 |
| LDV/SOF | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02249182 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01818596 |
| E/C/F/TAF Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01797445 |
| E/C/F/TDF Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT01797445 |
| E/C/F/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01797445 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01797445 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02378961 |
| VOX | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02378961 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02378961 |
| VOX | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02378961 |
| Idelalisib | Other | Phase PHASE4 | Lymphoid Malignancies | TERMINATED | NCT02739360 |
| Idelalisib | Other | Phase PHASE4 | Lymphoid Malignancies | TERMINATED | NCT02739360 |
| ledipasvir/sofosbuvir | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02683005 |
| ledipasvir/sofosbuvir | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02683005 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| RTV | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| ATV | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| E/C/F/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| RTV | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| ATV | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| E/C/F/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| RTV | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| ATV | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| E/C/F/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02652624 |
| Third agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| 3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| FTC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| Third agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| 3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| FTC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| Third agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| 3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| FTC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616783 |
| LDV/SOF | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02021656 |
| LDV/SOF | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02021656 |
| LDV/SOF | Other | Phase PHASE3 | Chronic HCV Infection | COMPLETED | NCT02021656 |
| Cytarabine | Other | Phase PHASE1 | Hematologic Malignancy | TERMINATED | NCT03135028 |
| Daunorubicin | Other | Phase PHASE1 | Hematologic Malignancy | TERMINATED | NCT03135028 |
| Entospletinib | Other | Phase PHASE1 | Hematologic Malignancy | TERMINATED | NCT03135028 |
| Cytarabine | Other | Phase PHASE1 | Hematologic Malignancy | TERMINATED | NCT03135028 |
| Daunorubicin | Other | Phase PHASE1 | Hematologic Malignancy | TERMINATED | NCT03135028 |
| Entospletinib | Other | Phase PHASE1 | Hematologic Malignancy | TERMINATED | NCT03135028 |
| SOF/VEL | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT03036852 |
| SOF/VEL | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT03036852 |
| LDV/SOF | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT02613871 |
| RBV | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02378935 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02378935 |
| VOX | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT02378935 |
| Placebo to match idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01569295 |
| Bendamustine | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01569295 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01569295 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01569295 |
| Placebo to match idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01569295 |
| Bendamustine | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01569295 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01569295 |
| Idelalisib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01569295 |
| F/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02121795 |
| FTC/TDF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02121795 |
| Allowed third antiretroviral agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02121795 |
| F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02121795 |
| FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02121795 |
| F/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02121795 |
| FTC/TDF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02121795 |
| Allowed third antiretroviral agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02121795 |
| F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02121795 |
| FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02121795 |
| Efavirenz, TDF, and 3TC | Other | Approved | HIV/AIDS | WITHDRAWN | NCT03405194 |
| Elvitegravir, Cobicistat, TAF, FTC | Other | Approved | HIV/AIDS | WITHDRAWN | NCT03405194 |
| Efavirenz, TDF, and 3TC | Other | Approved | HIV/AIDS | WITHDRAWN | NCT03405194 |
| Elvitegravir, Cobicistat, TAF, FTC | Other | Approved | HIV/AIDS | WITHDRAWN | NCT03405194 |
| Voxilaprevir | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT02402452 |
| Voxilaprevir | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT02402452 |
| Voxilaprevir | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT02402452 |
| AdhereTech Passive Monitoring | Other | Approved | Hepatitis C | COMPLETED | NCT02740556 |
| AdhereTech Active Features | Other | Approved | Hepatitis C | COMPLETED | NCT02740556 |
| HepCure ToolKit | Other | Approved | Hepatitis C | COMPLETED | NCT02740556 |
| AdhereTech Passive Monitoring | Other | Approved | Hepatitis C | COMPLETED | NCT02740556 |
| AdhereTech Active Features | Other | Approved | Hepatitis C | COMPLETED | NCT02740556 |
| HepCure ToolKit | Other | Approved | Hepatitis C | COMPLETED | NCT02740556 |
| Placebo | Other | Phase PHASE1 | Sickle Cell Anemia | COMPLETED | NCT02712346 |
| Ambrisentan | Other | Phase PHASE1 | Sickle Cell Anemia | COMPLETED | NCT02712346 |
| B/F/TAF | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT02397694 |
| DTG Placebo | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT02397694 |
| BIC Placebo | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT02397694 |
| DTG | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT02397694 |
| F/TAF | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT02397694 |
| BIC | Other | Phase PHASE2 | HIV-1 Infection | COMPLETED | NCT02397694 |
| Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC) | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT02858180 |
| Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC) | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT02858180 |
| Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC) | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT02858180 |
| Placebo to match SEL 18 mg | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053063 |
| Placebo to match SEL 6 mg | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053063 |
| SEL | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053063 |
| Placebo to match SEL 18 mg | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053063 |
| Placebo to match SEL 6 mg | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053063 |
| SEL | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053063 |
| Lanraplenib placebo | Other | Phase PHASE2 | Lupus Membranous Nephropathy | COMPLETED | NCT03285711 |
| Filgotinib placebo | Other | Phase PHASE2 | Lupus Membranous Nephropathy | COMPLETED | NCT03285711 |
| Lanraplenib | Other | Phase PHASE2 | Lupus Membranous Nephropathy | COMPLETED | NCT03285711 |
| Filgotinib | Other | Phase PHASE2 | Lupus Membranous Nephropathy | COMPLETED | NCT03285711 |
| Lanraplenib placebo | Other | Phase PHASE2 | Lupus Membranous Nephropathy | COMPLETED | NCT03285711 |
| Filgotinib placebo | Other | Phase PHASE2 | Lupus Membranous Nephropathy | COMPLETED | NCT03285711 |
| Lanraplenib | Other | Phase PHASE2 | Lupus Membranous Nephropathy | COMPLETED | NCT03285711 |
| Filgotinib | Other | Phase PHASE2 | Lupus Membranous Nephropathy | COMPLETED | NCT03285711 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02579382 |
| Vesatolimod | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02579382 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02579382 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02579382 |
| Vesatolimod | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02579382 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02579382 |
| Placebo | Other | Phase PHASE4 | Pulmonary Hypertension | TERMINATED | NCT00840463 |
| Ambrisentan | Other | Phase PHASE4 | Pulmonary Hypertension | TERMINATED | NCT00840463 |
| Placebo | Other | Phase PHASE4 | Pulmonary Hypertension | TERMINATED | NCT00840463 |
| Ambrisentan | Other | Phase PHASE4 | Pulmonary Hypertension | TERMINATED | NCT00840463 |
| Oxaliplatin | Other | Phase PHASE3 | Gastric Adenocarcinoma | COMPLETED | NCT02545504 |
| 5-fluorouracil | Other | Phase PHASE3 | Gastric Adenocarcinoma | COMPLETED | NCT02545504 |
| Leucovorin | Other | Phase PHASE3 | Gastric Adenocarcinoma | COMPLETED | NCT02545504 |
| Placebo | Other | Phase PHASE3 | Gastric Adenocarcinoma | COMPLETED | NCT02545504 |
| Andecaliximab | Other | Phase PHASE3 | Gastric Adenocarcinoma | COMPLETED | NCT02545504 |
| Oxaliplatin | Other | Phase PHASE3 | Gastric Adenocarcinoma | COMPLETED | NCT02545504 |
| 5-fluorouracil | Other | Phase PHASE3 | Gastric Adenocarcinoma | COMPLETED | NCT02545504 |
| Leucovorin | Other | Phase PHASE3 | Gastric Adenocarcinoma | COMPLETED | NCT02545504 |
| Placebo | Other | Phase PHASE3 | Gastric Adenocarcinoma | COMPLETED | NCT02545504 |
| Andecaliximab | Other | Phase PHASE3 | Gastric Adenocarcinoma | COMPLETED | NCT02545504 |
| Paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Irinotecan | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Bevacizumab | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| 5-FU | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Oxaliplatin | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Leucovorin | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Pemetrexed | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Carboplatin | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Andecaliximab | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Irinotecan | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Bevacizumab | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| 5-FU | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Oxaliplatin | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Leucovorin | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Pemetrexed | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Carboplatin | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Andecaliximab | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01803282 |
| Idelalisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01796470 |
| Entospletinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01796470 |
| Idelalisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01796470 |
| Entospletinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01796470 |
| Tenofovir Alafenamide | Other | Phase PHASE3 | Hepatitis B | ACTIVE_NOT_RECRUITING | NCT03489239 |
| Tenofovir Alafenamide | Other | Phase PHASE3 | Hepatitis B | ACTIVE_NOT_RECRUITING | NCT03489239 |
| Tenofovir Alafenamide | Other | Phase PHASE3 | Hepatitis B | ACTIVE_NOT_RECRUITING | NCT03489239 |
| Placebo to match SEL 18 mg | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053050 |
| Placebo to match SEL 6 mg | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053050 |
| SEL | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053050 |
| Placebo to match SEL 18 mg | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053050 |
| Placebo to match SEL 6 mg | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053050 |
| SEL | Other | Phase PHASE3 | Nonalcoholic Steatohepatitis | TERMINATED | NCT03053050 |
| SoC + iTab | Other | Phase PHASE4 | Patient Adherence | COMPLETED | NCT01761643 |
| SoC + iTab | Other | Phase PHASE4 | Patient Adherence | COMPLETED | NCT01761643 |
| Ruxolitinib | Other | Phase PHASE2 | Myelofibrosis | COMPLETED | NCT01369498 |
| Simtuzumab | Other | Phase PHASE2 | Myelofibrosis | COMPLETED | NCT01369498 |
| Raltegravir, tenofovir/emtricitabine | Other | Phase PHASE4 | HIV | COMPLETED | NCT01025427 |
| Raltegravir, tenofovir/emtricitabine | Other | Phase PHASE4 | HIV | COMPLETED | NCT01025427 |
| OraQuick HCV Rapid Antibody Test | Other | Phase EARLY_PHASE1 | Hepatitis C | COMPLETED | NCT03195205 |
| OraQuick HCV Rapid Antibody Test | Other | Phase EARLY_PHASE1 | Hepatitis C | COMPLETED | NCT03195205 |
| Vitamin D Supplement | Other | Phase PHASE4 | Patient Adherence | COMPLETED | NCT02367599 |
| Vitamin D Supplement | Other | Phase PHASE4 | Patient Adherence | COMPLETED | NCT02367599 |
| Vitamin D Supplement | Other | Phase PHASE4 | Patient Adherence | COMPLETED | NCT02367599 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616029 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02616029 |
| Placebo | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02856555 |
| Firsocostat | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02856555 |
| Norgestimate/ethinyl estradiol | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT02533427 |
| VOX | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT02533427 |
| SOF/VEL/VOX | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT02533427 |
| Placebo to match Andecaliximab | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT02077465 |
| Andecaliximab | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT02077465 |
| TDF Placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT02979613 |
| TAF Placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT02979613 |
| TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT02979613 |
| TAF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT02979613 |
| TDF Placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT02979613 |
| TAF Placebo | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT02979613 |
| TDF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT02979613 |
| TAF | Other | Phase PHASE3 | Chronic Hepatitis B | COMPLETED | NCT02979613 |
| Ruxolitinib | Other | Phase PHASE1 | Myelofibrosis | TERMINATED | NCT02436135 |
| Idelalisib | Other | Phase PHASE1 | Myelofibrosis | TERMINATED | NCT02436135 |
| Ruxolitinib | Other | Phase PHASE1 | Myelofibrosis | TERMINATED | NCT02436135 |
| Idelalisib | Other | Phase PHASE1 | Myelofibrosis | TERMINATED | NCT02436135 |
| SOF/VEL | Other | Phase PHASE1 | Hepatitis C Virus Infection | COMPLETED | NCT02185794 |
| Placebo to match voxilaprevir | Other | Phase PHASE1 | Hepatitis C Virus Infection | COMPLETED | NCT02185794 |
| Voxilaprevir | Other | Phase PHASE1 | Hepatitis C Virus Infection | COMPLETED | NCT02185794 |
| SOF/VEL | Other | Phase PHASE1 | Hepatitis C Virus Infection | COMPLETED | NCT02185794 |
| Placebo to match voxilaprevir | Other | Phase PHASE1 | Hepatitis C Virus Infection | COMPLETED | NCT02185794 |
| Voxilaprevir | Other | Phase PHASE1 | Hepatitis C Virus Infection | COMPLETED | NCT02185794 |
| Nivolumab | Other | Phase PHASE2 | Gastric Adenocarcinoma | COMPLETED | NCT02864381 |
| Andecaliximab | Other | Phase PHASE2 | Gastric Adenocarcinoma | COMPLETED | NCT02864381 |
| Nivolumab | Other | Phase PHASE2 | Gastric Adenocarcinoma | COMPLETED | NCT02864381 |
| Andecaliximab | Other | Phase PHASE2 | Gastric Adenocarcinoma | COMPLETED | NCT02864381 |
| Placebo to match cilofexor | Other | Phase PHASE2 | Primary Biliary Cholangitis | TERMINATED | NCT02943447 |
| Cilofexor | Other | Phase PHASE2 | Primary Biliary Cholangitis | TERMINATED | NCT02943447 |
| Placebo to match cilofexor | Other | Phase PHASE2 | Primary Biliary Cholangitis | TERMINATED | NCT02943447 |
| Cilofexor | Other | Phase PHASE2 | Primary Biliary Cholangitis | TERMINATED | NCT02943447 |
| Ambrisentan | Other | Phase PHASE3 | Pulmonary Hypertension | COMPLETED | NCT00777920 |
| Ambrisentan | Other | Phase PHASE3 | Pulmonary Hypertension | COMPLETED | NCT00777920 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT03022981 |
| SOF/VEL | Other | Phase PHASE2 | Hepatitis C Virus Infection | COMPLETED | NCT03022981 |
| Placebo | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02654002 |
| Cilofexor | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02654002 |
| Placebo | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02654002 |
| Cilofexor | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02654002 |
| Placebo | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02654002 |
| Cilofexor | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02654002 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02166047 |
| Vesatolimod | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02166047 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02166047 |
| Vesatolimod | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02166047 |
| SOF/VEL/VOX | Other | Phase PHASE2 | Hepatitis C Virus Infection | TERMINATED | NCT03820258 |
| SOF/VEL/VOX | Other | Phase PHASE2 | Hepatitis C Virus Infection | TERMINATED | NCT03820258 |
| Intervention Group | Other | Approved | HIV/AIDS | COMPLETED | NCT03343223 |
| Intervention Group | Other | Approved | HIV/AIDS | COMPLETED | NCT03343223 |
| Ambrisentan | Other | Phase PHASE4 | Systemic Sclerosis | COMPLETED | NCT01051960 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02600819 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02600819 |
| Dronedarone placebo | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01522651 |
| Ranolazine placebo | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01522651 |
| Dronedarone | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01522651 |
| Ranolazine | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01522651 |
| Dronedarone placebo | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01522651 |
| Ranolazine placebo | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01522651 |
| Dronedarone | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01522651 |
| Ranolazine | Other | Phase PHASE2 | Atrial Fibrillation | COMPLETED | NCT01522651 |
| Placebo | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT02275065 |
| Bictegravir | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT02275065 |
| Placebo | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT02275065 |
| Bictegravir | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT02275065 |
| B/F/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603120 |
| ABC/DTG/3TC Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603120 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603120 |
| ABC/DTG/3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603120 |
| B/F/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603120 |
| ABC/DTG/3TC Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603120 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603120 |
| ABC/DTG/3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603120 |
| Remdesivir | Other | Preclinical | SARS-CoV2 Infection | APPROVED_FOR_MARKETING | NCT04323761 |
| Remdesivir | Other | Preclinical | SARS-CoV2 Infection | APPROVED_FOR_MARKETING | NCT04323761 |
| Velpatasvir | Other | Phase PHASE1 | Hepatitis C Virus | COMPLETED | NCT02002767 |
| Velpatasvir | Other | Phase PHASE1 | Hepatitis C Virus | COMPLETED | NCT02002767 |
| Monitoring virus load | Other | Approved | ART | COMPLETED | NCT03986099 |
| Monitoring virus load | Other | Approved | ART | COMPLETED | NCT03986099 |
| Entospletinib SDD | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01799889 |
| Entospletinib MM | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01799889 |
| Entospletinib SDD | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01799889 |
| Entospletinib MM | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01799889 |
| BI 836826 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | TERMINATED | NCT02538614 |
| Idelalisib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | TERMINATED | NCT02538614 |
| BI 836826 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | TERMINATED | NCT02538614 |
| Idelalisib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | TERMINATED | NCT02538614 |
| BI 836826 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | TERMINATED | NCT02538614 |
| Idelalisib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | TERMINATED | NCT02538614 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03405935 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03405935 |
| Placebo to match SEL | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| Placebo to match CILO | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| Placebo to match FIR | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| CILO | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| FIR | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| SEL | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| Placebo to match SEL | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| Placebo to match CILO | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| Placebo to match FIR | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| CILO | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| FIR | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| SEL | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT03449446 |
| Enzalutamide | Other | Phase PHASE1 | Metastatic Castrate-Resistant Prostate Cancer | TERMINATED | NCT02607228 |
| Alobresib | Other | Phase PHASE1 | Metastatic Castrate-Resistant Prostate Cancer | TERMINATED | NCT02607228 |
| TAF | Other | Phase PHASE1 | Hepatitis B Virus | COMPLETED | NCT02296853 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis C Virus | COMPLETED | NCT01740791 |
| Velpatasvir | Other | Phase PHASE1 | Chronic Hepatitis C Virus | COMPLETED | NCT01740791 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis C Virus | COMPLETED | NCT01740791 |
| Velpatasvir | Other | Phase PHASE1 | Chronic Hepatitis C Virus | COMPLETED | NCT01740791 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis C Virus | COMPLETED | NCT01740791 |
| Velpatasvir | Other | Phase PHASE1 | Chronic Hepatitis C Virus | COMPLETED | NCT01740791 |
| Fenofibrate | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02891408 |
| Firsocostat | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02891408 |
| Fenofibrate | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02891408 |
| Firsocostat | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02891408 |
| Epclusa | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT02825212 |
| Harvoni | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT02825212 |
| Epclusa | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT02825212 |
| Harvoni | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT02825212 |
| Nivolumab | Other | Phase PHASE1 | Gastric Adenocarcinoma | TERMINATED | NCT02862535 |
| Oxaliplatin | Other | Phase PHASE1 | Gastric Adenocarcinoma | TERMINATED | NCT02862535 |
| Cisplatin | Other | Phase PHASE1 | Gastric Adenocarcinoma | TERMINATED | NCT02862535 |
| S-1 | Other | Phase PHASE1 | Gastric Adenocarcinoma | TERMINATED | NCT02862535 |
| Andecaliximab | Other | Phase PHASE1 | Gastric Adenocarcinoma | TERMINATED | NCT02862535 |
| Nivolumab | Other | Phase PHASE1 | Gastric Adenocarcinoma | TERMINATED | NCT02862535 |
| Oxaliplatin | Other | Phase PHASE1 | Gastric Adenocarcinoma | TERMINATED | NCT02862535 |
| Cisplatin | Other | Phase PHASE1 | Gastric Adenocarcinoma | TERMINATED | NCT02862535 |
| S-1 | Other | Phase PHASE1 | Gastric Adenocarcinoma | TERMINATED | NCT02862535 |
| Andecaliximab | Other | Phase PHASE1 | Gastric Adenocarcinoma | TERMINATED | NCT02862535 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603107 |
| ABC/3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603107 |
| FTC/TDF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603107 |
| DRV/co | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603107 |
| ATV/co | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603107 |
| COBI | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603107 |
| DRV | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603107 |
| ATV | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603107 |
| RTV | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02603107 |
| Fulvestrant | Other | Phase PHASE1 | Solid Tumors and Lymphomas | COMPLETED | NCT02392611 |
| Exemestane | Other | Phase PHASE1 | Solid Tumors and Lymphomas | COMPLETED | NCT02392611 |
| Alobresib | Other | Phase PHASE1 | Solid Tumors and Lymphomas | COMPLETED | NCT02392611 |
| Fulvestrant | Other | Phase PHASE1 | Solid Tumors and Lymphomas | COMPLETED | NCT02392611 |
| Exemestane | Other | Phase PHASE1 | Solid Tumors and Lymphomas | COMPLETED | NCT02392611 |
| Alobresib | Other | Phase PHASE1 | Solid Tumors and Lymphomas | COMPLETED | NCT02392611 |
| Placebo | Other | Phase PHASE1 | LQT2 Syndrome | COMPLETED | NCT02365506 |
| Eleclazine | Other | Phase PHASE1 | LQT2 Syndrome | COMPLETED | NCT02365506 |
| Placebo | Other | Phase PHASE1 | LQT2 Syndrome | COMPLETED | NCT02365506 |
| Eleclazine | Other | Phase PHASE1 | LQT2 Syndrome | COMPLETED | NCT02365506 |
| Standard of Care | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04292899 |
| Remdesivir | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04292899 |
| RTV | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| DRV | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| ARV regimen | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| TAF | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| BIC | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| GS-9131 | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| RTV | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| DRV | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| ARV regimen | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| TAF | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| BIC | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| GS-9131 | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| RTV | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| DRV | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| ARV regimen | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| TAF | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| BIC | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| GS-9131 | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT03472326 |
| Cilofexor | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02808312 |
| Cilofexor | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02808312 |
| Cilofexor | Other | Phase PHASE1 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02808312 |
| Ambrisentan | Other | Phase PHASE3 | Portopulmonary Hypertension | COMPLETED | NCT01224210 |
| Ambrisentan | Other | Phase PHASE3 | Portopulmonary Hypertension | COMPLETED | NCT01224210 |
| Ambrisentan | Other | Phase PHASE3 | Portopulmonary Hypertension | COMPLETED | NCT01224210 |
| no education | Other | Preclinical | Hepatitis B and Hepatitis C (Disorder) | COMPLETED | NCT03794791 |
| education | Other | Preclinical | Hepatitis B and Hepatitis C (Disorder) | COMPLETED | NCT03794791 |
| no education | Other | Preclinical | Hepatitis B and Hepatitis C (Disorder) | COMPLETED | NCT03794791 |
| education | Other | Preclinical | Hepatitis B and Hepatitis C (Disorder) | COMPLETED | NCT03794791 |
| Standard of Care | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04292730 |
| Remdesivir | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04292730 |
| Standard of Care | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04292730 |
| Remdesivir | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04292730 |
| Standard of Care | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04292730 |
| Remdesivir | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT04292730 |
| Selonsertib | Other | Phase PHASE1 | Diabetic Kidney Disease | COMPLETED | NCT02509624 |
| Selonsertib | Other | Phase PHASE1 | Diabetic Kidney Disease | COMPLETED | NCT02509624 |
| Selonsertib | Other | Phase PHASE1 | Diabetic Kidney Disease | COMPLETED | NCT02509624 |
| Placebo to match Andecaliximab | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT01831427 |
| Andecaliximab | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT01831427 |
| Placebo to match Andecaliximab | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT01831427 |
| Andecaliximab | Other | Phase PHASE1 | Ulcerative Colitis | COMPLETED | NCT01831427 |
| Cetuximab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT02953782 |
| Magrolimab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT02953782 |
| Cetuximab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT02953782 |
| Magrolimab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT02953782 |
| Cetuximab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT02953782 |
| Magrolimab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT02953782 |
| placebo | Other | Phase PHASE3 | Hepatitis B Chronic Infection | COMPLETED | NCT01745822 |
| tenofovir disoproxil fumarate | Other | Phase PHASE3 | Hepatitis B Chronic Infection | COMPLETED | NCT01745822 |
| placebo | Other | Phase PHASE3 | Hepatitis B Chronic Infection | COMPLETED | NCT01745822 |
| tenofovir disoproxil fumarate | Other | Phase PHASE3 | Hepatitis B Chronic Infection | COMPLETED | NCT01745822 |
| placebo | Other | Phase PHASE3 | Hepatitis B Chronic Infection | COMPLETED | NCT01745822 |
| tenofovir disoproxil fumarate | Other | Phase PHASE3 | Hepatitis B Chronic Infection | COMPLETED | NCT01745822 |
| Lenalidomide | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Chlorambucil | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Bortezomib | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Everolimus | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Fludarabine | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Ofatumumab | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Bendamustine | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Rituximab | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Idelalisib | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Lenalidomide | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Chlorambucil | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Bortezomib | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Everolimus | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Fludarabine | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Ofatumumab | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Bendamustine | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Rituximab | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Idelalisib | Other | Phase PHASE1 | Indolent Non-Hodgkin's Lymphoma | COMPLETED | NCT01088048 |
| Idelalisib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02242045 |
| Idelalisib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02242045 |
| ART | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03060447 |
| Placebo | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03060447 |
| Vesatolimod | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03060447 |
| ART | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03060447 |
| Placebo | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03060447 |
| Vesatolimod | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03060447 |
| IMMU-107 (hPAM4) | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT00603863 |
| IMMU-107 (hPAM4) | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT00603863 |
| IMMU-107 (hPAM4) | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT00603863 |
| milatuzumab | Other | Phase PHASE1 | Chronic Lymphocytic Lymphoma | COMPLETED | NCT00603668 |
| milatuzumab | Other | Phase PHASE1 | Chronic Lymphocytic Lymphoma | COMPLETED | NCT00603668 |
| veltuzumab | Other | Phase PHASE1 | Purpura, Thrombocytopenic, Idiopathic | TERMINATED | NCT00547066 |
| veltuzumab | Other | Phase PHASE1 | Purpura, Thrombocytopenic, Idiopathic | TERMINATED | NCT00547066 |
| veltuzumab | Other | Phase PHASE1 | NHL | COMPLETED | NCT00546793 |
| veltuzumab | Other | Phase PHASE1 | NHL | COMPLETED | NCT00546793 |
| milatuzumab | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00421525 |
| IMMU-132 plus Carboplatin infusion | Other | Phase PHASE2 | Triple-negative Breast Cancer | WITHDRAWN | NCT02161679 |
| IMMU-132 infusion is administered to participants in one arm for the study | Other | Phase PHASE2 | Triple-negative Breast Cancer | WITHDRAWN | NCT02161679 |
| IMMU-132 plus Carboplatin infusion | Other | Phase PHASE2 | Triple-negative Breast Cancer | WITHDRAWN | NCT02161679 |
| IMMU-132 infusion is administered to participants in one arm for the study | Other | Phase PHASE2 | Triple-negative Breast Cancer | WITHDRAWN | NCT02161679 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT05147740 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT05147740 |
| Rituximab | Other | Phase PHASE1 | Non-hodgkin Lymphoma | TERMINATED | NCT04502706 |
| GS-0189 | Other | Phase PHASE1 | Non-hodgkin Lymphoma | TERMINATED | NCT04502706 |
| No Intervention | Other | Approved | Liver Diseases | COMPLETED | NCT07580482 |
| Best Practice Alert | Other | Approved | Liver Diseases | COMPLETED | NCT07580482 |
| No Intervention | Other | Approved | Liver Diseases | COMPLETED | NCT07580482 |
| Best Practice Alert | Other | Approved | Liver Diseases | COMPLETED | NCT07580482 |
| Standard of Care | Other | Preclinical | Hepatitis C | COMPLETED | NCT05710120 |
| Hepatitis C Screening Alerts in CHORUS™ | Other | Preclinical | Hepatitis C | COMPLETED | NCT05710120 |
| Standard of Care | Other | Preclinical | Hepatitis C | COMPLETED | NCT05710120 |
| Hepatitis C Screening Alerts in CHORUS™ | Other | Preclinical | Hepatitis C | COMPLETED | NCT05710120 |
| No Intervention | Other | Approved | Liver Diseases | COMPLETED | NCT07580482 |
| Best Practice Alert | Other | Approved | Liver Diseases | COMPLETED | NCT07580482 |
| mFOLFOX6 | Other | Phase PHASE1 | Previously Untreated Pancreatic Ductal Adenocarcinoma | TERMINATED | NCT02468557 |
| Nab-paclitaxel | Other | Phase PHASE1 | Previously Untreated Pancreatic Ductal Adenocarcinoma | TERMINATED | NCT02468557 |
| Idelalisib | Other | Phase PHASE1 | Previously Untreated Pancreatic Ductal Adenocarcinoma | TERMINATED | NCT02468557 |
| mFOLFOX6 | Other | Phase PHASE1 | Previously Untreated Pancreatic Ductal Adenocarcinoma | TERMINATED | NCT02468557 |
| Nab-paclitaxel | Other | Phase PHASE1 | Previously Untreated Pancreatic Ductal Adenocarcinoma | TERMINATED | NCT02468557 |
| Idelalisib | Other | Phase PHASE1 | Previously Untreated Pancreatic Ductal Adenocarcinoma | TERMINATED | NCT02468557 |
| TAF | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03739866 |
| B/F/TAF | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03739866 |
| Placebo | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03739866 |
| Lenacapavir | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03739866 |
| TAF | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03739866 |
| B/F/TAF | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03739866 |
| Placebo | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03739866 |
| Lenacapavir | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT03739866 |
| COBI | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| FTC/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| ATV | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| RTV | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| EFV/FTC/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| E/C/F/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| COBI | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| FTC/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| ATV | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| RTV | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| EFV/FTC/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| E/C/F/TDF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| E/C/F/TAF | Other | Phase PHASE3 | HIV | COMPLETED | NCT01815736 |
| sofosbuvir/velpatasvir | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT03235154 |
| sofosbuvir/velpatasvir | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT03235154 |
| Pulmonary Function Test | Other | Preclinical | COVID-19 Pneumonia | UNKNOWN | NCT04868864 |
| CT scan | Other | Preclinical | COVID-19 Pneumonia | UNKNOWN | NCT04868864 |
| Placebo to match cilofexor | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | COMPLETED | NCT02943460 |
| Cilofexor | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | COMPLETED | NCT02943460 |
| Placebo to match cilofexor | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | COMPLETED | NCT02943460 |
| Cilofexor | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | COMPLETED | NCT02943460 |
| Matched placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| CB-0406 1,000 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| CB-0406 800 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| CB-0406 400 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| CB-0406 200 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| CB-0406 100 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| Matched placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| CB-0406 1,000 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| CB-0406 800 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| CB-0406 400 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| CB-0406 200 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| CB-0406 100 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04467684 |
| Sofosbuvir and Velpatasvir | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT03818308 |
| Sofosbuvir and Velpatasvir | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT03818308 |
| Direct-acting antiviral agents | Other | Preclinical | Hepatitis C, Chronic | UNKNOWN | NCT04952207 |
| Direct-acting antiviral agents | Other | Preclinical | Hepatitis C, Chronic | UNKNOWN | NCT04952207 |
| Sigmoidoscopy | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Physical Examination | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Pharmacological Study | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Laboratory Biomarker Analysis | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Idelalisib | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Colposcopic Biopsy | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Colonoscopy | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Biospecimen Collection | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Sigmoidoscopy | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Physical Examination | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Pharmacological Study | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Laboratory Biomarker Analysis | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Idelalisib | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Colposcopic Biopsy | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Colonoscopy | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Biospecimen Collection | Other | Preclinical | Absence of Signs or Symptoms | TERMINATED | NCT02928510 |
| Truvada | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT04965662 |
| Maraviroc | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT04965662 |
| Truvada | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT04965662 |
| Maraviroc | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT04965662 |
| Truvada | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT04965662 |
| Maraviroc | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT04965662 |
| Transient elastography | Other | Approved | Hepatitis C | COMPLETED | NCT02755402 |
| Xpert HCV Viral load | Other | Approved | Hepatitis C | COMPLETED | NCT02755402 |
| Transient elastography | Other | Approved | Hepatitis C | COMPLETED | NCT02755402 |
| Xpert HCV Viral load | Other | Approved | Hepatitis C | COMPLETED | NCT02755402 |
| Integrated intervention strategies | Other | Approved | Chronic Hepatitis b | UNKNOWN | NCT04980664 |
| Placebo | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | WITHDRAWN | NCT04827589 |
| Tirabrutinib | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | WITHDRAWN | NCT04827589 |
| Placebo | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | WITHDRAWN | NCT04827589 |
| Tirabrutinib | Other | Phase PHASE2 | Chronic Spontaneous Urticaria | WITHDRAWN | NCT04827589 |
| Inhaled Aztreonam | Other | Phase PHASE4 | Tracheostomy Infection | TERMINATED | NCT03158116 |
| Adefovir dipivoxil and hepatitis B vaccination | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01146808 |
| Adefovir dipivoxil and hepatitis B vaccination | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01146808 |
| Adefovir dipivoxil and hepatitis B vaccination | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT01146808 |
| Sacituzumab Govitecan-hziy (SG) | Other | Phase PHASE1 | Gastric Adenocarcinoma | COMPLETED | NCT01631552 |
| Sacituzumab Govitecan-hziy (SG) | Other | Phase PHASE1 | Gastric Adenocarcinoma | COMPLETED | NCT01631552 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Pancreatic Cancer | TERMINATED | NCT01956812 |
| placebo | Other | Phase PHASE3 | Metastatic Pancreatic Cancer | TERMINATED | NCT01956812 |
| IMMU-107 | Other | Phase PHASE3 | Metastatic Pancreatic Cancer | TERMINATED | NCT01956812 |
| TF2/IMP288 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | WITHDRAWN | NCT01273402 |
| TF2/IMP288 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | WITHDRAWN | NCT01273402 |
| hLL1-DOX (the doxorubicin conjugate of milatuzumab) | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT01101594 |
| milatuzumab | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT00421525 |
| 90Y-hLL2 | Other | Phase PHASE1 | NHL | COMPLETED | NCT00421395 |
| 90Y-hLL2 | Other | Phase PHASE1 | NHL | COMPLETED | NCT00421395 |
| 90Y-hLL2 | Other | Phase PHASE1 | NHL | COMPLETED | NCT00421395 |
| hLL2 (epratuzumab) | Other | Phase PHASE1 | Non-Hodgkins Lymphoma | TERMINATED | NCT00054834 |
| hLL2 (epratuzumab) | Other | Phase PHASE1 | Non-Hodgkins Lymphoma | TERMINATED | NCT00054834 |
| hLL2 (epratuzumab) | Other | Phase PHASE1 | Non-Hodgkins Lymphoma | TERMINATED | NCT00054834 |
| technetium Tc 99m epratuzumab | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00003338 |
| immunoscintigraphy | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00003338 |
| technetium Tc 99m epratuzumab | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00003338 |
| immunoscintigraphy | Other | Phase PHASE2 | Lymphoma | UNKNOWN | NCT00003338 |
| technetium Tc 99m epratuzumab | Other | Phase PHASE3 | Lymphoma | UNKNOWN | NCT00003337 |
| immunoscintigraphy | Other | Phase PHASE3 | Lymphoma | UNKNOWN | NCT00003337 |
| technetium Tc 99m epratuzumab | Other | Phase PHASE3 | Lymphoma | UNKNOWN | NCT00003337 |
| immunoscintigraphy | Other | Phase PHASE3 | Lymphoma | UNKNOWN | NCT00003337 |
| hA20-humanized anti-CD20 antibody | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00285428 |
| veltuzumab | Other | Phase PHASE1 | Non Hodgkin's Lymphoma | WITHDRAWN | NCT01101581 |
| 90Y-epratuzumab tetraxetan | Other | Phase PHASE1 | Non Hodgkin's Lymphoma | WITHDRAWN | NCT01101581 |
| Veltuzumab and 90Y-Epratuzumab Tetraxetan | Other | Phase PHASE1 | Non Hodgkin's Lymphoma | WITHDRAWN | NCT01101581 |
| veltuzumab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00596804 |
| veltuzumab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00596804 |
| IMMU-132 | Other | Preclinical | Metastatic Triple-Negative Breast Carcinoma | APPROVED_FOR_MARKETING | NCT04320693 |
| IMMU-132 | Other | Preclinical | Metastatic Triple-Negative Breast Carcinoma | APPROVED_FOR_MARKETING | NCT04320693 |
| Hepatitis B virus (HBV) OAV Therapy | Drug | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03491553 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03491553 |
| Selgantolimod | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03491553 |
| Hepatitis B virus (HBV) OAV Therapy | Drug | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03491553 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03491553 |
| Selgantolimod | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03491553 |
| IMMU 130 | Other | Phase PHASE2 | Metastatic Colorectal Cancer | WITHDRAWN | NCT01915472 |
| IMMU-114 | Other | Phase PHASE1 | Non-hodgkin's Lymphoma | TERMINATED | NCT01728207 |
| milatuzumab | Other | Phase PHASE1 | GVHD (Acute or Chronic) | TERMINATED | NCT01663766 |
| milatuzumab | Other | Phase PHASE1 | GVHD (Acute or Chronic) | TERMINATED | NCT01663766 |
| 90Y-hPAM4 + gemcitabine | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | WITHDRAWN | NCT01510561 |
| 90Y-hPAM4 | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | WITHDRAWN | NCT01510561 |
| 90Y-hPAM4 + gemcitabine | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | WITHDRAWN | NCT01510561 |
| 90Y-hPAM4 | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | WITHDRAWN | NCT01510561 |
| IMMU-130 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT01270698 |
| 90Y-hPAM4 | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT00597129 |
| 90Y-hPAM4 | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT00597129 |
| Epratuzumab (hLL2- anti-CD22 humanized antibody) | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | TERMINATED | NCT00113802 |
| Epratuzumab (hLL2- anti-CD22 humanized antibody) | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | TERMINATED | NCT00113802 |
| radiolabeled epratuzumab | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00061425 |
| hMN14 (labetuzumab) | Other | Phase PHASE1 | Colorectal Neoplasms | TERMINATED | NCT00041691 |
| hMN14 (labetuzumab) | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00041652 |
| hMN14 (labetuzumab) | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00041652 |
| hMN14 (labetuzumab) | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00041652 |
| hMN14 (labetuzumab) | Other | Phase PHASE1 | Pancreatic Neoplasms | COMPLETED | NCT00041639 |
| hMN14 (labetuzumab) | Other | Phase PHASE1 | Pancreatic Neoplasms | COMPLETED | NCT00041639 |
| hMN14 (labetuzumab) | Other | Phase PHASE1 | Pancreatic Neoplasms | COMPLETED | NCT00041639 |
| hMN14 (labetuzumab) | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00040599 |
| hMN14 (labetuzumab) | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00040599 |
| EC clinic support - whole of practice interventions delivery through nurse-led model | Other | Approved | Hepatitis C | UNKNOWN | NCT04061551 |
| Third Agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03631732 |
| NRTIs | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03631732 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03631732 |
| Third Agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03631732 |
| NRTIs | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03631732 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03631732 |
| Third Agent | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03631732 |
| NRTIs | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03631732 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT03631732 |
| Rifapentine weekly | Other | Phase PHASE4 | Tuberculosis | WITHDRAWN | NCT04551573 |
| Rifapentine daily | Other | Phase PHASE4 | Tuberculosis | WITHDRAWN | NCT04551573 |
| Rifapentine weekly | Other | Phase PHASE4 | Tuberculosis | WITHDRAWN | NCT04551573 |
| Rifapentine daily | Other | Phase PHASE4 | Tuberculosis | WITHDRAWN | NCT04551573 |
| Ledipasvir 90 MG | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT03312023 |
| Sofosbuvir 400 MG [Sovaldi] | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT03312023 |
| Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni] | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT03312023 |
| Ledipasvir 90 MG | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT03312023 |
| Sofosbuvir 400 MG [Sovaldi] | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT03312023 |
| Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni] | Other | Phase PHASE2 | Hepatitis B | COMPLETED | NCT03312023 |
| Patient portal message | Other | Approved | Hepatitis C | COMPLETED | NCT04873609 |
| Patient portal message | Other | Approved | Hepatitis C | COMPLETED | NCT04873609 |
| TAF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03180619 |
| TAF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03180619 |
| FTC/TAF | Other | Phase PHASE4 | Hiv | COMPLETED | NCT03350672 |
| FTC/TAF | Other | Phase PHASE4 | Hiv | COMPLETED | NCT03350672 |
| FTC/TAF | Other | Phase PHASE4 | Hiv | COMPLETED | NCT03350672 |
| hLL1-DOX (IMMU-115) | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | TERMINATED | NCT01585688 |
| Control writing exercise | Other | Approved | HIV Prevention | TERMINATED | NCT03278990 |
| Value Affirmation and Future Selves Combination | Other | Approved | HIV Prevention | TERMINATED | NCT03278990 |
| Control writing exercise | Other | Approved | HIV Prevention | TERMINATED | NCT03278990 |
| Value Affirmation and Future Selves Combination | Other | Approved | HIV Prevention | TERMINATED | NCT03278990 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT04211909 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT04211909 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT04211909 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT04211909 |
| SOF/VEL/VOX | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT04211909 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT04211909 |
| subcutaneous tocilizumab 162mg/biweekly | Other | Phase PHASE3 | Rheumatoid Arthritis | UNKNOWN | NCT05090410 |
| filgotinib 200mg/day | Other | Phase PHASE3 | Rheumatoid Arthritis | UNKNOWN | NCT05090410 |
| subcutaneous tocilizumab 162mg/biweekly | Other | Phase PHASE3 | Rheumatoid Arthritis | UNKNOWN | NCT05090410 |
| filgotinib 200mg/day | Other | Phase PHASE3 | Rheumatoid Arthritis | UNKNOWN | NCT05090410 |
| subcutaneous tocilizumab 162mg/biweekly | Other | Phase PHASE3 | Rheumatoid Arthritis | UNKNOWN | NCT05090410 |
| filgotinib 200mg/day | Other | Phase PHASE3 | Rheumatoid Arthritis | UNKNOWN | NCT05090410 |
| Sub-Trial: Dose combination 2-2 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | WITHDRAWN | NCT03639324 |
| Sub-Trial: Dose combination 2-1 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | WITHDRAWN | NCT03639324 |
| dose combination 1-4 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | WITHDRAWN | NCT03639324 |
| Dose combination 1-3 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | WITHDRAWN | NCT03639324 |
| dose combination 1-2 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | WITHDRAWN | NCT03639324 |
| Dose combination 1-1 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | WITHDRAWN | NCT03639324 |
| Telehealth Coaching | Other | Approved | Adolescent Behavior | WITHDRAWN | NCT03897725 |
| Telehealth Coaching | Other | Approved | Adolescent Behavior | WITHDRAWN | NCT03897725 |
| Placebo to Match RDV | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04501952 |
| RDV | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04501952 |
| Placebo to Match RDV | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04501952 |
| RDV | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04501952 |
| Placebo to Match RDV | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04501952 |
| RDV | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04501952 |
| Idelalisib | Other | Preclinical | Follicular Non-Hodgkin's Lymphoma Refractory | COMPLETED | NCT03568929 |
| Idelalisib | Other | Preclinical | Follicular Non-Hodgkin's Lymphoma Refractory | COMPLETED | NCT03568929 |
| LDV/SOF | Other | Preclinical | Hepatitis C Virus | COMPLETED | NCT02951364 |
| LDV/SOF | Other | Preclinical | Hepatitis C Virus | COMPLETED | NCT02951364 |
| HCV, HBV, HIV tests | Other | Approved | HCV | TERMINATED | NCT04286347 |
| HCV, HBV, HIV tests | Other | Approved | HCV | TERMINATED | NCT04286347 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT05147740 |
| Obinutuzumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02983617 |
| Entospletinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02983617 |
| Tirabrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02983617 |
| Obinutuzumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02983617 |
| Entospletinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02983617 |
| Tirabrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02983617 |
| Obinutuzumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02983617 |
| Entospletinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02983617 |
| Tirabrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02983617 |
| Sofosbuvir | Other | Preclinical | Hepatitis C Virus | COMPLETED | NCT02907996 |
| Sofosbuvir | Other | Preclinical | Hepatitis C Virus | COMPLETED | NCT02907996 |
| antiviral prophylaxis with Tenofovir Alafenamide Fumarate | Other | Phase PHASE4 | Hepatitis B, Chronic | UNKNOWN | NCT05177926 |
| antiviral prophylaxis with Tenofovir Alafenamide Fumarate | Other | Phase PHASE4 | Hepatitis B, Chronic | UNKNOWN | NCT05177926 |
| B/F/TAF Placebo | Other | Phase PHASE3 | HIV-1-infection | COMPLETED | NCT03110380 |
| F/TAF Placebo | Other | Phase PHASE3 | HIV-1-infection | COMPLETED | NCT03110380 |
| DTG Placebo | Other | Phase PHASE3 | HIV-1-infection | COMPLETED | NCT03110380 |
| DTG | Other | Phase PHASE3 | HIV-1-infection | COMPLETED | NCT03110380 |
| F/TAF | Other | Phase PHASE3 | HIV-1-infection | COMPLETED | NCT03110380 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | COMPLETED | NCT03110380 |
| Ambrisentan | Other | Phase PHASE4 | Exercise-induced Pulmonary Arterial Hypertension | COMPLETED | NCT01338636 |
| Ambrisentan | Other | Phase PHASE4 | Exercise-induced Pulmonary Arterial Hypertension | COMPLETED | NCT01338636 |
| Obinutuzumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02968563 |
| Idelalisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02968563 |
| Tirabrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02968563 |
| Obinutuzumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02968563 |
| Idelalisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02968563 |
| Tirabrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02968563 |
| Placebo | Other | Phase PHASE3 | COVID-19 Pneumonia | COMPLETED | NCT04409262 |
| Tocilizumab | Other | Phase PHASE3 | COVID-19 Pneumonia | COMPLETED | NCT04409262 |
| Remdesivir | Other | Phase PHASE3 | COVID-19 Pneumonia | COMPLETED | NCT04409262 |
| Placebo | Other | Phase PHASE3 | COVID-19 Pneumonia | COMPLETED | NCT04409262 |
| Tocilizumab | Other | Phase PHASE3 | COVID-19 Pneumonia | COMPLETED | NCT04409262 |
| Remdesivir | Other | Phase PHASE3 | COVID-19 Pneumonia | COMPLETED | NCT04409262 |
| Placebo Comparator | Other | Phase PHASE2 | Ebola | COMPLETED | NCT02818582 |
| GS-5734 | Other | Phase PHASE2 | Ebola | COMPLETED | NCT02818582 |
| Placebo Comparator | Other | Phase PHASE2 | Ebola | COMPLETED | NCT02818582 |
| GS-5734 | Other | Phase PHASE2 | Ebola | COMPLETED | NCT02818582 |
| B/F/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02607930 |
| ABC/DTG/3TC Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02607930 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02607930 |
| ABC/DTG/3TC | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02607930 |
| Placebo | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04539262 |
| Remdesivir (RDV) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04539262 |
| Placebo | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04539262 |
| Remdesivir (RDV) | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04539262 |
| B/F/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02607956 |
| F/TAF Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02607956 |
| DTG Placebo | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02607956 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02607956 |
| F/TAF | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02607956 |
| DTG | Other | Phase PHASE3 | HIV-1 Infection | COMPLETED | NCT02607956 |
| Wirelessly Observed Therapy | Drug | Approved | HEPATITIS C | COMPLETED | NCT02573376 |
| Directly Observed Therapy | Drug | Approved | HEPATITIS C | COMPLETED | NCT02573376 |
| Wirelessly Observed Therapy | Drug | Approved | HEPATITIS C | COMPLETED | NCT02573376 |
| Directly Observed Therapy | Drug | Approved | HEPATITIS C | COMPLETED | NCT02573376 |
| Wirelessly Observed Therapy | Drug | Approved | HEPATITIS C | COMPLETED | NCT02573376 |
| Directly Observed Therapy | Drug | Approved | HEPATITIS C | COMPLETED | NCT02573376 |
| Sofosbuvir/Velpatasvir/Voxilaprevir | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02745535 |
| Sofosbuvir/Velpatasvir/Voxilaprevir | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02745535 |
| Sofosbuvir/Velpatasvir/Voxilaprevir | Other | Phase PHASE2 | Chronic Hepatitis C | COMPLETED | NCT02745535 |
| VAS | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02781584 |
| FENO | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02781584 |
| CILO | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02781584 |
| FIR | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02781584 |
| SEL | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02781584 |
| VAS | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02781584 |
| FENO | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02781584 |
| CILO | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02781584 |
| FIR | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02781584 |
| SEL | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis (NASH) | COMPLETED | NCT02781584 |
| PCR based detection of azole resistance in A. fumigatus | Other | Preclinical | Aspergillosis, Invasive Pulmonary | COMPLETED | NCT03121235 |
| Tirabrutinib | Other | Phase PHASE1 | Relapsed/Refractory B-cell Malignancies | COMPLETED | NCT02457559 |
| Tirabrutinib | Other | Phase PHASE1 | Relapsed/Refractory B-cell Malignancies | COMPLETED | NCT02457559 |
| Ranolazine | Other | Phase PHASE2 | Long QT Syndrome | COMPLETED | NCT01648205 |
| Placebo | Other | Phase PHASE2 | Long QT Syndrome | COMPLETED | NCT01648205 |
| Ranolazine | Other | Phase PHASE2 | Long QT Syndrome | COMPLETED | NCT01648205 |
| Placebo | Other | Phase PHASE2 | Long QT Syndrome | COMPLETED | NCT01648205 |
| Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) | Other | Phase PHASE4 | Human Immunodeficiency Virus | COMPLETED | NCT01855867 |
| Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) | Other | Phase PHASE4 | Human Immunodeficiency Virus | COMPLETED | NCT01855867 |
| SOF/VEL | Other | Phase PHASE3 | Hepatitis C Virus Infection | COMPLETED | NCT04112303 |
| B/F/TAF | Other | Preclinical | HIV-1-infection | COMPLETED | NCT04009057 |
| TAF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03615066 |
| Selgantolimod | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03615066 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03615066 |
| TAF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03615066 |
| Selgantolimod | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03615066 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT03615066 |
| Switch to E/C/FTC/TAF daily | Other | Phase PHASE1 | HIV/AIDS | COMPLETED | NCT03251144 |
| Switch to E/C/FTC/TAF daily | Other | Phase PHASE1 | HIV/AIDS | COMPLETED | NCT03251144 |
| ELF Test | Other | Approved | Fatty Liver | UNKNOWN | NCT05370053 |
| ELF Test | Other | Approved | Fatty Liver | UNKNOWN | NCT05370053 |
| Placebo to match Tofacitinib | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| Tofacitinib 5 mg | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| Placebo to match GS-5718 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| GS-5718 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| Placebo to match Tofacitinib | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| Tofacitinib 5 mg | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| Placebo to match GS-5718 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| GS-5718 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| Placebo to match Tofacitinib | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| Tofacitinib 5 mg | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| Placebo to match GS-5718 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| GS-5718 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT05165771 |
| Fourth Generation Antigen/antibody (Ag/Ab) HIV Test | Other | Preclinical | Human Immunodeficiency Virus | COMPLETED | NCT04560556 |
| Point-of-Care (POC) Rapid HIV Test | Other | Preclinical | Human Immunodeficiency Virus | COMPLETED | NCT04560556 |
| Fourth Generation Antigen/antibody (Ag/Ab) HIV Test | Other | Preclinical | Human Immunodeficiency Virus | COMPLETED | NCT04560556 |
| Point-of-Care (POC) Rapid HIV Test | Other | Preclinical | Human Immunodeficiency Virus | COMPLETED | NCT04560556 |
| Other approved antivirals | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02862548 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02862548 |
| TAF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02862548 |
| Other approved antivirals | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02862548 |
| TDF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02862548 |
| TAF | Other | Phase PHASE2 | Chronic Hepatitis B | COMPLETED | NCT02862548 |
| Placebo | Other | Phase PHASE3 | Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization | TERMINATED | NCT03219164 |
| AZLI | Other | Phase PHASE3 | Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization | TERMINATED | NCT03219164 |
| Placebo | Other | Phase PHASE3 | Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization | TERMINATED | NCT03219164 |
| AZLI | Other | Phase PHASE3 | Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization | TERMINATED | NCT03219164 |
| Vinorelbine | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT02574455 |
| Gemcitabine | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT02574455 |
| Capecitabine | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT02574455 |
| Eribulin | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT02574455 |
| Sacituzumab govitecan | Other | Phase PHASE3 | Breast Cancer | COMPLETED | NCT02574455 |
| MBX-8025 10 mg Capsule | Other | Phase PHASE2 | Primary Biliary Cirrhosis | COMPLETED | NCT02955602 |
| MBX-8025 5 mg Capsule | Other | Phase PHASE2 | Primary Biliary Cirrhosis | COMPLETED | NCT02955602 |
| MBX-8025 2 mg Capsule | Other | Phase PHASE2 | Primary Biliary Cirrhosis | COMPLETED | NCT02955602 |
| MBX-8025 10 mg Capsule | Other | Phase PHASE2 | Primary Biliary Cirrhosis | COMPLETED | NCT02955602 |
| MBX-8025 5 mg Capsule | Other | Phase PHASE2 | Primary Biliary Cirrhosis | COMPLETED | NCT02955602 |
| MBX-8025 2 mg Capsule | Other | Phase PHASE2 | Primary Biliary Cirrhosis | COMPLETED | NCT02955602 |
| • TF2 and 68 Ga-IMP-288 | Other | Phase PHASE1 | Medullary Thyroid Carcinoma | COMPLETED | NCT01730638 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | COMPLETED | NCT03602560 |
| seladelpar 10 mg | Other | Phase PHASE3 | Primary Biliary Cholangitis | COMPLETED | NCT03602560 |
| seladelpar 5-10 mg | Other | Phase PHASE3 | Primary Biliary Cholangitis | COMPLETED | NCT03602560 |
| Kaletra (lopinavir/ritonavir) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00885664 |
| Truvada (tenofovir/emtricitabine) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00885664 |
| Kaletra (lopinavir/ritonavir) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00885664 |
| Truvada (tenofovir/emtricitabine) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00885664 |
| Kaletra (lopinavir/ritonavir) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00885664 |
| Truvada (tenofovir/emtricitabine) | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT00885664 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT04130919 |
| Tilpisertib | Other | Phase PHASE2 | Ulcerative Colitis | TERMINATED | NCT04130919 |
| Bictegravir/emtricitabine/tenofovir alafenamide | Other | Preclinical | HIV-1-infection | UNKNOWN | NCT05526118 |
| Bictegravir/emtricitabine/tenofovir alafenamide | Other | Preclinical | HIV-1-infection | UNKNOWN | NCT05526118 |
| Placebos | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | TERMINATED | NCT03551522 |
| Seladelpar | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | TERMINATED | NCT03551522 |
| Placebos | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | TERMINATED | NCT03551522 |
| Seladelpar | Other | Phase PHASE2 | NASH - Nonalcoholic Steatohepatitis | TERMINATED | NCT03551522 |
| Tenofovir disoproxil fumarate (TDF) | Other | Preclinical | HIV Infections | COMPLETED | NCT01066858 |
| Tenofovir disoproxil fumarate (TDF) | Other | Preclinical | HIV Infections | COMPLETED | NCT01066858 |
| Tenofovir disoproxil fumarate (TDF) | Other | Preclinical | HIV Infections | COMPLETED | NCT01066858 |
| Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] | Other | Preclinical | Hepatitis C in Substance Users | UNKNOWN | NCT05503979 |
| Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] | Other | Preclinical | Hepatitis C in Substance Users | UNKNOWN | NCT05503979 |
| Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] | Other | Preclinical | Hepatitis C in Substance Users | UNKNOWN | NCT05503979 |
| Current ART | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT03348163 |
| B/FTC/TAF | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT03348163 |
| Current ART | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT03348163 |
| B/FTC/TAF | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT03348163 |
| Evixapodlin | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT04049617 |
| Evixapodlin | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT04049617 |
| Evixapodlin | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT04049617 |
| HDV-Ab (IgG), HDV-RNA, RNA genotype | Other | Preclinical | Hepatitis D | UNKNOWN | NCT05394623 |
| HDV-Ab (IgG), HDV-RNA, RNA genotype | Other | Preclinical | Hepatitis D | UNKNOWN | NCT05394623 |
| HDV-Ab (IgG), HDV-RNA, RNA genotype | Other | Preclinical | Hepatitis D | UNKNOWN | NCT05394623 |
| Ledipasvir-Sofosbuvir | Other | Phase PHASE3 | Human Immunodeficiency Virus | COMPLETED | NCT02660905 |
| E/C/F/TAF; | Other | Phase PHASE3 | Human Immunodeficiency Virus | COMPLETED | NCT02660905 |
| Ledipasvir-Sofosbuvir | Other | Phase PHASE3 | Human Immunodeficiency Virus | COMPLETED | NCT02660905 |
| E/C/F/TAF; | Other | Phase PHASE3 | Human Immunodeficiency Virus | COMPLETED | NCT02660905 |
| Ledipasvir-Sofosbuvir | Other | Phase PHASE3 | Human Immunodeficiency Virus | COMPLETED | NCT02660905 |
| E/C/F/TAF; | Other | Phase PHASE3 | Human Immunodeficiency Virus | COMPLETED | NCT02660905 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | WITHDRAWN | NCT04880577 |
| TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY] | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | WITHDRAWN | NCT04880577 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | WITHDRAWN | NCT04880577 |
| TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY] | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | WITHDRAWN | NCT04880577 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | WITHDRAWN | NCT04880577 |
| TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY] | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | WITHDRAWN | NCT04880577 |
| PrEP Care Anywhere Services | Other | Approved | Adherence, Patient | TERMINATED | NCT03442192 |
| PrEP Care Anywhere Services | Other | Approved | Adherence, Patient | TERMINATED | NCT03442192 |
| Atripla Placebo | Other | Phase PHASE4 | HIV-1-infection | TERMINATED | NCT03532425 |
| B/F/TAF Placebo | Other | Phase PHASE4 | HIV-1-infection | TERMINATED | NCT03532425 |
| Atripla | Other | Phase PHASE4 | HIV-1-infection | TERMINATED | NCT03532425 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | TERMINATED | NCT03532425 |
| Placebo | Other | Phase PHASE2 | Diabetic Kidney Disease | COMPLETED | NCT04026165 |
| SEL | Other | Phase PHASE2 | Diabetic Kidney Disease | COMPLETED | NCT04026165 |
| Truvada | Other | Phase PHASE4 | HIV/AIDS | COMPLETED | NCT03842436 |
| Digital pill | Other | Phase PHASE4 | HIV/AIDS | COMPLETED | NCT03842436 |
| Digital Health Feedback System | Other | Approved | HIV Prevention | UNKNOWN | NCT03693040 |
| Digital Health Feedback System | Other | Approved | HIV Prevention | UNKNOWN | NCT03693040 |
| Digital Health Feedback System | Other | Approved | HIV Prevention | UNKNOWN | NCT03693040 |
| Digital Health Feedback System | Other | Approved | HIV Prevention | UNKNOWN | NCT03693040 |
| Digital Health Feedback System | Other | Phase PHASE4 | HIV | UNKNOWN | NCT02800655 |
| Digital Health Feedback System | Other | Phase PHASE4 | HIV | UNKNOWN | NCT02800655 |
| Digital Health Feedback System | Other | Phase PHASE4 | HIV | UNKNOWN | NCT02800655 |
| Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02510300 |
| Sofosbuvir/Velpatasvir (SOF/VEL) | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02510300 |
| Ledipasvir/Sofosbuvir (LDV/SOF) | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02510300 |
| Sofosbuvir (SOF) | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02510300 |
| Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02510300 |
| Sofosbuvir/Velpatasvir (SOF/VEL) | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02510300 |
| Ledipasvir/Sofosbuvir (LDV/SOF) | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02510300 |
| Sofosbuvir (SOF) | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02510300 |
| Genvoya Crushed Dose | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT03717129 |
| Genvoya Oral dose | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT03717129 |
| Genvoya Crushed Dose | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT03717129 |
| Genvoya Oral dose | Other | Phase PHASE4 | Healthy Volunteers | COMPLETED | NCT03717129 |
| Patient Telemedicine Questionnaire | Other | Approved | Hepatitis C | COMPLETED | NCT03581383 |
| Modified ECHO | Other | Approved | Hepatitis C | COMPLETED | NCT03581383 |
| PREP-C | Other | Approved | Hepatitis C | COMPLETED | NCT03581383 |
| Patient Telemedicine Questionnaire | Other | Approved | Hepatitis C | COMPLETED | NCT03581383 |
| Modified ECHO | Other | Approved | Hepatitis C | COMPLETED | NCT03581383 |
| PREP-C | Other | Approved | Hepatitis C | COMPLETED | NCT03581383 |
| TDF/3TC/EFV | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT04296695 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT04296695 |
| TDF/3TC/EFV | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT04296695 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | UNKNOWN | NCT04296695 |
| HIV and HCV screening | Other | Approved | Hepatitis C | COMPLETED | NCT03595527 |
| HIV and HCV screening | Other | Approved | Hepatitis C | COMPLETED | NCT03595527 |
| Placebo Tablets | Other | Phase PHASE4 | Herpes Simplex Type II | COMPLETED | NCT01448616 |
| Vaginal TFV Gel | Other | Phase PHASE4 | Herpes Simplex Type II | COMPLETED | NCT01448616 |
| Placebo Vaginal Gel | Other | Phase PHASE4 | Herpes Simplex Type II | COMPLETED | NCT01448616 |
| TDF | Other | Phase PHASE4 | Herpes Simplex Type II | COMPLETED | NCT01448616 |
| Placebo Tablets | Other | Phase PHASE4 | Herpes Simplex Type II | COMPLETED | NCT01448616 |
| Vaginal TFV Gel | Other | Phase PHASE4 | Herpes Simplex Type II | COMPLETED | NCT01448616 |
| Placebo Vaginal Gel | Other | Phase PHASE4 | Herpes Simplex Type II | COMPLETED | NCT01448616 |
| TDF | Other | Phase PHASE4 | Herpes Simplex Type II | COMPLETED | NCT01448616 |
| Placebo | Other | Phase PHASE4 | Myocardial Ischemia | WITHDRAWN | NCT02423265 |
| Ranolazine | Other | Phase PHASE4 | Myocardial Ischemia | WITHDRAWN | NCT02423265 |
| Placebo | Other | Phase PHASE4 | Myocardial Ischemia | WITHDRAWN | NCT02423265 |
| Ranolazine | Other | Phase PHASE4 | Myocardial Ischemia | WITHDRAWN | NCT02423265 |
| Fluconazole | Other | Phase PHASE2 | Cryptococcal Meningitis | RECRUITING | NCT03945448 |
| Single dose liposomal Amphotericin and Fluconazole | Other | Phase PHASE2 | Cryptococcal Meningitis | RECRUITING | NCT03945448 |
| Fluconazole | Other | Phase PHASE2 | Cryptococcal Meningitis | RECRUITING | NCT03945448 |
| Single dose liposomal Amphotericin and Fluconazole | Other | Phase PHASE2 | Cryptococcal Meningitis | RECRUITING | NCT03945448 |
| GeneXpert HCV VL Fingerstick test | Other | Preclinical | Hepatitis C, Chronic | COMPLETED | NCT04610762 |
| Standard of Care | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04745351 |
| RDV Placebo | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04745351 |
| Remdesivir | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04745351 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE3 | Hepatitis B, Chronic | COMPLETED | NCT02600117 |
| Tenofovir disoproxil fumarate | Other | Phase PHASE3 | Hepatitis B, Chronic | COMPLETED | NCT02600117 |
| Efavirenz | Other | Phase PHASE4 | Acquired Immune Deficiency Syndrome | TERMINATED | NCT00775606 |
| Lopinavir 400 mg/ritonavir 100 mg | Other | Phase PHASE4 | Acquired Immune Deficiency Syndrome | TERMINATED | NCT00775606 |
| Efavirenz | Other | Phase PHASE4 | Acquired Immune Deficiency Syndrome | TERMINATED | NCT00775606 |
| Lopinavir 400 mg/ritonavir 100 mg | Other | Phase PHASE4 | Acquired Immune Deficiency Syndrome | TERMINATED | NCT00775606 |
| Remdesivir | Other | Preclinical | COVID-19 | COMPLETED | NCT04582266 |
| Remdesivir | Other | Preclinical | COVID-19 | COMPLETED | NCT04582266 |
| Doravirine | Other | Preclinical | HIV-1-infection | COMPLETED | NCT04495348 |
| Doravirine | Other | Preclinical | HIV-1-infection | COMPLETED | NCT04495348 |
| Doravirine | Other | Preclinical | HIV-1-infection | COMPLETED | NCT04495348 |
| NY-ESO-1 expression testing | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03399448 |
| Fludarabine | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03399448 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03399448 |
| NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03399448 |
| NY-ESO-1 expression testing | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03399448 |
| Fludarabine | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03399448 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03399448 |
| NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03399448 |
| Harvoni | Other | Phase PHASE2 | Porphyria Cutanea Tarda | COMPLETED | NCT03118674 |
| Harvoni | Other | Phase PHASE2 | Porphyria Cutanea Tarda | COMPLETED | NCT03118674 |
| Skeletal Muscle Biomechanical Property Assessment | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Questionnaires | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Strength Testing | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Cardiopulmonary Exercise Test (CPET) | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Body Composition | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Muscle Biopsy | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Skeletal Muscle Mitochondrial Respiratory Capacity | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Disease Activity (DAS-28) Assessment | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Blood Draw | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Skeletal Muscle Biomechanical Property Assessment | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Questionnaires | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Strength Testing | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Cardiopulmonary Exercise Test (CPET) | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Body Composition | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Muscle Biopsy | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Skeletal Muscle Mitochondrial Respiratory Capacity | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Disease Activity (DAS-28) Assessment | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Blood Draw | Other | Approved | Rheumatoid Arthritis | COMPLETED | NCT04226131 |
| Cilofexor | Other | Phase PHASE1 | Primary Sclerosing Cholangitis | TERMINATED | NCT04060147 |
| Cilofexor | Other | Phase PHASE1 | Primary Sclerosing Cholangitis | TERMINATED | NCT04060147 |
| Cilofexor | Other | Phase PHASE1 | Primary Sclerosing Cholangitis | TERMINATED | NCT04060147 |
| Pharmacological Study | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Obinutuzumab | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Entospletinib | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Pharmacological Study | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Obinutuzumab | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Entospletinib | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Pharmacological Study | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Obinutuzumab | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Entospletinib | Other | Phase PHASE1 | Anemia | COMPLETED | NCT03010358 |
| Idelalisib | Other | Phase PHASE3 | Follicular Lymphoma | TERMINATED | NCT02536300 |
| Idelalisib | Other | Phase PHASE3 | Follicular Lymphoma | TERMINATED | NCT02536300 |
| Biktarvy | Other | Phase PHASE3 | HIV-1-infection | COMPLETED | NCT04416906 |
| Biktarvy | Other | Phase PHASE3 | HIV-1-infection | COMPLETED | NCT04416906 |
| Biktarvy | Other | Phase PHASE3 | HIV-1-infection | COMPLETED | NCT04416906 |
| TDF Placebo | Other | Phase PHASE3 | HBeAg-negative Chronic Hepatitis B | COMPLETED | NCT01940341 |
| TAF Placebo | Other | Phase PHASE3 | HBeAg-negative Chronic Hepatitis B | COMPLETED | NCT01940341 |
| TDF | Other | Phase PHASE3 | HBeAg-negative Chronic Hepatitis B | COMPLETED | NCT01940341 |
| TAF | Other | Phase PHASE3 | HBeAg-negative Chronic Hepatitis B | COMPLETED | NCT01940341 |
| Bictegravir/emtricitabine/tenofovir alafenamide | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT03998176 |
| Bictegravir/emtricitabine/tenofovir alafenamide | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT03998176 |
| Ineligible parent treatment | Drug | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| Other SOF-Based Regimen | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| SOF/VEL/VOX | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| SOF/VEL | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| LDV/SOF | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| Ribavirin | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| Sofosbuvir | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| Ineligible parent treatment | Drug | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| Other SOF-Based Regimen | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| SOF/VEL/VOX | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| SOF/VEL | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| LDV/SOF | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| Ribavirin | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| Sofosbuvir | Other | Preclinical | Hepatitis C Virus Infection | TERMINATED | NCT02292706 |
| TDF Placebo | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TAF Placebo | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TDF | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TAF | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TDF Placebo | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TAF Placebo | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TDF | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TAF | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TDF Placebo | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TAF Placebo | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TDF | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| TAF | Other | Phase PHASE3 | HBeAg-positive Chronic Hepatitis B | COMPLETED | NCT01940471 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT03797014 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT03797014 |
| Tenofovir Alafenamide | Other | Phase PHASE4 | Hepatitis B, Chronic | COMPLETED | NCT03471624 |
| Tenofovir Alafenamide | Other | Phase PHASE4 | Hepatitis B, Chronic | COMPLETED | NCT03471624 |
| mFOLFOX6 Regimen | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT03954704 |
| Dalutrafusp alfa | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT03954704 |
| mFOLFOX6 Regimen | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT03954704 |
| Dalutrafusp alfa | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT03954704 |
| mFOLFOX6 Regimen | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT03954704 |
| Dalutrafusp alfa | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT03954704 |
| Placebo | Other | Phase PHASE3 | Primary Sclerosing Cholangitis | TERMINATED | NCT03890120 |
| Cilofexor | Other | Phase PHASE3 | Primary Sclerosing Cholangitis | TERMINATED | NCT03890120 |
| Placebo | Other | Phase PHASE3 | Primary Sclerosing Cholangitis | TERMINATED | NCT03890120 |
| Cilofexor | Other | Phase PHASE3 | Primary Sclerosing Cholangitis | TERMINATED | NCT03890120 |
| Standard initiation of antiretroviral therapy (ART) | Drug | Phase PHASE4 | HIV/AIDS | TERMINATED | NCT04249037 |
| bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) | Other | Phase PHASE4 | HIV/AIDS | TERMINATED | NCT04249037 |
| F/TAF TOS (3 x 60/7.5 mg) | Other | Phase PHASE1 | Hiv | COMPLETED | NCT05489406 |
| DTG DT (6 x 5 mg) | Other | Phase PHASE1 | Hiv | COMPLETED | NCT05489406 |
| F/TAF TOS (3 x 60/7.5 mg) | Other | Phase PHASE1 | Hiv | COMPLETED | NCT05489406 |
| DTG DT (6 x 5 mg) | Other | Phase PHASE1 | Hiv | COMPLETED | NCT05489406 |
| birth dose vaccination against hepatitis B strategy | Other | Approved | Hepatitis B | COMPLETED | NCT04029454 |
| BIC/FTC/TAF | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT06177574 |
| BIC/FTC/TAF | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT06177574 |
| BIC/FTC/TAF | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT06177574 |
| Interleukin-2 | Other | Phase PHASE1 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | TERMINATED | NCT03912831 |
| Fludarabine | Other | Phase PHASE1 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | TERMINATED | NCT03912831 |
| Cyclophosphamide | Other | Phase PHASE1 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | TERMINATED | NCT03912831 |
| KITE-439 | Other | Phase PHASE1 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | TERMINATED | NCT03912831 |
| Interleukin-2 | Other | Phase PHASE1 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | TERMINATED | NCT03912831 |
| Fludarabine | Other | Phase PHASE1 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | TERMINATED | NCT03912831 |
| Cyclophosphamide | Other | Phase PHASE1 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | TERMINATED | NCT03912831 |
| KITE-439 | Other | Phase PHASE1 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | TERMINATED | NCT03912831 |
| Rnalozine | Other | Approved | Coronary Microcirculation | COMPLETED | NCT01815957 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT03992131 |
| Lucitanib | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT03992131 |
| Rucaparib | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT03992131 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT03992131 |
| Lucitanib | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT03992131 |
| Rucaparib | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT03992131 |
| Labetuzumab Govitecan (LG) | Other | Phase PHASE1 | Metastatic Colorectal Cancer | TERMINATED | NCT01605318 |
| Remdesivir | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04431453 |
| Remdesivir | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04431453 |
| Survey on socio-demographic variables and healthcare-seeking, sexual and drug-using behaviour | Drug | Preclinical | HIV Infections | COMPLETED | NCT04930614 |
| Survey on socio-demographic variables and healthcare-seeking, sexual and drug-using behaviour | Drug | Preclinical | HIV Infections | COMPLETED | NCT04930614 |
| Survey on socio-demographic variables and healthcare-seeking, sexual and drug-using behaviour | Drug | Preclinical | HIV Infections | COMPLETED | NCT04930614 |
| Symtuza | Other | Phase PHASE3 | Human Immunodeficiency Virus | COMPLETED | NCT04653194 |
| Biktarvy | Other | Phase PHASE3 | Human Immunodeficiency Virus | COMPLETED | NCT04653194 |
| Symtuza | Other | Phase PHASE3 | Human Immunodeficiency Virus | COMPLETED | NCT04653194 |
| Biktarvy | Other | Phase PHASE3 | Human Immunodeficiency Virus | COMPLETED | NCT04653194 |
| SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg | Other | Preclinical | Hepatitis C | COMPLETED | NCT03570112 |
| SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg | Other | Preclinical | Hepatitis C | COMPLETED | NCT03570112 |
| SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg | Other | Preclinical | Hepatitis C | COMPLETED | NCT03570112 |
| Dolutegravir 50 mg plus one RTI | Other | Phase PHASE3 | HIV-1-infection | TERMINATED | NCT03493568 |
| Genvoya 150Mg-150Mg-200Mg-10Mg Tablet | Other | Phase PHASE3 | HIV-1-infection | TERMINATED | NCT03493568 |
| Dolutegravir 50 mg plus one RTI | Other | Phase PHASE3 | HIV-1-infection | TERMINATED | NCT03493568 |
| Genvoya 150Mg-150Mg-200Mg-10Mg Tablet | Other | Phase PHASE3 | HIV-1-infection | TERMINATED | NCT03493568 |
| CPX-351 | Other | Phase PHASE2 | Acute Myeloid Leukemia | WITHDRAWN | NCT05829434 |
| 7+3 | Other | Phase PHASE2 | Acute Myeloid Leukemia | WITHDRAWN | NCT05829434 |
| Magrolimab | Other | Phase PHASE2 | Acute Myeloid Leukemia | WITHDRAWN | NCT05829434 |
| Magrolimab | Other | Preclinical | Relapsed/Refractory Acute Myeloid Leukemia | NO_LONGER_AVAILABLE | NCT05627466 |
| Magrolimab | Other | Preclinical | Relapsed/Refractory Acute Myeloid Leukemia | NO_LONGER_AVAILABLE | NCT05627466 |
| Magrolimab | Other | Preclinical | Relapsed/Refractory Acute Myeloid Leukemia | NO_LONGER_AVAILABLE | NCT05627466 |
| Standard of Care | Other | Preclinical | Hepatitis C | COMPLETED | NCT05725109 |
| Hepatitis C Treatment Alerts in CHORUS™ | Drug | Preclinical | Hepatitis C | COMPLETED | NCT05725109 |
| Standard of Care | Other | Preclinical | Hepatitis C | COMPLETED | NCT05725109 |
| Hepatitis C Treatment Alerts in CHORUS™ | Drug | Preclinical | Hepatitis C | COMPLETED | NCT05725109 |
| Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT04538040 |
| Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT04538040 |
| Placebo Oral Tablet | Other | Phase PHASE1 | B Cells-Tumors | TERMINATED | NCT03151057 |
| Idelalisib 100 MG | Other | Phase PHASE1 | B Cells-Tumors | TERMINATED | NCT03151057 |
| Placebo Oral Tablet | Other | Phase PHASE1 | B Cells-Tumors | TERMINATED | NCT03151057 |
| Idelalisib 100 MG | Other | Phase PHASE1 | B Cells-Tumors | TERMINATED | NCT03151057 |
| Placebo Oral Tablet | Other | Phase PHASE1 | B Cells-Tumors | TERMINATED | NCT03151057 |
| Idelalisib 100 MG | Other | Phase PHASE1 | B Cells-Tumors | TERMINATED | NCT03151057 |
| Descovy | Other | Preclinical | HIV Prevention | UNKNOWN | NCT05690815 |
| Descovy | Other | Preclinical | HIV Prevention | ACTIVE_NOT_RECRUITING | NCT05690815 |
| Virtual clinical visits with home lab kits and mailed HIV PrEP | Other | Approved | HIV Infections | COMPLETED | NCT05319613 |
| Virtual clinical visits with home lab kits and mailed HIV PrEP | Other | Approved | HIV Infections | COMPLETED | NCT05319613 |
| Virtual clinical visits with home lab kits and mailed HIV PrEP | Other | Approved | HIV Infections | COMPLETED | NCT05319613 |
| Avelumab | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT03558139 |
| Magrolimab | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT03558139 |
| Re-Link | Other | Preclinical | Hepatitis C | UNKNOWN | NCT06349902 |
| Re-Link | Other | Preclinical | Hepatitis C | UNKNOWN | NCT06349902 |
| Re-Link | Other | Preclinical | Hepatitis C | RECRUITING | NCT06349902 |
| Re-Link | Other | Preclinical | Hepatitis C | UNKNOWN | NCT06349902 |
| Standard of Care | Other | Phase PHASE1 | Cutaneous Lupus Erythematosus | TERMINATED | NCT04809623 |
| Placebo | Other | Phase PHASE1 | Cutaneous Lupus Erythematosus | TERMINATED | NCT04809623 |
| Edecesertib | Other | Phase PHASE1 | Cutaneous Lupus Erythematosus | TERMINATED | NCT04809623 |
| Standard of Care | Other | Phase PHASE1 | Cutaneous Lupus Erythematosus | TERMINATED | NCT04809623 |
| Placebo | Other | Phase PHASE1 | Cutaneous Lupus Erythematosus | TERMINATED | NCT04809623 |
| Edecesertib | Other | Phase PHASE1 | Cutaneous Lupus Erythematosus | TERMINATED | NCT04809623 |
| standard of care | Other | Preclinical | Hepatitis C Chronic | NOT_YET_RECRUITING | NCT06373198 |
| Standard of Care | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT05159531 |
| mHealth Model of Care | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT05159531 |
| PrEP | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT05159531 |
| Standard of Care | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT05159531 |
| mHealth Model of Care | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT05159531 |
| PrEP | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT05159531 |
| Standard of Care | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT05159531 |
| mHealth Model of Care | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT05159531 |
| PrEP | Other | Phase PHASE4 | HIV Infections | TERMINATED | NCT05159531 |
| Virtual Care Coordination | Other | Approved | Hepatitis C | COMPLETED | NCT05369507 |
| Usual Care (facilitated referral) | Other | Approved | Hepatitis C | COMPLETED | NCT03627546 |
| Rapid Treatment strategy | Drug | Approved | Hepatitis C | COMPLETED | NCT03627546 |
| TelePrEP | Other | Approved | Hiv | RECRUITING | NCT05520905 |
| TelePrEP | Other | Approved | Hiv | RECRUITING | NCT05520905 |
| TelePrEP | Other | Approved | Hiv | RECRUITING | NCT05520905 |
| Continue current regimen | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT05243602 |
| Switch to B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT05243602 |
| Continue current regimen | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT05243602 |
| Switch to B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT05243602 |
| CAL-101 | Other | Phase PHASE2 | Chronic Lymphocytic Leucemia | COMPLETED | NCT02445131 |
| GA101 | Other | Phase PHASE2 | Chronic Lymphocytic Leucemia | COMPLETED | NCT02445131 |
| Bendamustine | Other | Phase PHASE2 | Chronic Lymphocytic Leucemia | COMPLETED | NCT02445131 |
| CAL-101 | Other | Phase PHASE2 | Chronic Lymphocytic Leucemia | COMPLETED | NCT02445131 |
| GA101 | Other | Phase PHASE2 | Chronic Lymphocytic Leucemia | COMPLETED | NCT02445131 |
| Bendamustine | Other | Phase PHASE2 | Chronic Lymphocytic Leucemia | COMPLETED | NCT02445131 |
| CAL-101 | Other | Phase PHASE2 | Chronic Lymphocytic Leucemia | COMPLETED | NCT02445131 |
| GA101 | Other | Phase PHASE2 | Chronic Lymphocytic Leucemia | COMPLETED | NCT02445131 |
| Bendamustine | Other | Phase PHASE2 | Chronic Lymphocytic Leucemia | COMPLETED | NCT02445131 |
| BIKTARVY 50Mg-200Mg-25Mg Tablet | Other | Phase PHASE4 | Human Immunodeficiency Virus | TERMINATED | NCT04944654 |
| BIKTARVY 50Mg-200Mg-25Mg Tablet | Other | Phase PHASE4 | Human Immunodeficiency Virus | TERMINATED | NCT04944654 |
| BIKTARVY 50Mg-200Mg-25Mg Tablet | Other | Phase PHASE4 | Human Immunodeficiency Virus | TERMINATED | NCT04944654 |
| coformulated TDF/FTC | Other | Preclinical | HIV Chemoprophylaxis | COMPLETED | NCT02074891 |
| coformulated TDF/FTC | Other | Preclinical | HIV Chemoprophylaxis | COMPLETED | NCT02074891 |
| coformulated TDF/FTC | Other | Preclinical | HIV Chemoprophylaxis | COMPLETED | NCT02074891 |
| Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY] | Other | Preclinical | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT05064020 |
| Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY] | Other | Preclinical | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT05064020 |
| B/F/TAF | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT03960645 |
| B/F/TAF | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT03960645 |
| B/F/TAF | Other | Preclinical | HIV-1-infection | COMPLETED | NCT03580668 |
| B/F/TAF | Other | Preclinical | HIV-1-infection | COMPLETED | NCT03580668 |
| B/F/TAF | Other | Preclinical | HIV-1-infection | COMPLETED | NCT03580668 |
| Placebo | Other | Phase PHASE3 | Myelodysplastic Syndromes | TERMINATED | NCT04313881 |
| Azacitidine | Other | Phase PHASE3 | Myelodysplastic Syndromes | TERMINATED | NCT04313881 |
| Magrolimab | Other | Phase PHASE3 | Myelodysplastic Syndromes | TERMINATED | NCT04313881 |
| Placebo | Other | Phase PHASE3 | Myelodysplastic Syndromes | TERMINATED | NCT04313881 |
| Azacitidine | Other | Phase PHASE3 | Myelodysplastic Syndromes | TERMINATED | NCT04313881 |
| Magrolimab | Other | Phase PHASE3 | Myelodysplastic Syndromes | TERMINATED | NCT04313881 |
| Placebo | Other | Phase PHASE3 | Myelodysplastic Syndromes | TERMINATED | NCT04313881 |
| Azacitidine | Other | Phase PHASE3 | Myelodysplastic Syndromes | TERMINATED | NCT04313881 |
| Magrolimab | Other | Phase PHASE3 | Myelodysplastic Syndromes | TERMINATED | NCT04313881 |
| Sacituzumab Govitecan + Zimberelimab | Other | Phase PHASE2 | Bladder Cancer | NOT_YET_RECRUITING | NCT06528483 |
| Sacituzumab Govitecan + Zimberelimab | Other | Phase PHASE2 | Bladder Cancer | NOT_YET_RECRUITING | NCT06528483 |
| Anti Delta | Other | Preclinical | Chronic Hepatitis D Infection | RECRUITING | NCT06248580 |
| Anti Delta | Other | Preclinical | Chronic Hepatitis D Infection | RECRUITING | NCT06248580 |
| HIV care | Other | Phase PHASE4 | Harm Reduction | COMPLETED | NCT04650269 |
| Biktarvy 50Mg-200Mg-25Mg Tablet | Other | Phase PHASE4 | Harm Reduction | COMPLETED | NCT04650269 |
| HIV care | Other | Phase PHASE4 | Harm Reduction | COMPLETED | NCT04650269 |
| Biktarvy 50Mg-200Mg-25Mg Tablet | Other | Phase PHASE4 | Harm Reduction | COMPLETED | NCT04650269 |
| HIV care | Other | Phase PHASE4 | Harm Reduction | COMPLETED | NCT04650269 |
| Biktarvy 50Mg-200Mg-25Mg Tablet | Other | Phase PHASE4 | Harm Reduction | COMPLETED | NCT04650269 |
| Standard of Care (Substudy 03) | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| GS-6212 | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| Standard of Care (Substudy 02) | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| GS-1720 | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| Standard of Care (Substudy 01) | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| B/F/TAF | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| Bavtavirine | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| Standard of Care (Substudy 03) | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| GS-6212 | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| Standard of Care (Substudy 02) | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| GS-1720 | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| Standard of Care (Substudy 01) | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| B/F/TAF | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| Bavtavirine | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT05585307 |
| Docetaxel | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05089734 |
| Sacituzumab Govitecan-hziy (SG) | Other | Phase PHASE3 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05089734 |
| Leucovorin | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Fluorouracil | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Magrolimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Pembrolizumab | Other | Phase PHASE1 | Urothelial Cancer | RECRUITING | NCT04724018 |
| Enfortumab vedotin-ejfv (EV) | Other | Phase PHASE1 | Urothelial Cancer | RECRUITING | NCT04724018 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE1 | Urothelial Cancer | RECRUITING | NCT04724018 |
| Antiretroviral Combinations | Other | Phase PHASE3 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06630299 |
| ISL/LEN | Other | Phase PHASE3 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06630299 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05119907 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05119907 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05119907 |
| Optimized Background Regimen (OBR) | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT06749054 |
| Subcutaneous Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT06749054 |
| Oral Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT06749054 |
| PrEP | Other | Phase PHASE4 | Hiv | COMPLETED | NCT04782180 |
| Descovy 200Mg 25Mg Tablet | Other | Phase PHASE4 | Hiv | COMPLETED | NCT04782180 |
| BIC/LEN FDC | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT06532656 |
| Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT06532656 |
| Sacituzumab govitecan-hziy | Other | Phase PHASE2 | Thymoma | RECRUITING | NCT06248515 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT03964727 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT03964727 |
| ISL/LEN FDC | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| B/F/TAF | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| LEN | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| ISL | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| Carboplatin | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| Gemcitabine | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| nab-Paclitaxel | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| Paclitaxel | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| Carboplatin | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| Gemcitabine | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| nab-Paclitaxel | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| Paclitaxel | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| TENOFOVIR + CLEVUDINE PLACEBO | Other | Phase PHASE3 | HBe Negative Chronic Hepatitis B | TERMINATED | NCT00823342 |
| CLEVUDINE IN ASSOCIATION TENOFOVIR | Other | Phase PHASE3 | HBe Negative Chronic Hepatitis B | TERMINATED | NCT00823342 |
| CLEVUDINE + TENOFOVIR PLACEBO | Other | Phase PHASE3 | HBe Negative Chronic Hepatitis B | TERMINATED | NCT00823342 |
| No Intervention | Other | Approved | Liver Diseases | COMPLETED | NCT07580482 |
| Best Practice Alert | Other | Approved | Liver Diseases | COMPLETED | NCT07580482 |
| Biktarvy Pill | Other | Approved | Hiv | NOT_YET_RECRUITING | NCT06465862 |
| TruTag System | Other | Approved | Hiv | NOT_YET_RECRUITING | NCT06465862 |
| Biktarvy Pill | Other | Approved | Hiv | NOT_YET_RECRUITING | NCT06465862 |
| TruTag System | Other | Approved | Hiv | NOT_YET_RECRUITING | NCT06465862 |
| Tenofovir Disoproxil Fumarate | Other | Phase PHASE3 | Hiv | COMPLETED | NCT04937881 |
| Tenofovir alafenamide | Other | Phase PHASE3 | Hiv | COMPLETED | NCT04937881 |
| Docetaxel | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT04747470 |
| 5-Fluorouracil | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT04747470 |
| Carboplatin | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT04747470 |
| Cisplatin | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT04747470 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT04747470 |
| GS-3583 | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT04747470 |
| Sacituzumab Govitecan | Other | Phase EARLY_PHASE1 | Glioblastoma | COMPLETED | NCT03995706 |
| Sacituzumab Govitecan | Other | Phase EARLY_PHASE1 | Glioblastoma | COMPLETED | NCT03995706 |
| Seladelpar 5 mg | Other | Phase PHASE3 | Primary Biliary Cholangitis | COMPLETED | NCT04620733 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | COMPLETED | NCT04620733 |
| Seladelpar 10 mg | Other | Phase PHASE3 | Primary Biliary Cholangitis | COMPLETED | NCT04620733 |
| bictegravir/emtricitabine/tenofovir alafenamide | Other | Phase PHASE4 | Human Immunodeficiency Virus | COMPLETED | NCT03502005 |
| Loss framing plus not demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Gain framing plus not demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Loss framing plus demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Gain framing plus demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Loss framing plus not demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Gain framing plus not demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Loss framing plus demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Gain framing plus demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Loss framing plus not demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Gain framing plus not demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Loss framing plus demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| Gain framing plus demographically targeted photos | Other | Preclinical | HIV Prevention | COMPLETED | NCT05087927 |
| B/F/TAF | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT04143594 |
| BIC | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT04143594 |
| TAF | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT04143594 |
| Subcutaneous Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT04143594 |
| F/TAF | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT04143594 |
| Oral Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT04143594 |
| TDF Placebo | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836236 |
| TAF Placebo | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836236 |
| TDF | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836236 |
| TAF | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836236 |
| TDF Placebo | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836236 |
| TAF Placebo | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836236 |
| TDF | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836236 |
| TAF | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836236 |
| WeChat mobile mini-application | Other | Approved | HIV Preexposure Prophylaxis | COMPLETED | NCT04754139 |
| WeChat mobile mini-application | Other | Approved | HIV Preexposure Prophylaxis | COMPLETED | NCT04754139 |
| Truvada | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT06631365 |
| PrEPsmart mobile app | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT06631365 |
| Peginterferon Alfa-2a (PEG-IFN alfa) | Other | Phase PHASE2 | Chronic Hepatitis Delta | COMPLETED | NCT03852433 |
| Bulevirtide | Other | Phase PHASE2 | Chronic Hepatitis Delta | COMPLETED | NCT03852433 |
| TDF Placebo | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836249 |
| TAF Placebo | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836249 |
| TDF | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836249 |
| TAF | Other | Phase PHASE3 | HBV | COMPLETED | NCT02836249 |
| Vinorelbine | Other | Phase PHASE3 | Metastatic Breast Cancer | COMPLETED | NCT03901339 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Breast Cancer | COMPLETED | NCT03901339 |
| Capecitabine | Other | Phase PHASE3 | Metastatic Breast Cancer | COMPLETED | NCT03901339 |
| Eribulin | Other | Phase PHASE3 | Metastatic Breast Cancer | COMPLETED | NCT03901339 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Metastatic Breast Cancer | COMPLETED | NCT03901339 |
| Vinorelbine | Other | Phase PHASE3 | Metastatic Breast Cancer | COMPLETED | NCT03901339 |
| Gemcitabine | Other | Phase PHASE3 | Metastatic Breast Cancer | COMPLETED | NCT03901339 |
| Capecitabine | Other | Phase PHASE3 | Metastatic Breast Cancer | COMPLETED | NCT03901339 |
| Eribulin | Other | Phase PHASE3 | Metastatic Breast Cancer | COMPLETED | NCT03901339 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Metastatic Breast Cancer | COMPLETED | NCT03901339 |
| As usual | Other | Approved | Hepatitis C | COMPLETED | NCT04891445 |
| Nursing monitoring program | Other | Approved | Hepatitis C | COMPLETED | NCT04891445 |
| As usual | Other | Approved | Hepatitis C | COMPLETED | NCT04891445 |
| Nursing monitoring program | Other | Approved | Hepatitis C | COMPLETED | NCT04891445 |
| Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound | Other | Preclinical | Covid19 | COMPLETED | NCT04756193 |
| Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound | Other | Preclinical | Covid19 | COMPLETED | NCT04756193 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Differentiated Thyroid Cancer | RECRUITING | NCT06235216 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Differentiated Thyroid Cancer | RECRUITING | NCT06235216 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Differentiated Thyroid Cancer | RECRUITING | NCT06235216 |
| PET-CT | Other | Preclinical | Invasive Fungal Infections | RECRUITING | NCT05688592 |
| PET-CT | Other | Preclinical | Invasive Fungal Infections | RECRUITING | NCT05688592 |
| Derivation algorithms | Other | Approved | Non-alcoholic Fatty Liver Disease (NAFLD) | COMPLETED | NCT06688149 |
| Placebo | Other | Approved | Primary Biliary Cirrhosis | TERMINATED | NCT01614405 |
| TDF/FTC/LPV/r | Other | Approved | Primary Biliary Cirrhosis | TERMINATED | NCT01614405 |
| Placebo | Other | Approved | Primary Biliary Cirrhosis | TERMINATED | NCT01614405 |
| TDF/FTC/LPV/r | Other | Approved | Primary Biliary Cirrhosis | TERMINATED | NCT01614405 |
| Placebo | Other | Approved | Primary Biliary Cirrhosis | TERMINATED | NCT01614405 |
| TDF/FTC/LPV/r | Other | Approved | Primary Biliary Cirrhosis | TERMINATED | NCT01614405 |
| Remdesivir | Other | Preclinical | Covid19 | COMPLETED | NCT04847622 |
| Remdesivir | Other | Preclinical | Covid19 | COMPLETED | NCT04847622 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Esophageal Squamous Cell Carcinoma | RECRUITING | NCT06329869 |
| Rifabutin | Other | Phase PHASE1 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | TERMINATED | NCT05458102 |
| Voriconazole | Other | Phase PHASE1 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | TERMINATED | NCT05458102 |
| Cobicistat | Other | Phase PHASE1 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | TERMINATED | NCT05458102 |
| Vesatolimod | Other | Phase PHASE1 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | TERMINATED | NCT05458102 |
| Rifabutin | Other | Phase PHASE1 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | TERMINATED | NCT05458102 |
| Voriconazole | Other | Phase PHASE1 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | TERMINATED | NCT05458102 |
| Cobicistat | Other | Phase PHASE1 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | TERMINATED | NCT05458102 |
| Vesatolimod | Other | Phase PHASE1 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | TERMINATED | NCT05458102 |
| Time-and-Attention Control Session | Other | Preclinical | Hiv | COMPLETED | NCT04240691 |
| 60-Minutes-For-Health | Other | Preclinical | Hiv | COMPLETED | NCT04240691 |
| Time-and-Attention Control Session | Other | Preclinical | Hiv | COMPLETED | NCT04240691 |
| 60-Minutes-For-Health | Other | Preclinical | Hiv | COMPLETED | NCT04240691 |
| Ranolazine 1000 MG | Other | Phase PHASE2 | ALS | COMPLETED | NCT03472950 |
| Ranolazine 500 MG | Other | Phase PHASE2 | ALS | COMPLETED | NCT03472950 |
| Ranolazine 1000 MG | Other | Phase PHASE2 | ALS | COMPLETED | NCT03472950 |
| Ranolazine 500 MG | Other | Phase PHASE2 | ALS | COMPLETED | NCT03472950 |
| Placebo | Other | Phase PHASE4 | Cardiomyopathy | COMPLETED | NCT01345188 |
| Ranexa | Other | Phase PHASE4 | Cardiomyopathy | COMPLETED | NCT01345188 |
| Placebo | Other | Phase PHASE4 | Cardiomyopathy | COMPLETED | NCT01345188 |
| Ranexa | Other | Phase PHASE4 | Cardiomyopathy | COMPLETED | NCT01345188 |
| Digital Health Feedback System(DHFS) | Other | Phase PHASE4 | HIV/AIDS | COMPLETED | NCT04418037 |
| Digital Health Feedback System(DHFS) | Other | Phase PHASE4 | HIV/AIDS | COMPLETED | NCT04418037 |
| anti-HDV positive with the reflex testing methodology | Other | Preclinical | Hepatitis D Virus Infection | NOT_YET_RECRUITING | NCT06539052 |
| tenofovir-emtricitabine | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02815566 |
| tenofovir-alafenamide-emtricitabine | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02815566 |
| tenofovir-emtricitabine | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02815566 |
| tenofovir-alafenamide-emtricitabine | Other | Phase PHASE4 | Osteoporosis | COMPLETED | NCT02815566 |
| Obeldesivir Placebo | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT05603143 |
| Obeldesivir | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT05603143 |
| Obeldesivir Placebo | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT05603143 |
| Obeldesivir | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT05603143 |
| Obeldesivir Placebo | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT05603143 |
| Obeldesivir | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT05603143 |
| Obeldesivir Placebo | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05715528 |
| Obeldesivir | Other | Phase PHASE3 | COVID-19 | COMPLETED | NCT05715528 |
| Sofosbuvir-Velpatasvir Drug Combination | Drug | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT04382404 |
| Sofosbuvir-Velpatasvir Drug Combination | Drug | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT04382404 |
| Placebo to match Seladelpar | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | TERMINATED | NCT04024813 |
| Seladelpar | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | TERMINATED | NCT04024813 |
| Placebo to match Seladelpar | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | TERMINATED | NCT04024813 |
| Seladelpar | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | TERMINATED | NCT04024813 |
| Azacitidine | Other | Phase PHASE1 | Hematological Malignancies | TERMINATED | NCT03248479 |
| Magrolimab | Other | Phase PHASE1 | Hematological Malignancies | TERMINATED | NCT03248479 |
| Experimental PrEP:TAF/FTC once daily (weeks 0-26) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT04066881 |
| Control PrEP:TDF/FTC once daily (weeks 0-26) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT04066881 |
| Vaccine Group C: Saline placebo (weeks 0,4,24,48) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT04066881 |
| Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT04066881 |
| Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT04066881 |
| Experimental PrEP:TAF/FTC once daily (weeks 0-26) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT04066881 |
| Control PrEP:TDF/FTC once daily (weeks 0-26) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT04066881 |
| Vaccine Group C: Saline placebo (weeks 0,4,24,48) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT04066881 |
| Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT04066881 |
| Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT04066881 |
| Zinlirvimab | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT04811040 |
| Teropavimab | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT04811040 |
| Subcutaneous Lenacapavir | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT04811040 |
| Oral Lenacapavir | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT04811040 |
| Obeldesivir | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT05996744 |
| Obeldesivir | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT05996744 |
| EPIC-P | Other | Approved | HIV | COMPLETED | NCT04193787 |
| EPIC-P | Other | Approved | HIV | COMPLETED | NCT04193787 |
| EPIC-P | Other | Approved | HIV | COMPLETED | NCT04193787 |
| L-AmB standard dose | Other | Phase PHASE3 | Disseminated Histoplasma Capsulatum Infection | RECRUITING | NCT05814432 |
| Single high dose of liposomal amphotericin B | Other | Phase PHASE3 | Disseminated Histoplasma Capsulatum Infection | RECRUITING | NCT05814432 |
| L-AmB standard dose | Other | Phase PHASE3 | Disseminated Histoplasma Capsulatum Infection | RECRUITING | NCT05814432 |
| Single high dose of liposomal amphotericin B | Other | Phase PHASE3 | Disseminated Histoplasma Capsulatum Infection | RECRUITING | NCT05814432 |
| L-AmB standard dose | Other | Phase PHASE3 | Disseminated Histoplasma Capsulatum Infection | RECRUITING | NCT05814432 |
| Single high dose of liposomal amphotericin B | Other | Phase PHASE3 | Disseminated Histoplasma Capsulatum Infection | RECRUITING | NCT05814432 |
| Biopsies and bloood samplings | Other | Approved | HIV-1-infection | NOT_YET_RECRUITING | NCT05222945 |
| Biopsies and bloood samplings | Other | Approved | HIV-1-infection | NOT_YET_RECRUITING | NCT05222945 |
| Steroidal Eye Drops | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT04778397 |
| Idarubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT04778397 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT04778397 |
| Cytarabine | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT04778397 |
| Azacitidine | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT04778397 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT04778397 |
| Magrolimab | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT04778397 |
| Placebo | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| Filgotinib | Other | Phase PHASE3 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT02914535 |
| Regimen：BIC+FTC+TAF | Other | Phase PHASE4 | HIV Infection | NOT_YET_RECRUITING | NCT06830668 |
| Regimen：BIC+FTC+TAF | Other | Phase PHASE4 | HIV Infection | NOT_YET_RECRUITING | NCT06830668 |
| Enhanced adherence support | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT03386578 |
| Behavioral HIV risk reduction package | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT03386578 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT03386578 |
| Enhanced adherence support | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT03386578 |
| Behavioral HIV risk reduction package | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT03386578 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT03386578 |
| Experimental: Seladelpar / MBX-8025 200 mg | Other | Phase PHASE2 | Primary Biliary Cirrhosis (PBC) | TERMINATED | NCT02609048 |
| Experimental: Seladelpar 50 mg | Other | Phase PHASE2 | Primary Biliary Cirrhosis (PBC) | TERMINATED | NCT02609048 |
| Placebo Comparator | Other | Phase PHASE2 | Primary Biliary Cirrhosis (PBC) | TERMINATED | NCT02609048 |
| Experimental: Seladelpar / MBX-8025 200 mg | Other | Phase PHASE2 | Primary Biliary Cirrhosis (PBC) | TERMINATED | NCT02609048 |
| Experimental: Seladelpar 50 mg | Other | Phase PHASE2 | Primary Biliary Cirrhosis (PBC) | TERMINATED | NCT02609048 |
| Placebo Comparator | Other | Phase PHASE2 | Primary Biliary Cirrhosis (PBC) | TERMINATED | NCT02609048 |
| Sacituzumab Govitecan | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06167317 |
| GS-0201 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06167317 |
| Sacituzumab Govitecan | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06167317 |
| GS-0201 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06167317 |
| Seladelpar 10 mg or less | Other | Phase PHASE1 | Primary Biliary Cholangitis | COMPLETED | NCT04950764 |
| Seladelpar 10 mg | Other | Phase PHASE1 | Primary Biliary Cholangitis | COMPLETED | NCT04950764 |
| Placebo to match B/F/TAF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| F/TDF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| DTG | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| Placebo to match F/TDF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| Placebo to match DTG | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| Placebo to match B/F/TAF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| F/TDF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| DTG | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| Placebo to match F/TDF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| Placebo to match DTG | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| Placebo to match B/F/TAF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| F/TDF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| DTG | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| Placebo to match F/TDF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| Placebo to match DTG | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1/HBV Co-Infection | COMPLETED | NCT03547908 |
| CC-486 | Other | Phase PHASE2 | Myeloid Malignancies | TERMINATED | NCT04778410 |
| Cytarabine | Other | Phase PHASE2 | Myeloid Malignancies | TERMINATED | NCT04778410 |
| Etoposide | Other | Phase PHASE2 | Myeloid Malignancies | TERMINATED | NCT04778410 |
| Mitoxantrone | Other | Phase PHASE2 | Myeloid Malignancies | TERMINATED | NCT04778410 |
| Venetoclax | Other | Phase PHASE2 | Myeloid Malignancies | TERMINATED | NCT04778410 |
| Azacitidine | Other | Phase PHASE2 | Myeloid Malignancies | TERMINATED | NCT04778410 |
| Magrolimab | Other | Phase PHASE2 | Myeloid Malignancies | TERMINATED | NCT04778410 |
| HIV-1 infection | Other | Preclinical | HIV-1-infection | COMPLETED | NCT05481216 |
| COVID-19 | Other | Preclinical | HIV-1-infection | COMPLETED | NCT05481216 |
| HIV-1 infection | Other | Preclinical | HIV-1-infection | COMPLETED | NCT05481216 |
| COVID-19 | Other | Preclinical | HIV-1-infection | COMPLETED | NCT05481216 |
| HIV-1 infection | Other | Preclinical | HIV-1-infection | COMPLETED | NCT05481216 |
| COVID-19 | Other | Preclinical | HIV-1-infection | COMPLETED | NCT05481216 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05101096 |
| Case Management | Other | Approved | Hiv | COMPLETED | NCT04519970 |
| Case Management | Other | Approved | Hiv | COMPLETED | NCT04519970 |
| Case Management | Other | Approved | Hiv | COMPLETED | NCT04519970 |
| Nivolumab | Other | Phase PHASE2 | Urothelial Carcinoma | RECRUITING | NCT06682728 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE2 | Urothelial Carcinoma | RECRUITING | NCT06682728 |
| Nivolumab | Other | Phase PHASE2 | Urothelial Carcinoma | RECRUITING | NCT06682728 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE2 | Urothelial Carcinoma | RECRUITING | NCT06682728 |
| Ex Vivo Lung Perfusion (EVLP) | Other | Phase EARLY_PHASE1 | Lung Transplant Infection | ACTIVE_NOT_RECRUITING | NCT03112044 |
| Sofosbuvir-velpatasvir (400 mg/100 mg) | Other | Phase EARLY_PHASE1 | Lung Transplant Infection | ACTIVE_NOT_RECRUITING | NCT03112044 |
| Ex Vivo Lung Perfusion (EVLP) | Other | Phase EARLY_PHASE1 | Lung Transplant Infection | ACTIVE_NOT_RECRUITING | NCT03112044 |
| Sofosbuvir-velpatasvir (400 mg/100 mg) | Other | Phase EARLY_PHASE1 | Lung Transplant Infection | ACTIVE_NOT_RECRUITING | NCT03112044 |
| Ex Vivo Lung Perfusion (EVLP) | Other | Phase EARLY_PHASE1 | Lung Transplant Infection | ACTIVE_NOT_RECRUITING | NCT03112044 |
| Sofosbuvir-velpatasvir (400 mg/100 mg) | Other | Phase EARLY_PHASE1 | Lung Transplant Infection | ACTIVE_NOT_RECRUITING | NCT03112044 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Azacitidine | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Magrolimab | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Azacitidine | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Magrolimab | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Azacitidine | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Magrolimab | Other | Phase PHASE3 | Acute Myeloid Leukemia | TERMINATED | NCT05079230 |
| Beiwe | Other | Phase PHASE3 | HIV Infections | RECRUITING | NCT05378399 |
| ID-Cap System | Other | Phase PHASE3 | HIV Infections | RECRUITING | NCT05378399 |
| Descovy or Truvada | Other | Phase PHASE3 | HIV Infections | RECRUITING | NCT05378399 |
| bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg | Other | Phase PHASE4 | HIV Infections | RECRUITING | NCT06374758 |
| The Accelerate model of care | Other | Phase PHASE4 | HIV Infections | RECRUITING | NCT06374758 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Anatomic Stage IV Breast Cancer AJCC v8 | ACTIVE_NOT_RECRUITING | NCT04647916 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Anatomic Stage IV Breast Cancer AJCC v8 | ACTIVE_NOT_RECRUITING | NCT04647916 |
| Placebo | Other | Phase PHASE1 | Aicardi Goutières Syndrome | WITHDRAWN | NCT03304717 |
| Tenofovir (TDF) and Emtricitabine (FTC) | Other | Phase PHASE1 | Aicardi Goutières Syndrome | WITHDRAWN | NCT03304717 |
| Placebo | Other | Phase PHASE1 | Aicardi Goutières Syndrome | WITHDRAWN | NCT03304717 |
| Tenofovir (TDF) and Emtricitabine (FTC) | Other | Phase PHASE1 | Aicardi Goutières Syndrome | WITHDRAWN | NCT03304717 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Pomalidomide | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Magrolimab | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Pomalidomide | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Magrolimab | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT04892446 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | ACTIVE_NOT_RECRUITING | NCT06060665 |
| Seladelpar 10 mg | Other | Phase PHASE3 | Primary Biliary Cholangitis | ACTIVE_NOT_RECRUITING | NCT06060665 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | ACTIVE_NOT_RECRUITING | NCT06060665 |
| Seladelpar 10 mg | Other | Phase PHASE3 | Primary Biliary Cholangitis | ACTIVE_NOT_RECRUITING | NCT06060665 |
| Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab | Other | Phase PHASE2 | NSCLC Stage IV | RECRUITING | NCT06401824 |
| Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab | Other | Phase PHASE2 | NSCLC Stage IV | RECRUITING | NCT06401824 |
| Docetaxel | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT04827576 |
| Magrolimab | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT04827576 |
| Docetaxel | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT04827576 |
| Magrolimab | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT04827576 |
| Making PrEP Smart | Other | Approved | HIV/AIDS | COMPLETED | NCT05111119 |
| Making PrEP Smart | Other | Approved | HIV/AIDS | COMPLETED | NCT05111119 |
| Sample Collection | Other | Preclinical | COVID-19 | RECRUITING | NCT05467930 |
| Medical History Review | Other | Preclinical | COVID-19 | RECRUITING | NCT05467930 |
| Survey | Other | Preclinical | COVID-19 | RECRUITING | NCT05467930 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT03725761 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT03725761 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT03725761 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06532565 |
| GS-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06532565 |
| Fibroscan® 430 Mini Plus | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT03987503 |
| Standard of care | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT03987503 |
| Epclusa (SOF/VEL) | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT03987503 |
| Fibroscan® 430 Mini Plus | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT03987503 |
| Standard of care | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT03987503 |
| Epclusa (SOF/VEL) | Other | Phase PHASE4 | Hepatitis C, Chronic | COMPLETED | NCT03987503 |
| Allopurinol | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT02953509 |
| Oxaliplatin | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT02953509 |
| Gemcitabine | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT02953509 |
| Rituximab | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT02953509 |
| Magrolimab | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT02953509 |
| Allopurinol | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT02953509 |
| Oxaliplatin | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT02953509 |
| Gemcitabine | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT02953509 |
| Rituximab | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT02953509 |
| Magrolimab | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT02953509 |
| Rapid diagnostic orientation tests (TROD) HIV, Hepatitis, syphilis | Other | Approved | Vulnerable Population | RECRUITING | NCT06996938 |
| Rapid diagnostic orientation tests (TROD) HIV, Hepatitis, syphilis | Other | Approved | Vulnerable Population | RECRUITING | NCT06996938 |
| bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) | Other | Preclinical | HIV Positive People Who Inject Drugs | COMPLETED | NCT07004933 |
| bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) | Other | Preclinical | HIV Positive People Who Inject Drugs | COMPLETED | NCT07004933 |
| Sacituzumab govitecan | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05552001 |
| Sacituzumab govitecan | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05552001 |
| Drug level counseling at Weeks 8 and 13 | Drug | Phase PHASE4 | HIV | COMPLETED | NCT02732730 |
| Truvada | Other | Phase PHASE4 | HIV | COMPLETED | NCT02732730 |
| Drug level counseling at Weeks 8 and 13 | Drug | Phase PHASE4 | HIV | COMPLETED | NCT02732730 |
| Truvada | Other | Phase PHASE4 | HIV | COMPLETED | NCT02732730 |
| Emtricitabine/Tenofovir | Other | Phase PHASE4 | HIV | ACTIVE_NOT_RECRUITING | NCT02656511 |
| Dolutegravir | Other | Phase PHASE4 | HIV | ACTIVE_NOT_RECRUITING | NCT02656511 |
| Emtricitabine/Tenofovir | Other | Phase PHASE4 | HIV | ACTIVE_NOT_RECRUITING | NCT02656511 |
| Dolutegravir | Other | Phase PHASE4 | HIV | ACTIVE_NOT_RECRUITING | NCT02656511 |
| Obinutuzumab | Other | Phase PHASE1 | B-cell Malignancies | TERMINATED | NCT02457598 |
| Entospletinib | Other | Phase PHASE1 | B-cell Malignancies | TERMINATED | NCT02457598 |
| Idelalisib | Other | Phase PHASE1 | B-cell Malignancies | TERMINATED | NCT02457598 |
| Tirabrutinib | Other | Phase PHASE1 | B-cell Malignancies | TERMINATED | NCT02457598 |
| Obinutuzumab | Other | Phase PHASE1 | B-cell Malignancies | TERMINATED | NCT02457598 |
| Entospletinib | Other | Phase PHASE1 | B-cell Malignancies | TERMINATED | NCT02457598 |
| Idelalisib | Other | Phase PHASE1 | B-cell Malignancies | TERMINATED | NCT02457598 |
| Tirabrutinib | Other | Phase PHASE1 | B-cell Malignancies | TERMINATED | NCT02457598 |
| TAF/FTC 25mg/200mg fixed-dose combination tablets | Other | Phase PHASE3 | HIV/AIDS | RECRUITING | NCT05813964 |
| TDF/FTC 300mg/200mg fixed-dose combination tablets | Other | Phase PHASE3 | HIV/AIDS | RECRUITING | NCT05813964 |
| TAF/FTC 25mg/200mg fixed-dose combination tablets | Other | Phase PHASE3 | HIV/AIDS | RECRUITING | NCT05813964 |
| TDF/FTC 300mg/200mg fixed-dose combination tablets | Other | Phase PHASE3 | HIV/AIDS | RECRUITING | NCT05813964 |
| Obeldesivir Placebo | Other | Phase PHASE2 | RSV Infection | TERMINATED | NCT06784973 |
| Obeldesivir | Other | Phase PHASE2 | RSV Infection | TERMINATED | NCT06784973 |
| Obeldesivir Placebo | Other | Phase PHASE2 | RSV Infection | TERMINATED | NCT06784973 |
| Obeldesivir | Other | Phase PHASE2 | RSV Infection | TERMINATED | NCT06784973 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT06665178 |
| Zydelig | Other | Phase PHASE2 | Non Hodgkin Lymphoma | COMPLETED | NCT03133221 |
| Boosted PIs | Other | Phase PHASE2 | HIV-1 | COMPLETED | NCT02285114 |
| 3rd ARV agent | Other | Phase PHASE2 | HIV-1 | COMPLETED | NCT02285114 |
| F/TAF | Other | Phase PHASE2 | HIV-1 | COMPLETED | NCT02285114 |
| Boosted PIs | Other | Phase PHASE2 | HIV-1 | COMPLETED | NCT02285114 |
| 3rd ARV agent | Other | Phase PHASE2 | HIV-1 | COMPLETED | NCT02285114 |
| F/TAF | Other | Phase PHASE2 | HIV-1 | COMPLETED | NCT02285114 |
| Leucovorin | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Fluorouracil | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Magrolimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Leucovorin | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Fluorouracil | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Bevacizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Magrolimab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT05330429 |
| Placebo to match filgotinib | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT03025308 |
| Filgotinib | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT03025308 |
| Placebo to match filgotinib | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT03025308 |
| Filgotinib | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT03025308 |
| Placebo to match filgotinib | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT03025308 |
| Filgotinib | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT03025308 |
| Magrolimab | Other | Phase PHASE1 | Brain Cancer | COMPLETED | NCT05169944 |
| Magrolimab | Other | Phase PHASE1 | Brain Cancer | COMPLETED | NCT05169944 |
| Magrolimab | Other | Phase PHASE1 | Brain Cancer | COMPLETED | NCT05169944 |
| P4P intervention | Other | Approved | HIV/AIDS | ACTIVE_NOT_RECRUITING | NCT06353295 |
| Sacituzumab govitecan-hziy | Other | Phase PHASE2 | Mesothelioma | RECRUITING | NCT06477419 |
| Sacituzumab govitecan-hziy | Other | Phase PHASE2 | Mesothelioma | RECRUITING | NCT06477419 |
| Sacituzumab govitecan-hziy | Other | Phase PHASE2 | Mesothelioma | RECRUITING | NCT06477419 |
| Antiretroviral Therapy | Drug | Phase PHASE2 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT05729568 |
| Lenacapavir Injection | Other | Phase PHASE2 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT05729568 |
| Lenacapavir Tablet | Other | Phase PHASE2 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT05729568 |
| Zinlirvimab | Other | Phase PHASE2 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT05729568 |
| Teropavimab | Other | Phase PHASE2 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT05729568 |
| Antiretroviral Therapy | Drug | Phase PHASE2 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT05729568 |
| Lenacapavir Injection | Other | Phase PHASE2 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT05729568 |
| Lenacapavir Tablet | Other | Phase PHASE2 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT05729568 |
| Zinlirvimab | Other | Phase PHASE2 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT05729568 |
| Teropavimab | Other | Phase PHASE2 | HIV Infection | ACTIVE_NOT_RECRUITING | NCT05729568 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Salivary Gland Cancer | RECRUITING | NCT06923826 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Salivary Gland Cancer | RECRUITING | NCT06923826 |
| Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening | Other | Approved | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06019988 |
| Obeldesivir Placebo | Other | Phase PHASE2 | RSV Infection | TERMINATED | NCT06585150 |
| Obeldesivir | Other | Phase PHASE2 | RSV Infection | TERMINATED | NCT06585150 |
| Vinflunine | Other | Phase PHASE3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | COMPLETED | NCT04527991 |
| Docetaxel | Other | Phase PHASE3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | COMPLETED | NCT04527991 |
| Paclitaxel | Other | Phase PHASE3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | COMPLETED | NCT04527991 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | COMPLETED | NCT04527991 |
| No intervention | Other | Preclinical | Breast Cancer | COMPLETED | NCT06683482 |
| No intervention | Other | Preclinical | Breast Cancer | COMPLETED | NCT06683482 |
| Sofosbuvir/velpatasvir (Epclusa®) | Other | Phase PHASE4 | Hepatitis C | COMPLETED | NCT03949764 |
| Sofosbuvir/velpatasvir (Epclusa®) | Other | Phase PHASE4 | Hepatitis C | COMPLETED | NCT03949764 |
| Tenofovir Disoproxil | Other | Preclinical | HIV | ACTIVE_NOT_RECRUITING | NCT04453436 |
| BIC/F/TAF 50Mg-200Mg-25Mg Tablet | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT04530630 |
| BIC/F/TAF 50Mg-200Mg-25Mg Tablet | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT04530630 |
| BIC/F/TAF 50Mg-200Mg-25Mg Tablet | Other | Phase PHASE4 | HIV Infections | COMPLETED | NCT04530630 |
| I'm Fully Empowered for Her (IFE4Her) | Other | Approved | HIV Prevention | COMPLETED | NCT05644834 |
| I'm Fully Empowered for Her (IFE4Her) | Other | Approved | HIV Prevention | COMPLETED | NCT05644834 |
| Colposcopy | Other | Phase PHASE1 | Cervix Cancer | COMPLETED | NCT06165614 |
| Artesunate pessary | Other | Phase PHASE1 | Cervix Cancer | COMPLETED | NCT06165614 |
| Colposcopy | Other | Phase PHASE1 | Cervix Cancer | COMPLETED | NCT06165614 |
| Artesunate pessary | Other | Phase PHASE1 | Cervix Cancer | COMPLETED | NCT06165614 |
| Combination zimberelimab + domvanalimab | Other | Phase PHASE2 | Locally Advanced Gastric Adenocarcinoma | RECRUITING | NCT06250036 |
| Single agent zimberelimab | Other | Phase PHASE2 | Locally Advanced Gastric Adenocarcinoma | RECRUITING | NCT06250036 |
| Combination zimberelimab + domvanalimab | Other | Phase PHASE2 | Locally Advanced Gastric Adenocarcinoma | RECRUITING | NCT06250036 |
| Single agent zimberelimab | Other | Phase PHASE2 | Locally Advanced Gastric Adenocarcinoma | RECRUITING | NCT06250036 |
| Bulevirtide | Other | Phase PHASE3 | Chronic Hepatitis Delta | COMPLETED | NCT03852719 |
| Bulevirtide | Other | Phase PHASE3 | Chronic Hepatitis Delta | COMPLETED | NCT03852719 |
| Bulevirtide | Other | Phase PHASE3 | Chronic Hepatitis Delta | COMPLETED | NCT03852719 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06513312 |
| Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT02344290 |
| Pitavastatin | Other | Phase PHASE3 | HIV | COMPLETED | NCT02344290 |
| Placebo | Other | Phase PHASE3 | HIV | COMPLETED | NCT02344290 |
| Pitavastatin | Other | Phase PHASE3 | HIV | COMPLETED | NCT02344290 |
| Zimberelimab | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06082960 |
| GS-9911 | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06082960 |
| Sacituzumab Govitecan + Anastrozole / Exemestane | Other | Phase PHASE1 | Stage IV (Metastatic) Breast Cancer | NOT_YET_RECRUITING | NCT07163481 |
| Sacituzumab Govitecan + Fulvestrant | Other | Phase PHASE1 | Stage IV (Metastatic) Breast Cancer | NOT_YET_RECRUITING | NCT07163481 |
| Sacituzumab Govitecan + Anastrozole / Exemestane | Other | Phase PHASE1 | Stage IV (Metastatic) Breast Cancer | NOT_YET_RECRUITING | NCT07163481 |
| Sacituzumab Govitecan + Fulvestrant | Other | Phase PHASE1 | Stage IV (Metastatic) Breast Cancer | NOT_YET_RECRUITING | NCT07163481 |
| SoC Chemotherapy | Drug | Phase PHASE3 | Breast Cancer | NOT_YET_RECRUITING | NCT07178730 |
| Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA] | Other | Phase PHASE3 | Breast Cancer | NOT_YET_RECRUITING | NCT07178730 |
| Sacituzumab govitecan | Other | Phase PHASE3 | Breast Cancer | NOT_YET_RECRUITING | NCT07178730 |
| Truvada | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT03512418 |
| Digital pill | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT03512418 |
| PrEPsteps | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT03512418 |
| Truvada | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT03512418 |
| Digital pill | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT03512418 |
| PrEPsteps | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT03512418 |
| Bulevirtide (BLV) | Other | Phase PHASE1 | Chronic Hepatitis D Infection | COMPLETED | NCT05760300 |
| Bulevirtide (BLV) | Other | Phase PHASE1 | Chronic Hepatitis D Infection | COMPLETED | NCT05760300 |
| Bulevirtide (BLV) | Other | Phase PHASE1 | Chronic Hepatitis D Infection | COMPLETED | NCT05760300 |
| Carboplatin | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| Gemcitabine | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| nab-Paclitaxel | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| Paclitaxel | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| Pembrolizumab | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| Carboplatin | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| Gemcitabine | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| nab-Paclitaxel | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| Paclitaxel | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| Pembrolizumab | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382286 |
| PrEP-RN | Other | Approved | Pre-Exposure Prophylaxis (PrEP) | COMPLETED | NCT05095818 |
| PrEP-RN | Other | Approved | Pre-Exposure Prophylaxis (PrEP) | COMPLETED | NCT05095818 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101329 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101329 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101329 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101329 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101329 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101329 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101329 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101329 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101329 |
| Descovy | Other | Phase PHASE4 | HIV Prevention | COMPLETED | NCT05528653 |
| Descovy | Other | Phase PHASE4 | HIV Prevention | COMPLETED | NCT05528653 |
| Descovy | Other | Phase PHASE4 | HIV Prevention | COMPLETED | NCT05528653 |
| Remdesivir (RDV) | Other | Phase PHASE2 | COVID - 19 | RECRUITING | NCT07197164 |
| Remdesivir (RDV) | Other | Phase PHASE2 | COVID - 19 | RECRUITING | NCT07197164 |
| Sacituzumab Govitecan-hiy | Other | Phase PHASE4 | Metastatic Solid Tumors | COMPLETED | NCT04319198 |
| Sacituzumab Govitecan-hiy | Other | Phase PHASE4 | Metastatic Solid Tumors | COMPLETED | NCT04319198 |
| Capecitabine | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Nab-paclitaxel | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Paclitaxel | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Capecitabine | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Nab-paclitaxel | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Paclitaxel | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Capecitabine | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Nab-paclitaxel | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Paclitaxel | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Locally Advanced or Unresectable Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05840211 |
| Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs | Other | Phase PHASE4 | HIV - Human Immunodeficiency Virus | RECRUITING | NCT07160075 |
| Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs | Other | Phase PHASE4 | HIV - Human Immunodeficiency Virus | RECRUITING | NCT07160075 |
| Stable Baseline Regimen | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT05502341 |
| BIC/LEN FDC | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT05502341 |
| Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT05502341 |
| Bictegravir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT05502341 |
| Pembrolizumab | Other | Phase PHASE2 | Invasive Breast Cancer | RECRUITING | NCT04230109 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Invasive Breast Cancer | RECRUITING | NCT04230109 |
| Pembrolizumab | Other | Phase PHASE2 | Invasive Breast Cancer | RECRUITING | NCT04230109 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Invasive Breast Cancer | RECRUITING | NCT04230109 |
| Standard of Care | Other | Phase PHASE1 | HIV-1-infection | TERMINATED | NCT07115368 |
| BVY | Other | Phase PHASE1 | HIV-1-infection | TERMINATED | NCT07115368 |
| GS-1219 | Other | Phase PHASE1 | HIV-1-infection | TERMINATED | NCT07115368 |
| Standard of Care | Other | Phase PHASE1 | HIV-1-infection | TERMINATED | NCT07115368 |
| BVY | Other | Phase PHASE1 | HIV-1-infection | TERMINATED | NCT07115368 |
| GS-1219 | Other | Phase PHASE1 | HIV-1-infection | TERMINATED | NCT07115368 |
| Docetaxel | Other | Phase PHASE2 | Head Neck | TERMINATED | NCT06046482 |
| cetuximab | Other | Phase PHASE2 | Head Neck | TERMINATED | NCT06046482 |
| Magrolimab | Other | Phase PHASE2 | Head Neck | TERMINATED | NCT06046482 |
| Pembrolizumab | Other | Phase PHASE2 | Head Neck | TERMINATED | NCT06046482 |
| co-formulated 25mg TAF/ 200mg FTC | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT05140954 |
| co-formulated 25mg TAF/ 200mg FTC | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT05140954 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05675579 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Paclitaxel | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Nab-Paclitaxel | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Magrolimab | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Paclitaxel | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Nab-Paclitaxel | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Magrolimab | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Paclitaxel | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Nab-Paclitaxel | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Magrolimab | Other | Phase PHASE2 | Triple-Negative Breast Cancer | TERMINATED | NCT04958785 |
| Placebo to match BIC/LEN | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| Placebo to match B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| Lenacapavir | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| Bictegravir | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| Placebo to match BIC/LEN | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| Placebo to match B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| Lenacapavir | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| Bictegravir | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06333808 |
| NAVAH | Other | Approved | Breast Cancer | COMPLETED | NCT05978232 |
| NAVAH | Other | Approved | Breast Cancer | COMPLETED | NCT05978232 |
| NAVAH | Other | Approved | Breast Cancer | COMPLETED | NCT05978232 |
| Doravirine (DOR) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Second-Line TB Treatment | Drug | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| First-Line TB Treatment | Drug | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Ritonavir | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Cobicistat | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Lopinavir/ritonavir (LPV/r) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Darunavir/ritonavir (DRV/r) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Atazanavir/ritonavir (ATV/r) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Dolutegravir (DTG) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Cabotegravir (CAB) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Tenofovir alafenamide (TAF) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Bictegravir (BIC) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Doravirine (DOR) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Second-Line TB Treatment | Drug | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| First-Line TB Treatment | Drug | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Ritonavir | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Cobicistat | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Lopinavir/ritonavir (LPV/r) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Darunavir/ritonavir (DRV/r) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Atazanavir/ritonavir (ATV/r) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Dolutegravir (DTG) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Cabotegravir (CAB) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Tenofovir alafenamide (TAF) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| Bictegravir (BIC) | Other | Preclinical | HIV Infections | COMPLETED | NCT04518228 |
| PTM ISL/LEN | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06630286 |
| PTM B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06630286 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06630286 |
| ISL/LEN | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06630286 |
| PTM ISL/LEN | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06630286 |
| PTM B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06630286 |
| B/F/TAF | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06630286 |
| ISL/LEN | Other | Phase PHASE3 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT06630286 |
| F/TDF Placebo | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02842086 |
| F/TAF Placebo | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02842086 |
| F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02842086 |
| F/TAF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02842086 |
| F/TDF Placebo | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02842086 |
| F/TAF Placebo | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02842086 |
| F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02842086 |
| F/TAF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02842086 |
| Antiretroviral Combinations | Other | Phase PHASE3 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06630299 |
| ISL/LEN | Other | Phase PHASE3 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06630299 |
| Bulevirtide | Other | Preclinical | Chronic Hepatitis D Infection | ACTIVE_NOT_RECRUITING | NCT05718700 |
| Bulevirtide | Other | Preclinical | Chronic Hepatitis D Infection | ACTIVE_NOT_RECRUITING | NCT05718700 |
| Pembrolizumab | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT06081244 |
| Sacituzumab govitecan | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT06081244 |
| Pembrolizumab | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT06081244 |
| Sacituzumab govitecan | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT06081244 |
| Pembrolizumab | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT06081244 |
| Sacituzumab govitecan | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT06081244 |
| Zimberelimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Carboplatin | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Cisplatin | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| 5-FU | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Docetaxel | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Magrolimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Zimberelimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Carboplatin | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Cisplatin | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| 5-FU | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Docetaxel | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Magrolimab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | TERMINATED | NCT04854499 |
| Sacituzumab govitecan | Other | Phase PHASE3 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04595565 |
| Cisplatin | Other | Phase PHASE3 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04595565 |
| Carboplatin | Other | Phase PHASE3 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04595565 |
| Capecitabine | Other | Phase PHASE3 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04595565 |
| Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT05520723 |
| Loperamide | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT05520723 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT05520723 |
| Granulocyte Colony-Stimulating Factor | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT05520723 |
| Loperamide | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT05520723 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Triple Negative Breast Cancer | COMPLETED | NCT05520723 |
| Debio 0123 and Sacituzumab govitecan | Other | Phase PHASE1 | Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06612203 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06238921 |
| Zimberelimab | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06238921 |
| Stereotactic Radiation | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06238921 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06238921 |
| Zimberelimab | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06238921 |
| Stereotactic Radiation | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT06238921 |
| electronic medical record alert linked to orders | Other | Approved | HIV | NOT_YET_RECRUITING | NCT07031219 |
| electronic medical record alert linked to orders | Other | Approved | HIV | NOT_YET_RECRUITING | NCT07031219 |
| Opt Out of Questionnaire | Other | Preclinical | Breast Cancer | RECRUITING | NCT07014618 |
| Pre & Post Surveys | Other | Preclinical | Breast Cancer | RECRUITING | NCT07014618 |
| Opt Out of Questionnaire | Other | Preclinical | Breast Cancer | RECRUITING | NCT07014618 |
| Pre & Post Surveys | Other | Preclinical | Breast Cancer | RECRUITING | NCT07014618 |
| Deferred Intervention Arm | Other | Phase PHASE2 | HIV Prevention | COMPLETED | NCT04742491 |
| Immediate Intervention Arm | Other | Phase PHASE2 | HIV Prevention | COMPLETED | NCT04742491 |
| Deferred Intervention Arm | Other | Phase PHASE2 | HIV Prevention | COMPLETED | NCT04742491 |
| Immediate Intervention Arm | Other | Phase PHASE2 | HIV Prevention | COMPLETED | NCT04742491 |
| Symtuza | Other | Phase PHASE3 | HIV/AIDS | COMPLETED | NCT03696160 |
| Biktarvy | Other | Phase PHASE3 | HIV/AIDS | COMPLETED | NCT03696160 |
| Symtuza | Other | Phase PHASE3 | HIV/AIDS | COMPLETED | NCT03696160 |
| Biktarvy | Other | Phase PHASE3 | HIV/AIDS | COMPLETED | NCT03696160 |
| Symtuza | Other | Phase PHASE3 | HIV/AIDS | COMPLETED | NCT03696160 |
| Biktarvy | Other | Phase PHASE3 | HIV/AIDS | COMPLETED | NCT03696160 |
| Medical Record Review | Other | Preclinical | HER2-negative Breast Cancer | RECRUITING | NCT06774027 |
| Non-Investigational Antibody-Drug Conjugates (ADC) | Drug | Preclinical | HER2-negative Breast Cancer | RECRUITING | NCT06774027 |
| Specimen collection | Other | Preclinical | HER2-negative Breast Cancer | RECRUITING | NCT06774027 |
| Medical Record Review | Other | Preclinical | HER2-negative Breast Cancer | RECRUITING | NCT06774027 |
| Non-Investigational Antibody-Drug Conjugates (ADC) | Drug | Preclinical | HER2-negative Breast Cancer | RECRUITING | NCT06774027 |
| Specimen collection | Other | Preclinical | HER2-negative Breast Cancer | RECRUITING | NCT06774027 |
| Sacituzumab govetican | Other | Phase PHASE1 | Gastrointestinal Cancer | RECRUITING | NCT06065371 |
| Capecitabine | Other | Phase PHASE1 | Gastrointestinal Cancer | RECRUITING | NCT06065371 |
| Sacituzumab govetican | Other | Phase PHASE1 | Gastrointestinal Cancer | RECRUITING | NCT06065371 |
| Capecitabine | Other | Phase PHASE1 | Gastrointestinal Cancer | RECRUITING | NCT06065371 |
| PrEP | Other | Phase PHASE4 | Hiv | COMPLETED | NCT04782180 |
| Descovy 200Mg 25Mg Tablet | Other | Phase PHASE4 | Hiv | COMPLETED | NCT04782180 |
| PrEP | Other | Phase PHASE4 | Hiv | COMPLETED | NCT04782180 |
| Descovy 200Mg 25Mg Tablet | Other | Phase PHASE4 | Hiv | COMPLETED | NCT04782180 |
| F/TAF (for US participants only) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| PTM Oral LEN | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| PTM F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| Placebo SC LEN | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| Sub-cutaneous (SC) Lenacapavir (LEN) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| Oral Lenacapavir (LEN) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| F/TAF (for US participants only) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| PTM Oral LEN | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| PTM F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| Placebo SC LEN | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| Sub-cutaneous (SC) Lenacapavir (LEN) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| Oral Lenacapavir (LEN) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| F/TAF (for US participants only) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| PTM Oral LEN | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| PTM F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| Placebo SC LEN | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| Sub-cutaneous (SC) Lenacapavir (LEN) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| Oral Lenacapavir (LEN) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04925752 |
| Seladelpar 10 mg Capsule | Other | Phase PHASE3 | Primary Biliary Cirrhosis | ACTIVE_NOT_RECRUITING | NCT03301506 |
| Seladelpar 5 mg Capsule | Other | Phase PHASE3 | Primary Biliary Cirrhosis | ACTIVE_NOT_RECRUITING | NCT03301506 |
| Seladelpar 10 mg Capsule | Other | Phase PHASE3 | Primary Biliary Cirrhosis | ACTIVE_NOT_RECRUITING | NCT03301506 |
| Seladelpar 5 mg Capsule | Other | Phase PHASE3 | Primary Biliary Cirrhosis | ACTIVE_NOT_RECRUITING | NCT03301506 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT06263543 |
| GPC2 CAR T cells | Other | Phase PHASE1 | Refractory Neuroblastoma | RECRUITING | NCT05650749 |
| GPC2 CAR T cells | Other | Phase PHASE1 | Refractory Neuroblastoma | RECRUITING | NCT05650749 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05007782 |
| Denikitug | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05007782 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05007782 |
| Denikitug | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05007782 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05007782 |
| Denikitug | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05007782 |
| Placebo to Match GS1720/GS-4182 FDC | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| GS-1720/GS-4182 FDC | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Bictegravir/emtricitabine/tenofovir alafenamide | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Placebo to Match BVY | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| GS-4182 | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| GS-1720 | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| sacituzumab govitecan-hziy | Other | Phase PHASE1 | Solid Malignancies | ACTIVE_NOT_RECRUITING | NCT05006794 |
| Docetaxel | Other | Phase PHASE1 | Solid Malignancies | ACTIVE_NOT_RECRUITING | NCT05006794 |
| zamzetoclax | Other | Phase PHASE1 | Solid Malignancies | ACTIVE_NOT_RECRUITING | NCT05006794 |
| sacituzumab govitecan-hziy | Other | Phase PHASE1 | Solid Malignancies | ACTIVE_NOT_RECRUITING | NCT05006794 |
| Docetaxel | Other | Phase PHASE1 | Solid Malignancies | ACTIVE_NOT_RECRUITING | NCT05006794 |
| zamzetoclax | Other | Phase PHASE1 | Solid Malignancies | ACTIVE_NOT_RECRUITING | NCT05006794 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Esophagogastric Adenocarcinoma | COMPLETED | NCT06123468 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Esophagogastric Adenocarcinoma | COMPLETED | NCT06123468 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Esophagogastric Adenocarcinoma | COMPLETED | NCT06123468 |
| E/C/F/TAF (Low Dose) | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | COMPLETED | NCT01854775 |
| E/C/F/TAF | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | COMPLETED | NCT01854775 |
| Placebo | Other | Phase PHASE4 | Bronchiectasis Adult | TERMINATED | NCT03696290 |
| Aztreonam lysine | Other | Phase PHASE4 | Bronchiectasis Adult | TERMINATED | NCT03696290 |
| Placebo | Other | Phase PHASE4 | Bronchiectasis Adult | TERMINATED | NCT03696290 |
| Aztreonam lysine | Other | Phase PHASE4 | Bronchiectasis Adult | TERMINATED | NCT03696290 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT06486441 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT06486441 |
| Sacituzumab govitecan-hziy | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT06486441 |
| Paclitaxel | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT06486441 |
| Doxorubicin | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT06486441 |
| Sacituzumab govitecan-hziy | Other | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT06486441 |
| CAP256V2LS | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT05281510 |
| VRC07523LS | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT05281510 |
| Vesatolimod | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT05281510 |
| CAP256V2LS | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT05281510 |
| VRC07523LS | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT05281510 |
| Vesatolimod | Other | Phase PHASE2 | HIV-1-infection | COMPLETED | NCT05281510 |
| Capecitabine | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| Pembrolizumab | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| Sacituzumab govitecan-hziy (SG) | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| Capecitabine | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| Pembrolizumab | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| Sacituzumab govitecan-hziy (SG) | Other | Phase PHASE3 | Triple Negative Breast Cancer | RECRUITING | NCT05633654 |
| Patients received the Drug: liposomal amphotericin B（AmBisome） for treatment | Drug | Preclinical | Fungal Disease | RECRUITING | NCT07357038 |
| Patients received the Drug: liposomal amphotericin B（AmBisome） for treatment | Drug | Preclinical | Fungal Disease | RECRUITING | NCT07357038 |
| Patients received the Drug: liposomal amphotericin B（AmBisome） for treatment | Drug | Preclinical | Fungal Disease | RECRUITING | NCT07357038 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06902519 |
| GS-0151 | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06902519 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06902519 |
| GS-0151 | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT06902519 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05770895 |
| GS-6779 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05770895 |
| GS-2829 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05770895 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05770895 |
| GS-6779 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05770895 |
| GS-2829 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05770895 |
| Placebo | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05770895 |
| GS-6779 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05770895 |
| GS-2829 | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT05770895 |
| Bulevirtide | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT05765344 |
| Sacituzumab govitecan-hziy | Other | Phase PHASE2 | Thymoma | RECRUITING | NCT06248515 |
| General educational messages | Other | Approved | HIV Prevention | NOT_YET_RECRUITING | NCT05968755 |
| A chatbot designed to promote PrEP awareness and uptake for Black MSM | Other | Approved | HIV Prevention | NOT_YET_RECRUITING | NCT05968755 |
| General educational messages | Other | Approved | HIV Prevention | NOT_YET_RECRUITING | NCT05968755 |
| A chatbot designed to promote PrEP awareness and uptake for Black MSM | Other | Approved | HIV Prevention | NOT_YET_RECRUITING | NCT05968755 |
| General educational messages | Other | Approved | HIV Prevention | NOT_YET_RECRUITING | NCT05968755 |
| A chatbot designed to promote PrEP awareness and uptake for Black MSM | Other | Approved | HIV Prevention | NOT_YET_RECRUITING | NCT05968755 |
| Zimberelimab | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05840224 |
| GS-4528 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05840224 |
| Zimberelimab | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05840224 |
| GS-4528 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05840224 |
| Interview and survey to evaluate patient reported outcomes between the two medications. | Drug | Preclinical | HIV Pre-exposure Prophylaxis | NOT_YET_RECRUITING | NCT07379658 |
| Interview and survey to evaluate patient reported outcomes between the two medications. | Drug | Preclinical | HIV Pre-exposure Prophylaxis | NOT_YET_RECRUITING | NCT07379658 |
| Durvalumab | Other | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | RECRUITING | NCT07339059 |
| Atezolizumab | Other | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | RECRUITING | NCT07339059 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | RECRUITING | NCT07339059 |
| Filgotinib Maleate | Other | Phase PHASE4 | Ulcerative Colitis | RECRUITING | NCT06964113 |
| Sacituzumab Govitecan-hziy (SG) | Other | Phase PHASE1 | Triple Negative Breast Cancer | RECRUITING | NCT06926920 |
| Sacituzumab Govitecan-hziy (SG) | Other | Phase PHASE1 | Triple Negative Breast Cancer | RECRUITING | NCT06926920 |
| TDF Placebo | Other | Phase PHASE3 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT01651403 |
| Tenofovir DF | Other | Phase PHASE3 | Chronic Hepatitis B | ACTIVE_NOT_RECRUITING | NCT01651403 |
| Lenacapavir long-acting | Other | Phase PHASE4 | HIV Prevention | RECRUITING | NCT07218211 |
| Lenacapavir long-acting | Other | Phase PHASE4 | HIV Prevention | RECRUITING | NCT07218211 |
| Lenacapavir long-acting | Other | Phase PHASE4 | HIV Prevention | RECRUITING | NCT07218211 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Metastatic Triple-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04454437 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Metastatic Triple-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04454437 |
| PrEP perspectives | Other | Preclinical | People Who Inject Drugs | NOT_YET_RECRUITING | NCT07385183 |
| PrEP adherence | Other | Preclinical | People Who Inject Drugs | NOT_YET_RECRUITING | NCT07385183 |
| PrEP perspectives | Other | Preclinical | People Who Inject Drugs | NOT_YET_RECRUITING | NCT07385183 |
| PrEP adherence | Other | Preclinical | People Who Inject Drugs | NOT_YET_RECRUITING | NCT07385183 |
| PrEP perspectives | Other | Preclinical | People Who Inject Drugs | NOT_YET_RECRUITING | NCT07385183 |
| PrEP adherence | Other | Preclinical | People Who Inject Drugs | NOT_YET_RECRUITING | NCT07385183 |
| Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet | Other | Phase PHASE4 | Hepatitis C, Chronic | RECRUITING | NCT05140941 |
| ISL/LEN FDC | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| B/F/TAF | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| LEN | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| ISL | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| ISL/LEN FDC | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| B/F/TAF | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| LEN | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| ISL | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT05052996 |
| Tenofovi-Emtricitabine (TDF/FTC) tablet | Other | Preclinical | HIV | NOT_YET_RECRUITING | NCT07390409 |
| Cabotegravir (CAB) LA | Other | Preclinical | HIV | NOT_YET_RECRUITING | NCT07390409 |
| Lenacapavir Injection | Other | Preclinical | HIV | NOT_YET_RECRUITING | NCT07390409 |
| Tenofovi-Emtricitabine (TDF/FTC) tablet | Other | Preclinical | HIV | NOT_YET_RECRUITING | NCT07390409 |
| Cabotegravir (CAB) LA | Other | Preclinical | HIV | NOT_YET_RECRUITING | NCT07390409 |
| Lenacapavir Injection | Other | Preclinical | HIV | NOT_YET_RECRUITING | NCT07390409 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT05838521 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT05838521 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT05838521 |
| Placebo | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| GS-2872 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| GS-5423 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| Vesatolimod (VES) | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| MVA.tHIVconsv4 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| MVA.tHIVconsv3 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| ChAdOx1.HIVconsv62 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| ChAdOx1.tHIVconsv1 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| Placebo | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| GS-2872 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| GS-5423 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| Vesatolimod (VES) | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| MVA.tHIVconsv4 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| MVA.tHIVconsv3 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| ChAdOx1.HIVconsv62 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| ChAdOx1.tHIVconsv1 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| Placebo | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| GS-2872 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| GS-5423 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| Vesatolimod (VES) | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| MVA.tHIVconsv4 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| MVA.tHIVconsv3 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| ChAdOx1.HIVconsv62 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| ChAdOx1.tHIVconsv1 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT06071767 |
| Vinorelbine injection | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Gemcitabine Injection | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Capecitabine Oral Product | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Eribulin Mesylate Injection | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Vinorelbine injection | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Gemcitabine Injection | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Capecitabine Oral Product | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Eribulin Mesylate Injection | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Vinorelbine injection | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Gemcitabine Injection | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Capecitabine Oral Product | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Eribulin Mesylate Injection | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04639986 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT06104306 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT06104306 |
| B/F/TAF | Other | Phase PHASE4 | HIV-1-infection | COMPLETED | NCT06104306 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT06029972 |
| Tilpisertib Fosmecarbil | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT06029972 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT06029972 |
| Tilpisertib Fosmecarbil | Other | Phase PHASE2 | Ulcerative Colitis | RECRUITING | NCT06029972 |
| Cisplatin | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Carboplatin | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Pembrolizumab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Sacituzumab Govitecan-hziy (SG) | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Cisplatin | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Carboplatin | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Pembrolizumab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Sacituzumab Govitecan-hziy (SG) | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Cisplatin | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Carboplatin | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Pembrolizumab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Sacituzumab Govitecan-hziy (SG) | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05186974 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumor | RECRUITING | NCT04617522 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumor | RECRUITING | NCT04617522 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumor | RECRUITING | NCT04617522 |
| Edecesertib Placebo | Other | Phase PHASE2 | Cutaneous Lupus Erythematosus (CLE) | TERMINATED | NCT05629208 |
| Edecesertib | Other | Phase PHASE2 | Cutaneous Lupus Erythematosus (CLE) | TERMINATED | NCT05629208 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Endometrial Carcinoma | ACTIVE_NOT_RECRUITING | NCT04251416 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Endometrial Carcinoma | ACTIVE_NOT_RECRUITING | NCT04251416 |
| Cetuximab | Other | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | RECRUITING | NCT07063212 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | RECRUITING | NCT07063212 |
| Cetuximab | Other | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | RECRUITING | NCT07063212 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | RECRUITING | NCT07063212 |
| Trastuzumab and Hyaluronidase-oysk | Other | Phase PHASE2 | Her 2 Positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06100874 |
| Trastuzumab | Other | Phase PHASE2 | Her 2 Positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06100874 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Her 2 Positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06100874 |
| Trastuzumab and Hyaluronidase-oysk | Other | Phase PHASE2 | Her 2 Positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06100874 |
| Trastuzumab | Other | Phase PHASE2 | Her 2 Positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06100874 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Her 2 Positive Breast Cancer | ACTIVE_NOT_RECRUITING | NCT06100874 |
| Nasal Swab | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Biospecimen Collection | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Survey Administration | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Remdesivir | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Nasal Swab | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Biospecimen Collection | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Survey Administration | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Remdesivir | Other | Phase PHASE2 | Hematopoietic and Lymphatic System Neoplasm | RECRUITING | NCT06817889 |
| Standard of Care | Other | Approved | HIV Infections | RECRUITING | NCT05866523 |
| Team Based Inpatient ARTAS | Other | Approved | HIV Infections | RECRUITING | NCT05866523 |
| Standard of Care | Other | Approved | HIV Infections | RECRUITING | NCT05866523 |
| Team Based Inpatient ARTAS | Other | Approved | HIV Infections | RECRUITING | NCT05866523 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Muscle Invasive Bladder Carcinoma | RECRUITING | NCT05581589 |
| Radical Cystectomy | Other | Phase PHASE2 | Muscle Invasive Bladder Carcinoma | RECRUITING | NCT05581589 |
| Lymphadenectomy | Other | Phase PHASE2 | Muscle Invasive Bladder Carcinoma | RECRUITING | NCT05581589 |
| Pembrolizumab | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT04468061 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT04468061 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101342 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101342 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101342 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101342 |
| Lenacapavir Tablet | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101342 |
| Lenacapavir Injection | Other | Phase PHASE2 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT06101342 |
| Lenacapavir Tablet | Other | Phase PHASE3 | HIV Pre-exposure Prophylaxis | RECRUITING | NCT07047716 |
| Lenacapavir Injection | Other | Phase PHASE3 | HIV Pre-exposure Prophylaxis | RECRUITING | NCT07047716 |
| Lenacapavir Tablet | Other | Phase PHASE3 | HIV Pre-exposure Prophylaxis | RECRUITING | NCT07047716 |
| Lenacapavir Injection | Other | Phase PHASE3 | HIV Pre-exposure Prophylaxis | RECRUITING | NCT07047716 |
| Standard of Care | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT07001319 |
| BVY | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT07001319 |
| GS-3242 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT07001319 |
| Standard of Care | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT07001319 |
| BVY | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT07001319 |
| GS-3242 | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT07001319 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Ovarian Carcinoma | ACTIVE_NOT_RECRUITING | NCT06028932 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Ovarian Carcinoma | ACTIVE_NOT_RECRUITING | NCT06028932 |
| B/F/TAF | Other | Phase PHASE1 | HIV-1-infection | RECRUITING | NCT07055451 |
| PrEP Awareness and Uptake Educational Program | Other | Approved | HIV Prevention Program | ENROLLING_BY_INVITATION | NCT07053527 |
| PrEP Awareness and Uptake Educational Program | Other | Approved | HIV Prevention Program | ENROLLING_BY_INVITATION | NCT07053527 |
| Pre-Exposure Prophylaxis (PrEP) Persistence | Other | Approved | HIV Pre-exposure Prophylaxis | NOT_YET_RECRUITING | NCT07462611 |
| PrEP Uptake with Rapid Start | Other | Approved | HIV Pre-exposure Prophylaxis | NOT_YET_RECRUITING | NCT07462611 |
| Standard care dietary and exercice advice. | Other | Approved | Metabolic Dysfunction-Associated Steatotic Liver Disease | ENROLLING_BY_INVITATION | NCT07456332 |
| Digital nutritional program | Other | Approved | Metabolic Dysfunction-Associated Steatotic Liver Disease | ENROLLING_BY_INVITATION | NCT07456332 |
| Standard care dietary and exercice advice. | Other | Approved | Metabolic Dysfunction-Associated Steatotic Liver Disease | ENROLLING_BY_INVITATION | NCT07456332 |
| Digital nutritional program | Other | Approved | Metabolic Dysfunction-Associated Steatotic Liver Disease | ENROLLING_BY_INVITATION | NCT07456332 |
| Placebo-to-match GS-1427 | Other | Phase PHASE2 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT06290934 |
| GS-1427 | Other | Phase PHASE2 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT06290934 |
| HIV team implementation | Other | Approved | HIV Infection | RECRUITING | NCT06900829 |
| HIV team implementation | Other | Approved | HIV Infection | RECRUITING | NCT06900829 |
| HIV team implementation | Other | Approved | HIV Infection | RECRUITING | NCT06900829 |
| Epclusa | Other | Phase PHASE2 | End Stage Renal Disease | COMPLETED | NCT04075916 |
| Adaptive Radiotherapy | Drug | Phase PHASE1 | Localized Muscle Invasive Bladder Urothelial Carcinoma | RECRUITING | NCT05833867 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Localized Muscle Invasive Bladder Urothelial Carcinoma | RECRUITING | NCT05833867 |
| Adaptive Radiotherapy | Drug | Phase PHASE1 | Localized Muscle Invasive Bladder Urothelial Carcinoma | RECRUITING | NCT05833867 |
| Sacituzumab govitecan | Other | Phase PHASE1 | Localized Muscle Invasive Bladder Urothelial Carcinoma | RECRUITING | NCT05833867 |
| Optimized Background Regimen (OBR) | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Failing ARV Regimen | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Subcutaneous Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Oral Lenacapavir Placebo | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Oral Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Optimized Background Regimen (OBR) | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Failing ARV Regimen | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Subcutaneous Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Oral Lenacapavir Placebo | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Oral Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Optimized Background Regimen (OBR) | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Failing ARV Regimen | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Subcutaneous Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Oral Lenacapavir Placebo | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Oral Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT04150068 |
| Lopinavir Boosted with ritonavir (LPV/r) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| DRV | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| ATV | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Nucleos(t)ide reverse transcriptase inhibitors (NRTI) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| 3rd ARV Agent | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (Lowest Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (Low Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (High Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (Low Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (High Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Cobicistat (TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Cobicistat (Low Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Cobicistat (High Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| E/C/F/TAF (Low Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| E/C/F/TAF | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Lowest Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Low Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (High Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Lowest Dose Tablet) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Low Dose Tablet) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (High Dose Tablet) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Lopinavir Boosted with ritonavir (LPV/r) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| DRV | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| ATV | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Nucleos(t)ide reverse transcriptase inhibitors (NRTI) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| 3rd ARV Agent | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (Lowest Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (Low Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (High Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (Low Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| B/F/TAF (High Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Cobicistat (TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Cobicistat (Low Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Cobicistat (High Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| E/C/F/TAF (Low Dose) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| E/C/F/TAF | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Lowest Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Low Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (High Dose TOS) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Lowest Dose Tablet) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (Low Dose Tablet) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| F/TAF (High Dose Tablet) | Other | Phase PHASE4 | HIV-1-infection | RECRUITING | NCT06337032 |
| Enfortumab Vedotin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Domvanalimab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Gemcitabine | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Zimberelimab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Enfortumab Vedotin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Domvanalimab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Gemcitabine | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Zimberelimab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Enfortumab Vedotin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Domvanalimab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Gemcitabine | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Zimberelimab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Avelumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Cisplatin | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE2 | Metastatic Urothelial Cancer | RECRUITING | NCT03547973 |
| Atirmociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Metformin | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Palbociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Empagliflozin | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Inavolisib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Inavolisib (Dose #2) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Letrozole | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ribociclib (Dose #2) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Trastuzumab Deruxtecan | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Inavolisib (Dose #1) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ribociclib (Dose #1) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Fulvestrant | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Abemaciclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Sacituzumab Govitecan | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Nab-Paclitaxel | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Tocilizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Selicrelumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Chemotherapy (Gemcitabine + Carboplatin or Eribulin) | Drug | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Bevacizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| SGN-LIV1A | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ipatasertib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Atezolizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Capecitabine | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Atirmociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Metformin | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Palbociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Empagliflozin | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Inavolisib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Inavolisib (Dose #2) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Letrozole | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ribociclib (Dose #2) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Trastuzumab Deruxtecan | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Inavolisib (Dose #1) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ribociclib (Dose #1) | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Fulvestrant | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Abemaciclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Sacituzumab Govitecan | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Nab-Paclitaxel | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Tocilizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Selicrelumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Chemotherapy (Gemcitabine + Carboplatin or Eribulin) | Drug | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Bevacizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| SGN-LIV1A | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Ipatasertib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Atezolizumab | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Capecitabine | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT03424005 |
| Omeprazole | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| GS-4571 | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Omeprazole | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Placebo | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| GS-4571 | Other | Phase PHASE1 | Weight Management | RECRUITING | NCT06562907 |
| Ofatumumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02135133 |
| Idelalisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02135133 |
| Ofatumumab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02135133 |
| Idelalisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02135133 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| GS-5319 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT07128303 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Amrubicin (Japan only) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Topotecan | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Sacituzumab Govitecan (SG) | Other | Phase PHASE3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | RECRUITING | NCT06801834 |
| Placebo for CAB LA | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| CAB LA | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| Placebo for cabotegravir oral tablet | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| Placebo for TDF/FTC tablets | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| TDF/FTC tablets | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| Cabotegravir Oral Tablet | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| Placebo for CAB LA | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| CAB LA | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| Placebo for cabotegravir oral tablet | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| Placebo for TDF/FTC tablets | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| TDF/FTC tablets | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| Cabotegravir Oral Tablet | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT02720094 |
| Bulevirtide | Other | Preclinical | Chronic Hepatitis Delta Virus Infection | AVAILABLE | NCT06780579 |
| Bulevirtide | Other | Preclinical | Chronic Hepatitis Delta Virus Infection | AVAILABLE | NCT06780579 |
| obeldesivir | Other | Phase PHASE2 | Filovirus Disease | WITHDRAWN | NCT06682234 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Gland | RECRUITING | NCT05884320 |
| F/TAF TOS | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Cobicistat TOS | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Third Unboosted Drug | Drug | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| LPV/r | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| F/TAF | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Cobicistat | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| DRV | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| ATV | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| B/F/TAF (TOS) | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02881320 |
| B/F/TAF (Low Dose) | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02881320 |
| B/F/TAF (Adult Strength) | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02881320 |
| B/F/TAF (TOS) | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02881320 |
| B/F/TAF (Low Dose) | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02881320 |
| B/F/TAF (Adult Strength) | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02881320 |
| B/F/TAF (TOS) | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02881320 |
| B/F/TAF (Low Dose) | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02881320 |
| B/F/TAF (Adult Strength) | Other | Phase PHASE2 | HIV-1 Infection | ACTIVE_NOT_RECRUITING | NCT02881320 |
| PTM F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| PTM F/TAF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| PTM Oral LEN | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| Placebo SC LEN | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| F/TDF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| F/TAF | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| Subcutaneous (SC) Lenacapavir (LEN) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| Oral Lenacapavir (LEN) | Other | Phase PHASE3 | Pre-Exposure Prophylaxis of HIV Infection | ACTIVE_NOT_RECRUITING | NCT04994509 |
| Bictegravir, emtricitabine, and tenofovir alafenamide | Other | Phase PHASE4 | HIV -1 Infection | NOT_YET_RECRUITING | NCT07476339 |
| Placebo to Match GS1720/GS-4182 FDC | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| Placebo to Match BVY | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| GS-1720/GS-4182 FDC | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| Bictegravir/emtricitabine/tenofovir alafenamide | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| GS-4182 | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| GS-1720 | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Placebo | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Seladelpar | Other | Phase PHASE3 | Primary Biliary Cholangitis | RECRUITING | NCT06051617 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT06031415 |
| GS-0272 | Other | Phase PHASE1 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT06031415 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT06031415 |
| GS-0272 | Other | Phase PHASE1 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT06031415 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT06031415 |
| GS-0272 | Other | Phase PHASE1 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT06031415 |
| Standard of Care (SOC) | Other | Phase PHASE4 | HIV | ACTIVE_NOT_RECRUITING | NCT07210125 |
| Lenacapavir long-acting | Other | Phase PHASE4 | HIV | ACTIVE_NOT_RECRUITING | NCT07210125 |
| emtricitabine / tenofovir disoproxil fumarate / raltegravir . | Other | Phase PHASE2 | HIV-2 Infection | COMPLETED | NCT01605890 |
| emtricitabine / tenofovir disoproxil fumarate / raltegravir . | Other | Phase PHASE2 | HIV-2 Infection | COMPLETED | NCT01605890 |
| emtricitabine / tenofovir disoproxil fumarate / raltegravir . | Other | Phase PHASE2 | HIV-2 Infection | COMPLETED | NCT01605890 |
| Tenofovir-Emtricitabine | Other | Phase PHASE2 | Leukoencephalopathy, Progressive Multifocal | COMPLETED | NCT00120367 |
| Enfuvirtide | Other | Phase PHASE2 | Leukoencephalopathy, Progressive Multifocal | COMPLETED | NCT00120367 |
| Lenacapavir Tablet | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Cabotegravir (CAB) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Emtricitabine/tenofovir alafenamide (F/TAF) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Lenacapavir Injection | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Lenacapavir Tablet | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Cabotegravir (CAB) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Emtricitabine/tenofovir alafenamide (F/TAF) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| Lenacapavir Injection | Other | Preclinical | HIV Infections | RECRUITING | NCT07473778 |
| GS-4321 Placebo | Other | Phase PHASE1 | Chronic Hepatitis Delta | RECRUITING | NCT07096193 |
| GS-4321 | Other | Phase PHASE1 | Chronic Hepatitis Delta | RECRUITING | NCT07096193 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | RECRUITING | NCT02932150 |
| TAF | Other | Phase PHASE2 | Chronic Hepatitis B | RECRUITING | NCT02932150 |
| Placebo | Other | Phase PHASE2 | Chronic Hepatitis B | RECRUITING | NCT02932150 |
| TAF | Other | Phase PHASE2 | Chronic Hepatitis B | RECRUITING | NCT02932150 |
| Carboplatin | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| Gemcitabine | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| nab-Paclitaxel | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| Paclitaxel | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| Sacituzumab Govitecan-hziy | Other | Phase PHASE3 | Triple Negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05382299 |
| lopinavir or efavirenz | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00302822 |
| emtricitabine/tenofovir | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00302822 |
| enfuvirtide | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00302822 |
| lopinavir or efavirenz | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00302822 |
| emtricitabine/tenofovir | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00302822 |
| enfuvirtide | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00302822 |
| lopinavir or efavirenz | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00302822 |
| emtricitabine/tenofovir | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00302822 |
| enfuvirtide | Other | Phase PHASE3 | HIV Infections | COMPLETED | NCT00302822 |
| Placebo-to-match emvistegrast | Other | Phase PHASE2 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT06290934 |
| emvistegrast | Other | Phase PHASE2 | Ulcerative Colitis | ACTIVE_NOT_RECRUITING | NCT06290934 |
| Trifluridine-Tipiracil | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | NOT_YET_RECRUITING | NCT07527858 |
| Bevacizumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | NOT_YET_RECRUITING | NCT07527858 |
| Nivolumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | NOT_YET_RECRUITING | NCT07527858 |
| Denikitug | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | NOT_YET_RECRUITING | NCT07527858 |
| Trifluridine-Tipiracil | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | NOT_YET_RECRUITING | NCT07527858 |
| Bevacizumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | NOT_YET_RECRUITING | NCT07527858 |
| Nivolumab | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | NOT_YET_RECRUITING | NCT07527858 |
| Denikitug | Other | Phase PHASE2 | Advanced Microsatellite Stable Colorectal Cancer | NOT_YET_RECRUITING | NCT07527858 |
| B/F/TAF | Other | Phase PHASE1 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT07055451 |
| B/F/TAF | Other | Phase PHASE1 | HIV-1-infection | ACTIVE_NOT_RECRUITING | NCT07055451 |
| Placebo to Match GS1720/GS-4182 FDC | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| Placebo to Match BVY | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| lepetegravir/lenacapavir pacfosacil FDC | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| Bictegravir/emtricitabine/tenofovir alafenamide | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| lenacapavir pacfosacil | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| lepetegravir | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| Placebo to Match GS1720/GS-4182 FDC | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| Placebo to Match BVY | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| lepetegravir/lenacapavir pacfosacil FDC | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| Bictegravir/emtricitabine/tenofovir alafenamide | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| lenacapavir pacfosacil | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| lepetegravir | Other | Phase PHASE2 | HIV-1-infection | TERMINATED | NCT06613685 |
| Zimberelimab | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06082960 |
| GS-9911 | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06082960 |
| Zimberelimab | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06082960 |
| GS-9911 | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06082960 |
| Placebo to Match GS1720/GS-4182 FDC | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Lepetegravir/Lenacapavir pacfosacil FDC | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Bictegravir/emtricitabine/tenofovir alafenamide | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Placebo to Match BVY | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Lenacapavir pacfosacil | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Lepetegravir | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Placebo to Match GS1720/GS-4182 FDC | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Lepetegravir/Lenacapavir pacfosacil FDC | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Bictegravir/emtricitabine/tenofovir alafenamide | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Placebo to Match BVY | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Lenacapavir pacfosacil | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Lepetegravir | Other | Phase PHASE2 | HIV-1-Infection | ACTIVE_NOT_RECRUITING | NCT06544733 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06532565 |
| GS-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06532565 |
| Zimberelimab | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06532565 |
| GS-2121 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06532565 |
| F/TAF TOS | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Cobicistat TOS | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Third Unboosted Drug | Drug | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| LPV/r | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| F/TAF | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Cobicistat | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| DRV | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| ATV | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| F/TAF TOS | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Cobicistat TOS | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Third Unboosted Drug | Drug | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| LPV/r | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| F/TAF | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Cobicistat | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| DRV | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| ATV | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| F/TAF TOS | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Cobicistat TOS | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Third Unboosted Drug | Drug | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| LPV/r | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| F/TAF | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Cobicistat | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| DRV | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| ATV | Other | Phase PHASE2 | Acquired Immune Deficiency Syndrome (AIDS) | ACTIVE_NOT_RECRUITING | NCT02016924 |
| Sacituzumab govitecan | Other | Phase PHASE3 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04595565 |
| Cisplatin | Other | Phase PHASE3 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04595565 |
| Carboplatin | Other | Phase PHASE3 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04595565 |
| Capecitabine | Other | Phase PHASE3 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04595565 |
| Paclitaxel | Other | Phase PHASE2 | HER2-negative | NOT_YET_RECRUITING | NCT07546812 |
| Ramucirumab | Other | Phase PHASE2 | HER2-negative | NOT_YET_RECRUITING | NCT07546812 |
| Nivolumab | Other | Phase PHASE2 | HER2-negative | NOT_YET_RECRUITING | NCT07546812 |
| Denikitug | Other | Phase PHASE2 | HER2-negative | NOT_YET_RECRUITING | NCT07546812 |
| Durvalumab | Other | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | RECRUITING | NCT07339059 |
| Atezolizumab | Other | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | RECRUITING | NCT07339059 |
| Sacituzumab govitecan | Other | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | RECRUITING | NCT07339059 |
| Optimized Background Regimen (OBR) | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT06749054 |
| Subcutaneous Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT06749054 |
| Oral Lenacapavir | Other | Phase PHASE2 | HIV-1-infection | RECRUITING | NCT06749054 |
| No Intervention | Other | Approved | Liver Diseases | COMPLETED | NCT07580482 |
| Best Practice Alert | Other | Approved | Liver Diseases | COMPLETED | NCT07580482 |
Total products: 5376